<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /scratch/yujieq/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761067Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review CLINICAL STUDIES -MEMO</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<affiliation key="aff0">
								<orgName type="department">U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office</orgName>
								<orgName type="institution">Translational Sciences Office of Biostatistics S T A T I S T I C A L R E V I E W A N D E V A L U A T I O N</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">DEPARTMENT OF HEALTH &amp; HUMAN SERVICES Public Health Service Food and Drug Administration Center for Drug Evaluation and Research ___________________________________________________________ MEMORANDUM</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 761067Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review CLINICAL STUDIES -MEMO</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
				</biblStruct>
			</sourceDesc>
		</fileDesc>

		<encodingDesc>
			<appInfo>
				<application version="0.6.0-SNAPSHOT" ident="GROBID-SDO" when="2020-09-21T05:37+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid-sdo"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 6       <ref type="table" target="#tab_67">Table 62</ref>: Summary of midazolam PK parameters following a single oral dose of 2 mg midazolam as part of a CYP probe cocktail at Day 1 (baseline) and Day 57 (following two SC doses of 200 mg tildrakizumab at Weeks 0 and 4) in subjects with moderate to severe plaque psoriasis <ref type="formula">(</ref>    BLA Multi-disciplinary Review and Evaluation -BLA 761067 <ref type="bibr">ILUMYA (tildrakizumab)</ref>   <ref type="bibr">ILUMYA (tildrakizumab)</ref> injection for subcutaneous use is a humanized IgG1/ monoclonal antibody that specifically binds to the p19 protein subunit of the IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine, composed of 2 subunits (IL-23p19 and IL-12/23p40), that is involved in inflammatory and immune responses.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table of Tables</head><p>Tildrakizumab is an original BLA. The proposed indication is treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The proposed dose is 100 mg at Weeks 0, 4, and every twelve weeks thereafter administered by subcutaneous (SC) injection. The proposed commercial presentation for tildrakizumab drug product (100 mg/mL) is a single-use pre-filled syringe (PFS) with a 1.0 mL fill volume.</p><p>The Agency concluded that the proposed proprietary name, ILUMYA, was acceptable from both a promotional and safety perspective under BLA 761067 [Proprietary Name Review by Sherly Abraham, RPh, Division of Medication Error Prevention and Analysis (DMEPA) dated 6/28/2017].</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions on the Substantial Evidence of Effectiveness</head><p>The applicant submitted data from two adequate and well-controlled trials (Trial P010 and Trial P011), which provided evidence of the effectiveness of tildrakizumab for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. The trials assessed the changes from Baseline to Week 12 compared to placebo in the two co-primary endpoints:</p><p>the proportion of subjects who achieved at least a 75% reduction in the PASI composite score (PASI 75) the proportion of subjects who achieved a Physician's Global Assessment (PGA) score of score of 0 ("cleared") or 1 ("minimal") and at least a 2-point improvement.</p><p>Tildrakizumab was statistically superior to placebo (p-values &lt; 0.001) on the co-primary endpoints in Trial P010 and P011. The applicant has demonstrated that tildrakizumab is effective for its intended use in the target population, and has met the evidentiary standard required by 21 CFR 314.126(a)(b) to support approval.</p><p>BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>27</head><p>Reference ID: 4233639 BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 28 2 Therapeutic Context</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Condition</head><p>Psoriasis is a common, chronic, immune-mediated skin disorder. The characteristic lesion is a sharply demarcated erythematous plaque with micaceous scale, and the plaques may be localized or widespread in distribution 2 . Psoriasis is a complex autoimmune inflammatory disease that occurs in genetically susceptible individuals. The pathophysiology of psoriasis involves the activation of innate immune cells in the skin, which produce proinflammatory cytokines which trigger and perpetuate the inflammatory cascade 3 .</p><p>In the U.S. and Canada, prevalence as high as 4.6% and 4.7% have been reported, respectively. 2 It is estimated that approximately 7.5 million people in the United States have psoriasis. Approximately 80 percent of those affected with psoriasis have mild to moderate disease, while 20 percent have moderate to severe psoriasis affecting more than 5 percent of the body surface area. The most common form of psoriasis is plaque psoriasis, affecting about 80 to 90 percent of patients with psoriasis 4 .</p><p>Psoriasis can first appear at any age, from infancy to the eighth decade of life. Two peaks in age of onset have been reported: one at 20-30 years of age and a second peak at 50-60 years.</p><p>In approximately 75% of patients, the onset is before the age of 40 years, and in 35-50%, it is before the age of 20 years. The age of onset is earlier in women than in men. <ref type="bibr">2</ref> The natural history of psoriasis is chronic with intermittent remissions. Although plaque psoriasis is the most common presentation, other forms of psoriasis include guttate, pustular, erythrodermic, and inverse psoriasis. Psoriasis may affect fingernails and toenails, most frequently in association with psoriatic arthritis. A diagnosis of psoriasis can be made by history and physical examination in the vast majority of cases. The differential diagnosis of psoriasis may include seborrheic dermatitis, lichen simplex chronicus, atopic dermatitis, and nummular eczema. Occasionally, a skin biopsy is performed to rule out other conditions. 2</p><p>The presentation of psoriasis in the pediatric population can be different from that in adults. Psoriasis in infants often presents with involvement of the diaper area. Infants with diaper-area involvement typically develop symmetrical, well-demarcated erythematous patches with little scale. Maceration may be present. Unlike irritant diaper dermatitis, the inguinal folds are usually involved. Affected infants may also have psoriatic plaques in other body areas. These plaques are often smaller and thinner than the psoriatic plaques in adult patients. In children, scalp involvement is a common and often initial presentation of chronic plaque psoriasis. In addition, children with chronic plaque psoriasis are more likely to have facial involvement than adults. 2 A number of comorbid systemic conditions occur more frequently in patients with psoriasis. Examples of these conditions include cardiovascular disease, malignancy, diabetes, hypertension, metabolic syndrome, inflammatory bowel disease, serious infections, and autoimmune disorders. Psychiatric comorbidities associated with psoriasis include depression and suicidal ideation; neurotic, stress-related, or somatoform disorders; and personality and behavioral disorders. <ref type="bibr">5</ref> The impact of psoriasis on the daily lives of patients was among the topics discussed at a Patient-Focused Drug Development Meeting for psoriasis held by the Agency on March 17, 2016. Patients who attended the meeting described severe physical, social and emotional impact including: depression, anxiety, limitations on activities, embarrassment, stigma, and social discrimination. Patients shared their experiences with currently available therapies, and they described varying degrees of success in managing symptoms with these therapies.</p><p>Patients stressed need to enhance the treatment armamentarium, given current challenges with variability in effectiveness, tolerability, access to available treatments, and uncertainty regarding long-term effects of available treatments.</p><p>Psoriasis is a chronic, debilitating disease with significant impacts on the lives of affected patients. At the Patient Focused Drug Development meeting, patients discussed current challenges with variability in effectiveness, tolerability, access to available treatments, and uncertainty regarding long-term effects of available treatments. Therefore, development of additional safe and effective therapies continues to be an important goal. This is especially true for certain subgroups of patients with psoriasis, such as women during pregnancy and pediatric patients. BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Current Treatment Options</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>30</head><p>Although there are multiple topical therapies available for the treatment of psoriasis, topical therapies are not typically used alone for the treatment of moderate to severe disease. Approved systemic therapies for the treatment of moderate to severe plaque psoriasis are described in the table below.  </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>T-Cell Inhibitor/ Immunosuppressant</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>U.S. Regulatory Actions and Marketing History</head><p>Because tildrakizumab is an original BLA and is not currently marketed in the United States, this section is not applicable.  <ref type="bibr">, 2011</ref><ref type="bibr">, July 29, 2013</ref><ref type="bibr">, April 22, 2015</ref><ref type="bibr">, and August 28, 2015</ref>; End-of-Phase 2 (EOP2) April 11, 2012, and Pre-BLA August 31, 2016.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of Presubmission/Submission Regulatory Activity</head><p>The applicant submitted a protocol on July 27, 2010 for a Phase 2 dose-ranging trial (Trial P05495, later re-designated P003), to evaluate 4 doses (5, 25, 100, 200 mg) of their product against placebo. In the advice letter dated December 17, 2010, the Agency recommended that the primary efficacy endpoint be success on PGA where success is defined as a score of 0 ("Cleared") or 1 ("Almost Clear") with at least 2-grade improvement from baseline and PASI may be used as a secondary endpoint.</p><p>At the Guidance meeting on June 1, 2011, the Agency advised the applicant of the need to characterize the pharmacokinetic (PK) profile of their to-be-marketed drug product (rather than the lyophilized powder drug product formulation used in early trials) in the target patient population. The Agency also advised the applicant regarding optimal timepoints during the Phase 3 trials for collection of samples for drug concentrations and immunogenicity. The Agency noted the applicant's plan to use the pre-filled syringe (PFS) presentation in the Phase 3 trials as well as their plan to instruct subjects to perform self-administration of study drug after the first 2 injections. The Agency recommended that the applicant conduct a dedicated human factors usability study for the PFS in addition to the Phase 3 trials. During the EOP2 meeting, the applicant agreed to include success on PGA at Week 12 as a coprimary endpoint with PASI 75 at Week 12 in their Phase 3 trials. The Agency recommended that the applicant propose a definition for relapse/rebound during the maintenance period based on PGA as well as PASI 75 so that the same endpoints are used throughout the various periods of the trial. The Agency also provided advice regarding documentation and adjudication of major adverse cardiovascular events (MACE). In addition, the Agency provided advice regarding the applicant's proposed anti-drug antibody (ADA) assay, and recommended the use of a cell-based biological assay for the detection of neutralizing antibodies.</p><p>Regarding device development, at the EOP2 meeting the Agency offered detailed advice regarding the applicant's proposed Human Factors Study.</p><p>The following briefly summarizes the statistical comments provided to the applicant regarding their Phase 3 trials and EOP2 meeting package:</p><p>The Agency commented that the proposed stepwise method to control multiplicity does not fully control the Type I error rate. The Agency commented that there was insufficient information to provide concurrence on the applicant's proposed interim futility analysis and requested more detail on the statistical methodology. It should be noted that the interim analysis was removed from all Phase 3 protocols after the EOP2 meeting. Trial P012 did not include a placebo arm and the Agency commented that this trial should include a placebo to avoid potential issues in interpreting trial findings.</p><p>The Agency commented that randomization should be stratified by center and the analysis should account for such stratification. In addition, the Agency recommended the applicant reduce the number of centers and enroll a minimum number of subjects per arm per center (i.e., 8 subjects). For handling missing data, the applicant proposed imputing missing data as non-responders as the primary imputation method and using LOCF as a sensitivity analysis. Since the justification for LOCF is limited, the Agency stated that the applicant provide their rationale for LOCF or propose an alternate method. In addition, the Agency noted that imputing missing data as non-responders and LOCF will produce similar results; therefore, the Agency recommended including a sensitivity analysis that uses an alternate framework from the primary imputation method.</p><p>The applicant submitted three Phase 3 protocols (Trials P010, P011, and P012) for Special Protocol Assessment (SPA) on June 8, 2012. Since all three protocols were different, three separate SPA letters (Agreement letters) were sent to the applicant on July 18, 2012. It should be noted that all the comments conveyed in the SPA letter for Trial P011 were also conveyed in the SPA letter for Trial P012 except for two comments that dealt with the maintenance period (the first 28-weeks Trial P011 and Trial P012 are identical). The Agency reiterated the comments from the EOP2 meeting regarding the definition of relapse/rebound, randomization, and the handling of missing data. The Agency recommended the primary analysis population be the intent-to-treat (ITT) population, defined as all randomized subjects (the applicant proposed requiring subjects have at least one dose of study treatment to be included). For Trials P011 and P012, the Agency recommended the placebo arm continue to Week 28 as the applicant planned to establish an efficacy claim related to tildrakizumab vs. etanercept at Week 28.</p><p>The applicant provided responses to all of the <ref type="table" target="#tab_0">Non-Agreements and Additional Comments for  Trial P010, and submitted an amended protocol for Trial P010 based on their responses on  September 20, 2012. On October 26, 2012, the applicant provided responses to all of the Non-Agreements and Additional Comments for Trials P011 and P012, and submitted an amended  for only Trial P011</ref>. Advice letters for all three trials were sent to the applicant on March 14, 2013. While the Agency acknowledged the applicant's responses regarding the randomization and number of centers (i.e., not stratify by center and not reducing the number of centers), not having the placebo arm continue to Week 28 in Trials P011 and P012, and not using the ITT population as the primary analysis population, the Agency still reiterated their recommendations regarding these issues.</p><p>A Guidance meeting was scheduled for April 22, 2015; however, after receiving the pre-meeting communication, the applicant cancelled the meeting and stated that the guidance provided by the Agency was clear and that further discussion was not necessary. The purpose of the meeting was to discuss the applicant's proposed revised developmental program. The applicant stated:</p><p>"The company has modified the scope of the Phase 3 program and is conducting two of the previously-proposed Phase 3 studies (Protocols P010 and P011). The company does not plan to conduct Protocol P012 and does not intend to seek a comparative efficacy claim vs. etanercept."</p><p>For the guidance meeting on April 22, 2015, the applicant asked whether the revised safety database (i.e., without Trial P012) would be sufficient to support a BLA. The Agency commented that the size of the proposed safety database ( <ref type="table" target="#tab_90">Table 2</ref> in meeting package) may be acceptable if the adverse reaction profile is comparable to that seen in the Phase 2 program. In addition, the Agency stated that if the actual numbers are less than proposed, then additional data may be needed.</p><p>On November 24, 2015, the applicant submitted amended protocols for Trials P010 and P011. In the amended protocols, the applicant proposed to include PASI 90 and PASI 100 as key secondary efficacy endpoints and modified the multiplicity testing strategy (i.e., a sequential gatekeeping approach) to include these endpoints. An advice letter regarding this submission was sent to the applicant on December 29, 2015. In the advice letter, the Agency stated that the proposal to include PASI 90 and PASI 100 at Week 12 as key secondary efficacy endpoints in Trials P010 and P011 is acceptable. In addition, the Agency stated:</p><p>"As you have decided not to conduct Trial P012 and, consequently, not seek a comparative efficacy claim against etanercept, we recommend that you consider modifying your multiplicity testing strategy for Trial P011 such that all comparisons of tildrakizumab against placebo come before comparisons against etanercept."</p><p>The applicant submitted an initial Pediatric Study Plan (iPSP) on December 11, 2015. The Agency sent a Written Response to the applicant's iPSP on March 10, 2016. The applicant submitted an agreed iPSP on May 20, 2016. In the agreed iPSP, the applicant requested a partial waiver for studies in children younger than 6 years of age on the grounds that necessary studies are impossible or highly impractical due to the extremely low prevalence of moderate to severe psoriasis in this population. The applicant also requested deferral of studies in pediatric subjects age 6 years to less than 18 years until safety and efficacy in the adult indication have We have approved the stability protocols in your license application for the purpose of extending the expiration dating of your drug substance and drug product under 21 CFR 601.12. Exempt from lot release o ILUMYA is exempted from lot release because it is a specified product per 601.2(a)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>C. Benefit/Risk Considerations:</head><p>Tildrakizumab is an IL-23 antagonist indicated for the treatment of adults with moderate tosevere plaque psoriasis who are candidates for systemic therapy or phototherapy. The data submitted in this application support the conclusion that the manufacture of tildrakizumab is well controlled and yields a consistently high quality product. The conditions used in manufacturing have been sufficiently validated, and a consistent product is prepared from the multiple production runs presented. From a product quality perspective, this product is approvable for human use.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>D. Recommendation on Phase 4 (Post-Marketing) Commitments, Requirements, Agreements, and/or Risk Management Steps, if approvable:</head><p>There are no PMCs from the CMC review team. <ref type="table" target="#tab_14">Table 3</ref> below is a summary of critical quality attributes and the associated control strategies for attributes that are relevant to both Drug Substance and Drug Product. For additional information, see the technical document in primary reviews of the Drug Substance Quality and Drug Product Quality by OBP/DBRR-II, and the Drug Substance Microbiology and the Drug Product Microbiology by OPF/DMA.  <ref type="table" target="#tab_15">Table 4</ref> below is a summary of the risk identification and lifecycle knowledge management for drug substance CQAs that are derived from the drug substance manufacturing process and general drug substance attributes. Tildrakizumab is a recombinant humanized IgG1 monoclonal antibody that binds human IL-23p19. The amino acid sequence of the variable domain is of murine origin and that of the constant region is of human origin. Tildrakizumab consists of 4 polypeptide chains (2 identical heavy chains, 446 amino acids each, and 2 identical light chains 214 amino acids each) and has a molecular weight of 147 kDa. The tildrakizumab expression construct is expressed in a CHO cell line. Amino acid sequencing and tryptic peptide mapping with mass spectrometry analysis confirms the correct amino acid sequence. Tildrakizumab drug substance has the same formulation as the drug product</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>II. Summary of Quality Assessments:</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A. CQA Identification, Risk and Lifecycle Knowledge Management</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mechanism of Action (MoA):</head><p>Tildrakizumab binds specifically to IL-23p19 and blocks interaction with IL-23R. IL-23 is a naturally occurring cytokine known to be involved with multiple inflammatory pathways. Engagement of IL-23R by IL-23 leads to JAK2-mediated phosphorylation of tyrosine residues. This initiates downstream signaling cascade where STAT3 is recruited and homodimered. A signal from the phosphorylated homodimer STAT3 complex is sent to the nucleus to induce a transcription of the inflammatory cytokines, IL-17. IL-17 activates inflammatory pathways associated with psoriasis. Tildrakizumab binds to the p19 subunit of IL-23 and binds to IL-23 molecules and prevents its interaction with the IL-23R, blocking the downstream signaling cascade.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Potency Assay:</head><p>The potency assay is a cell-based assay that measures neutralization of soluble IL-23. In the assay, tildrakizumab binds to IL-23 via its p19 subunit preventing IL-23 binding to the IL-23R, resulting in inhibition of IL-23-induced STAT3 phosphorylation. Cells are lysed and p-STAT3 is measured by ELISA. The loss of signal from the ELISA from the neutralization activity of tildrakizumab is dose-dependent and is reported as a relative percentage of the activity of the reference standard.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reference Materials:</head><p>A well characterized primary reference standard was derived from a clinical batch. Merck has a two-tiered reference standard system with appropriate protocols in place that will ensure sufficient inventory of working reference standard for routine release and stability testing while</p><formula xml:id="formula_0">Reference ID: 4233639 (b) (4) (b) (4) (b) (4)</formula><p>Tildrakizumab is supplied at 100 mg / 1 mL syringe. Potency of tildrakizumab is determined as a percent IL-23 neutralization activity to the current reference standard. The potency assay is the same as described in the drug substance section of this review.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of Product Design:</head><p>Tildrakizumab is supplied as a sterile, single-dose, preservative-free solution for subcutaneous injection in a pre-filled syringe that is assembled with a safety device. The drug product formulation consists of histidine, 7% sucrose, and 0.05% polysorbate 80 at pH . The extractable volume is 1.0 mL.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>List of Excipients:</head><p>Excipients include histidine, 7% sucrose, and 0.05% polysorbate 80.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reference Materials:</head><p>The same reference material is used for drug substance and drug product.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Manufacturing process summary:</head><p>Container closure:</p><p>The primary container closure system for tildrakizumab drug product consists of a 1 mL syringe barrel with a staked needle, rigid needle shield and plunger stopper. The safety device components include a needle guard, plunger rod, and finger flange ). Appropriate compatibility studies were performed for the container closure system.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dating period and storage conditions:</head><p>Reference ID: 4233639 </p><formula xml:id="formula_1">(b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Microbiology</head><p>Not applicable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Devices and Companion Diagnostic Issues</head><p>During the pivotal Phase 3 trials, tildrakizumab was supplied and administered via a singledose, prefilled syringe (PFS) with needle guard. This is the device with which tildrakizumab is to be marketed. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Executive Summary</head><p>Tildrakizumab is a humanized recombinant IgG1/ monoclonal antibody that selectively binds to the p19 subunit of human interleukin 23 (IL-23p19) and blocks the interaction of IL-23 with the IL-23 receptor. Neutralization of IL-23 in a humanized mouse model of psoriasis shows therapeutic effects. Tildrakizumab does not bind to human IL-12 or rodent IL-23. Monkey is the only pharmacologically relevant species and was used in toxicology studies.</p><p>In a 3-month repeat dose toxicity study, subcutaneous (SC) doses of 0 (vehicle), 40, and 140 mg/kg and intravenous (IV) doses of 140 mg/kg tildrakizumab were administered to cynomolgus monkeys once every two weeks for 3 months. No significant adverse effects were noted. In a 9-month repeat dose toxicity study, SC doses of 0 (vehicle), 10, and 100 mg/kg tildrakizumab were administered to cynomolgus monkeys once every two weeks for 9 months. No significant adverse effects were noted. The NOAELs identified in the two studies were the highest dose tested in both studies. The high dose in the 9-month study, 100 mg/kg, is 45 times the maximum recommended human dose (MRHD), based on AUC comparison.</p><p>The effects on fertility were assessed by examination of reproductive organs in the repeat dose toxicity studies. No adverse effects were noted. In an embryofetal developmental study, SC doses of 0, 10, 100 and 300 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks during gestation days 20-118. No maternal or embryofetal toxicities were observed. The NOAEL, 300 mg/kg, is 79 times the MRHD. Tildrakizumab crossed the placenta in monkeys.</p><p>In a pre-and postnatal developmental study, SC doses of 0, 10, and 100 mg/kg tildrakizumab were administered to pregnant cynomolgus monkeys once every two weeks from gestation day 50 to parturition. No significant maternal toxicity was noted. Seven infants died or were euthanized within 15 days of age: 1/12 in the control group, 2/12 in the low dose group, and 4/14 in the high dose group. While the overall fetal/infant losses were within the historical control range, the deaths of 2 high dose infants (histopathology examination suggested viral infection) were considered as possibly related to tildrakizumab treatment. No tildrakizumabrelated adverse effects were noted in the remaining infants from birth through 6 months of age. The NOAEL for maternal toxicity was identified as 100 mg/kg (30 times the MRHD) and the NOAEL for developmental toxicity was identified as 10 mg/kg (3 times the MRHD).</p><p>No genetic toxicology or carcinogenicity studies were conducted with tildrakizumab. The applicant provided a carcinogenic risk assessment, mainly using information from published literature. The nonclinical information does not suggest an increased carcinogenic risk associated with the use of tildrakizumab. However, the relevance of various animal models to humans is unknown.</p><p>This BLA is approvable from a Pharmacology/Toxicology perspective. There is no recommended nonclinical PMC/PMR for this BLA.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Referenced NDAs, BLAs, DMFs</head><p>All the pivotal nonclinical data have been reviewed under IND 101389. Summary pharmacology/toxicology information is provided in this review. The code names used for ILUMYA (tildrakizumab) are SCH 900222 and MK-3222.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacology</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary pharmacology</head><p>Tildrakizumab is a humanized recombinant immunoglobulin G1/kappa isotype (IgG1/ ) monoclonal antibody (mAb) that binds to human interleukin 23 (IL-23) and blocks the interaction of IL-23 with the IL-23 receptor. IL-23 is a pro-inflammatory cytokine that has been implicated in the pathogenesis of immune diseases, including psoriasis. Literature shows that neutralization of IL-23 in a humanized mouse model of psoriasis inhibits inflammation and counteracts inflammation-induced tissue damage leading to disease remission.</p><p>Tildrakizumab binds to human IL-23 with an affinity of 297 pM (dissociation constant, Kd). An analysis of the crystal structure of the antigen binding fragment F(ab) of tildrakizumab bound to human IL-23 shows that the epitope of tildrakizumab on human IL-23 is primarily on the p19 subunit of IL-23 (IL-23p19), with limited interaction with the IL-12/23p40 subunit. As assessed by surface plasmon resonance (Biacore) and indirect ELISA techniques, tildrakizumab does not bind to human IL-12 (IL-12/23p40 and IL-12p35 heterodimer) or the human IL-12/23p40 monomer. The ability of tildrakizumab to neutralize the biological activity of human IL-23 in vitro was measured in three different assays. In all three assays (using a transfected BAF/3 cell line, primary human splenocytes, and a KIT225 leukemic T-cell line, respectively), tildrakizumab showed consistent and reproducible inhibition of IL-23-induced biological activity, with IC 50 values ranging from 59 to 187 pM.</p><p>Tildrakizumab binds to cynomolgus monkey IL-23 with higher affinity (Kd: 47 pM) than human IL-23. In the KIT225 assay tildrakizumab neutralized the biological activity of cynomolgus monkey IL-23 with an IC 50 of 118 pM (comparable to the IC 50 of 130 pM in the assay with human IL-23), demonstrating that cynomolgus monkey is a pharmacologically relevant species. Tildrakizumab does not bind to mouse or rat IL-23 (no detectable binding). A surrogate mouse anti-mouse IL-23p19 IgG1 mAb, SCH 900598, was developed and used in in vivo pharmacology studies. SCH 900598 binds relatively weakly to mouse IL-23 (Kd: ~3-6 nM) and shows lower potency in in vitro assays (IC 50 ranging from 8 to 11 nM).</p><p>The anatomical distribution of IL-23p19, its two receptor subunits (IL-23R and IL-12R 1), and IL-12/23p40 was assessed by quantitative gene expression in normal human, cynomolgus monkey, and mouse tissues. The general pattern of the IL-12/23p40 and IL-23p19 subunits and the IL-23R and IL-12R 1 receptor expression were similar among human, monkey, and mouse, with low level expression detected primarily in the immune tissues and in the gastrointestinal tract.</p><p>The applicant conducted a number of nonclinical studies using various infection models and also provided a number of literature references to address the infection risk of anti-IL-23p19 treatment. The study results suggest that IL-23 neutralization with an anti-IL-23p19 antibody appeared to be less immunosuppressive than the neutralization of both IL-23 and IL-12 with an anti-IL-12/23p40 antibody. From the nonclinical data it appears that the infection risk associated with IL-23 neutralization is less than that associated with IL-12+IL-23 neutralization. However, IL-23 does play a role in host defense and anti-IL-23p19 treatment may still impose an infection risk. The relevance of various animal models, especially the knockout models, to humans is not clear. The final assessment of infection risk will be conducted based on the results of clinical trials.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary Pharmacology</head><p>No specific secondary pharmacology studies were conducted with tildrakizumab. The potential for off-target binding was assessed in tissue cross-reactivity studies described in Section 5.5.5.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Pharmacology</head><p>No stand-alone safety pharmacology studies were conducted with tildrakizumab. The evaluation of safety pharmacology endpoints was included in the repeat dose toxicity studies in monkeys. Mouse After a single IV dose of fluoroprobe-labeled tildrakizumab (5.8 mg/kg), its distribution to organs was limited and characteristic of normal IgGs. Tissue-to-blood ratios were below 0.5 at all time points, indicating no substantial tissue uptake or accumulation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ADME/PK</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Type of Study</head><p>Major Findings Pre-and postnatal development study of MK-3222 administered by SC injection to pregnant cynomolgus monkeys <ref type="bibr">(Study# 20022343)</ref> Monkey Tildrakizumab crossed the placenta. The infant-to-dam ratios for mean tildrakizumab serum concentrations ranged from 0.963 to 0.996 on postpartum day (PPD) 7 (see Section 5.5.4).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Excretion</head><p>Pre-and postnatal development study of MK-3222 administered by SC injection to pregnant cynomolgus monkeys <ref type="bibr">(Study# 20022343)</ref> Monkey Tildrakizumab excretion in breast milk was minimal. The mean tildrakizumab concentrations in milk were approximately 0.09 -0.2% of that in serum on PPD 28 and 91 (see Section 5.5.4). TK data from general toxicology studies 3-month IV and SC toxicity and TK study of SCH 900222 in cynomolgus monkeys with a six-month postdose period (Study# 07184) 9-month SC injection toxicity and TK study with SCH 900222 in cynomolgus monkeys with a 4-month recovery phase (Study# 6377-625) Monkey (biweekly doses for 3 months) T1/2: 17.9-21.0 days for SC dosing, 17.7 days for IV dosing AUC0-14 day (following the 7 th dose, Days 84-98, sex combined):</p><p>40 mg/kg SC: 14100 g day/ml 140 mg/kg SC: 40500 g day/ml 140 mg/kg IV: 47200 g day/ml Accumulation: 2-2.6-fold comparing AUC after 7 th dose to AUC after 1 st dose Dose proportionality: The AUC increase was slightly less than dose proportional Anti-tildrakizumab antibody was only detected in one animal dosed with 140 mg/kg IV.</p><p>Monkey (biweekly doses for 9 months) AUC0-14 day [mean of dosing intervals 13 (Days 169-183) and 19 (Days 253-267) as they were similar, sex combined]:</p><p>10 mg/kg SC: 3290 g day/ml 30 mg/kg SC: 9250 g day/ml 100 mg/kg SC: 27500 g day/ml Accumulation: 2.69-2.95-fold comparing mean AUC of dosing intervals 13 and 19 to AUC of dosing interval 1 Dose proportionality: The AUC increase was approximately dose proportional Anti-tildrakizumab antibody was not detected.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TK data from reproductive toxicology studies</head><p>Embryofetal developmental toxicity and TK study of SCH 900222 administered subcutaneously in pregnant cynomolgus monkeys (Study# SNBL.120.06)</p><p>Pre-and postnatal development study of MK-3222 administered by SC injection to pregnant cynomolgus monkeys <ref type="bibr">(Study# 20022343)</ref> Maternal Monkey (biweekly doses during gestation days 20-118) AUC0-14 day (gestation day 118): 10 mg/kg SC: 1720 g day/ml 100 mg/kg SC: 16300 g day/ml 300 mg/kg SC: 48500 g day/ml</p><p>Maternal Monkey (biweekly doses from gestation day 50 to parturition) AUC0-336 hr (gestation day 120): 10 mg/kg SC: 47500 g hr/ml (1980 g day/ml) 100 mg/kg SC: 434000 g hr/ml (18080 g day/ml)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Toxicology</head><p>Reference ID: 4233639</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>General Toxicology</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 1</head><p>Three-month intravenous and subcutaneous toxicity and toxicokinetic study of SCH 900222 in cynomolgus monkeys with a six-month post-dose period (Study# 07184) SC doses of 0 (vehicle: 10 mM citrate, 7% sucrose, 0.02% tween, pH 5.5), 40, and 140 mg/kg/dose and IV doses of 140 mg/kg/dose tildrakizumab were administered to cynomolgus monkeys (6/sex/group including recovery animals, 29 to 53 months old at study initiation) once every two weeks for a total of 7 or 8 doses. Three monkeys/sex/group were sacrificed during Week 15 (receiving 8 doses). The remaining monkeys were sacrificed during Week 40 after a 6-month recovery period (receiving 7 doses).</p><p>There were no significant treatment-related adverse effects on mortality, clinical observations, body weight, food consumption, hematology, clinical chemistry, urinalysis, ECG, gross pathology, organ weights, or histopathology, either at the end of treatment or at the end of recovery period. ECG examination included heart rate, waveform magnitude and morphology, RR, PR, QRS, QT and QT c intervals. At the end of treatment, some minor to moderate changes in relative organ weights were noted in adrenal gland, thymus, and spleen, when compared with control. As there were no correlated histopathology findings and such changes were not seen after the recovery period, these findings were not considered significantly adverse.</p><p>The NOAEL was identified as the high dose, 140 mg/kg/dose, administered by IV or SC injection, once every 2 weeks for 3 months. See <ref type="table" target="#tab_18">Table 7</ref> for TK information.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study 2 Nine-month subcutaneous injection toxicity and toxicokinetic study with SCH 900222 in cynomolgus monkeys with a 4-month recovery phase (Study# 6377-625)</head><p>SC doses of 0 (vehicle: same as in Study 1), 10, 30 and 100 mg/kg/dose tildrakizumab were administered to cynomolgus monkeys (4/sex/group, 25-28 months old at study initiation) once every two weeks for 9 months (20 doses in total), followed by a 4-month recovery period (2/sex/group).</p><p>There were no significant treatment-related adverse effects on mortality, clinical observations, body weight, food consumption, physical examination, ophthalmology, ECG, blood pressure, hematology, clinical chemistry, urinalysis, menstrual cycle or hormone analysis for females (estradiol and progesterone), gross pathology, organ weights, or histopathology, either at the end of treatment or at the end of recovery period. Minimal to slight perivascular mononuclear infiltrates was observed at the injection sites microscopically in all test article-treated groups at the dosing phase necropsy. There was no clear dose relationship and such finding was not noted at the recovery necropsy. This finding was considered a general response to the injection of a foreign protein and was not considered significantly adverse.</p><p>The NOAEL was identified as the high dose, 100 mg/kg/dose, once every 2 weeks for 9 months. See <ref type="table" target="#tab_18">Table 7</ref> for TK information.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Genetic Toxicology</head><p>Genetic toxicology studies were not needed to support the development of tildrakizumab, per the ICH S6(R1) guidance.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Carcinogenicity</head><p>Conventional rodent carcinogenicity studies were not conducted for the evaluation of the carcinogenic potential of tildrakizumab, as rodents are not pharmacologically relevant species. The applicant provided a weight-of-evidence analysis of available information mainly from published literature. A similar carcinogenic risk assessment was previously submitted to IND 101389 and reviewed by the Executive CAC of CDER on 03/20/2012.</p><p>The weight-of-evidence analysis included studies on the role of IL-23 or IL-23 receptor in cancer, effects of IL-23 or dual IL-12 and IL-23 blockade in various tumor models (including tumor induction models, tumor transplantation models, and tumor metastases models), studies in mice using tildrakizumab or SCH 900598 (the mouse surrogate antibody), studies using genetically-modified mice deficient in IL-23p19, IL-12p35, or IL-12/23p40, influence of IL-23 and IL-12 on photo-carcinogenesis, clinical observations with IL-12 and IL-23 inhibitors, and human genetic analysis.</p><p>The results from studies using genetically-modified mice and using antibodies to block IL-23 and/or IL-12 indicated that blockade of IL-12 and IL-23 had very different effects on tumorigenicity. The nonclinical information does not suggest an increased carcinogenic risk associated with the blockade of IL-23 alone by an anti-IL-23p19 antibody like tildrakizumab. However, the relevance of various animal models to humans is unknown.</p><p>No additional nonclinical studies are recommended to evaluate the carcinogenic potential of tildrakizumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Reproductive and Developmental Toxicology</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fertility and Early Embryonic Development</head><p>Per the ICH S6(R1) guidance, as nonhuman primates (NHPs) are the only relevant species, the potential for effects on male and female fertility can be assessed by examination of reproductive tract in repeat dose toxicity studies of at least 3 months duration using sexually mature NHPs. The applicant provided the number of sexually mature females and sexually mature/peripubertal males in the 3-month and 9-month repeat dose monkey studies in the table below (copied from submission). No tildrakizumab-related effects on hormone parameters (estrogen and progesterone) or histological findings in reproductive organs were noted in sexually mature monkeys in the repeat dose toxicity studies described in Section 5.5.1. It would be preferable if more sexually mature males were evaluated, especially in the 9-month study. However, considering that there were no histopathological findings in male reproductive organs that could elicit a concern, the evaluation on both male and female fertility is acceptable. The NOAEL for fertility was identified as 140 mg/kg/dose, the high dose tested in the 3-month toxicity study. See SC doses of 0 (vehicle: same as in Study 1), 10, 100 and 300 mg/kg/dose tildrakizumab were administered to pregnant cynomolgus monkeys (12 females/group) once every 2 weeks, during gestation day (GD) 20-118 (comprising the period of organogenesis and the second and third trimesters). Cesarean section was conducted on GD 140 (Â± 3 days). Necropsies were not conducted on maternal animals. All fetuses were necropsied and examined for macroscopic observation.</p><p>There were no significant treatment-related adverse effects on mortality, clinical observations, body weight, or food consumption in maternal animals. There were no test article-related effects on placenta weight or placenta observations. All fetuses retrieved by scheduled cesarean section were alive. There were no test articlerelated effects on fetal weight, external measurements, or fetal sex ratio. No external abnormalities were noted in any fetus. There were no test article-related effects on fetal organ weight. There were no test article-related fetal visceral findings or fetal skeletal findings.</p><p>No significant maternal toxicity or embryofetal toxicity was noted. The NOAEL for both maternal toxicity and embryofetal toxicity was identified as the high dose, 300 mg/kg/dose, once every 2 weeks during GD 20-118. See <ref type="table" target="#tab_18">Table 7</ref> for TK information for maternal monkeys. In addition, tildrakizumab crossed placenta during pregnancy. At the time of cesarean section, tildrakizumab was detected in fetal serum (0.6 -0.8 fetal/dam ratio). SC doses of 0 (vehicle: same as in Study 1), 10 and 100 mg/kg/dose tildrakizumab were administered to pregnant cynomolgus monkeys (15 females/group) once every 2 weeks, from GD 50 to parturition (for a maximum of 9 total doses). Postnatal development was evaluated for 6 months after birth.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prenatal and Postnatal Development</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>F0 Maternal Responses:</head><p>A low dose female was found dead at delivery on GD 155, likely due to birthing difficulties (extensive blood loss from marked transmural hemorrhage of the uterus). There were no significant treatment-related adverse effects on clinical observations, body weight, or food consumption in maternal animals.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>F1 Litter Responses:</head><p>The numbers of fetal losses (including abortions and stillbirths) were 3 in the control group, 3 in the low dose group and 1 in the high dose group, all occurring in the third trimester. The fetal loss rate was within the historical control range for the testing facility (7-29%). A total of 11 BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 58 infants in the control group, 12 infants in the low dose group, and 13 infants in the high dose group were delivered by natural birth; and 1 control infant and 1 high dose infant were delivered by C-section. The gestation length at delivery was comparable between the control and dose groups.</p><p>Seven infants died or were euthanized within 15 days of age: 1/12 (8%) in the control group, 2/12 (17%) in the low dose group, and 4/14 (29%) in the high dose group. In 5 of the 7 cases, the cause of infant death was related to lack of maternal care. While the overall fetal/infant losses were within the historical control range, the deaths of 2 high dose infants (found dead on birth day 12 and 15) were considered as possibly related to tildrakizumab treatment. At necropsy, generalized yellowing of the skin, mucous membranes and sclera consistent with icterus was observed in both infants. Histopathological examination showed diffuse degeneration/necrosis of hepatocytes and disorganization and collapse of the liver parenchyma. In kidney, very slight vacuolation or slight necrosis were noted in tubular epithelial cells. Eosinophilic intranuclear inclusion bodies were observed in the renal cortical tubular epithelial cells. Very slight or marked lymphoid depletion in the thymus and moderate depletion of the spleen were also noted. These histopathological findings suggested viral infection.</p><p>For infants surviving through 6 months of age to scheduled necropsy, no significant treatmentrelated adverse findings were noted in any of the parameters examined, including clinical observations, physical examinations, body weights, morphometric measurements, external assessments, neurobehavioral evaluations, clinical pathology, lymphocyte phenotyping evaluation (flow cytometry), T-cell dependent antibody response (TDAR), or evaluation at necropsy (organ weights, gross pathology and histopathology evaluation).</p><p>The NOAEL for maternal toxicity was identified as the high dose, 100 mg/kg/dose once every two weeks. Considering the relationship to tildrakizumab could not be ruled out for the two infant deaths possibly due to viral infection at high dose, the NOAEL for developmental toxicity was identified as the low dose, 10 mg/kg/dose once every two weeks administered to maternal animals. See <ref type="table" target="#tab_18">Table 7</ref> for TK information for maternal monkeys.</p><p>In addition, tildrakizumab milk/maternal monkey serum concentration ratios are shown in the table below (copied from submission). The tildrakizumab excretion in breast milk was minimal. Tildrakizumab infant/maternal monkey serum concentration ratios are shown in the table below (copied from submission). The TK data showed that tildrakizumab crossed placenta during pregnancy. Anti-tildrakizumab antibodies were observed in one maternal monkey at low dose and one maternal monkey at high dose. After parturition, anti-tildrakizumab antibodies were observed in 5 maternal monkeys at low dose and 2 maternal monkeys at high dose. Antitildrakizumab antibodies were not observed in infants. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other Toxicology Studies</head><p>A local tolerance study was conducted in New Zealand White rabbits. The local tolerance of tildrakizumab was assessed in female rabbits by IV injection, , as well as routes of potential misapplication, including intramuscular (IM) injection, intra-arterial (IA) injection, and paravenous (PV) injection. In Group 1, a single IV dose of 0.5 ml test article (tildrakizumab or saline) was injected into the marginal ear vein and a single IM dose of 0.5 ml test article was injected into the sacrospinalis muscle (dorsal back). In Group 2, a single IA dose of 0.5 ml test article was injected into the medial ear artery and a single PV dose of 0.2 ml test article was injected into area adjacent to the marginal ear vein. There were no signs of edema or erythema in any rabbit. There were no significant test articlerelated macroscopic or microscopic findings.</p><p>The cross-reactivity of tildrakizumab was evaluated with cryosections of normal cynomolgus monkey tissues and normal human tissues.</p><p>In monkey tissues, tildrakizumab staining was observed in cytoplasm and/or cytoplasmic granules of intrinsic and/or vascular smooth muscle in adrenal, small intestine, kidney, liver, lymph node, prostate, thyroid, urinary bladder, and uterus; epithelium in adrenal (cortex), small intestine (mucosa), stomach (mucosa, mucus neck cells), pancreas (acini, ducts), prostate (ducts), salivary gland (glands), and skin (sweat glands); mononuclear cells in spleen. Tildrakizumab staining of intraglandular proteinaceous material was observed in prostate.</p><p>Reference ID: 4233639</p><formula xml:id="formula_2">(b) (4) (b) (4)</formula><p>In human tissues, tildrakizumab staining was observed in cytoplasm and/or cytoplasmic granules of intrinsic and/or vascular smooth muscle in colon, stomach, liver, fallopian tube, pancreas, peripheral nerve, placenta, prostate, testis, and urinary bladder; epithelium in eye (conjunctiva), esophagus (glands, submucosa), small intestine (mucosa), stomach (mucosa, mucus neck cells), pancreas (acini), and salivary gland (acini); myocytes in heart; and round cells in skin.</p><p>IL-23 expression and/or synthesis have not been reported for the tissue elements stained with tildrakizumab in this study, with the exception of mononuclear cells (monkey). The observed staining of these tissue elements might represent either previously unrecognized sites of IL-23p19 expression or true tissue cross-reactivity. However, with the exception of the proteinaceous material in prostate (monkey), the staining observed in this study was generally cytoplasmic in nature, and it is unlikely that cytoplasm and cytoplasmic structures would be accessible to the test article in vivo, which may suggest minimal toxicological consequence. The toxicological significance of the staining of proteinaceous material in the prostate is unknown.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Juvenile Animal Toxicology Studies</head><p>No juvenile animal toxicology studies were conducted with tildrakizumab. The applicant previously submitted a pediatric study plan to IND 101389, . Based on animal age and study findings in the 3month and 9-month toxicity studies and the pre-and postnatal developmental toxicity study, it has been determined that no additional juvenile animal toxicology studies are needed to support the proposed pediatric population.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Labeling</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommended revisions to the nonclinical portions of labelling</head><p>Revisions to the applicant's proposed wording for the nonclinical and related sections of the labeling are provided below. It is recommended that the underlined wording be inserted into and the strikethrough wording be deleted from the ILUMYA label proposed by the applicant. The subheadings in Section 8.1 should be in underlined format which has been proposed by the applicant. Refer to the clinical review for recommended revisions to the clinical portions of labeling in Section 8. A clean copy of the recommended nonclinical portions of labeling is provided in Section 13.4 as an appendix to this review.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HIGHLIGHTS OF PRESCRIBING INFORMATION INDICATIONS AND USAGE</head><p>ILUMYA is an interleukin-23 antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.1">Pregnancy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk Summary</head><p>Reference ID: 4233639</p><formula xml:id="formula_3">(b) (4) (b) (4) (b) (4)</formula><p>monkeys at 100 mg/kg dose ( times the MRHD based on AUC comparison). The clinical significance of these nonclinical findings is unknown. No tildrakizumab-related adverse effects were noted in the remaining infants from birth through 6 months of age.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8.2">Lactation</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk Summary</head><p>Tildrakizumab was detected in breast milk of monkeys [see Data]. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ILUMYA and any potential adverse effects on the breastfed child from ILUMYA or from the underlying maternal condition.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animal Data</head><p>Very low levels of tildrakizumab were detected in breast milk of monkeys in the pre-and postnatal developmental study described in 8.1. The mean tildrakizumab concentrations in milk were approximately 0.09 -0.2% of that in serum on postpartum days 28 and 91.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="12.1">Mechanism of Action</head><p>Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.1">Carcinogenesis, Mutagenesis, Impairment of Fertility</head><p>Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of ILUMYA.</p><p>No effects on fertility parameters were observed in male or female cynomolgus monkeys that were administered tildrakizumab at subcutaneous or intravenous doses up to 140 mg/kg once every two weeks for 3 months ( times the MRHD, respectively, based on AUC comparison). The monkeys were not mated to evaluate fertility.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6">Clinical Pharmacology</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Executive Summary</head><p>Tildrakizumab (also known as MK-3222 and SCH 900222) is a humanized immunoglobulin G1/kappa (IgG1/ ) monoclonal antibody that binds to the p19 subunit of IL-23. The applicant evaluated 100 mg and 200 mg tildrakizumab doses in two Phase 3 trials. Tildrakizumab was administered by SC injection at Weeks 0, 4, and every 12 weeks thereafter. The applicant conducted a Phase 2 dose-ranging trial to support the dose selection for Phase 3 trials. The applicant additionally submitted the results of five Phase 1 trials in healthy subjects and subjects with psoriasis to support clinical pharmacology information of tildrakizumab.</p><p>The key review findings with specific recommendations and comments are summarized in <ref type="table" target="#tab_0">Table  12</ref>: </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review Issues Recommendations and Comments</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pivotal or supportive evidence of effectiveness</head><p>The efficacy of tildrakizumab for the treatment of moderate to severe psoriasis is established in two Phase 3 trials (P010 and P011).</p><p>Dose-response and exposure-response analysis for efficacy based on data from Phase 2 dose ranging study (P05495) and Phase 3 trials provide supportive evidence for effectiveness.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>General dosing instructions</head><p>The efficacy data from Phase 3 trials overall support an evidence that the proposed tildrakizumab 100 mg dosage regimen, administered by SC injection at Weeks 0, 4, and every 12 weeks thereafter, is acceptable.</p><p>We do not recommend including an option of a dose of 200 mg because the available data did not show a preferential treatment benefit with 200 mg dose in any particular subsets of patients including subjects weighing &gt;90 kg.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dosing in patient subgroups (intrinsic and extrinsic factors)</head><p>We do not recommend dose individualization based on intrinsic or extrinsic factors.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Drug interactions</head><p>The pharmacokinetic results of clinical drug interaction study (P009) suggest that the potential for a clinically relevant drug interaction for drugs metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and</p><p>Reference ID: 4233639</p><formula xml:id="formula_4">(b) (4)</formula><p>CYP3A4 may be low. The greatest exposure change was observed for dextromethorphan (CYP2D6 substrate), where the AUCinf was increased by 20% following tildrakizumab treatment in subjects with moderate to severe psoriasis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunogenicity</head><p>Neutralizing antibodies to tildrakizumab were associated with reduced drug concentrations and reduced efficacy.</p><p>Subjects who developed antibodies to tildrakizumab were more likely to experience hypersensitivity or injection-site reaction compared to subjects who were antibody negative.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bridge between the tobe-marketed and clinical trial formulations</head><p>The to-be-marketed formulation was used in Phase 3 trials; therefore, there is no need to bridge the to-be-marketed formulation to the clinical trial formulation.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations</head><p>From a Clinical Pharmacology's standpoint, the BLA is acceptable to support the approval of ILUMYA (tildrakizumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy, provided that the applicant and the Agency come to a mutually satisfactory agreement regarding the labeling.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Post-Marketing Requirements and Commitments</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>None</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary of Clinical Pharmacology Assessment</head><p>Pharmacology and Clinical Pharmacokinetics</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.2.1.1">Mechanism of action and pharmacodynamics</head><p>Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines. The pharmacodynamic (PD) effect of tildrakizumab in subjects with psoriasis has not been characterized. The absolute bioavailability of tildrakizumab was estimated to be 73-80% following SC injection. The geometric mean (CV%) systemic clearance was 0.32 L/day (38%) and the half-life was approximately 23 days (23%) in subjects with psoriasis. The geometric mean (CV%) volume of distribution is 10.8 L (24%) in subjects with psoriasis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.2.1.2.">Pharmacokinetics of tildrakizumab</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.2.1.3.">Drug interactions</head><p>The applicant conducted clinical drug interaction Study P009 to evaluate the effect of tildrakizumab, 200 mg administered SC at Weeks 0 and 4, on the PK of caffeine (metabolized by CYP1A2), warfarin (metabolized by CYP2C9), omeprazole (metabolized by CYP2C19), dextromethorphan (metabolized by CYP2D6), and midazolam (metabolized by CYP3A4) coadministered as a cocktail in subjects with moderate to severe psoriasis. The PK results suggest that the potential for a clinically relevant drug interaction for drugs metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 may be low. The greatest exposure change was observed for dextromethorphan, where the AUC inf was increased by 20%.</p><p>Overall, the drug interaction study results support that upon initiation or discontinuation of tildrakizumab in patients who are receiving concomitant CYP2D6 substrates, particularly those with a narrow therapeutic index, clinicians may consider monitoring for therapeutic effect or drug concentration and consider dosage adjustment as needed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.2.1.4">Immunogenicity</head><p>Up to Week 64, approximately 6.8% of subjects treated with tildrakizumab at the proposed 100 mg dosage regimen developed antibodies to tildrakizumab. Of the subjects who developed antibodies to tildrakizumab, approximately 40% had antibodies that were classified as neutralizing antibodies (NAbs). Neutralizing antibodies to tildrakizumab were associated with reduced drug concentrations and reduced efficacy. Subjects who developed antibodies to tildrakizumab were more likely to experience hypersensitivity or injection-site reactions compared to subjects who were antibody negative. See section 13.5.3 in Clinical Pharmacology Appendices for detailed information.</p><p>Dosing and Therapeutic Individualization</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.2.2.1.">General dosing</head><p>The data from Phase 3 trials and the exposure-response analysis results overall support that the proposed tildrakizumab 100 mg dosage regimen, administered by SC injection at Weeks 0, 4, and every 12 weeks thereafter, is acceptable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.2.2.2.">Therapeutic individualization</head><p>Therapeutic individualization based on intrinsic factors is not necessary. Population PK analysis identified body weight as a significant covariate on tildrakizumab PK; tildrakizumab concentration was lower in subjects with higher body weight. Body weight also showed an impact on efficacy; subjects with higher body weight were associated with a lower response rate than subjects with lower body weight at the same dose (see section 6.3.2.3). However, dose adjustment based on body weight is not necessary based on the available efficacy data in Phase 3 trials. Exposure-response analysis further showed that there is no preferential treatment benefit with 200 mg dose in any particular subset of patients including subjects with high body weight.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outstanding Issues</head><p>There are no outstanding issues that would preclude the approval of tildrakizumab from a Clinical Pharmacology's perspective.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comprehensive Clinical Pharmacology Review General Pharmacology and Pharmacokinetic Characteristics</head><p>A summary of the general clinical pharmacology, pharmacokinetics and immunogenicity of tildrakizumab is provided in <ref type="table" target="#tab_0">Table 13</ref>. Mechanism of action Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacodynamics</head><p>The pharmacodynamic effect of tildrakizumab in subjects with psoriasis has not been characterized.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>General Information</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bioanalysis</head><p>Tildrakizumab concentrations in human serum were quantified using a validated electrochemiluminescence (ECL)-based bridging immunoassay. The sensitivity of the ECL assay was 3.13 ng/mL.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PK model</head><p>A one-compartment linear model with first-order absorption and first-order elimination following SC administration adequately described the PK of tildrakizumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Healthy subjects vs subjects with psoriasis</head><p>Healthy subjects showed approximately 31% higher exposure compared to subjects with psoriasis after accounting for body weight in population PK analysis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Drug concentrations at steady state</head><p>Steady-state concentrations were achieved by Week 16 following SC administration of tildrakizumab at Weeks 0, 4, and every 12 weeks thereafter. At the proposed100 mg dose at Week 16, the mean (Â±SD) steady-state trough concentrations were 1.22Â±0.94 mcg/mL and 1.47Â±1.12 mcg/mL in the two Phase 3 trials. At the 200 mg dose at Week 16, the mean (Â±SD) steadystate trough concentrations were 2.25Â±1.88 mcg/mL and 2.99Â±2.16 mcg/mL in the two Phase 3 trials.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose linearity</head><p>Tildrakizumab exhibited dose proportional PK in subjects with plaque psoriasis over a dose range from 50 mg to 200 mg following SC administration.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Body weight</head><p>Tildrakizumab concentrations were lower in subjects with higher body weight. Population PK analysis also identified body weight as a significant covariate affecting serum tildrakizumab concentrations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Renal or Hepatic impairment</head><p>No formal clinical trial was conducted to evaluate the effect of hepatic or renal impairment on the pharmacokinetics of tildrakizumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ADME</head><p>Reference ID: 4233639</p><p>Absorption Following a single SC dose of 200 mg in subjects with psoriasis, tildrakizumab reached geometric mean (CV%) peak concentration (Cmax) of 14.8 mcg/mL (36.5%) by approximately 6 days. Following SC administration of tildrakizumab at Weeks 0 and 4, and every 12 weeks thereafter, the geometric mean (CV%) steady-state Cmax were 8.1 mcg/mL (34%) and 16.3 mcg/mL (33%) at the 100 mg and 200 mg doses, respectively. The absolute bioavailability of tildrakizumab was estimated to be 73-80% following SC injection.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Distribution</head><p>The geometric mean (CV%) volume of distribution is 10.8 L (24%) in subjects with psoriasis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Elimination</head><p>The geometric mean (CV%) systemic clearance was 0.32 L/day (38%) and the half-life was approximately 23 days (23%) in subjects with psoriasis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Metabolism</head><p>The metabolic pathway of tildrakizumab has not been characterized. As a humanized IgG1/k monoclonal antibody, tildrakizumab is expected to be degraded into small peptides and amino acids via catabolic pathways in a manner similar to endogenous IgG.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Excretion</head><p>The renal excretion of tildrakizumab has not been studied. Tildrakizumab is a human monoclonal antibody with a molecular weight of approximately 147 kDa; therefore, intact tildrakizumab is unlikely to be filtered by kidney or excreted in urine.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunogenicity</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Incidence</head><p>In the combined Phase 3 trials P010 and P011, approximately 4.3% (26/611) and 3.6% (22/614) of subjects had treatment-emergent anti-drug antibodies (TE-ADA) to tildrakizumab following the initial 12 weeks treatment with the 100 mg or 200 mg dosage regimens, respectively. The TE-ADA incidences were 6.8% (25/369) and 8.8% (29/329) following treatment up to 64 weeks for the 100 mg or 200 mg dosage regimens, respectively. The incidences for neutralizing antibodies (NAb) among TE-ADA+ subjects were 40.0% (10/25) and 37.9% (11/29) for the 100 mg or 200 mg dosage regimens through Week 64, respectively.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impact on PK</head><p>The PK results showed that subjects who developed TE-ADA with neutralizing activities were associated with lower tildrakizumab concentrations compared with ADA negative subjects.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impact on efficacy</head><p>The development of TE-ADA with neutralizing activities was associated with reduced efficacy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Impact on safety</head><p>Subjects who developed antibodies to tildrakizumab were more likely to experience hypersensitivity or injection-site reactions compared to subjects who were antibody negative.</p><p>Clinical Pharmacology Questions</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6.3.2.1">Does the clinical pharmacology information provide supportive evidence of effectiveness?</head><p>Section 7 of this multi-discipline review for details of the study design and efficacy/safety results of the Phase 3 trials.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dose-response in Phase 2 (Study P05495):</head><p>The Phase 2 efficacy results for PASI 75 and PGA of "cleared" or "minimal" demonstrated a clear dose-response relationship and support the selection of the 100 mg and 200 mg doses for Phase 3 <ref type="figure" target="#fig_3">(Figure 1</ref>).   <ref type="table" target="#tab_0">Table 11-11 and Table 11-</ref> BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 74 (GMRs) for Cmax ranged from 0.96 to 1.17 and the upper bounds and lower bounds of the 90% CIs (confidence intervals) for the GMRs were all within the range of [0.85, 1.43]. The geometric mean ratios for AUC inf ranged from 0.96 to 1.20 and the upper bounds and lower bounds of the 90% CIs (confidence intervals) for the GMRs were all within the range of [0.77, 1.45]. In general, the PK results suggest that the potential for a clinically relevant drug interaction for drugs metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 may be low (except for narrow therapeutic index drugs). The greatest exposure change was observed for dextromethorphan (CYP2D6 substrate), where the AUC inf was increased by 20%.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exposure-response in pooled</head><p>Overall, the results support that upon initiation or discontinuation of tildrakizumab in patients who are receiving concomitant CYP2D6 substrates, particularly those with a narrow therapeutic index, clinicians may consider monitoring for therapeutic effect or drug concentration and consider dosage adjustment as needed. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sources of Clinical Data and Review Strategy</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table of Clinical Studies</head><p>The development program for tildrakizumab included 9 clinical trials. The applicant completed 6 Phase 1 trials (P05382, P05661, P05776, P05839, P06306, and P009), one Phase 2 trial (P05495), and two Phase 3 trials (P010 and P011). The primary data used to support the safety and efficacy of tildrakizumab for the treatment of moderate to severe plaque psoriasis in adults was provided by the Phase 2 and Phase 3 trials. In addition, long term safety was supported by integrated data from the ongoing Phase 3 extension trials (P010 and P011) with a cutoff date of April 15, 2016. The data associated with different doses, dosing regimens, routes of administration, study populations and indications were considered supportive of the conclusions of the primary analyses.</p><p>Primary trials in the target population and safety trial in 59 healthy Japanese, Chinese, and White subjects to determine the influence of race and ethnic origin on the PK Subjects with moderate-to-severe plaque psoriasis P05382 (P001): randomized, double-blind, placebo-controlled, ascending, multiple IV dose trial (0.05, 0.1, 0.5, 3, 5, 10 mg/kg IV vs placebo) in 77 subjects with moderate-to-severe psoriasis.</p><p>P009: randomized, fixed-sequence, 2-period, parallel group, open-label, multiple-dose trial to assess effects of tildrakizumab on cytochrome P450 enzymes (via CYP450 cocktail) and relative bioavailability using a PFS compared with PFS housed in an autoinjector in 20 subjects with moderate-to-severe psoriasis.</p><p>Crohn's disease P05839 (P006): Phase 1 PK and safety trial of IV administration (0.5, 3, 10 mg/kg IV vs placebo) of tildrakizumab in 24 subjects with Crohn's disease <ref type="table" target="#tab_0">Table 19</ref> provides a summary of all trials pertinent to the evaluation of the efficacy and safety of tildrakizumab for the treatment of moderate to severe plaque psoriasis. For a discussion of the pharmacokinetic trials, the reader may refer to Section 6 of this review).</p><p>Reference ID: 4233639 </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review Strategy</head><p>The sources of data used for the evaluation of the efficacy and safety of tildrakizumab for the proposed indication included final study reports submitted by the applicant, datasets [Study Data Tabulation Model (SDTM) and Analysis Data Model (ADaM)] and literature references. This application was submitted in eCTD format and entirely electronic. The electronic submission including protocols, statistical analysis plans (SAPs), clinical study reports, SAS transport datasets in legacy, Study Data Tabulation Modal (SDTM), and Analysis Data Model (ADaM) format were in the following network path:</p><p>Original submission: \\cdsesub5\EVSPROD\BLA761067\0000\m5\datasets</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data and Analysis Quality</head><p>In collaboration with the Office of Computational Science (OCS) (JumpStart Data Fitness Consult Response dated 5/8/2017), the statistical and clinical teams evaluated the data fitness. This included an assessment of the compatibility of the data with the review tools and data quality metrics such as the following:</p><p>-Availability of appropriate variables -Variables populated by expected data points -Appropriate use of standard terminology -Data well described by metadata.</p><p>In general, the data submitted by the applicant to support the efficacy and safety of tildrakizumab for the proposed indication appeared adequate. OCS findings included the following: </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of Relevant Individual Trials Used to Support Efficacy Study Design and Endpoints</head><p>The applicant conducted two pivotal Phase 3 trials (Trials P010 and P011). For both trials, the key inclusion criteria that defined the study population were identical and are as follows: Male or female 18 years of age or older Diagnosis of plaque psoriasis for at least 6 months Candidates for either systemic therapy or phototherapy Have moderate to severe plaque psoriasis at baseline defined by: o Physician's Global Assessment (PGA) score of at least 3 (moderate), see <ref type="figure" target="#fig_3">Figure 16</ref> on Section 13.3 in for details on the PGA scale o Psoriasis Area and Severity Index (PASI) 12, see <ref type="figure" target="#fig_3">Figure 17</ref> in Section 13.3 for details on the calculation of PASI o Body Surface Area (BSA) involvement 10% <ref type="figure">Figure 5</ref> and <ref type="figure">Figure 6</ref> present the study design schematics for Trials P010 and P011, respectively. Both were randomized, multicenter, double-blind, placebo-controlled, parallelgroup Phase 3 trials evaluating the safety and efficacy of two doses (100 and 200 mg) of tildrakizumab for the treatment of moderate to severe plaque psoriasis. Trial P011 also included an active-comparator (etanercept). For Trial P010, the randomization was conducted by region (i.e., North America, EU, and Japan) and stratified by baseline weight ( 90 kg and &gt;90 kg), prior exposure to biologics therapy for psoriasis (Yes/No), and baseline psoriatic arthritis (Yes/No; only for subjects in Japan). For Trial P011, the randomization was conducted by region and stratified by baseline weight ( 90 kg and &gt;90 kg), prior exposure to biologics therapy for psoriasis (Yes/No), and failure to respond to at least one traditional systemic medication (Yes/No).</p><p>Trial P010 consisted of three parts, an optional long-term safety extension, and a follow-up period.</p><p>Part 1 (Weeks 0 to 12): the protocol specified randomizing approximately 750 subjects to one of the following treatment arms in a 2:2:1 ratio BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 85 Partial responders (50% PASI &lt; 75%) at Week 28 continued on 200 mg of tildrakizumab every 12 weeks (Q12W) through Week 64. Responders (PASI 75%) at Week 28 were re-randomized in a 1:1 ratio to either receive 200 mg of tildrakizumab Q12W through Week 64 or placebo Q4W till relapse (reduction in maximum PASI response by 50%). Once relapse occurred, subjects re-initiated 200 mg of tildrakizumab at the visit when the relapse occurred; subsequent dosing of tildrakizumab was given 4 weeks after treatment re-initiation, and Q12W thereafter through Week 64. o Subjects originally randomized to tildrakizumab 100 mg (Arm B):</p><p>Non-responders (PASI &lt; 50%) at Week 28 were discontinued. Partial responders (50% PASI &lt;75%) at Week 28 were re-randomized in a 1:1 ratio to receive either 200 or 100 mg of tildrakizumab Q12W through Week 64. Responders (PASI 75%) at Week 28 were re-randomized in a 1:1 ratio to receive either 100 mg of tildrakizumab Q12W or placebo Q4W till relapse. Once relapse occurred, subjects re-initiated 100 mg of tildrakizumab at the visit when the relapse occurred; subsequent dosing of tildrakizumab was given 4 weeks after treatment reinitiation, and Q12W thereafter through Week 64. o Subjects originally randomized to Placebo (Arm C):</p><p>Non-responders (PASI &lt; 50%) at Week 28 were discontinued. Responders and partial responders continued to receive tildrakizumab (200 or 100 mg) according to their re-randomized treatment assignment (Week 12) Q12W through Week 64. Subjects were evaluated at screening, baseline (Week 0) and <ref type="bibr">Weeks 4,</ref><ref type="bibr">8,</ref><ref type="bibr">12,</ref><ref type="bibr">16,</ref><ref type="bibr">22,</ref><ref type="bibr">28,</ref><ref type="bibr">32,</ref><ref type="bibr">36,</ref><ref type="bibr">40,</ref><ref type="bibr">44,</ref><ref type="bibr">48,</ref><ref type="bibr">52,</ref><ref type="bibr">56,</ref><ref type="bibr">60,</ref><ref type="bibr">and 64</ref>. Long-Term Safety Extension (Weeks 64 to 256): at the end of Part 3, subjects who were eligible may have entered the long-term extension study to assess the long-term safety/tolerability of tildrakizumab. Subjects who were not eligible or who opted not to enter the extension study entered a 20-week follow-up period. Subjects will receive 200 or 100 mg Q12W (the same treatment received at the time of completion of Part 3). Subjects received treatment in a double-blind manner until the base study (Parts 1, 2, and 3) was completed. Following database lock of the base study, subjects will receive study medication in an open-label manner for the remainder of the extension study.</p><p>Trial P011 consisted of three parts, an optional long-term safety extension, and a follow-up period.</p><p>Part 1 (Weeks 0 to 12): the protocol specified randomizing approximately 1050 subjects to one of the following treatment arms in a 2:2:1:2 ratio: Part 2 (Weeks 12 to 28): all subjects assigned to placebo in Part 1 were re-randomized at Week 12 in a 1:1 ratio to either tildrakizumab 200 mg or 100 mg. These subjects received their new treatment at Weeks 12, 16 and 28. Subjects in Arms A, B and D received placebo at Week 12 to maintain the blind. Subjects in Arms A and B received their assigned treatment (200 or 100 mg of tildrakizumab) at Week 16. Subjects in Arms D continued to receive etanercept 50 but with once weekly doses until Week 28. Subjects in Arms A, B, and C received placebo for etanercept once weekly from Week 12 through Week 28 to maintain the blind. Part 3 (Weeks 28 to 64): beginning at Week 28, treatment for all subjects was based on their level of response (i.e., improvement in PASI from baseline).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>o Subjects originally randomized to tildrakizumab 200 mg (Arm A):</head><p>Non-responders (PASI &lt; 50%) at Week 28 were discontinued. Partial responders (50% PASI &lt; 75%) at Week 28 continued on 200 mg of tildrakizumab Q12W through Week 52. Responders (PASI 75%) at Week 28 were re-randomized in a 1:1 ratio to either receive 200 or 100 mg of tildrakizumab Q12W through Week 52. o Subjects originally randomized to tildrakizumab 100 mg (Arm B):</p><p>Non-responders (PASI &lt; 50%) at Week 28 were discontinued. Partial responders (50% PASI &lt;75%) at Week 28 were re-randomized in a 1:1 ratio to receive either 200 or 100 mg of tildrakizumab Q12W through Week 52. Responders (PASI 75%) at Week 28 received 100 mg of tildrakizumab Q12W through Week 52. o Subjects originally randomized to Placebo (Arm C): subjects continued to receive tildrakizumab (200 or 100 mg) according to their re-randomized treatment assignment (Week 12) Q12W through Week 64. o Subjects originally randomized to Etanercept (Arm D):</p><p>Responders (PASI 75%) at Week 28 were discontinued. Non-responders (PASI &lt; 50%) and partial responders (50% PASI &lt;75%) at Week 28 were switched to 200 mg of tildrakizumab, receiving their first dose at Week 32, and additional doses at Weeks 36 and 48. o Additional doses of matching placebo (i.e., for tildrakizumab and etanercept) were administered as appropriate in order to maintain the study blinding. Subjects were evaluated at screening, baseline (Week 0) and <ref type="bibr">Weeks 4,</ref><ref type="bibr">8,</ref><ref type="bibr">12,</ref><ref type="bibr">16,</ref><ref type="bibr">22,</ref><ref type="bibr">28,</ref><ref type="bibr">32,</ref><ref type="bibr">36,</ref><ref type="bibr">40,</ref><ref type="bibr">46,</ref><ref type="bibr">and 52</ref>. Long-Term Safety Extension (Weeks 64 to 256): at the end of Part 3, subjects who were eligible may have entered the long-term extension study to assess the long-term safety/tolerability of tildrakizumab. Subjects who were not eligible or who opted not to enter the extension study entered a 20-week follow-up period. Subjects will receive 200 mg or 100 mg Q12W (the same treatment received at the time of completion of Part 3). Subjects received treatment in a double-blind manner until the base study (Parts 1, 2, and 3) was completed. Following database lock of the base study, subjects will receive study medication in an open-label manner for the remainder of the extension study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subject Disposition, Demographics and Baseline Disease Characteristics</head><p>Trial P010 enrolled and randomized a total of 772 subjects from 112 investigational sites. Trial P011 enrolled and randomized a total of 1090 subjects from 123 investigational sites. <ref type="table" target="#tab_29">Table 22</ref> presents the disposition of subjects during the first 12 weeks of Trials P010 and P011. The discontinuation rates for the two tildrakizumab arms were similar within the two trials. In both trials, the discontinuation rate was slightly higher in the placebo arm compared to the active treatment arms. The discontinuation rates were slightly higher in Trial P011 compared to Trial P010. The demographics for both trials are presented in <ref type="table" target="#tab_14">Table 23</ref>. The demographics were generally balanced across the treatment arms within each trial. Trial P010 had a higher percentage of subjects identify as Asian than Trial P011 (i.e., 25% in Trial P010 vs. 3% in Trial P011), which was primarily due to Trial P010 having investigational sites in Japan while Trial P011 did not have investigational sites in Japan. Trial P010 had a higher percentage of subjects from the United Stated than Trial P011 (i.e., 42% in Trial P010 vs. 28% in Trial P011). The percentage of subjects that had prior biologic therapy for psoriasis was higher in Trial P010 compared to Trial P011 (i.e., 23% in Trial P010 vs. 12% in Trial P011). <ref type="table" target="#tab_15">Table 24</ref> presents the baseline disease characteristics. For enrollment, subjects should have had a PGA score 3 (moderate), PASI score 12, and BSA involvement 10%, as these were specified as inclusion criteria in the protocols. For Trial P010, one subject had a baseline PGA score of 2 (mild) and a different subject had a baseline PASI score of 9. In addition, one subject in Trial P010 was randomized to placebo but discontinued from the trial prior to receiving study product; therefore, this subject was not included in the FAS. For Trial P011, a total of 53 subjects did not meet the key inclusion criteria related to disease severity: 36 subjects had a PGA score &lt; 3 (moderate), 13 subjects had a PASI score &lt; 12, 1 subject had a BSA &lt; 10%, 2 subjects had both a PGA score &lt; 3 (moderate) and a PASI score &lt; 12, and 1 subject had both a PGA score &lt; 3 (moderate) and a BSA &lt; 10%. In addition, 7 subjects had missing baseline PGA scores, 2 subjects had missing PASI scores and 9 subjects had missing BSA values. It should BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 92 be noted that subjects with missing baseline PGA and PASI scores were imputed as nonresponders for efficacy endpoints based on the PGA and PASI. BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 93  <ref type="formula">(18)</ref> 30 <ref type="formula">(17)</ref> 30 <ref type="formula">(17)</ref> 32 <ref type="formula">(17)</ref> 34 <ref type="formula">(18)</ref> 32 <ref type="formula">(17)</ref> 31 <ref type="formula">(15)</ref>   <ref type="table" target="#tab_33">Table 25</ref> presents the results for the co-primary efficacy endpoints at Week 12 for Trials P010 and P011. Both doses of tildrakizumab were statistically superior to placebo for both co-primary efficacy endpoints in both trials (p-values &lt; 0.001). The results for the FAS and PP populations were very similar. (1) Full Analysis Set (FAS): all randomized subjects who received at least one dose of study product. Missing data was imputed using non-responder imputation (NRI). Subjects with missing baseline value were also imputed using NRI.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results for the Co-Primary Efficacy Endpoints</head><p>(2) Per-Protocol (PP) population (see Section 7.2.2) (3) Response is defined as a PGA score of 0 or 1 with at least a 2-grade improvement from baseline. (4) Comparison against placebo. P-value based on a CMH test stratified by baseline weight ( 90 kg / &gt;90 kg) and prior exposure to biologic therapy for psoriasis (Yes/No). <ref type="table" target="#tab_34">Table 26</ref> presents the number of subjects with missing PGA and PASI data by week, treatment arm, and trial. Overall, the proportion of subjects with missing data was relatively low. In both trials, the proportion of subjects with missing data for Week 12 (i.e., primary efficacy timepoint) was slightly higher in the placebo arm compared to the two tildrakizumab arms. The proportion of subjects with missing data for Week 12 was slightly higher in Trial P011 compared to Trial P010. For both trials, the primary method for handling missing data specified in the protocols was nonresponder imputation (NRI). The protocols specified the following two sensitivity analyses for the handling of missing data: (i) impute missing data using the last observation carried forward (LOCF) approach and (ii) impute missing data using multiple imputation (MI). The statistical reviewer conducted an additional sensitivity analysis under the worst case scenario (i.e., missing data for tildrakizumab is imputed as non-responders and missing data for placebo is imputed as responders). <ref type="table" target="#tab_18">Table 27</ref> presents the results for the co-primary efficacy endpoints in both trials by the various imputation methods. For both trials, the results were very similar across the various imputation methods. In the extreme case (i.e., worst case scenario), tildrakizumab remained statistically superior to placebo for both co-primary efficacy endpoints in both trials (p-values &lt; 0.001). (1) Response is defined as a PGA score of 0 or 1 with at least a 2-grade improvement from baseline.</p><p>(2) Missing data imputed using the last observation carried forward (LOCF).</p><p>(3) Multiple Imputation (MI): missing data was imputed 10 times using a model with age, gender, race, region, body mass index (BMI), psoriatic arthritis, prior exposure to biologics therapy, baseline PASI, baseline PGA, and baseline BSA as factors in the model. The values displayed are the averages over the 10 imputed datasets. (4) Missing data for tildrakizumab is imputed as non-responders and missing data for placebo is imputed as responders. <ref type="table" target="#tab_19">Table 28</ref> presents the results for the secondary efficacy endpoints against placebo at Week 12 for Trials P010 and P011 in the FAS population. Both doses of tildrakizumab were statistically superior to placebo for both secondary efficacy endpoints in both trials (p-values &lt; 0.001). The response rates were very similar between the two doses of tildrakizumab for both secondary efficacy endpoints. The results in the PP population (not shown) were very similar to those in the FAS population.   <ref type="table" target="#tab_21">Table 29</ref>, the response rates for etanercept were generally similar between the two subgroups for all of the secondary efficacy endpoints except PASI 90 at Week 12, which was relatively large and in the opposite direction (i.e., the response rate was higher in the U.S. subgroup compared to the non-U.S. subgroup).  <ref type="formula">(1)</ref> Response is defined as a PGA score of 0 or 1 with at least a 2-grade improvement from baseline.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results for the Secondary Efficacy Endpoints</head><p>(2) Missing data was imputed using non-responder imputation (NRI). Subjects with missing baseline value were also imputed using NRI. The applicant's results for the secondary efficacy endpoints at Week 28 differ from the above because the applicant excluded subjects that did not enter Part 2 (i.e., subjects that discontinued prior to Week 12 were not included in the applicant's analysis). These subjects are included in the above results as non-responders. The protocols for Trials P010 and P011 specified a sequential gatekeeping approach to control the Type I error rate for testing multiple doses and efficacy endpoints (i.e., <ref type="figure">Figure 7</ref> and <ref type="figure">Figure 8</ref> in Section 7.2.2). <ref type="table" target="#tab_14">Table 30</ref> presents the ordering and corresponding p-values for the co-primary and secondary efficacy endpoints included in the multiplicity testing strategy.</p><p>Reference ID: 4233639 . As all of the endpoints based on the PROs were designated as either "other" secondary endpoints or exploratory endpoints and were not included in the multiplicity testing strategy, the results for these endpoints are not presented in this review. Trial P010 evaluated maintenance of efficacy for an additional 36 weeks (Weeks 28 to 64). Subjects randomized to tildrakizumab (200 and 100 mg) at Week 0 and who were PASI 75 responders at Week 28 were re-randomized to either continue treatment with the same dose of tildrakizumab Q12W or withdrawn therapy. Subjects re-randomized to treatment withdrawal received placebo Q4W till relapse, which was defined as the reduction in maximum PASI response by 50%. Subjects that relapsed re-initiated their original dose of tildrakizumab at the visit when the relapse occurred; subsequent dosing of tildrakizumab was given 4 weeks after treatment re-initiation, and Q12W thereafter through Week 64. It should be noted that the Agency recommended that the definition of relapse also be based on PGA (see Section 3.1). <ref type="table" target="#tab_0">Table 31</ref> presents the percentage of PASI 75 responders at Week 28 who were responders at Week 64. The table also presents the percentage of PGA responders at Week 28 who were responders at Week 64. It should be noted that the PGA responders at Week 28 in <ref type="table" target="#tab_0">Table 31</ref> is a subset of the PASI 75 responders because the re-randomization was only based on PASI 75. <ref type="figure" target="#fig_3">Figure 11</ref> presents the response rates (PASI 75 and PGA response) from Week 28 to 64 for subjects who were responders at Week 28 in Trial P010. (2) Response is defined as a PGA score of 0 or 1 with at least a 2-grade improvement from baseline.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy Over Time</head><p>(3) Subjects that relapsed were imputed as non-responders.  <ref type="figure" target="#fig_3">Figure 12</ref> and <ref type="figure" target="#fig_3">Figure 13</ref> present the results for the co-primary efficacy endpoints by sex, age (18-64 and 65+ years), race (White, Black, Asian, and Other), weight ( 90 kg and &gt;90 kg), baseline PGA score, and prior use of biologic therapy for Trials P010 and P011, respectively. In both trials, the majority of subjects were less than 65 years of age (approximately 91%); therefore, any differences between the two subgroups would be difficult to detect. For sex, the treatment effect was larger in females compared to males for both co-primary efficacy endpoints in Trial P010; however, there was more variability in the treatment effects across in Trial P011. In both trials, the sample size for the non-White subgroups (i.e., Black, Asian [small in Trial P011], and Other) were relatively small. In Trial P010, the treatment effect for subjects that identify as White was larger than those that identify as Asian. For weight, the treatment effect was larger in those that weighed 90 kg compared to &gt; 90 kg in both trials; however, it should be noted that the results within each subgroup were similar between the two tildrakizumab doses. For baseline disease severity, the treatment effect tended to be larger for subjects with less disease severity at baseline (i.e., PGA score of 3 [moderate]) in both trials; however, it should be noted that the sample size for the very high disease severity (i.e., PGA score of 5 [very severe]) was relatively small.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of Safety Safety Review Approach</head><p>The primary review of safety of tildrakizumab for the treatment of moderate to severe plaque psoriasis focused on the evaluation of pooled data from Phase 2 Trial P05495 (P003) and Phase 3 Trials MK-3222 P010 (P010) and MK-3222 P011 (P011).</p><p>Phase 2 Trial P05495 (P003) was a 5-arm trial [tildrakizumab (5 mg, 25 mg, 100 mg, 200 mg) and placebo]. The study product was administered at Week 0, 4, 16, 28, 40 and 52 by SC injection at the study site. A total of 270 subjects age 18 to 82 years of age were randomized in a 1:2:2:2:1 ratio.. At Week 16, the dose was adjusted based on the responder status (e.g., "nonresponders" received an increased dose and "responders" received the same or decreased dose.) Subjects received their assigned treatment until Week 52 and then received no treatment during the wash-out period until Week 72. Refer to <ref type="table" target="#tab_0">Table 19</ref> Listing of Clinical Trials Relevant to BLA 761067.</p><p>Phase 3 Trial P010 and Trial P011 were similar in terms of design, study population, doses evaluated (100 mg and 200 mg SC), dosing regimen, primary endpoints and key secondary endpoints. The Base Periods consisted of three parts with an optional long-term safety extension, and a follow-up period. Both trials included a placebo comparator through Week 12 (Part 1). In addition, Trial P011 also included an active comparator, etanercept 18 up to Week 28. Subjects who were assigned to placebo in Part 1 were re-randomized to receive tildrakizumab 100 mg or 200 mg at Week 12 (Part 2: Week 12-28). From Week 28 (Part 3: P010 Weeks 28-64 and P011 Weeks 28-52), treatment assignment was based on the responder status. For a description treatment groups after Week 28, detailed study designs and schematic representations refer to Section 7.2.1.</p><p>The Long-Term Safety Extension (Weeks 64 to 256) followed Part 3. Eligible subjects continued to receive the same dose as Part 3 (200 or 100 mg Q12W). Subjects who were not eligible or who elected not to enter the extension trial entered a 20-week follow-up period. Subjects received treatment in a double-blind manner until the base trail (Parts 1, 2, and 3) was completed. Following database lock of the base study, subjects received study medication in an open-label manner for the remainder of the extension trial.</p><p>In the pooled safety database (Trial P003, Trial P010 and Trial P011), a total of 1083 subjects with plaque psoriasis were treated with the proposed dose and dosing regimen of tildrakizumab 100 mg administered SC, at Weeks 0 and 4 and then q12W thereafter. Of these, 672 subjects were exposed for at least 12 months, 587 for 18 months, and 469 for 24 months.</p><p>The analysis of the safety of tildrakizumab in adults with moderate to severe psoriasis was performed using 5 pools of safety data representing different treatment periods as follows:</p><p>The mean duration of treatment was 53.9 weeks for tildrakizumab during the Base trial periods, corresponding to an exposure of 2059.04 subject-years. A total of 588 subjects received placebo during the Base trial periods. The mean duration of treatment with placebo was 19.4 weeks, corresponding to an exposure of 218.86 subject-years. During the Base and Extension trial periods, the mean duration of treatment with tildrakizumab was 91.7 weeks, corresponding to an exposure duration of 3505.39 subject-years.</p><p>The 120 Day Safety Update Report (SUR) was received 10/2/2017. In the SUR, the applicant reported an updated mean duration of treatment with tildrakizumab of 108.1 weeks, with a total exposure of 4130.24 subject-years during the Base and Extension trial periods.</p><p>During the Base period of Trials P003, P010, and P011, the number of subjects treated with the proposed dose of tildrakizumab 100 mg was 1083. The number of subjects treated with the proposed dose of tildrakizumab 200 mg was 1041. This safety database is sufficient to evaluate the safety of tildrakizumab for the proposed indication in the target population.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Relevant characteristics of the safety population:</head><p>Demographic characteristics of the subject population in the tildrakizumab development program are presented in greater detail in Section 7.2.1.3 of this review. A brief summary of demographic information relevant to the evaluation of safety will be presented here.</p><p>In Trial P003, P010, and P011, the subjects were mostly White (81.8%) and male (71.4%). The median age was 46.0 years (range 18-82 years). Across these 3 trials, 8.9% of subjects were 65 years of age or older.</p><p>In the Phase 2/3 population, the mean baseline Psoriasis Area and Severity Index (PASI) score was 20.0 (standard deviation [SD] 7.7). The baseline Physician's Global Assessment (PGA) Score was 3 in 65.9% and 4 in 33.7% of subjects. The median body surface area (BSA) involved was 26% (range 5-100%).</p><p>Most subjects (82.5%) had no prior exposure to biologic therapy and most (84.1%) reported no history of psoriatic arthritis. A total of 40.2% of subjects had a history of treatment with conventional systemic therapy, and 31.6% had a history of treatment with phototherapy.</p><p>In the Phase 2/3 population, the medical histories of the trial population were remarkable for cardiovascular risk factors:</p><p>Hypertension (27.1%), hyperlipidemia (6.4%), and hypercholesterolemia (6.0%) Obesity (6.8%) and Type 2 diabetes mellitus (5.1%)</p><p>The medical histories were also remarkable for psoriatic arthropathy (10.8%) and back pain (4.8%). Less than 1% of subjects reported a history of squamous cell (SCC) or basal cell carcinoma (BCC) of the skin.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adequacy of the safety database:</head><p>The total exposure to tildrakizumab 100 mg and 200 mg SC at Week 0 and 4, then every 12 weeks thereafter for 52 weeks, provides adequate data for the evaluation of safety. The demographics of the study population are sufficiently representative of the target population.</p><p>Therefore, the safety database presented by the applicant is sufficient to characterize the safety profile of tildrakizumab for the treatment of moderate to severe plaque psoriasis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adequacy of Applicant's Clinical Safety Assessments</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Issues Regarding Data Integrity and Submission Quality</head><p>Overall, the quality of the data submitted is adequate to characterize the safety and efficacy of tildrakizumab. Data quality and fitness were evaluated in conjunction with the JumpStart team. We discovered no significant deficiencies that would impede a thorough analysis of the data presented by the applicant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Categorization of Adverse Events</head><p>The definitions and collection of adverse events (AE) were similar among all the trials, each of which recorded spontaneously reported AEs. For example, the following definitions were adapted from those in Trial P010. The applicant defined and AE as "any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment." An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.</p><p>AEs were categorized by system-organ class (SOC) and preferred term (PT) using the Medical Dictionary for Regulatory Activities (MedDRA). The adverse events included in analyses performed by the JumpStart team matched 100% to MedDRA dictionary version 19.1. The coding of adverse events in the BLA submission appeared adequate and allowed for accurate estimation of AE risks.</p><p>All AEs were to be recorded in the subject's source documentation and on the CRF. The onset and end dates, severity, and relationship to the investigational product were recorded for each AE. Any action or outcome (e.g., discontinuation of therapy) was also recorded for each AE.</p><p>The following definitions were used for grading the severity of AEs:</p><p>Mild: awareness of sign, symptom, or event, but easily tolerated; Moderate: discomfort enough to cause interference with usual activity and may have warranted intervention; or Severe: incapacitating with inability to do usual activities or significantly affected clinical status, and warranted intervention</p><p>The investigator also assessed the relationship of any AE to the use of the trial medication, based on available information and according to the following guidelines: Adjudication of major CV events and all deaths was conducted by external committees. Tier 2 AEs constituted the commonly occurring AEs in at least 4 subjects in any treatment group. Tier 2 AEs included:</p><p>Percentage of subjects with AEs (not including worsening of underlying psoriasis unless it meets criteria for an SAE). Percentage of subjects with SAEs. Percentage of subjects with drug-related AEs (i.e., AEs considered by the investigator to be at least possibly associated with blinded trial medication). Percentage of subjects with a discontinuation due to AEs. Percentage of subjects reporting specific AEs. Percentage of subjects discontinuing trial medication due to drug-related AEs. Percentage of subjects who died. Percentage of subjects with anti-drug antibodies (ADAs) associated with AEs.</p><p>Other AEs of clinical interest included:</p><p>Overdose An elevated AST or ALT lab value that was 3 Ã the ULN and an elevated total bilirubin lab value that was 2 Ã ULN and, at the same time, an ALP lab value that was &lt;2 Ã ULN Nonserious infections requiring IV antibiotics</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypertension requiring emergency room visit</head><p>Any other AEs including laboratory assessments not analyzed in Tier 1 and Tier 2 were considered Tier 3 safety endpoints. Summary statistics and incidence rates were provided for the Tier 3 endpoints. Additionally, any nonserious events of infections that required IV antibiotics but did not meet the definition of an SAE were considered "closely monitored" events during the trial and are a subset of Tier 1 events. The applicant also performed analyses of exposure-response for safety as well as the effect of immunogenicity on safety.</p><p>The definition of AE, TEAE, and SAE are acceptable. The classification system used by investigators to describe the severity of AE as well as the causal relationship between AE and study product are also acceptable. The applicant's identification and presentation of AE of special interest was appropriate.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Routine Clinical Tests</head><p>In Trial P003, P010 and P011, the evaluation of safety was conducted during visits to the clinic, which were scheduled to occur at the following timepoints: The evaluation of safety included clinical laboratory tests, vital signs, physical examinations, electrocardiograms (ECG), and evaluation for TB. These will be discussed in more detail below. Safety monitoring also included recording of adverse events, which was discussed in the previous section. In all three trials, serum pregnancy testing was performed at screening for women of childbearing potential. In addition, urine pregnancy testing was performed at the following timepoints: Because the 3 trials had different visit schedules, for the purpose of comparison of results across time, only the trial visits common across the Phase 2 and 3 trials are summarized. Common time points for measurement of ECG parameters across the Phase 2/3 trials during the base period were Weeks 0, 4, 12, 28, and 52/64.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Deaths</head><p>There were no deaths reported in the 6 Phase 1 trials in subjects receiving tildrakizumab (P05661, P05776, P06306, P05382, P009, and P05839).</p><p>During the Base Periods of the pooled Phase 2 (Base period: 52 weeks) and Phase 3 trials (Base periods P010: 64 weeks and P011: 52 weeks), a total of 7 subjects experienced fatal adverse events. There were five deaths among subjects who received 100 mg tildrakizumab [unknown cause, alcoholic cardiomyopathy and steatohepatitis]; 1 death in a subject who received tildrakizumab 200 mg [aneurysm]; and 1 death in a subject who received etanercept in Part 1 but switched to tildrakizumab 200 mg in Part 3 of the trial [sepsis]. None of the deaths was assessed as causally related to the study product. In the Gastrointestinal disorders SOC, there was an imbalance in the incidence of SAEs in the tildrakizumab 100 mg group (diarrhea, abdominal pain, constipation, diverticulitis, dyspepsia, gastritis, thrombosed hemorrhoids, esophageal polyp and pancreatitis) compared with the placebo group (food poisoning). There was no apparent dose response in GI SAEs. By comparison, there was a dose response in the incidence of SAEs in the Musculoskeletal and connective tissue disorder SOC; more than twice the number of subjects reported SAEs who received tildrakizumab 200 mg than tildrakizumab 100 mg. This imbalance in the rate of SAEs by dose was confirmed in subjects who received continuous treatment, with tildrakizumab 200 mg compared to 100 mg.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Selected narratives of serious adverse events</head><p>The following SAEs were assessed as related to the study product and resulted in discontinuation from the trial:</p><p>A 58-year-old Asian male with a history of chronic cough, abnormal chest x-ray, negative transbronchial needle biopsy and negative Mantoux tuberculin skin test, tobacco usage (11 pack years) and low back pain experienced severe back pain on an unknown day. On Day 178 the subject was diagnosed with tuberculosis (TB) of the spine based on the results of a bone biopsy (histology, culture, smear and PCR were positive for TB) after 3 doses of tildrakizumab 200 mg. The drug-related serious adverse event of bone tuberculosis (tuberculosis of vertebral column) led to discontinuation of the study product. Refer to Section 7.3.5 for additional details A 42-year-old Asian male with a medical history of Type 2 diabetes mellitus, psoriatic arthritis, and pruritus had a serious adverse event of erythrodermic psoriasis on Day 87 which led to discontinuation of study medication after 2 doses of tildrakizumab 200 mg. Cultures were negative and no other cause was identified for the exacerbation of psoriasis. On Day 99 the subject was discontinued from the trial and the event was Reference ID: 4233639</p><formula xml:id="formula_5">(b) (6) (b) (6)</formula><p>resolved on Day 508. The event of psoriasis aggravated was assessed as moderate in intensity and related to study medication.</p><p>A 32-year-old White male with a history of tobacco usage (7.5 pack years), experienced a serious, drug-related adverse event of headache after 10 doses of etanercept 50 mg. On Day 37, the subject experienced a headache and was hospitalized. ECG showed sinus rhythm, with first degree atrioventricular block, and no ischemia. Electroencephalogram and a magnetic resonance tomography were unremarkable. Laboratory results included an elevated neutrophil count and erythrocyte sedimentation rate (ESR). The subject improved the same day and was released from the hospital with a diagnosis of corticoid responsive bilateral cephalalgia which was treated with prednisolone from Day 39 to Day 60 when the event of headache resolved. The headache was assessed as severe in intensity and related to study medication. The subject was withdrawn from the trial on Day 47.</p><p>A 74-year-old White male with a history of obesity, nephrolithiasis, tobacco usage (7.5 pack years), and prostatic hyperplasia experience hematuria on Day 155 and 256 and was diagnosed with serious adverse event of transitional cell carcinoma of the bladder stage 0 after 4 doses for tildrakizumab 100 mg. On Day 271, the subject was hospitalized for diagnostic transurethral surgical procedure. The tumor identified in the bladder was resected and diagnosed as non-invasive papillary urothelial carcinoma (G2 high grade pTa). The subject was withdrawn from the trial. The neoplasm resolved with the diagnostic procedure. The neoplasm was assessed as severe in intensity and related to study medication.</p><p>A 74-year-old White female with a history of diabetes experienced a serious, drug-related adverse event of herpes zoster after 2 doses of tildrakizumab 200 mg. On Day 107, the subject was hospitalized with erythema, blistering, pain and pruritus in the distribution of the right trigeminal nerve. There was periorbital erythema which involved the conjunctiva. The subject was diagnosed with herpes zoster V1 + V2 and treated with acyclovir, eye drops and pain medication. The event appeared to be resolved on Day 118 but on Day 134, the signs and symptoms resumed. On Day 224, the subject experienced another event of herpes zoster. The initial event of herpes zoster was assessed as moderate in intensity and related to study medication. The subject withdrew from the trial on Day 140.</p><p>A 39-year-old White female with a history of breast and cervical carcinoma (not disclosed at entry), and tobacco usage (14 pack years), developed a serious, drug-related adverse event of breast cancer on Day 248 in the other breast. The subject received etanercept 50 mg until Week 28 and then 2 doses of tildrakizumab 200 mg. A biopsy and then excision of the tumor was performed. The subject was discontinued from the trial and lost to followup. The event of breast cancer was not resolved, was assessed as moderate in intensity, and related to study medication.</p><p>Other SAEs included the following:</p><p>43-year-old White male subject with a history of Type 2 diabetes mellitus, hypertriglyceridemia, cholecystectomy and gastroesophageal reflux disease experienced acute pancreatitis after 1 dose of tildrakizumab 200 mg. He presented to the emergency room with severe abdominal pain and diarrhea and was admitted to the hospital for Reference ID: 4233639</p><formula xml:id="formula_6">(b) (6) (b) (6) (b) (6) (b) (6) (b) (6)</formula><p>treatment of acute pancreatitis secondary to hypertriglyceridemia (354 mg/dL). CT scan of abdomen and pelvis and ultrasound of the biliary tract were negative. He had no risk factors for pancreatitis except poor compliance with the prescribed low fat diet. The adverse event was assessed as moderate in severity and not related to the study product. Investigators withdrew him from the trial due to protocol violation.</p><p>60-year-old White male subject ( with a history of dyslipidemia and treatment with methotrexate experienced pancreatitis after 3 doses of tildrakizumab 100 mg. He presented to the emergency room with atypical chest pain and laboratory evaluation showed elevated lipase (1930 U/L). CT scan of abdomen and ultrasound of the abdomen and kidneys were negative. He had no risk factors for pancreatitis except poorly controlled dyslipidemia. The adverse event was assessed as moderate in severity, not related to the study product and did not result in discontinuation of tildrakizumab.</p><p>67-year-old White male subject with a history of type II diabetes, gastroesophageal reflux disease (GERD), and hypertriglyceridemia experienced severe gastroenteritis after 3 doses of tildrakizumab 100mg. The subject presented to the emergency room(ER) with vomiting, nausea, diarrhea and severe headache and received treatment with IV fluids and antiemetic medications. The subject continued to experience severe nausea, vomiting, dehydration and headache and presented to the ER on the following 2 days. On the third day when the subject returned to the ER, he was admitted for observation, IV fluids, antiemetic and pain medication. The subject denied fever, chills, sore throat, weakness, numbness or tingling. Assessments included a normal white cell count, normal liver function tests (except for a slightly elevated bilirubin), and negative head CT. The adverse event resolved on the fourth day and the subject was discharged with the diagnosis of gastroenteritis. The adverse event was assessed as severe and not likely to be related to the study product. The subject withdrew from the trial due to lack of efficacy.</p><p>21 -year -old Asian female subject experienced a gastroenteritis after 4 doses of tildrakizumab 100mg. One month after returning from a trip to the Philippines, the subject presented to the hospital with fever and confusion (other symptoms not described). A stool sample was positive for salmonella. The adverse event was assessed as moderate in severity, not related to the study product and did not result in discontinuation of tildrakizumab.</p><p>71-year-old White female subject with a history of asthma experienced gastroenteritis after 5 doses of tildrakizumab 100 mg. The subject presented to the emergency room with severe abdominal pain and was admitted for evaluation. Chest xray was unchanged and abdominal x-ray showed no evidence of obstruction. The abdominal pain was treated with an unspecified IV analgesic and resolved on the following day. The subject was discharged from the hospital with a diagnosis of gastroenteritis. The adverse event was assessed as moderate in severity, not related to the study product and did not result in discontinuation of tildrakizumab.</p><p>A 46-year-old White female subject with a history of elevated high density lipoprotein (HDL) and elevated gamma-glutamyl transferase (GGT) experienced moderate antral gastritis after 4 doses of tildrakizumab 100 mg. The subject presented to the ER with dyspepsia, nausea, vomiting, malaise, dyspnea, and tachycardia and was Reference ID: 4233639</p><formula xml:id="formula_7">(b) (6) (b) (6) (b) (6) (b) (6) (b) (6)</formula><p>admitted for evaluation. Gastroscopy showed discrete chronic antral gastritis but helicobacter pylori testing was negative. Abdominal sonography, chest X-ray, transthoracic echocardiography (TTE) and laboratory parameters were unremarkable. The subject was treated symptomatically with proton pump inhibitors, antiemetics and "infusion therapy." The subject recovered 3 days later and was discharged from the hospital. The adverse event was assessed as moderate in severity and not likely to be related to the study product. The subject withdrew from the trial due to protocol violation.</p><p>A 36-year -old White female subject with a history of chronic lumbar spine syndrome (diagnosed in 2012) experienced back pain after 4 doses of tildrakizumab 100 mg. The subject presented to the hospital with acute severe lower back pain. X-ray showed degeneration L5-S1. The subject improved with pain medication and physical therapy during a 4-day hospitalization. The adverse event was assessed as severe, not related to the study product and did not result in discontinuation of tildrakizumab.</p><p>60-year-old White male subject with a history of gastritis experienced stomach pain after 4 doses of tildrakizumab. The subject presented to the outpatient clinic with a stomach ache of moderate severity and was admitted to the hospital for evaluation. Ultrasound and CT scan of the abdomen and colonoscopy were unremarkable. Gastroscopy showed inflamed gastric mucosa. The subject received pain medication and a proton pump inhibitor. The abdominal pain continued. The adverse event was assessed as moderate in severity, not related to the study product and did not result in discontinuation of tildrakizumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dropouts and/or Discontinuations Due to Adverse Effects</head><p>During the placebo controlled safety period, the number of subjects who discontinued trial medication due to adverse events was 0.6% in the tildrakizumab 100 mg group, 1.3% in the tildrakizumab 200 mg group, 1.1% in the placebo group and 1.0% in the etanercept group. In the tildrakizumab groups, the SOC of Cardiac disorders had the highest number of discontinuations with 2/704 (0.3%) in the 100 mg group (alcoholic cardiomyopathy and tachycardia) and 2/708 (0.3%) in the 200 mg group (atrial fibrillation and coronary artery disease.)</p><p>In the Base Period Safety Pool, the rate of discontinuations due to AEs was 2.20 per 100 subject years (subj-yrs) in the tildrakizumab 100 mg group, 2.15 per 100 sub-yrs, in the tildrakizumab 200 mg group, and 2.28 per 100 subj-yrs in the placebo group, compared with 5.87 per 100 sub-yrs in the etanercept group. The SOC of Neoplasms had the highest number of discontinuations. In subjects receiving tildrakizumab 100 mg, 6 subjects (0.60 subjects per 100 subj-years) discontinued the trial due to the event of a neoplasm. These included 2 subjects with squamous cell carcinoma (SCC) and 1 subject each with acute myeloid leukemia, transitional cell bladder cancer, malignant melanoma in situ and rectal cancer. In subjects receiving tildrakizumab 200 mg, 3 subjects (0.32 per 100 subj-yrs) discontinued the trial due to the event of a neoplasm. These included 2 subjects with pancreatic carcinoma and 1 subject with breast cancer. The neoplasms assessed as related to tildrakizumab included malignant melanoma, transitional cell bladder cancer, and breast cancer.</p><p>The Cardiac Disorders SOC had the second highest rate of discontinuations among subjects receiving tildrakizumab. In subjects receiving tildrakizumab 100 mg, 3 subjects (0.3 subjects per 100 subj-years) discontinued due to cardiac disorders (atrial fibrillation, alcoholic cardiomyopathy and tachycardia.). In subjects receiving tildrakizumab 200 mg, 2 subjects (0.22</p><p>Reference ID: 4233639</p><formula xml:id="formula_8">(b) (6) (b) (6)</formula><p>per 100 subj-years) discontinued due to cardiac disorders (atrial fibrillation and coronary artery disease.) Only one of these events, tachycardia, was assessed as related to tildrakizumab.</p><p>In the Infection and Infestation SOC, 4 subjects (0.43 per 100 subj-yrs) who received tildrakizumab 200 mg discontinued the trials because of an infection (tuberculosis, diverticulitis, herpes zoster and pustular rash). No subjects who received tildrakizumab 100 mg discontinued the trials because of an infection. The infections assessed as related to tildrakizumab included tuberculosis, herpes zoster and pustular rash.</p><p>Refer to Serious Adverse Events for selected narratives for subjects who discontinued the study product due to adverse events.</p><p>In the extension phase (through June 12, 2016 for Trial P010 and June 21, 2016 for Trial P011), adverse events leading to discontinuation of trial medication included hyperthyroidism, thyrotoxic crisis, dysphagia, staphylococcal infection, arthritis, psoriatic arthropathy, breast cancer, diffuse large B-cell lymphoma, leiomyosarcoma, rectal adenocarcinoma, cerebrovascular accident, eczema and urticaria in the tildrakizumab 100 mg group, and pneumonia, back pain, and psoriasis in the tildrakizumab 200 mg group.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Significant Adverse Events</head><p>Refer to Section 7.3.5 "Analysis of Submission-specific Safety Issues".</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Treatment Emergent Adverse Events and Adverse Reactions</head><p>In the placebo controlled safety pool (Week 0-16 of Trial P003, Week 0-12 of Trials P010 and P011), treatment-emergent adverse events (TEAE) occurred in 48.2% of subjects treated with tildrakizumab 100 mg, 47.9% of subjects treated with tildrakizumab 200 mg, and 53.5% of subjects in the placebo group. The most common TEAE were in the system/organ class (SOC) of infections and infestations and included upper respiratory infections (URI) and gastroenteritis. For Trial P003, only safety data from subjects treated with tildrakizumab100 mg or 200 mg are included here. Because AEs of URI, injection site reactions (ISR), and abdominal pain were reported under multiple preferred terms, we pooled these AEs to better evaluate their overall frequency of occurrence (see <ref type="table" target="#tab_14">Table 39</ref> below).</p><p>The AE category of upper respiratory infections (URI) is comprised of pooled preferred terms nasopharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, and pharyngitis. The URIs were the most commonly reported AE, occurring in &gt;10% frequency in all treatment groups. Although URIs are common illnesses, the difference in frequency of URIs between subjects treated with tildrakizumab and placebo was greater than 1%. URI occurred in 13.9% of subjects treated with tildrakizumab 100 mg, 12.7% of subjects treated with tildrakizumab 200 mg, and 11.5% of subjects in the placebo group.</p><p>The AE category of injection Site Reactions (ISR) is comprised of the following pooled preferred terms: injection site urticaria, pruritus, pain, reaction, erythema, inflammation, edema, swelling, bruising, hematoma, and hemorrhage. A total of 93 events of ISR were reported by 53/1413 (3.8%) subjects treated with tildrakizumab 100 or 200 mg and 8/357 (2.2%) of subjects treated with placebo. The breakdown of AE by dose is as follows. A total of 24/705 (3.4%) subjects treated with tildrakizumab 100 mg reported 44 AE, and 29/708 (4.1%) subjects treated with tildrakizumab 200 mg reported 49 AE of ISR. For subjects treated with tildrakizumab, subject race was White in 51/53 (96.2%), Asian in 1/53 (1.9%), and missing in 1/53 (1.9%); 35/53 (66.0%) subjects were male and 18/53 (34.0%) were female. Although the mean duration of ISR was 9.3 days (range 1-605 days), the duration was 2 days or fewer in 69/93 (74.2%) events. The reported severity of ISR was mild in 88/93 (94.6%) and moderate in 5/93 (5.4%) of events. Investigators considered the relationship of ISR to treatment to be related in 76/93 (81.7%) and not related in 17/93 (18.3%) events. No abnormal laboratory studies or vital signs correlated temporally with ISR. All ISR events resolved. None of the ISR events resulted in interruption or discontinuation of treatment.</p><p>A total of 24 AE of fatigue were reported by 24/1413 (1.7%) subjects treated with tildrakizumab 100 or 200 mg and 6/357 (1.7%) of subjects treated with placebo. The breakdown of AE by dose is as follows. A total of 17/705 (2.4%) subjects treated with tildrakizumab 100 mg reported 17 AE, and 7/708 (1.0%) subjects treated with tildrakizumab 200 mg reported 7 AE of fatigue. For subjects treated with tildrakizumab, subject race was White in 24/24 (100%); 12/24 (50%) subjects were male and 12/24 (50%) were female. Although the mean duration of resolved fatigue events was 77.4 days (range 1-614 days), the duration of fatigue was 8 days or fewer in 10/22 (45.5%) events. The reported severity of fatigue was mild in 20/24 (83.3%) and moderate in 4/24 (16.7%) of events. The relationship of fatigue to treatment was judged by investigators to be not related in 12/24 (50%) and related in 12/24 (50%) events. Associated conditions reported as AE included nasopharyngitis in 3/24 (12.5%). One subject (a 48-year-old male, Subject #3222-010_011600003) had sinus bradycardia from Screening through the end of the study, and reported AE of fatigue from Day 43 until the end of the study. No abnormalities in laboratory studies or vital signs occurred concomitantly with AE of fatigue. Another subject (a 40-year-old female, Subject #3222-011_492300006) reported fatigue with concomitant "pressure" in her back, chest, and throat of Day 1 of the study. A total of 22/24 (91.7%) of the fatigue events resolved; 2/24 (9.3%) were not resolved. None of the fatigue events resulted in interruption or discontinuation of treatment. Although the difference in frequency of fatigue between subjects treated with tildrakizumab 100 mg and placebo is small, investigators judged half of the AE of fatigue to be related to treatment with tildrakizumab. Therefore, we recommend fatigue to be included as an Adverse Reaction (AR) in product labeling.</p><p>A total of 30 AE of diarrhea were reported by 23/1413 (1.6%) subjects treated with tildrakizumab 100 or 200 mg and 5/357 (1.4%) of subjects treated with placebo. The breakdown of AE by dose is as follows. A total of 13/705 (1.8%) subjects treated with tildrakizumab 100 mg reported 16 AE, and 10/708 (1.2%) subjects treated with tildrakizumab 200 mg reported 14 AE of diarrhea. For subjects treated with tildrakizumab, subject race was White in 23/23 (100%); 16/23 (69.6%) subjects were male and 7/23 (30.4%) were female. Although the mean duration was 26.2 days (range 1-523 days), the duration of diarrhea was 6 days or fewer in 22/30 (73.3%) events. The reported severity of diarrhea was mild in 21/30 (70%) and moderate in 9/30 (30%) events. Investigators considered the relationship of diarrhea to treatment to be related in 16/30 (53.3%) and not related in 14/30 (46.7%) events. Associated conditions reported as AE included upper abdominal pain with 2/30 (6.7%) events; abdominal pain with dyspepsia and gastroesophageal reflux disease with 1/30 (3.3%) events, and tonsillitis, fever, nausea, nasopharyngitis, chills, vomiting, and headache each occurring with 1/30 (3.3%) events of diarrhea. Laboratory studies were normal in 17/23 (73.9%) subjects; 6/23 (26.1%) subjects had elevated liver enzymes (ALT, AST, GGT) or bilirubin. The liver enzyme/bilirubin elevations also occurred at other timepoints in the trial which did not correlate temporally with AE of diarrhea. Additionally, the presence or absence of fever was not recorded for any subject with diarrhea. All the diarrhea events resolved. None of the diarrhea events resulted in interruption or discontinuation of treatment. Although the difference in frequency of diarrhea between subjects treated with tildrakizumab 100 mg and placebo is small, investigators judged over half of the AE of diarrhea to be related to treatment with tildrakizumab. Diarrhea of severe intensity was also reported as an AE in the tildrakizumab 200 mg dose group in Phase 1 Study P06306. Furthermore, the applicant included diarrhea as an AR in their proposed labeling. Therefore, we recommend diarrhea to be included as an Adverse Reaction (AR) in product labeling.</p><p>A total of 23 AE of back pain were reported by 21/1413 (1.5%) subjects treated with tildrakizumab 100 or 200 mg and 4/357 (1.1%) of subjects treated with placebo. The breakdown of AE by dose is as follows. A total of 9/705 (1.3%) subjects treated with tildrakizumab 100 mg reported 10 AE of back pain, and 12/708 (1.7%) subjects treated with tildrakizumab 200 mg reported 13 AE of back pain. For subjects treated with tildrakizumab, subject race was White in 19/21 (90.5%), and Asian in 2/21 (9.5%); 16/21 (76.2%) subjects were male and 5/21 (23.8%) were female. The mean duration of back pain AE was 22.3 days (range 1-104 days). The mean duration of back pain AE was longer for subjects treated with tildrakizumab 200 mg (37.2 days, range 1-104 days) than for subjects treated with tildrakizumab 100 mg (15.9 days, range 2-59 days). The reported severity of back pain was mild in 13/23 (56.5%) and moderate in 10/23 (43.5%) of events. Investigators considered the relationship of back pain to treatment to be not related in 22/23 (95.7%) and related in 1/23 (4.3%) event. Associated conditions reported as AE included 1/21 (4.8%) subject with abdominal pain and hematuria, 1 with pyrexia, 1 with arthralgia, and 1 with headache. A total of 22/23 (95.7%) of the back pain events resolved; 1/23 (5.9%) was resolved with sequelae. None of the back pain events resulted in interruption or discontinuation of treatment. Although the difference in frequency of back pain between subjects treated with tildrakizumab 100 mg and placebo is small, both the frequency of subjects reporting AE and the exposure-adjusted AE of back pain were greater in subjects treated with tildrakizumab 200 mg. This indicates that the AE of back pain was dose-dependent. In addition, the mean duration of back pain was longer in subjects treated with tildrakizumab 200 mg.</p><p>Therefore, we recommend back pain to be included as an Adverse Reaction (AR) in product labeling.</p><p>The AE category of abdominal pain is comprised of the following pooled preferred terms: abdominal pain, abdominal discomfort, abdominal pain upper, and abdominal pain lower. A total of 17 events of abdominal pain were reported by 16/1413 (1.1%) subjects treated with tildrakizumab 100 or 200 mg and 2/357 (0.6%) of subjects treated with placebo. The breakdown of AE by dose is as follows. A total of 9/705 (1.3%) subjects treated with tildrakizumab 100 mg reported 9 AE, and 7/708 (1.0%) subjects treated with tildrakizumab 200 mg reported 8 AE of abdominal pain. For subjects treated with tildrakizumab, subject race was White in 13/16 (81.3%), Asian in 1/16 (6.3%), Hawaiian/Pacific Islander in 1/16 (6.3%), and multiracial in 1/16 (6.3%); 7/16 (43.8%) subjects were male and 9/16 (56.2%) were female. No past medical history of gastrointestinal (GI) disease was present in 12/16 (75%), while 4/16 (25%) subjects reported a history of GI disease. Of the 4 subjects with a history of GI disease, one had a history of gastroesophageal reflux disease, one had "inflammatory bowel syndrome" (coded by investigators under preferred term inflammatory bowel disease), one had hemorrhoids, and one had dyspepsia, constipation, and rectal bleeding. Although the mean duration was 13 days (range 1-83 days), the duration of abdominal pain was 6 days or fewer in 11/17 (64.7%) subjects. The reported severity of abdominal pain was mild in 15/17 (88.2%) and moderate in 2/17 (11.8%) of events. Investigators considered the relationship of abdominal pain to treatment to be not related in 10/17 (58.8%) and related in 7/17 (41.2%) events. Associated conditions reported as AE occurring concomitantly with abdominal pain included diarrhea with 3/17 (17.6%) events, decreased appetite and nasopharyngitis, each with 2/17 (11.8%) events; back pain and hematuria, vomiting, sinusitis and oropharyngeal pain, and nausea each with 1/17 (5.9%) events. No abnormal laboratory studies or vital signs correlated temporally with AE of abdominal pain. A total of 16/17 (94.1%) abdominal pain events resolved, and 1/17 (5.9%) Reference ID: 4233639</p><formula xml:id="formula_9">(b) (4) (b) (4)</formula><p>was not resolved. None of the abdominal pain events resulted in interruption or discontinuation of treatment. Although the difference in frequency of abdominal pain between subjects treated with tildrakizumab 100 mg and placebo is small, investigators judged almost half of the AE of abdominal pain to be related to treatment with tildrakizumab. Furthermore, abdominal pain was reported as an AE in 13% of subjects treated with tildrakizumab in Phase 1 Study P05839, and abdominal pain was reported as an adverse reaction in Phase 1 Study P06306. Therefore, we recommend abdominal pain to be included as an Adverse Reaction (AR) in product labeling.</p><p>A total of 21 AE of gastroenteritis (from the SOC of Infections and Infestations) were reported by 21/1413 (1.5%) subjects treated with tildrakizumab 100 or 200 mg and 4/357 (1.1%) of subjects treated with placebo. The breakdown of AE by dose is as follows. A total of 8/705 (1.1%) subjects treated with tildrakizumab 100 mg reported 8 AE, and 13/708 (1.8%) subjects treated with tildrakizumab 200 mg reported 13 AE of gastroenteritis. For subjects treated with tildrakizumab, subject race was White in 18/21 (85.7%), Asian in 2/21 (9.5%), and multiracial in 1/21 (4.8%); 14/21 (66.7%) subjects were male and 7/21 (33.3%) were female. No past medical history of gastrointestinal (GI) disease was present in 14/21 (66.7%), while 7/21 (33.3%) subjects reported a history of GI disease. Of the 7 subjects with a history of GI disease, four had a history remarkable only for gastroesophageal reflux disease (GERD), one had a history of hemorrhoids, one had a history of constipation, and one had a history of GERD, Crohn's disease, and nausea. Although the mean duration was 5.1 days (range 1-21 days), the duration of gastroenteritis was 3 days or fewer in 10/21 (47.6%) subjects. The reported severity of gastroenteritis was mild in 9/21 (42.9%) and moderate in 12/21 (57.1%) of subjects. Investigators considered the relationship of gastroenteritis to treatment to be not related in 19/21 (90.5%) and related in 2/21 (9.5%). Associated conditions reported as AE occurring concomitantly with gastroenteritis include 1/21 (4.8%) subject with anxiety, 1/21 (4.8%) subject with nasopharyngitis, and 1/21 (4.8%) subject with AE of headache, vomiting, herpes zoster, and sunburn. Laboratory studies were normal in 20/21 (95.2%) subjects; 1/21 (4.8%) subject had elevated GGT. The GGT elevation was less than twice the upper limit of normal, and also occurred at other timepoints in the trial which did not correlate temporally with AE of gastroenteritis. Additionally, the presence or absence of fever was not recorded for any subject with gastroenteritis. All the gastroenteritis events resolved. None of the gastroenteritis events resulted in interruption or discontinuation of treatment. Because the 200 mg dose of tildrakizumab will not be included in product labeling, and the frequency of gastroenteritis was the same in the tildrakizumab 100 mg and the placebo groups, gastroenteritis will not be included as an AR in product labeling.</p><p>A total of 19 AE of nausea were reported by 18/1413 (1.3%) subjects treated with tildrakizumab 100 or 200 mg and 3/357 (0.8%) of subjects treated with placebo. The breakdown of AE by dose is as follows. A total of 7/705 (1.0%) subjects treated with tildrakizumab 100 mg reported 7 AE, and 11/708 (1.6%) subjects treated with tildrakizumab 200 mg reported 12 AE of nausea. For subjects treated with tildrakizumab, subject race was White in 16/18 (88.9%), Asian in 1/18 (5.6%), and mixed race in 1/18 (5.6%); 9/18 (50%) subjects were male and 9/18 (50%) were female. Although the mean duration of resolved nausea events was 11.3 days (range 1-170 days), the duration of nausea was 3 days or fewer in 16/19 (84.2%) events. The reported severity of nausea was mild in 17/19 (89.5%) and moderate in 2/19 (10.5%) of events. Investigators considered the relationship of nausea to treatment to be not related in 13/19 (68.4%) and related in 6/19 (31.6%) events. Associated conditions reported as AE included dizziness in 4/18 (22.2%, including one subject who sustained a concussion and fracture of the nose), headache in 2/18 (11.1%), and abdominal pain, renal colic, vomiting, fatigue, rash, and dry mouth; each occurring in 1/18 (5.6%) subject. Laboratory studies were normal in 12/18 (66.7%) subjects; 6/18 (33.3%) subjects had elevated liver enzymes (ALT, AST, GGT) or BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 128 bilirubin. The liver enzyme/bilirubin elevations also occurred at other timepoints in the trial which did not correlate temporally with AE of nausea. Additionally, the presence or absence of fever was not recorded for any subject with nausea. A total of 18/19 (94.7%) of the nausea events resolved, and 1/19 (5.3%) was not resolved. None of the nausea events resulted in interruption or discontinuation of treatment. Although the difference in frequency of nausea between subjects treated with tildrakizumab 100 mg and placebo is small, both the frequency of subjects reporting AE and the exposure-adjusted AE of nausea were greater in subjects treated with tildrakizumab 200 mg. This indicates that the AE of nausea was dose-dependent. In addition, in Phase 1 Study P05839, nausea was reported as an AE in 8% of subjects treated with tildrakizumab; nausea was reported as an AR also.</p><p>. Therefore, we recommend nausea to be included as an Adverse Reaction (AR) in product labeling.</p><p>To evaluate the potential relationship between treatment with tildrakizumab and common gastrointestinal AE, we pooled AE of gastroenteritis (GE) with AE of symptoms commonly associated with GE (abdominal pain, nausea, vomiting, and diarrhea). These are displayed in <ref type="table" target="#tab_14">Table 38</ref> below. After pooling, the frequency of GE related events was corrected for duplicates (i.e. subjects reporting two different GE related AE [e.g. vomiting and diarrhea] were only counted once). No subject reported more than two different GE related AE during the Placebocontrolled period. A total of 36/705 (5.1%) of subjects treated with tildrakizumab 100 mg and 41/708 (5.8%) of subjects treated with tildrakizumab 200 mg reported GE related TEAE, compared to 14/357 (3.9%) of subjects in the placebo group. It should be noted that approximately 13% of subjects who received tildrakizumab (100/200 mg) reported more than one GE related AE; in contrast, no subjects in the placebo group reported more than one GE related AE during the Placebo-controlled period. It should also be noted that in cryosections of normal human tissues, tildraklizumab staining was observed in cytoplasm and/or cytoplasmic granules of intrinsic and/or vascular smooth muscle in colon, stomach, liver, and pancreas; and of epithelium of esophagus (glands, submucosa), small intestine (mucosa), stomach (mucosa, mucus neck cells), pancreas (acini), and salivary glands (acini). (Tildrakizumab staining of human tissue is discussed in more detail in Section 5.5.5 of this review.) These data further support inclusion of these events in the Adverse Reactions section of product labeling. A total of 17 AE of dizziness were reported by 15/1413 (1.1%) subjects treated with tildrakizumab 100 or 200 mg and 0/357 of subjects treated with placebo. The breakdown of AE by dose is as follows. A total of 5/705 (0.7%) subjects treated with tildrakizumab 100 mg reported 5 AE, and 10/708 (1.4%) subjects treated with tildrakizumab 200 mg reported 12 AE of dizziness. For subjects treated with tildrakizumab, subject race was White in 9/15 (60%), African American in 2/15 (13.3%), Asian in 1/15 (6.7%), and mixed race in 1/15 (6.7%); 10/15 (66.7%) subjects were male and 5/15 (33.3%) were female. Although the mean duration of resolved dizziness events was 9.9 days (range 1-57 days), the duration of dizziness was 3 days or fewer in 12/17 (70.6%) events. The reported severity of dizziness was mild in 15/17 (88.2%) and moderate in 2/17 (11.8%) of events. Investigators considered the relationship of dizziness to treatment to be not related in 13/17 (76.5%) and related in 4/17 (23.5%) events. Associated conditions reported as AE included nausea in 3/15 (20%, including one subject who sustained a concussion and fracture of the nose), and fatigue, tinnitus, and diarrhea; each occurring in 1/18 (5.6%) subjects. No abnormalities in laboratory studies or vital signs occurred concomitantly with AE of dizziness. A total of 16/17 (94.1%) of the dizziness events resolved; 1/17 (5.9%) was not resolved. None of the dizziness events resulted in interruption or discontinuation of treatment.</p><p>Through the Base Period (Week 52 of Trials P003 and P011, and Week 64 of Trial P010), no new adverse reactions were identified with tildrakizumab use and the frequency of the adverse reactions was similar to that observed during the placebo-controlled period.</p><p>After review of the safety database, we identified the TEAE occurring in greater than 1% of subjects treated with tildrakizumab and more frequently than in the placebo group during the placebo controlled safety period in Trials P003, P010 and P011. AE of injection site reactions, back pain, gastroenteritis, nausea, and dizziness occurred more frequently in subjects treated with tildrakizumab 200 mg than tildrakizumab 100 mg. <ref type="table" target="#tab_14">Table 39</ref> displays the TEAE, along with the terms pooled for each AE, where applicable.</p><p>Data regarding the tildrakizumab 200 mg dose (refer to Section 6.3.2.2 of this review) and etanercept (refer to Section 7.2.5 of this review) will not be included in approved product labeling. <ref type="table" target="#tab_15">Table 40</ref> displays adverse reactions recommended to be included in section 6 of product labeling.  We compared exposure-adjusted abnormal laboratory values reported as adverse events during the Placebo-controlled Period and the Base Period. We observed no clinically relevant drugrelated trends in abnormal laboratory values during the Phase 2/3 trials. Additionally, there were no clinically meaningful changes in laboratory values during the 120-day Safety Update reporting period.</p><p>Laboratory evaluations including hematology, serum chemistry and urinalysis were also obtained pre-and postdose at various time points during the Phase 1 trials. There were no clinically meaningful trends for changes in laboratory values within any of the Phase 1 trials.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Vital Signs</head><p>As discussed in section 7.4.3 of this review, vital signs were assessed at every clinic visit during the Phase 2/3 trials and included measurement of temperature, respiratory rate, resting pulse rate and blood pressure. Vitals signs were summarized and compared across common timepoints in the Phase 2/3 trials.</p><p>There were no clinically meaningful changes in blood pressure, respiratory rate, pulse rate, or temperature during the Phase 2/3 trials. Additionally, there were no clinically meaningful changes in vital signs during the 120-day Safety Update reporting period.</p><p>Reference ID: 4233639</p><formula xml:id="formula_10">(b) (4)</formula><p>Vital signs measured during the Phase 1 trials included blood pressure, pulse rate, and body temperature. As in the Phase 2/3 trials, investigators reported no AE related to vital signs, and no clinically relevant changes in vital signs were noted.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Electrocardiograms (ECGs)</head><p>The applicant summarized changes from baseline in electrocardiogram (ECG) findings for the Phase 2/3 Base Period Safety Pool. Due to re-randomizations in different parts of the trial, these summaries were restricted to the 4 continuous exposure arms. Because the 3 trials had different visit schedules, for the purpose of comparison of results across time, only the trial visits common across the Phase 2 and 3 trials were summarized. Common time points for measurement of ECG parameters were Week 0, 4, 12, 28, and 52 (Trial P003 and P011) or 64 (P010). In Trial P003, P010, and P011, the applicant reported that no clinically relevant changes from baseline in ECG parameters.</p><p>The evaluation of safety included ECGs in Phase 1 Trials P05382 in subjects with psoriasis; and trials P05661, P05776, and P06306 in healthy subjects. An integrated analysis of ECG data from these Phase 1 trials revealed no evidence of QTc prolongation.</p><p>Per the consult review by Dr. Christine Garnett, the QT Interdisciplinary Review Team (QT-IRT) concluded that, "Based on analysis of the ISS data sets tildrakizumab does not appear to prolong QTc, PR or QRS."</p><p>Evaluation of the effect of tildrakizumab on the QT interval will be discussed in the next subsection of this review.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>QT</head><p>The ICH E14 guideline regarding the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs does not specifically address QT assessments for biologic agents. Recent publications, however, indicate a consensus that, because of their large size and high target specificity, mAbs such as tildrakizumab have a very low likelihood for ion channel interactions and therefore thorough QT/QTc studies are not generally needed.</p><p>Although a thorough QT study was not performed for tildrakizumab, the applicant nonetheless explored a relationship between tildrakizumab concentrations and QTc during the development program. The QT Interdisciplinary Review Team (QT-IRT) reviewed data including pre-and posttreatment ECG parameters submitted by the applicant and a revised ECG outlier analysis. Per the QT-IRT consult review by Dr. Christine Garnett, "Based on analysis of the ISS data sets tildrakizumab does not appear to prolong QTc, PR or QRS."</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunogenicity</head><p>Because therapeutic proteins have the potential to elicit an immune response, the applicant used validated assays to assess the immunogenicity of tildrakizumab in human serum in 8 trials in the development program (P05661, P05776, P06306, P05382, P009, P010, P011, P05495</p><p>[P003]). Because the applicant used different assays for the immunogenicity assessment in different phases of the development program, the analysis of the impact of antibody production on safety was conducted with data from pooled Phase 3 trials only.</p><p>After up to 64 weeks of treatment, the incidence of treatment-emergent anti-drug antibodies (TE-ADA) to tildrakizumab in the pooled Phase 3 trials P010 and P011 was 6.8% (25/369) for subjects receiving 100 mg and 8.8% (29/329) for subjects receiving 200 mg of tildrakizumab. Among the subjects with TE-ADA, the incidence of neutralizing antibodies was 40.0% (10/25) for subjects receiving 100 mg and 37.9% (11/29) for subjects receiving 200 mg. Although the numbers of subjects with TE-POS NAb-POS was limited (21 subjects), some adverse events were observed with greater frequency in the TE-POS NAb-POS group (increased injection site reactions and hypersensitivity reactions). Refer to the assessment of immunogenicity by Dr. Jie Wang in Section 6.2.1.4 and the Pharmacology Appendix of this review for a discussion of the immunogenicity findings and incidence rates.</p><p>The following information from the Phase 3 trials is recommended to be included in Section 6.2 of labeling regarding 100 mg dose of tildrakizumab:</p><p>"Up to Week 64, approximately 6 % of subjects treated with ILUMYA developed antibodies to tildrakizumab. Of the subjects who developed antibodies to tildrakizumab, approximately 40% had antibodies that were classified as neutralizing antibodies. Neutralizing antibodies to tildrakizumab were associated with reduced drug concentrations and reduced efficacy. Subjects who developed antibodies to tildrakizumab were more likely to experience hypersensitivity or injection-site reaction compared to subjects who were antibody negative."</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Rebound</head><p>The applicant evaluated rebound of psoriasis during Part 3 of Trial 010 following withdrawal of tildrakizumab treatment among re-randomized tildrakizumab responders. Rebound of disease was defined as worsening of psoriasis over Baseline PASI score (PASI &gt;125%), or new pustular, erythrodermic, or more inflammatory psoriasis occurring within 2 months of stopping therapy. No subjects in either treatment group (100 mg placebo or 200 mg placebo), experienced rebound of disease during Part 3 (Weeks 32 to 64).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of Submission-Specific Safety Issues</head><p>The applicant analyzed the safety parameters using a tiered approach with pre-specified analyses associated with each tier. <ref type="bibr">19</ref> Tier 1 adverse events (AEs) represented "adverse events of special interest" which were related to the proposed tildrakizumab mechanism of action (immunomodulation via cytokine blockade), class effects associated with other anti-cytokine antibody therapies and the specific risks and co-morbidities observed in the target population.</p><p>Adverse events identified as Tier 1 were as follows:</p><p>Serious infections (defined as any infection meeting the regulatory definition of an SAE, or any infection requiring IV antibiotics regardless of whether it was reported as an SAE, as per the regulatory definition) Malignancies (excluding carcinoma in situ of the cervix) </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Severe Infections</head><p>During the Placebo-controlled period, the incidence of severe infections was the same in the tildrakizumab 200 mg group and the placebo group (0.3/100 subject-years) and was less in the tildrakizumab 100 mg group (0.1/100 subject-years). During the base period, there were more severe infections among subjects receiving tildrakizumab 200 mg (14 subjects or 1.61/100 subject-years) than receiving tildrakizumab 100 mg (11 subjects or 1.10/100 subject-years) or placebo (2 subjects or 0.91/100 subject-years). However, among subjects with continuous exposure to tildrakizumab 100 mg or 200 mg, the incidence of severe infections was comparable (0.8 subject years). Severe infections reported during the Base period by more than 1 subject included appendicitis, cellulitis, diverticulitis, epiglottitis, gastroenteritis, herpes zoster, sinusitis, and wound infection. Other severe infections reported by a single subject include tuberculosis, erysipelas, pneumonia, sepsis, septic shock, pyelonephritis, soft tissue infection, and urosepsis. There was a higher percentage of subjects with infections/infestations among partial responders in Part 3 who started with 100 mg and received 200 mg compared to those who continued to receive 100 mg. In the Extension period, the incidence of severe infections was comparable (1.3%) among subjects receiving tildrakizumab 100 mg and 200 mg.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Selected Narratives of Drug-Related Infections</head><p>Tildrakizumab 200 mg A 53-year-old Asian male with a medical history of tobacco usage (40 pack years) who received tildrakizumab 200 mg experienced a drug-related adverse event of epiglottitis. On Day 1, the subject was randomized to tildrakizumab 200 mg. Approximately 49 days after the last dose of tildrakizumab (Day 79), he was diagnosed with epiglottitis and hospitalized. After treatment with antibiotics and dexamethasone, the swelling improved. The subject was withdrawn from the trial. The event resolved on Day 323.</p><p>Two subjects (41-year-old White male and 63-year-old black male) with a history of smoking who received tildrakizumab 200 mg experienced drug-related adverse events of cellulitis. Both subjects received the diagnosis of cellulitis (sacrum and right face, respectively) on approximately Day 450 and were hospitalized. The events resolved with antibiotics and both subjects continued tildrakizumab and completed the base period.</p><p>A 74-year-old White female ) with a history of diabetes who received tildrakizumab 200 mg had a serious, drug-related adverse event of herpes zoster, which led to discontinuation from the trial. On Day 107 the subject was hospitalized with erythema, blistering, pain and pruritus localized to area innervated by the right trigeminus nerve (V1 and V2). Her last dose of tildrakizumab was on Day 28. She improved after treatment with acyclovir and gabapentin and was discharged from the hospital on Day 118. On Day 134, the signs and symptoms of herpes zoster recurred.</p><p>A 58-year-old White male with a history of obesity and tobacco usage (28 pack years) who was receiving tildrakizumab 200 mg, experienced a severe, drug-related event of wound infection. On Day 76, the subject experienced infection of incised wound on his left thenar eminence and was hospitalized for hand surgery. The subject was treated with clindamycin and was discharged from the hospital on Day 83. On day 96, the subject resumed the study medication. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tildrakizumab 100 mg</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Opportunistic infections</head><p>Opportunistic infections (OIs), which have been defined as infections that are more frequent or more severe because of immunosuppression 21 , include tuberculosis (TB), muco-cutaneous candidiasis, herpes infections, and progressive multifocal leukoencephalopathy/JC virus infection. <ref type="bibr">21</ref> Guidelines for Prevention and Treatment of Opportunistic Infections in HIV Infected Adults and Adolescents. Downloaded from https://aidsinfo.nih.gov/guidelines on 8/21/2017</p><p>Reference ID: 4233639</p><formula xml:id="formula_11">(b) (6) (b) (6) (b) (6) (b) (6) (b) (6)</formula><p>In the development program for tildrakizumab, one subject developed a TB infection. The following is a brief narrative:</p><p>A 58-year-old Asian male (P010:</p><p>) from Canada with a history of chronic cough, abnormal chest x-ray, tobacco usage (11 pack years), low back pain and enrollment in an apremilast trial developed tuberculosis of vertebral column on Day 178 after 3 doses of tildrakizumab. Prior to randomization, the subject was evaluated for chronic cough with a transbronchial needle biopsy of the left upper lobe. Results showed non-necrotizing granulomas that were negative for fungal organisms and acid fast bacilli. A Mantoux tuberculin skin test conducted at screening was negative. On an unknown date the subject experienced worsening back pain. The evaluation included a bone biopsy which was positive for acid fast bacilli at T8. The subject was diagnosed with active tuberculosis of the spine on Day 178. On Day 191, a CT scan showed a left upper lobe mass and multiple destructive lesions in the right scapula, bilateral ribs, and the vertebral bodies. His last dose of tildrakizumab prior to the AE was on Day 118.The only risk factor that was reported by the subject was occasional travel to Asia for business. The subject completed his last study visit on Day 156 and was discontinued from the trial on Day 202. On Day 570 the event was considered resolved after treatment with ethambutol, isoniazid, rifampin, pyridoxine, pyrazinamide, and moxifloxacin. The event was assessed as related to tildrakizumab.</p><p>Ten events of herpes zoster occurred in the Base period and 5 events in the extension period with exposure to tildrakizumab doses ranging from 25 mg to 200 mg (total doses of 150-1600 mg of tildrakizumab) or etanercept (2 subjects). There was no clear evidence of a dose response. The mean age of subjects who developed herpes zoster was 53 years (range 25-74 years). Most AEs were moderate in severity, occurred late in the course of treatment and resolved without sequelae. Age was the only risk factor identified in most subjects. A 74-yearold female was hospitalized for herpes zoster and withdrawn from the trial. For the remainder of the subjects who developed herpes zoster, the AE did not result in a change in the dose of the study drug or discontinuation from the trial.</p><p>There were no reports of progressive multifocal leukoencephalopathy or a significant imbalance in candidal or herpes simplex infections.</p><p>The following language is recommended to be included in Section 5.3 of product labeling: "In clinical trials, of 55 subjects with latent TB who were concurrently treated with ILUMYA and appropriate TB prophylaxis, no subjects developed active TB (during the mean followup of 56.5 weeks)."</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Malignancy</head><p>The Phase 2 and Phase 3 trials excluded subjects with prior malignancy or concurrent malignancy (except for successfully treated basal cell carcinoma, squamous cell carcinoma of the skin in situ, squamous cell carcinoma with no evidence of recurrence within 5 years, or carcinoma in situ of the cervix that has been adequately treated).</p><p>The number of subjects who reported the development of malignancies (solid tumors, hematologic malignancies and malignant melanoma) during the Base period is summarized in the table below. The only solid tumor reported by more than one subject (aged 58 years and 67 years) in the tildrakizumab groups was pancreatic cancer. Both subjects who developed pancreatic cancer received tildrakizumab 200 mg (3 or 5</p><p>Reference ID: 4233639</p><formula xml:id="formula_12">(b) (6) (b) (6) (b) (6)</formula><p>doses), the events were assessed as not related and the subjects withdrew from the trial. One subject had a history of hyperlipidemia ; the other subject had no relevant risk factors but assessment of causality was confounded by previous use of cyclosporine and apremilast for the treatment of plaque psoriasis. Per applicant, the other malignancies which were assessed as related to tildrakizumab were transitional cell carcinoma of the bladder in a 74-year-old White male with a history of prostatic hypertrophy and previous use of cyclosporine, methotrexate and monoethyl/diethyl fumarate for the treatment of plaque psoriasis (after 4 doses of tildrakizumab 100 mg) and thyroid cancer in a 35-year-old White female with a history of nodular goiter receiving methimazole which was an incidental finding after surgical removal of the thyroid gland (after 6 doses of tildrakizumab 100 mg).</p><p>The only solid tumor reported by more than one subject (aged 39 years and 50 years) in the etanercept group was breast cancer. The events were assessed as moderate or severe and related to the study product. However, the younger subject had an undisclosed history of breast cancer and was withdrawn from the trial. This subject also received 1 dose of tildrakizumab 200 mg. The event was assessed as unlikely to be related to tildrakizumab. The second subject had no risk factors for breast cancer (no long-term use of hormone replacement therapy and no personal or family history of breast cancer). Assessment of causality was confounded by previous use of monoethyl/diethyl fumarate and an investigational janus kinase inhibitor for the treatment of plaque psoriasis.</p><p>There were 3 subjects who received tildrakizumab 100 mg and developed malignant melanoma. A 28 year-old male without documented risk factors developed malignant melanoma on Day 135 after 3 doses of tildrakizumab 100 mg. The subject was withdrawn from the trial. The event was assessed as severe (lymph nodes positive for melanoma) and related to the study product. A 56 year-old male with a history of a dysplastic nevus developed a malignant melanoma in situ within a dysplastic nevus on Day 343 after 5 doses of tildrakizumab 100 mg. The event of melanoma did not result in interruption or discontinuation of treatment. The event was assessed as moderate and not related. In addition, a 24 year-old male with a history of many nevi and use of tanning beds experienced 2 events of malignant melanoma in situ (Day 197 and Day 208) after 2 doses of 100 mg and 1 dose of 25 mg of tildrakizumab. The subject was withdrawn from the trial. The events were assessed as moderate and not related to the study product.</p><p>During the Base period, 15 subjects who received one of the proposed doses of tildrakizumab (9 subjects receiving 100 mg and 6 subjects receiving 200 mg) developed basal cell carcinomas (BCCs). The onset of the events occurred between Day 29 and Day 266. Subjects in the tildrakizumab group were exposed to 1 to 6 doses prior to the event of BCC. The reported severity of basal cell carcinoma was mild in 4 subjects, moderate in 9 subjects and severe in 2 subjects. The majority were White males ranging in age from 50 to 72 years old. Four of 13 subjects (31%) had a history of BCC or actinic keratosis (AK) or a family history of skin cancer. Two subjects (15%) had a document history of using photosensitizing medications (acitretin and furosemide) and no subjects had a documented history of phototherapy. Four subjects (31%) developed BCCs and squamous cell carcinomas (SCCs) during treatment with tildrakizumab 100 mg. Two subjects (15%) who developed BCCs received etanercept for 28 weeks and then tildrakizumab 200 mg. All subjects who developed BCC while receiving tildrakizumab continued in the trial without interruption or discontinuation of treatment. All events resolved and were assessed as not related.</p><p>Reference ID: 4233639</p><formula xml:id="formula_13">(b) (6) (b) (6) (b) (6) (b) (6) (b) (6) (b) (6)</formula><p>A 39-year-old, White male with a history of multiple allergies, tobacco usage (21 pack years) experienced urticaria on Day 326 after 5 doses of tildrakizumab 200 mg. Concomitant therapy included ibuprofen and clarithromycin for an infection. The subject received fluprednidene acetate, clemastine fumarate and dimetindene maleate and the urticaria resolved on Day 332. The event of urticaria was assessed as moderate in intensity and related to study medication. No action was taken regarding the study medication. The subject completed the base study on Day 361.</p><p>A 33-year-old, White female with a history of tobacco use (12 pack years) experienced urticaria and face swelling on Day 227 after 4 doses of tildrakizumab 100 mg. Concomitant therapy included ibuprofen, clemastine fumarate, and fexofenadine hydrochloride. The subject stated the urticaria and facial swelling occurred after exposure to a new ketchup brand the day after the last injection. The facial swelling resolved on Day 230 and the urticaria resolved on Day 240 after treatment with cetirizine hydrochloride, loratadine and prednisolone. Both urticaria and face swelling were both considered to be moderate in intensity and were assessed as related to the study product. On Day 347, the subject experienced another event of urticaria on her arms and legs 65 days after the previous dose of tildrakizumab. The subject attributed the urticaria to alcoholic drinks. The urticaria did not occur after subsequent doses and the subject completed the Base period. .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Selected narratives of discontinuations due to hypersensitivity reactions</head><p>A 62-year-old, White female with a history of fruit allergy, diabetes mellitus and no new medications or prior episodes of edema experienced swelling of her tongue, face, and lips on Day 124 after 2 doses of tildrakizumab 100 mg. Her last dose of tildrakizumab prior to the event was on Day 114. The event resolved on the same day with administration of dimetindene maleate and prednisolone. On Day 130, the subject experienced face swelling and lip swelling which resolved with the same treatment. She received another dose of tildrakizumab 100 mg on Day 142. On Day 143, the subject experienced swollen tongue on the left side which resolved the same day with administration of prednisolone, ranitidine, and clemastine fumarate. On Day 155, the subject experienced lip swelling which resolved the same day. Concomitant therapy included ramipril, hydrochlorothiazide, and prednisolone. Investigators observed no further episodes of swelling. The subject withdrew from the study on Day 226. These events were assessed as related to study medication.</p><p>A 44-year-old Native Hawaiian or Pacific Islander female with a history of seasonal allergy and no prior history of drug allergy experienced pruritus of the face, neck, and arm on Day 116 after 2 doses of tildrakizumab 100 mg. Initially, the subject was randomized to placebo; at the Week 12 visit, the subject was re-randomized to tildrakizumab 100 mg. Concomitant therapy included general anesthesia, amoxicillin, and ibuprofen. On Day 114 the subject received tildrakizumab 100 mg and on Day 116, the subject experienced facial, neck, and arm itching without oral or throat swelling. The subject received outpatient treatment with hydroxyzine hydrochloride, diphenhydramine hydrochloride, cetirizine hydrochloride. The subject withdrew from the trial on Day 127. On Day 142, the event of hypersensitivity resolved. The event was assessed as related to study medication.</p><p>A 53-year-old Asian female with a history of multiple allergies and asthma, developed angioedema and urticaria after her first dose of placebo. On Day 1, the subject experienced flushing all over her body and on Day 3 and noted urticaria on her extremities, ears, and face. On Day 5 the subject experienced angioedema and an urticaria drug eruption. The subject denied new medications, foods or other triggers. The subject withdrew from the trial Reference ID: 4233639</p><formula xml:id="formula_14">(b) (6) (b) (6) (b) (6) (b) (6) (b) (6)</formula><p>on Day 7 and the events of urticaria and angioedema resolved on Day 25. The events of angioedema and urticaria were assessed severe in intensity and as related to study medication Although no events of anaphylaxis, there were events of angioedema in subjects receiving tildrakizumab and placebo. Therefore, information regarding hypersensitivity is recommended to be included in the Warnings and Precautions (Section 5.1) and in Clinical Trials Experience (Section 6.1) of the product labeling.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other Adverse Events of Special Interest</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neuropsychiatric Adverse events</head><p>Patients with psoriasis have a greater risk of the development of psychiatric disorders than the general population. <ref type="bibr">27</ref> To address the concern that anticytokine therapies may potentiate this risk, the applicant agreed to conduct a retrospective analysis of suicidal ideation and behavior (SIB) events using the Columbia Classification Algorithm of Suicide Assessment (C-CASA) for submission with the Safety Update Report.</p><p>All the SIB events occurred in subjects receiving tildrakizumab. During the base period of the pooled safety analysis set (P003, P010, P011), there was 1 suicide attempt and 2 events of suicidal ideation in one subject during a single hospitalization. During the extension Phase, there were 2 completed suicides and 1 event of suicidal ideation. In addition, there was one suicide attempt during the Phase 1 Trial P007. These events are briefly summarized below.</p><p>A 43-year-old Asian male subject enrolled in Trial P010 with a history of schizophrenia which was treated with anti-psychotic medications and benzodiazepines attempted suicide by cutting his abdominal wall on Day 12 after 1 dose of tildrakizumab 200 mg.</p><p>A 35-year-old multi-racial female with history of a suicide attempt, anxiety, bipolar disorder, depression, and insomnia reported suicidal ideation while hospitalized for management for worsening depression and bipolar disorder on Day 278 after 4 doses of 100 mg tildrakizumab. Her psychotropic medications had been interrupted for a span of 2 months prior to the event.</p><p>A 45-year-old White male with history of facial nerve pain and concomitant treatment with pregabalin and methylphenidate (MPH) and mixed amphetamine salts died on Day 1306 by jumping off a roof after receiving tildrakizumab 200 mg in the base period (6 doses) and tildrakizumab 100 mg (10 doses) in the extension period. After the event, the family reported that the subject had financial issues and concerns that "the CIA (was) following the subject" and he had few likes of his photograph on Facebook.</p><p>A 47-year-old White male with a history of anxiety which was treated with alprazolam and atomoxetine died on Day 1227 of a self-inflicted gunshot to the head. The subject had not reported suicidal ideation, depression, or psychosocial stressor. Reference ID: 4233639</p><formula xml:id="formula_15">(b) (6) (b) (6) (b) (6) (b) (6) (b) (6)</formula><p>11 doses of tildrakizumab 100 mg. The trigger for episode of depression was loss of employment. The subject continued to receive tildrakizumab.</p><p>A 24-year-old Japanese male enrolled in Phase 1 Trial P007 reported suicidal ideation of severe intensity (suicide note/plan) on Day 63 after a single 400 mg dose of tildrakizumab. He had no history of depression or suicidal ideation but experienced significant financial and psychosocial stressors related to unemployment and compulsive gambling.) The subject was discontinued from the trial.</p><p>In addition, there were deaths which were difficult to define as SIB events due to insufficient information. The cause of death for one subject with a history of depression and suicidal ideation was reported as a toxic reaction between fluoxetine and cyclobenzaprine. There were 2 other deaths related to alcohol abuse. Refer to Section 7.3.4 of this review for brief narratives.</p><p>Jean Kim MD, MA, Division of Psychiatry Products (DPP), provided WHO based causality assessments of the SIB events and suspicious deaths summarized above (Review dated 10/19/2017). She concluded that only the suicide attempt by Subject was possibly related to tildrakizumab due to the temporal association with drug administration.</p><p>The blinded, external Clinical Adjudication Committee (CAC) at Columbia University reviewed data which was submitted with the original BLA from the 9 trials in the tildrakizumab clinical development program (Safety Update Report dated 10/2/2017; SD 18). The CAC identified 3 cases in the base period of the Phase 2 and Phase 3 trials: 1 suicide attempt and 2 events of suicidal ideation in one subject during a single hospitalization. The exposure adjusted rates for tildrakizumab in the base period were compared with results of the DEPI-I analysis 28 of pooled Phase 2/3 data for biologics (excluding brodalumab), the exposure-adjusted rates were 0 vs. 14.5 per 100,000 PY for completed suicides; 28.5 vs. 50.7 per 100,000 PY for suicide attempts; and 28.5 vs. 25.4 per 100,000 PY for ideation. The CAC concluded that "the results are considered generally comparable with the low rates observed in the development programs for other biologics." There were 3 additional SIB events after the C-CASA analysis period (2 completed suicides and 1 suicidal ideation). All three events were assessed as unrelated to tildrakizumab by the adjudication committee and did not change the safety conclusion.</p><p>Dr. Kim stated that the rates of psychiatric AEs were low in the tildrakizumab treatment groups in the Phase 2 and 3 trials. The crude rates for the placebo controlled period were: 1.6% (tildrakizumab 100 mg), 2.3% (tildrakizumab 200 mg) and 0.84% (placebo). She indicated that these differences were not nominally statistically significant. The 2 completed suicides which occurred during the extension trials (Safety Update Report dated 10/2/2017; SD 18) occurred in the context of pre-existing psychiatric disease and were not likely to be related to tildrakizumab. In addition, adverse events of depression, anxiety and insomnia, the most common psychotic adverse events, were not likely to be related to tildrakizumab.</p><p>Dr. Kim did not recommend specific psychiatric warning language in the tildrakizumab labeling. Dr. Kim concluded that "there is insufficient evidence of increased risk of SI/B or other psychiatric issues thus far with tildrakizumab, in terms of direct drug-related effect, based on the current clinical trial data available. There is also no preliminary research thus far showing any clear association with IL-23 and psychiatric sequelae." See review by Dr. Kim dated 10/19/2017.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Analyses by Demographic Subgroups</head><p>The review team conducted multiple analyses to evaluate the safety profile of tildrakizumab in different populations. The results indicated that there were no substantial differences in the risk of adverse reactions in demographic subgroups. However, because the trials were not powered for these analyses, the data must be interpreted with caution. A slightly greater proportion of females who received tildrakizumab reported adverse reactions of injection site reaction, fatigue, abdominal pain, diarrhea and nausea than males. Approximately 90% of subjects enrolled in the pooled Phase 2 and Phase 3 trials were adults 64 years of age; therefore, because of the limited number of subjects age &gt;65 years, it would be difficult to detect any differences in safety compared with younger subjects. The data for safety by race is difficult to interpret due to the relatively small sample sizes of the non-White subgroups (White; 80%; Asian 14%;others races 3% each). The safety findings across the weight subgroups ( 90 kg and &gt; 90 kg) were similar although a greater percentage of subjects in the &gt;90 kg subgroup who received tildrakizumab experienced injection site reactions. Refer to Appendix 13.3 for the results of the safety analyses by demographic subgroup.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Specific Safety Studies/Supportive Clinical Trials</head><p>The applicant completed 6 Phase 1 trials with different doses, dosing regimens, routes of administration, study populations, and indications which provided supportive safety data (P05382, P05661, P05776, P05839, P06306, and P009). The following are brief descriptions of the trials and key pertinent safety findings. This was a three part, multiple-dose, randomized, placebo-controlled, patient and evaluatorblind, multi-center trial of IV administered tildrakizumab (0.05, 0.1, 0.5, 3 and 10 mg/kg) in 77 subjects aged 22-65 years with moderate to severe psoriasis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Results</head><p>There were no deaths but 10% (N=8) subjects reported a total of 11 serious adverse events (SAEs). A single severe SAE in tildrakizumab 10 mg/kg group (convulsion, 17 days after his second dose of tildrakizumab in a 48-year-old subject with a history of heavy alcohol use) was considered possibly related to treatment. Other SAEs assessed as not related included pulmonary embolism, pulmonary hypertension, and deep venous thrombosis (DVT) in a 57year-old male with a history of DVT (132 days after his last dose of study medication); cardiac enzymes increased, myositis, followed by cytomegalovirus infection in a 63 -year-old female diagnosed with myositis / scleromyositis (311 days after the last dose of tildrakizumab 3 mg/kg) and SAE related to falls/injuries in 5 subjects (fracture of orbital bones, meniscal abrasion, ankle fractures, left arm fracture, pneumothorax). Two (3%) subjects discontinued from the study due to AEs: convulsion (10 mg/kg group), arthralgia (placebo group) and psoriasis (placebo group). There were no AEs of special interest.</p><p>A total of 62 out of 77 (81%) subjects reported AEs. The most frequently reported AEs were headache and upper respiratory tract infection reported by 14 (18%) subjects each. Most AEs were mild or moderate in intensity. Seven (9%) subjects reported a total of 12 AEs of severe intensity (10 of which also met the criteria for a SAE). A total of 15 subjects (19%) reported adverse reactions (ARs). The most frequent ARs were arthralgia and increased blood creatine phosphokinase, each reported by 2 (3%) subjects. Single subjects reported all other ARs. There were no clear dose related trends in AEs. There were no clinically meaningful changes in laboratory parameters, vital signs or ECG parameters. PROTOCOL P05661 (single dose) "A Rising Single-Dose Tolerability, Safety, and Pharmacokinetic Study of Intravenous SCH 900222 (tildrakizumab; MK-3222) in Healthy Volunteers."</p><p>This was a single-dose, randomized, placebo-controlled, third-party, evaluator-blind, trial of IV administered tildrakizumab (0.1, 0.5, 3 and 10 mg/kg) in 29 healthy subjects aged 18-44 years.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Results</head><p>There were no deaths, but 2 subjects reported SAEs (placebo group: upper airway obstruction and rhinitis in a subject with a history of cartilaginous overgrowth; 10 mg/kg group: Chikungunya virus infection on Day 199) which were assessed as unlikely and not related, respectively. One subject who received 210 mg of tildrakizumab reported a pregnancy on Day 112 and delivered a healthy infant with mild jaundice. A total of 24 (83%) subjects reported at least one AE during the trial: 2 (50%) subjects in the 0.1 mg/kg group, 4 (100%) subjects in the 0.5 mg/kg group, 7 (88%) subjects in the 3 mg/kg group, 6 (100%) subjects in the 10 mg/kg group, and 5 (71%) subjects in the placebo group. The most common AEs were upper respiratory tract infection (N=11), headache (N=8), vessel puncture site hematoma (N=4), lethargy (N=3), pharyngitis (N=3), dysmenorrhea (N=2), nasopharyngitis (N=2), nausea (N=2), rhinitis (N=2), and seasonal allergy (N=2). The most frequent ARs were headache (N=3), and upper respiratory tract infection (N=2). There were no clinically meaningful changes in laboratory parameters, vital signs or ECG parameters. PROTOCOL P05776 (single dose) "A Single-Dose Safety and Tolerability, Placebo-controlled Study of Subcutaneous (SC) SCH 900222 (tildrakizumab; MK-3222) in Healthy Volunteers."</p><p>This was a single-dose, randomized, double-blind, placebo-controlled, trial of SC administered tildrakizumab (50 mg, 200 mg) in 37 healthy subjects age 18-45 years.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Results</head><p>There were no deaths or SAEs. One subject reported a tildrakizumab-related injection site reaction (hematoma.) There were no adverse events of special interest.</p><p>A total of 24 (65%) subjects reported at least one treatment-emergent adverse event (TEAE) during the trial: 9 (64%) subjects in the 50 mg group, 8 (57%) subjects in the 200 mg group, and 7 (78%) subjects in the placebo group. The most common TEAEs were upper respiratory tract infection (12/37 [32%]) and headache (10/37 [27%]). TEAEs reported in 2 or more subjects included: upper respiratory tract infection (n=12), headache (n=10), acne (n=2), gastroenteritis (n=2), injection site erythema (n=2), insomnia (n=2), migraine (n=2), rhinitis allergic (n=2), and rash (n=2).</p><p>Headache was the most common adverse reaction (AR). Only one subject (7%) who received 50 mg of SCH 900222 reported a AR (headache). Five (36%) of the subjects who received 200 mg of tildrakizumab had an AR: headache (n=2), gastroenteritis (n=1), dry skin (n=1), erythema (n=1), injection site hematoma (n=1), rash (n=1), rash generalized (n=1), and tonsillitis (n=1). In addition, five subjects (56%) who received placebo had an AR: headache (n=2), gastroenteritis (n=1), injection site erythema (n=2), and rhinitis (n=1).</p><p>There were no clinically meaningful changes in laboratory parameters, vital signs or ECG parameters. PROTOCOL P05839 (1 or 2 doses) "Safety, and Pharmacokinetics of Intravenous Anti-IL-23 Antibody SCH 900222 (tildrakizumab; MK-3222) in Crohn's Disease."</p><p>This was a randomized, placebo-controlled, patient and evaluator-blind (open-label for pharmacist), multi-center trial of IV administered tildrakizumab (one dose of 0.5, 3 or 2 doses of 10 mg/kg) in 24 subjects aged 24-64 years with active Crohn's Disease.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Results</head><p>There were no deaths or SAEs. A 28-year old female in the 3 mg/kg treatment group discontinued the trial on Day 41 due to pregnancy and had an elective termination. A total of 15 subjects (63%) reported AEs during the study: 4 subjects (67%) in the 0.5mg/kg group, 5 subjects (83%) in the 3 mg/kg group, and 3 subjects (50%) each in the 10mg/kg and placebo group. The most commonly reported AEs were headache, fatigue, and lower abdominal pain (3 subjects each, 13%); vomiting, dizziness, and nausea (2 subjects each, 8%).</p><p>ARs were reported by 1 subject (17%) in the 3mg/kg group; 2 subjects (33%) each in the 10mg/kg and placebo group. Other ARs were headache, nausea, vomiting, fatigue, dizziness, flushing, catheter site pain, dysgeusia, edema peripheral, and somnolence. Most of the ARs were assessed as (15/24, or 63%) either mild (4 subjects, 17%) or moderate (11 subject, 46%) in severity and none resulted in discontinuation of the study product. There were no adverse events of special interest. However, 1 subject experienced a hypersensitivity reaction to a concomitant medication in the 50 mg group.</p><p>There were no clinically meaningful changes in laboratory parameters, vital signs or ECG parameters.</p><p>PROTOCOL P06306 (single dose) "Influence of Race and Ethnic Origin on the Pharmacokinetics of SCH 900222 (tildrakizumab; MK-3222)"</p><p>This was a 2 part, open-label, single dose trial of SC and IV tildrakizumab (50mg, 200mg,400mg SC or 10 mg/kg IV) in 59 healthy Japanese, Chinese and White subjects age 19-44.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Results</head><p>There were no deaths; but 2 subjects reported SAEs (appendicitis assessed as not related and suicidal ideation assessed as unlikely related). Of the 59 subjects enrolled in the study, 50 (85%) reported at least one AE: 17 (89%) Caucasian subjects, 11 (92%) Chinese subjects, 17 (77%) Japanese subjects in Part 1 and 5 (83%) Japanese subjects in Part 2. The most frequent AEs in the trial were headache, upper respiratory tract infection and injection site hematoma reported by 14 (24%), 11 (19%) and 9 (15%) subjects respectively. There was no clear relationship between dose and incidence or severity of AE's. ARs were reported by 24 (41%) subjects in the study: 10 (53%) Caucasian subjects, 5 (42%) Chinese subjects and 9 (41%) Japanese (Part 1) subjects. The most common ARs in the trial were injection site hematoma, injection site pain and injection site erythema reported by 9 (15%), 6 (10%) and 5 (8%) subjects respectively. Most AEs were mild in intensity. Nineteen (32%) subjects reported adverse events of moderate intensity. Three of the 19 AEs were assessed as possibly related to treatment: abdominal pain (Japanese subject: 50 mg dose group), disturbance in attention and lethargy (Caucasian subject: 200 mg dose group), Three (16%) Caucasian subjects reported AEs of severe intensity: diarrhea, vomiting and headache (200 mg dose group), depression (50 mg dose group), appendicitis (50 mg dose group).After a single dose 400mg, one 24-year-old subject withdrew from the trial and was hospitalized due to suicidal ideation on Day 63 due to gambling debts and unemployment. There were no other adverse events of special interest. This was a randomized, fixed-sequence, 2-period, parallel group, multi-center, open-label, multiple-dose trial of SC tildrakizumab 100 mg administered via prefilled syringe (PFS) vs PFS housed in an autoinjector in 20 subjects with moderate to severe psoriasis age 18-65 years. This trial evaluated the effect of tildrakizumab on CYP metabolism (CYP probe substrates: caffeine, warfarin, vitamin K, omeprazole, dextromethorphan, and midazolam), the PK and relative bioavailability of tildrakizumab when administered via the PFS compared with PFS in an AI.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Results</head><p>There were no deaths; 1 subject experienced an SAE resulting in discontinuation from the trial on Day 56 (infected dermal cyst assessed as related to tildrakizumab). The SAE was considered moderate in intensity and resolved after incision, drainage and antibiotics. There were no adverse events of special interest.</p><p>Overall, 14 of the 20 randomized subjects (70.0%) reported a total of 30 AEs, 9 of which assessed as related to tildrakizumab. The most common AE was hyperglycemia which was reported by 6 subjects (30.0%), none of which were assessed related to treatment. Three (3) subjects (15.0%) reported alanine aminotransferase (ALT) increase. Other AEs that occurred in more than one subject included aspartate aminotransferase (AST) increase (n=2, 10.0%), blood bilirubin increase (n=2, 10.0 %) and headache (n=2, 10.0 %). There was one AE of Type 2 diabetes mellitus (T2DM) which was mild in intensity and assessed as not related to study drug. Most AEs were mild in severity. There were five subjects with AR (ALT/AST/ bili increased, headache, infected dermal cyst, streptococcal pharyngitis, vulvovaginal mycotic infection). In addition, ARs of moderate in intensity included: pharyngitis streptococcal, hepatotoxicity, and vulvovaginal mycotic infection, and infected dermal cyst. There were no clinically meaningful trends in laboratory parameters, vital signs or ECG parameters. withdrew from the 200 mg arm. The most common reasons were subject decision, adverse event and lost to followup. Five subjects withdrew due to pregnancy.</p><p>The long-term safety extension phases of the 2 Phase 3 trials provided approximately 11 months of additional safety data. Safety data from the Base period (64 weeks from P010 and 52 weeks from P011) was recoded from MedDRA Version 19.1 to MedDRA Version 20.0 to allow a comparison with this long-term safety data. The summary provides key findings and relevant comparisons of the safety of the 100 mg and 200 mg doses.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Suicidal Ideation and Behavior (SIB)</head><p>In the tildrakizumab development program, subjects were not excluded from enrollment based on a history of psychopathology. In response to the Agency concern regarding the relationship between immunomodulatory mechanisms of action of biologics and neuropsychiatric events, the applicant conducted a retrospective identification and adjudication of potential occurrences of suicidal ideation and behavior (SIB), using the Columbia Classification Algorithm of Suicide Assessment (C-CASA) methodology. A blinded, external Clinical Adjudication Committee (CAC) at reviewed the data across the development program through June 2016. During the C-CASA analysis period, there were 3 adjudicated SIB events: 1 suicide attempt and 2 events of suicidal ideation in 1 subject (considered 1 event of suicidal ideation). Per CAC, the results of the C-CASA analysis do not support a safety signal for SIB in association with exposure to tildrakizumab. However, after the C-CASA analysis period, there were 3 reports of subjects with SIB events: 2 completed suicides and a subject reporting suicidal ideation. The assessment of causality is confounded in both cases. CAC indicated that these cases did not change their conclusions. See review by Jean Kim MD, Medical Officer from the Division of Psychiatry Products (DPP) (dated 10/19/2017) and section 7.3.5 Adverse Events of Special Interest.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Deaths</head><p>There were 6 deaths among subjects enrolled in the Phase 3 Extension periods. Refer to Section 7.3.4 for a tabulation and discussion of the fatal adverse events.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Serious Adverse Events</head><p>In the SUR extension period, the overall rate of SAEs was 11.3% (65 subjects) in the 100 mg group and 10.4% (61 subjects) in the 200 mg group. Among these SAEs, 1.7% (10 subjects) experienced SAEs which were assessed as related to tildrakizumab in the 100 mg group and 1.0% (6 subjects) experienced SAEs which were assessed as related to tildrakizumab in the 200 mg group.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tier 1 Adverse Events</head><p>In the SUR extension period, the overall rate of Tier 1 AEs after adjudication (severe Infections, malignancies, melanoma and non-melanoma skin cancer, confirmed extended MACE, injection site reactions and drug-related hypersensitivity reactions) was greater in the 200 mg group (7.5%, 46 subjects) than the 100 mg group (6.9%, 43 subjects). The adverse events which appeared to show a dose response were injection site reactions (1.6%,10 subjects receiving 100 mg and 2.1%, 13 subjects receiving 200 mg), confirmed extended MACE (1.1%, 7 subjects receiving 100 mg and 1.6%, 10 receiving 200 mg) and melanoma (0%, 0 subjects receiving 100 mg and 0.2%, 1 receiving 200 mg) and non-melanoma skin cancer (0.2%, 1 subjects receiving 100 mg and 0.6%, 4 subjects receiving 200 mg).Note that not all non-melanoma skin cancers are included as Tier 1 events.</p><p>Reference ID: 4233639</p><formula xml:id="formula_16">(b) (4)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Infections</head><p>The overall incidence of severe infections (serious infections plus those requiring IV antibiotics) from the SUR was 2.7 % (17 subjects) in the tildrakizumab 100 mg group and 1.9 % (12) in the tildrakizumab 200 mg group. The types of severe infections reported in the long-term safety extension were similar to those observed in the Base period: sinusitis, pneumonia, cellulitis, gastroenteritis, urinary tract infection, and diverticulitis. In addition, a 68 -year-old Asian male receiving tildrakizumab 200 mg in the Extension period for approximately 22 months with normal liver function tests at baseline presented with nausea, abdominal pain and elevated liver function tests (total bilirubin 3.2 mg/dL, AST was 276 U/L, ALT 755 U/L, gamma GT 234 U/L, and ALP 410 U/L). Testing for Hepatitis E was positive. The source of the infection was consumption of wild boar meat. The study medication was withdrawn and the subject was discontinued from the trial.</p><p>Opportunistic Infections There were no new cases of tuberculosis or opportunistic infections (e.g. deep fungal or viral such as PML) reported in the Phase 3 Extension period. However, the SUR included 7 additional adverse events of herpes zoster (3 events associated with tildrakizumab 100 mg and 4 events associated with tildrakizumab 200 mg) and 1 event of ophthalmic herpes zoster associated with tildrakizumab 200 mg. In the pooled Phase 2 and Phase 3 trials and the extension periods, there were a total of 15 cases of herpes zoster (7 events associated with tildrakizumab 100 mg and 8 events associated with tildrakizumab 200 mg.) A total of 5/15 of these cases was assessed as related to the study product (3 events associated with tildrakizumab 100 mg and 2 events associated with tildrakizumab 200 mg.) See Section 7.3.5 [Opportunistic infections (OIs)] of this review for a discussion of the herpes zoster cases.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Malignancy</head><p>Greater numbers of neoplasms were identified in the SUR extension periods of the two Phase 3 trials than in the Base period of the pooled Phase 2/3 trials. Investigators reported equal numbers of solid tumors/hematologic malignancies in each dose group (10 or 1.6%). Small imbalances in non-melanoma/melanoma skin cancers were observed. The most common solid tumor was breast cancer but no malignancy was reported in greater than 0.5% of subjects.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Injection site reactions</head><p>Because subjects in the 200 mg group receive twice the number of injections as subjects in the 100 mg group, an imbalance in injection site reactions is expected in the 200 mg group compared to the 100 mg group. Injection site reactions in the 100 mg tildrakizumab group included: injection site bruising, injection site pain, and injection site pruritus. Injection site reactions in the 200 mg tildrakizumab group included injection site bruising, injection site discomfort, injection site laceration, injection site pain and injection site swelling. A greater number of subjects in the 200 mg experienced pain/discomfort associated with administration of the study product in the 200 mg group (4 subjects) than the 100 mg group (1 subject.)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Hypersensitivity Reactions</head><p>Four hypersensitivity reactions were reported in the SUR. All adverse events were assessed as unrelated to the study product.</p><p>A 69-year-old female with a history of drug hypersensitivity receiving tildrakizumab 100 mg developed a diffuse large B-cell lymphoma on Day 721 and was discontinued from the trial. Two events of drug eruption occurred (Day 761 and 782) were assed as mild and related to other medications (filgrastim and lansoprazole).</p><p>Reference ID: 4233639</p><formula xml:id="formula_17">(b) (6)</formula><p>A 38-year-old Asian male experienced transient urticaria (10 minutes) on Day 1026 which occurred 73 days after her last dose of tildrakizumab 100 mg. The event was assessed as mild and did not result in interruption in treatment. A 62-year-old Asian male receiving tildrakizumab experienced urticaria on Day 1030 which resolved with treatment on Day 185. The event was assessed as mild and did not result in interruption in treatment. A 58-year-old White male with a history of drug hypersensitivity, experienced 2 adverse events of urticaria on Day 45 and Day 1192. On Day 45 (16 days after his last dose of placebo) he experienced urticaria with swelling of the tongue and left side of the throat. The event was assessed as a food allergy which resolved in 2 days with treatment with diphenhydramine 50 mg PO BID. On Day 1192, the subject experienced urticaria occurring 71 day after his last dose of tildrakizumab 100. The subject received diphenhydramine and prednisone and the event resolved by Day 1200. Both events were assessed a moderate and did not result in interruption in treatment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MACE</head><p>In the SUR extension period, total of 15 subjects (1.2%) had MACE events and 17 subjects (1.4%) had extended MACE events. One subject with a confirmed MACE event had a fatal outcome. See Section 7.3.4 and Section 7.4.5.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discontinuations Due to Adverse Effects</head><p>In the 100 mg tildrakizumab group, new AEs leading to discontinuation of trial medication during the SUR period included diverticulitis, aspartate aminotransferase increased, psoriatic arthropathy (2 subjects), clear cell renal cell carcinoma, invasive lobular breast carcinoma, metastatic carcinoma of the bladder, non-Hodgkin's lymphoma, and ovarian cancer. In the tildrakizumab 200-mg group, AEs leading to discontinuation of trial medication included hyperglycemia, breast cancer metastatic, papillary thyroid cancer, prostate cancer, coronary artery disease, tachycardia, inappropriate antidiuretic hormone secretion, bronchitis, Hepatitis E, transient ischemic attack, asphyxia, chronic obstructive pulmonary disease, and psoriasis.</p><p>The SOC which accounted for the greatest number of discontinuations was the Neoplasms, benign, malignant and unspecified SOC (1.2% in the 100 mg group and 0.7% in the 200 mg group.) In addition, all the drug-related AEs leading to discontinuation in the 100 mg tildrakizumab group were in the Neoplasms SOC (diffuse B cell lymphoma, metastatic carcinoma of the bladder and Non-Hodgkin's lymphoma.) The single drug-related AEs leading to discontinuation in the 200 mg tildrakizumab group was in the Respiratory, thoracic and mediastinal disorders SOC (chronic obstructive pulmonary disease/bronchitis.)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other Adverse Events</head><p>In the SUR period, a greater percentage of subjects in the tildrakizumab 200 mg group (3.6%) reported levels of aminotransferase ALT or AST 3 x ULN than subjects in the tildrakizumab 100 mg group (1.5%). Shift tables for the extension pool in the SUR showed the greatest upward shifts from normal baseline values in ALT (24-26%), followed by GGT (17-19%) and then AST (11-13%). In all cases, there was a dose response with greater shifts in the liver function tests in tildrakizumab 200 mg group compared to the 100 mg group.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human Reproduction and Pregnancy</head><p>Requirements for females of childbearing potential who were enrolled in the tildrakizumab development program included the use of effective forms of contraception, negative pregnancy Reference ID: 4233639</p><formula xml:id="formula_18">(b) (6) (b) (6) (b) (6)</formula><p>tests at screening/baseline and urine pregnancy testing at appropriate intervals. Subjects who became pregnant withdrew from treatment and, where feasible, were followed until delivery. Pregnancy outcomes such as spontaneous abortion, stillbirth, and congenital anomalies were reported as SAEs. Based on the characteristics of therapeutic monoclonal antibodies (large molecular with limited exposure in semen) and data from nonclinical studies with tildrakizumab, the applicant concluded that tildrakizumab does not pose a pregnancy risk for exposed partners. Therefore, the applicant did not document the occurrence of partner pregnancies. Refer to Section 5 for a discussion of the nonclinical findings.</p><p>Among subjects receiving tildrakizumab in the development program through May 27, 2017, there were 14 pregnancies: 2 pregnancies reported in the Phase 1 trials [(P05661 and P05839 (subject with active Crohn's disease)], and 2 pregnancies in in the Phase 2 trial (P05495), and 10 pregnancies in the Phase 3 trials/extension. Pregnancy outcomes included 6 cases of fetal loss (2 spontaneous abortions and 4 elective abortions) and 7 full-term live births, and 1 pending pregnancy outcome. The 7 full-term live births produced healthy infants with no reported congenital anomalies. The 2 spontaneous abortions occurred at 4 and 8 weeks of gestation in smokers who were exposed to tildrakizumab 200 mg. One of the subjects who experienced a spontaneous pregnancy loss had a history of 2 full term live births, a prior ectopic pregnancy and a miscarriage.</p><p>In addition, 2 subjects In Trial P011 receiving etanercept 50 mg became pregnant during the trial [last menstrual period (LMP) on Day 77 and Day 27] and delivered healthy infants without congenital anomalies.</p><p>The information that will be conveyed in labeling (Section 8.1 Pregnancy and Section 8.2 Lactation) regarding the risks of exposure to tildrakizumab during pregnancy and lactation is presented in Section 5.6 of this review. In addition, refer to the review (dated 12/21/2017) by Christos Mastroyannis, M.D., Division of Pediatric and Maternal Health, for recommendations regarding post marketing requirements to evaluate the risks of exposure to tildrakizumab during pregnancy and lactation.</p><p>Because the available data are insufficient to inform tildrakizumab associated risk in pregnant women, we will require that the applicant conduct: 1) a prospective, registry based observational exposure cohort study that compares the maternal, fetal, and infant outcomes of women exposed to tildrakizumab during pregnancy to an unexposed control population, and 2) a retrospective cohort study using claims or electronic medical record data or a case control study to assess adverse pregnancy, neonatal and infant outcomes of women exposed to tildrakizumab during pregnancy compared to an unexposed control population.Refer to Section 12 Postmarketing Requirements and Commitments for further details.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human Carcinogenicity or Tumor Development</head><p>As large proteins, monoclonal antibodies are not expected to gain access to the nucleus and directly interact with DNA to promote carcinogenesis. Tildrakizumab will be catabolized to peptides and constituent amino acids via normal metabolic pathways. However, for any product that produces immunosuppression and which is indicated for chronic administration, there is a theoretical risk of increased malignancy. In patients with psoriasis, this risk may be potentiated by prior exposure to other immunosuppressive agents or other therapies that may enhance tumor development such as phototherapy.</p><p>No animal studies have been conducted to evaluate the carcinogenic or mutagenic potential of Reference ID: 4233639 tildrakizumab. Refer to Section 5.5.3 for a discussion of the carcinogenicity risk from a Pharmacology /Toxicology perspective.</p><p>Data from the nonclinical and clinical development programs do not support the conclusion that chronic administration of tildrakizumab is associated with an increased risk of carcinogenesis. However, the limited duration of observation during the drug development program is unlikely to allow detection of rare events with a long latency periods such as malignancy. Therefore, postmarketing data are needed to evaluate the long-term risk of malignancy in patients with psoriasis receiving tildrakizumab.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pediatrics and Assessment of Effects on Growth</head><p>The applicant has not conducted an evaluation of the safety and efficacy of tildrakizumab in the pediatric population. Because the proposed product is a new active ingredient, approval of tildrakizumab for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy triggers the Pediatric Research Equity Act (PREA)(21 U.S.C. 355c). Per the Food and Drug Administration Safety and Innovation Act (FDASIA), the applicant submitted an initial Pediatric Study Plan (iPSP) on December 11, 2015. The Agency agreed with the iPSP (Agreement Letter dated 6/9/2016).</p><p>In this submission, the applicant requested a partial waiver for studies in the pediatric population from birth to less than 6 years of age as "Necessary studies are impossible or highly impracticable due to the extremely low prevalence of moderate to severe psoriasis in this population." (Section 505B (a)(4)(B)(i) of the Act). Although the epidemiologic data are limited regarding the pediatric population with moderate to severe plaque psoriasis, in general the prevalence of plaque psoriasis increases with age. In addition, the sponsor requested a deferral of studies in the pediatric population from age 6 years to &lt;18 years "until safety and efficacy in the adult indication has been demonstrated in Phase 3 studies" (Section 505B (a)(3)(A)(ii) of the Act).</p><p>In the discussion with PeRC (12/20/2017) regarding the evaluation of tildrakizumab in the pediatric population, the Division conveyed their agreement with the proposed pediatric development program in the Agreed iPSP and the proposed timeline. PeRC concurred with the Division. Refer to Section 12 for the pediatric study requirement for tildrakizumab under PREA.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overdose, Drug Abuse Potential, Withdrawal, and Rebound</head><p>Overdose Overdose of the study product was defined as any dose higher than the dose specified in the individual trial protocol. During the Base period of the pooled Phase 2 and Phase 3 trials, there were 28 incidents of accidental overdose in 27 subjects. Among the 27 subjects with an incident of overdose, 5 subjects were randomized to tildrakizumab 100 mg, 13 subjects randomized to tildrakizumab 200 mg, 4 subjects randomized to placebo, and 5 subjects randomized to etanercept 50 mg. Most overdoses were mild in intensity (5 assessed as moderate) and did not result in adverse events. All overdoses resolved without sequelae.</p><p>No subject received a single dose of tildrakizumab greater than 200 mg. One of 28 subjects received two injections of 200 mg of tildrakizumab administered 2 weeks apart. Another subject was randomized to 200 mg of tildrakizumab in Part 1 and received 100 mg on Day 31, 100 mg on Day 35 and 100 mg on Day 39. The applicant states that during Reference ID: 4233639</p><formula xml:id="formula_19">(b) (6) (b) (6)</formula><p>the Phase 1 trials, subjects tolerated doses as high as 10 mg/kg IV and 400 mg SC. There were no events of overdose in the Phase 3 extension safety pool up to June 2016.</p><p>Recommended to be included in the labeling for tildrakizumab: 10 OVERDOSAGE In the event of Overdosage, monitor the patient for any signs or symptoms of adverse reactions and administer appropriate symptomatic treatment immediately.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abuse, Withdrawal and Rebound</head><p>There is no data to support an association of monoclonal antibodies including tildrakizumab with the potential for addiction, abuse, withdrawal or rebound. Therefore, the applicant did not evaluate abuse potential.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety in the Postmarket Setting</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Concerns Identified Through Postmarket Experience</head><p>Tildrakizumab is not marketed in any jurisdiction. Therefore, postmarketing safety data are not available.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Expectations on Safety in the Postmarket Setting</head><p>The comprehensive analysis of the tildrakizumab safety data identified no safety signals. There are no safety concerns that are expected to change the favorable risk/benefit assessment or lead to increased risk with administration of tildrakizumab in the postmarket setting. However, additional data are needed to characterize the safety profile of the proposed product in special populations (pregnant and lactating females and the pediatric population age 6 years) and assess the risk of adverse events associated with long latency periods (malignancy) assess the risk of adverse events associated with long latency periods (malignancy). Refer to Section 12 of this review for the postmarketing requirements and commitments.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Integrated Assessment of Safety</head><p>The safety profile for tildrakizumab was adequately characterized during the drug development program. The primary safety database consisted of subjects from the Phase 2 Trial P003 and Phase 3 Trials P010 and P011, and included 1083 subjects treated with tildrakizumab at the proposed dose of 100 mg SC. Of these 1083 subjects, 672 subjects were exposed for at least 12 months, 587 for 18 months, and 469 for 24 months.</p><p>Although there were no events of anaphylaxis, infrequent events of angioedema occurred in subjects treated with tildrakizumab. Information regarding hypersensitivity reactions will be conveyed in Section 4 (Contraindications) and Section 5.1 (Warnings and Precautions) in product labeling.</p><p>Treatment with tildrakizumab did not appear to increase the risk of mortality. There were no deaths reported in the 6 Phase 1 trials in subjects receiving tildrakizumab. During the Base period of the pooled Phase 2/3 trials, there were five deaths among subjects who received 100 mg tildrakizumab (unknown cause, alcoholic cardiomyopathy and steatohepatitis), and one death in a subject who received tildrakizumab 200 mg (aneurysm). Through May 27, 2017 (cutoff date for Safety Update Report), there were 6 additional deaths during the ongoing Phase 3 extension trials. None of the deaths occurring during the Base or Extension periods were assessed as causally related to the study product. Deaths are described in more detail in sections 7.3.4 and 7.3.8 of this review. Treatment with tildrakizumab was not associated with an increased incidence of treatment-related adverse reactions in the categories of suicidal ideation and behavior (SIB) and major adverse cardiovascular events (MACE).</p><p>During the Placebo-controlled period of the pooled Phase 2/3 trials, SAEs occurred in 1.4% of subjects treated with tildrakizumab 100 mg, 2.3% of subjects treated with tildrakizumab 200 mg, 1.7% of subjects treated with placebo, and 2.2% of subjects treated with etanercept. Exposure adjusted rates of SAEs during the Base period were 5.81 per 100 subj years (yrs) in the tildrakizumab 100 mg group, 7.21 per 100 subj yrs in the tildrakizumab 200 mg group, 6.4 per 100 subj yrs placebo group and 13.4 per 100 subj yrs in the etanercept group.</p><p>During the Placebo-controlled period, the most common adverse reactions (AR) in subjects treated with tildrakizumab 100 mg were upper respiratory infections (13.9%), injection site reactions (3.4%), fatigue (2.4%), diarrhea (1.8%), back pain (1.3%), abdominal pain (1.3%), and nausea (1.0%). The frequency of AR was similar across all age and demographic groups. These are discussed in more detail in section 7.3.4 of this review. These AR are recommended to be included in Section 6 (Adverse Reactions) of tildrakizumab labeling.</p><p>Because of the mechanism of action of tildrakizumab, malignancy is a potential risk. A comparison of the number of malignancies (other than cervical cancers in situ or NMSC) from Phase 2/3 trials (P003, P010 and P011) in the tildrakizumab groups with data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (2010-2014)* adjusted for age, sex, and race) indicated that the rate of these events in subjects with moderate to severe psoriasis treated with tildrakizumab for up to 64 weeks was no higher than that expected for the general US population. However, because the risk of malignancy is biologically plausible and may exhibit a long-latency effect after initial exposure, more long-term data are needed to characterize the risk of malignancy.</p><p>Consultants from the Office of Surveillance and Epidemiology (OSE) evaluated the sufficiency of the Active Risk and identification Analysis system (ARIA) to address the long-term risk of malignancy. ARIA is considered to be sufficient to assess the short-term risk for lymphoma, because lymphomas are reasonably well-validated in claims data, short-term risk is of interest, and the other domains (population, exposure, covariates, and analytic tools) were determined to be sufficient. However, ARIA is determined to be insufficient to assess the long-term risk for malignancy (i.e., all types), due to limited long-term follow-up, poor validation of certain malignancy types, and incomplete capture of potentially critical confounders. A long-term observational study would be a more appropriate post-marketing study design to better assess malignancy risk among tildrakizumab users; this study will be required post-approval.</p><p>Among subjects receiving tildrakizumab in the development program through May 27, 2017, there were 14 pregnancies: 2 pregnancies reported in the Phase 1 trials [(P05661 and P05839 (subject with active Crohn's disease)], and 2 pregnancies in in the Phase 2 trial (P003), and 10 pregnancies in the Phase 3 trials/extension. Pregnancy outcomes included 6 cases of fetal loss (2 spontaneous abortions and 4 elective abortions) and 7 full-term live births, and 1 pending pregnancy outcome. The effect of tildrakizumab on human reproduction and pregnancy is discussed in further detail in section 7.3.8 of this review. Because the available data are insufficient to inform tildrakizumab-associated risk in pregnant women, we will require postapproval prospective and retrospective studies assessing maternal, fetal and neonatal BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 157 outcomes of women exposed to tildrakizumab during pregnancy compared to an unexposed control population. Refer to Section 12 Postmarketing Requirements and Commitments for further details.</p><p>The safety data currently available demonstrate that tildrakizumab is safe for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Postmarketing risk management will include professional labeling (including a Medication Guide), prescription status and routine pharmacovigilance. In addition, the ARIA system will be used to assess the risk of lymphoma over the short term. The long-term risk of malignancy will be assessed by a long-term observational study. The maternal, fetal, and infant outcomes of women exposed to tildrakizumab during pregnancy will be evaluated by a registry based observational exposure cohort study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Summary and Conclusions</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Issues</head><p>There were no major statistical issues affecting overall conclusions. The treatment effects for tildrakizumab were large and consistent across trials and endpoints. There were no substantial differences in efficacy among subgroups. The amount of missing data was relatively small (&lt; 6%) at Week 12 (i.e., the primary efficacy timepoint). For the handling of missing data, the statistical reviewer conducted an additional sensitivity analysis under the worst case scenario (i.e., missing data for tildrakizumab was imputed as non-responders and missing data for placebo was imputed as responders). In this extreme case, tildrakizumab remained statistically superior to placebo (p-values &lt; 0.001) for both co-primary efficacy endpoints in both pivotal trials (Trials P010 and P011).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions and Recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="7.4.2.">Conclusions and Recommendations</head><p>To establish the effectiveness of tildrakizumab, the applicant submitted data from two randomized, multicenter, placebo-controlled, parallel-group, pivotal Phase 3 trials (Trial P010 and Trial P011). The trials enrolled subjects 18 years of age and older who had plaque psoriasis with PASI score 12, Physician's Global Assessment (PGA) score of 3 ("moderate") and a minimum body surface area (BSA) of involvement of 10%. The co-primary efficacy endpoints were the proportion of subjects achieving a PGA score of 0 ("cleared") or 1 ("minimal") with at least a 2-point improvement from baseline at Week 12 and the proportion of subjects achieving PASI 75 at Week 12. In both trials, tildrakizumab was statistically superior to placebo (p-values &lt; 0.001) for both co-primary efficacy endpoints at Week 12. Secondary endpoints for both trials included the proportion of subjects at Week 12 who achieved i) PASI 90 and ii) PASI 100. In both trials, tildrakizumab was statistically superior to placebo at Weeks 12 for both PASI 90 and PASI 100 (see Section 7.2.).</p><p>In To support the safety of tildrakizumab, the applicant pooled data from the Phase 3 trials with data from the proposed doses used in the Phase 2 Trial P05495 (P003), a 5-arm, dose rangefinding trial comparing 4 doses of tildrakizumab (5 mg, 25 mg,100 mg, 200 mg) with placebo. The applicant conducted a comprehensive assessment of the safety of tildrakizumab in the target population. The size of the safety database and the safety evaluations were adequate to identify local and systemic treatment-emergent adverse reactions.</p><p>Safety and efficacy data submitted by the applicant support approval of this BLA for tildrakizumab for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="8">Advisory Committee Meeting and Other External Consultations</head><p>The Agency held no Advisory Committee Meeting regarding this application because the safety profile was expected to be comparable to that of other biologic products approved for this indication.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="9">Pediatrics</head><p>Refer to the following sections of this review for the proposed development program for tildrakizumab in the pediatric population:</p><p>Section 7 Pediatrics and Assessment of Effects on Growth for a discussion regarding the Pediatric Study Plan Section 12 Postmarketing Requirements and Commitments for the deferred pediatric studies, which are required under the Pediatric Research Equity Act (PREA) (21 CFR 314.55(b) and 601.27(b)).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="10">Labeling Recommendations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prescribing Information</head><p>The applicant submitted proposed Prescribing Information (PI) and carton/container labels for ILUMYA (tildrakizumab). The review team provided recommendations regarding the PI which Based on the favorable safety profile of this product, risk mitigation measures beyond professional labeling and a Medication Guide are not required at this time. Under 21CFR208.1, the Medication Guide is required to help prevent serious adverse effects. See Section 10.1 Labeling Recommendations. As no additional risk management strategies are required, the subsequent subsections are not applicable for this review and are omitted.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety Issue(s) that Warrant Consideration of a REMS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conditions of Use to Address Safety Issue(s)</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations on REMS 12 Postmarketing Requirements and Commitments</head><p>Clinical postmarketing requirements are intended to characterize the risks of tildrakizumab use in special populations (pregnancy) and address the long-term safety of this novel biologic product in the target population. Development of final pharmacovigilance plans is ongoing.</p><p>The available safety data regarding tildrakizumab use during pregnancy are limited. The study population as defined by the entry criteria excluded pregnant and breastfeeding females, and females planning to become pregnant or breastfeed during the trials. Because exposures to tildrakizumab during pregnancy are likely to occur and the available data are insufficient to characterize the associated risk in pregnant women, the Agency will require the applicant to conduct the post-marketing assessments to characterize the drug associated risk.</p><p>Analysis of expected adverse reactions based on biologic plausibility and potential class effects did not identify a definitive safety signal. However, based on the mechanism of action, the Agency will require post-marketing safety studies to assess the risk of malignancy and other serious adverse events which may not be identified during clinical trials due to a long latency period or low incidence rate.</p><p>Based on review of the data in this submission, the following postmarketing requirements (PMRs) were conveyed to the applicant:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>POSTMARKETING REQUIREMENTS UNDER 505(o) PMR 1:</head><p>A prospective, registry based observational exposure cohort study that compares the maternal, fetal, and infant outcomes of women exposed to tildrakizumab during pregnancy to an unexposed control population. The registry will detect and record major and minor congenital malformations, spontaneous abortions, stillbirths, elective terminations, small for gestational age, and any other adverse pregnancy outcomes. These outcomes will be assessed throughout pregnancy. Infant outcomes, including neonatal deaths, infections in the first 6 months of life, and effects on postnatal growth and development, will be assessed through at least the first year of life.</p><p>Final Protocol Submission: 06/2019 Trial completion: 01/2029 Submission of final study report: 01/2030 BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 161 PMR 2: Conduct a retrospective cohort study using claims or electronic medical record data or a case control study to assess adverse pregnancy outcomes such as major congenital malformations, spontaneous abortions, stillbirths, small for gestational age, neonatal deaths, and infant infections in women exposed to tildrakizumab during pregnancy compared to an unexposed control population.</p><p>Final Protocol Submission: 08/2019 Trial completion: 01/2026 Submission of final study report: 01/2027</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PMR 3:</head><p>Conduct an observational study to assess the long-term safety of tildrakizumab compared to other therapies used in the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in the course of actual clinical care. The study's primary outcome is the risk of malignancy in the long-term. Secondary outcomes include, but are not limited to, serious infections, tuberculosis, opportunistic infections, hypersensitivity reactions, autoimmune disease, neurologic or demyelinating disease, cardiovascular, gastrointestinal, and hematologic adverse events. Describe and justify the choice of appropriate comparator population(s) and estimated background rate(s) relative to tildrakizumab-exposed patients; clearly define the primary comparator population for the primary objective. Design the study around a testable hypothesis to assess, with sufficient sample size and power, a clinically meaningful increase in malignancy risk above the comparator background rate(s), with a prespecified statistical analysis method. Specify concise case definitions and validation algorithms for both primary and secondary outcomes. For the tildrakizumab-exposed and comparator(s) cohorts, clearly define the study drug initiation period and any exclusion and inclusion criteria. Enroll patients over an initial 4 year period and follow for a minimum of 8 years from the time of enrollment.</p><p>Final Protocol Submission: 02/2020 Trial completion: 02/2033 Submission of final study report: 02/2034</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PREA Requirements</head><p>Tildrakizumab triggers the Pediatric Research Equity Act (PREA) as a new active ingredient.</p><p>The following studies in the pediatric population age 6 years to less than 18 years of age were included in the Agreed iPSP and will be deferred:</p><p>A placebo-controlled PK, safety and efficacy study with 2 components:</p><p>a. An open label PK trial (2 sequential cohorts: 10 subjects age 12-17 years and 10 subjects age 6-11 years)</p><p>Reference ID: 4233639 We are waiving the pediatric study requirement for ages 0 to less than 6 years because necessary studies are impossible or highly impracticable. This is because:</p><p>The prevalence of psoriasis in the 0 to less than 6 years age group is low (with the highest prevalence published of 0.3%) and the proportion of children with a severe condition in need of a systemic treatment is 4%, giving a final prevalence of the condition to be about 1 per 10,000 in this age group.</p><p>We are deferring submission of pediatric studies for ages 6 years to less than 18 years for this application because this product is ready for approval for use in adults and the pediatric studies have not been completed.</p><p>The required study is listed below.</p><p>Conduct a pharmacokinetics (PK), safety and efficacy study in pediatric subjects 6 years to &lt;18 years of age with moderate to severe plaque psoriasis (with a duration of exposure to tildrakizumab of at least one year).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Final Protocol Submission: 12/2018</head><p>Trial completion: 02/2025 Submission of final study report: 10/2025</p><p>Reference ID: 4233639</p><formula xml:id="formula_20">(b) (4)</formula><p>13 Appendices</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>References</head><p>The references are included in footnotes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Financial Disclosure</head><p>In compliance with 21 CFR Part 54, the applicant provided Certification/Disclosure Forms from clinical investigators and sub-investigators who participated in covered clinical studies for tildrakizumab. Prior to trial initiation, the investigators certified the absence of certain financial interests or arrangements or disclosed, as required, those financial interests or arrangements as delineated in 21 CFR 54.4(a)(3)(i-iv).</p><p>The covered clinical studies as defined in 21 CFR 54.2(e) were Trial P003, Trial P010 and Trial P011 which provided the primary data to establish effectiveness and safety of this product. Refer to Section 7.2.1 for the trial designs.</p><p>A total of two investigators from Trial P010 and one investigator from Trial P011 had disclosable financial interests and arrangements, and are listed in <ref type="table" target="#tab_15">Table 48</ref> below. One investigator from Trial P011 had certification of due diligence. Information regarding this investigator is displayed in <ref type="table" target="#tab_15">Table 49</ref> below. Financial disclosure forms for Trial P003, P010, and P011 are also displayed below.</p><p>The applicant adequately disclosed financial interests involving clinical investigators. Because the number of investigators with financial disclosures was limited and assessments were blinded, the strategies employed by the applicant to minimize potential bias arising from investigator financial interests/arrangements appear reasonable. Compensation to the investigator for conducting the study where the value could be influenced by the outcome of the study: N/A Significant payments of other sorts: N/A Proprietary interest in the product tested held by investigator: N/A Significant equity interest held by investigator in sponsor of covered study: N/A Is an attachment provided with details of the disclosable financial interests/arrangements:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Covered Clinical Study: P003</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes</head><p>No (Request details from applicant) Is a description of the steps taken to minimize potential bias provided:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes</head><p>No (Request information from applicant) Number of investigators with certification of due diligence (Form FDA 3454, box 3) 0 Is an attachment provided with the reason:</p><p>Yes No (Request explanation from applicant) *Rationale or steps taken to minimize bias: N/A; no investigators from Trial P003 had disclosable financial interests or certification of due diligence. Compensation to the investigator for conducting the study where the value could be influenced by the outcome of the study: 0 Significant payments of other sorts: 1 Proprietary interest in the product tested held by investigator: 0 Significant equity interest held by investigator in sponsor of covered study: 1 Is an attachment provided with details of the disclosable financial interests/arrangements:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes</head><p>No (Request details from applicant) Is a description of the steps taken to minimize potential bias provided:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes</head><p>No (Request information from applicant) Number of investigators with certification of due diligence (Form FDA 3454, box 3) 0 Is an attachment provided with the reason:</p><p>Yes No (Request explanation from applicant) *Rationale or steps taken to minimize bias: No investigator with a disclosure enrolled/ randomized more than 7 subjects in this study. Compensation to the investigator for conducting the study where the value could be influenced by the outcome of the study: 0 Significant payments of other sorts: 0 Proprietary interest in the product tested held by investigator: 0 Significant equity interest held by investigator in sponsor of covered study: 1 Is an attachment provided with details of the disclosable financial interests/arrangements:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Covered Clinical Study: P011</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes</head><p>No (Request details from applicant) Is a description of the steps taken to minimize potential bias provided:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes</head><p>No (Request information from applicant) Number of investigators with certification of due diligence (Form FDA 3454, box 3) 1 Is an attachment provided with the reason:</p><p>Yes No (Request explanation from applicant) *Rationale or steps taken to minimize bias: No investigator with a disclosure or certification of due diligence enrolled/ randomized more than 14 subjects in this study.  </p><formula xml:id="formula_21">(b) (6) (b) (6) (b) (6) (b) (6) (b) (6)</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 17: Psoriasis Area and Severity Index (PASI)</head><p>Source: protocols for Trials P010 and P011</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results of the Safety Analyses by Demographic Subgroups</head><p>The following tables provide an analysis of selective safety findings by demographic Subgroup in the pooled Phase 2 (P003) and Phase 3 trials (P010 and P011).        <ref type="table">Tables   Table 55:</ref>    </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk Summary</head><p>Tildrakizumab was detected in milk of monkeys [see Data]. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ILUMYA and any potential adverse effects on the breastfed child from ILUMYA or from the underlying maternal condition.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animal Data</head><p>Very low levels of tildrakizumab were detected in breast milk of monkeys in the pre-and postnatal developmental study described in 8.1. The mean tildrakizumab concentrations in milk were approximately 0.09 -0.2% of that in serum on postpartum days 28 and 91.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="12.1">Mechanism of Action</head><p>Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.1">Carcinogenesis, Mutagenesis, Impairment of Fertility</head><p>Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of ILUMYA.</p><p>No effects on fertility parameters were observed in male or female cynomolgus monkeys that were administered tildrakizumab at subcutaneous or intravenous doses up to 140 mg/kg once every two weeks for 3 months ( times the MRHD, respectively, based on AUC comparison). The monkeys were not mated to evaluate fertility.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Pharmacology Appendices</head><p>The tildrakizumab development program included 8 clinical trials in support of the proposed indication:</p><p>Five Phase 1 trials in healthy subjects and subjects with psoriasis:</p><p>Study P05661: single IV dose PK trial in healthy subjects Study P05776: single SC dose PK trial in healthy subjects Study P06306: intrinsic factor PK trial in healthy Japanese, Chinese, and Caucasian subjects Study P05382: multiple IV doses PK trial in subjects with psoriasis Study P009: relative BA between PFS and AI and effect of tildrakizumab on PK of CYP450 isoenzymes in subjects with psoriasis Reference ID: 4233639</p><formula xml:id="formula_22">(b) (4) (b) (4) (b) (4)</formula><p>One Phase 2 dose-ranging trial in subjects with psoriasis: Study P05495</p><p>Two Phase 3 pivotal trials in subjects with psoriasis: Study P010 Study P011</p><p>The applicant also conducted population PK analysis to support the characterization of tildrakizumab PK. The population PK analysis included covariate analyses to evaluate the effect of intrinsic and extrinsic factors. In addition to the results from the Phase 2 dose ranging trial, the applicant conducted integrated E-R (population PK/PD) analyses for efficacy and safety using pooled data from the Phase 2 and Phase 3 trials to justify the proposed dosing regimen.</p><p>The biopharmaceutics program is summarized below.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Drug substance (DS)</head><p>Tildrakizumab DS is expressed by Chinse Hamster Ovary (CHO) cell line. There had been two tildrakizumab DS manufacturing processes (Process 1 and Process 2) throughout different clinical development stages. Process 1 was the initial tildrakizumab DS manufacturing process which was used to supply Phase 1/2 clinical trials. Process 2 was used to supply Phase 3 clinical trials and is the commercial DS manufacturing process. Manufacturing changes from Process 1 to Process 2 included a manufacturing scale change in order to meet increased supply demands during clinical development. The applicant conducted analytical comparability evaluations to support manufacturing changes of the DS used in clinical trials (see Product Quality review).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Drug products</head><p>Three different tildrakizumab drug products including lyophilized powder (LYO), 1.0 mL PFS, and 1.0 mL autoinjector (AI) have been used across the clinical trials <ref type="table" target="#tab_18">(Table 57</ref>). The two Phase 3 trials (P010 and P011) used the 1.0 mL PFS presentation which is also the to-be-marketed product proposed for registration in the BLA. The 1.0 mL AI presentation was only used in Study P009. Study P009 explored the relative BA between the PFS and AI presentations in a limited number of subjects with psoriasis. The applicant did not propose to register the AI presentation in the BLA.</p><p>Because the to-be-marketed formulation/presentation was used in Phase 3 trials, there is no need to bridge the to-be-marketed drug product to the clinical trial drug product. The applicant did not conduct dedicated clinical trials comparing PK between LYO used in Phase 1/2 clinical trials and PFS used in Phase 3 trials. The Applicant's exploratory population PK analysis indicated that LYO had approximately 5% lower bioavailability than PFS. The applicant developed and validated an electrochemiluminescence (ECL)-based bridging immunoassay for measurement of tildrakizumab concentrations in human serum. The ECL assay used biotinylated IL-23 as capture agent and SULFO-TAG TM -labelled IL-23 as detection agent. In brief, biotinylated hIL-23, SULFO-TAGâ¢-labeled hIL-23, were incubated with standards, QCs, and test samples and subsequently transferred to a streptavidin-coated Meso Scale Discovery Â® plate. After incubation and washing, the ECL response from the bound SULFO-TAGâ¢-labeled IL-23 was measured. The design of the assay using IL-23 as both capture and detection agent indicate that the ECL assay measures free drug concentrations. The validation parameters and performance of the ECL assay are summarized in <ref type="table" target="#tab_19">Table 58</ref>. 13.5.1.2 Immunogenicity assays: bioanalytical methods for testing antidrug antibodies (ADA) and neutralizing ADA</p><p>The applicant used electrochemiluminescence (ECL)-based bridging immunoassays for assessment of anti-drug antibodies (ADA) in tildrakizumab clinical trials. In brief, immunogenicity samples were diluted and incubated with biotinylated tildrakizumab (capture reagent) and SULFO-TAG TM -labeled tildrakizumab (detection reagent), and aliquots of the mixture were then pipetted onto streptavidin-coated Meso Scale Discovery Â® plate. After washing and removal of unbound molecules, the ECL response from the bound SULFO-TAG TM -labeled tildrakizumab was detected.</p><p>Confirmed ADA positive samples were tested for neutralizing ADA (NAb). The NAb assay was a competitive ligand binding assay using biotinylated human IL-23 as capture reagent and SULFO-TAG TM -labeled human IL-23 as detection reagent. There were three generations of ADA and NAb immunoassays for immunogenicity assessment during the clinical development program. The three generations used the same ECL bridging design but differed in assay reagents (e.g., positive antibody controls) and assay characterization. <ref type="table" target="#tab_21">Table 59</ref> and <ref type="table" target="#tab_64">Table 60</ref> provide the sensitivity and drug tolerance level of the ADA and NAb immunogenicity assays. Below is a summary of immunogenicity assay information relevant to Phase 3 immunogenicity data assessment.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sensitivity and drug tolerance of the immunogenicity assays used in Phase 3 trials</head><p>The ECL bridging assay had drug tolerance levels of 6 mcg/mL and &lt;1 mcg/mL of tildrakizumab in serum for detection of 500 ng/mL and 30 ng/mL ADA, respectively. In Phase 3 trials, the meanÂ±SD steady state tildrakizumab trough concentrations at Week 16 were 2.25Â±1.88 mcg/mL and 1.22Â±0.939 for the 200 mg and 100 mg doses, respectively, in Study P010; and 2.99Â±2.16 mcg/mL and 1.47Â±1.12 for the 200 mg and 100 mg doses, respectively, in Study P011. The Phase 3 PK data suggest that drug concentrations in immunogenicity samples would interfere the ECL bridging assay for detection of ADA &lt; 30 ng/mL and would not interfere ADA detection when ADA levels are 500 ng/mL.</p><p>The detection of NAb could be interfered with the presence of tildrakizumab in serum because the meanÂ±SD steady state serum tildrakizumab concentrations were above the drug tolerance level of 99 ng/mL of the NAb assay.</p><p>Refer to the Product Quality Review for more information regarding the performance and validation of the immunogenicity assays.  Study P009 was a randomized, fixed-sequence, two periods, parallel group, open-label, clinical drug interaction study that evaluated the effect of tildrakizumab on PK of CYP450 substrates in subjects with moderate to severe plaque psoriasis. Study P009 also explored the relative bioavailability of tildrakizumab delivered via prefilled syringe (PFS) and autoinjector (AI) presentations.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design and treatment:</head><p>Period 1: On Day 1 of Period 1, subjects received a single oral dose of a cocktail containing CYP450 probe substrates CYP3A4 (2 mg of midazolam), 2C19 (40 mg of omeprazole), CYP1A2 (200 mg of caffeine), CYP2C9 (10 mg of warfarin) and CYP2D6 (30 mg of dextromethorphan). There was at least 7-days washout period between Period 1 and Period 2. Blood samples to evaluate the PK of the probe substrates and tildrakizumab were collected during the study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p>Twenty subjects were randomized: 17 subjects completed the study and 3 subjects (1 in PFS arm and 2 in AI arm) discontinued.</p><p>The demographic data based on the 20 subjects are summarized below: Sex: 13 male (65%); 7 female (35%) Age <ref type="formula">(</ref>  <ref type="table" target="#tab_0">Table 61</ref>. Note that the current study is not powered to demonstrate PK comparability between PFS and AI presentations and the applicant did not propose to register the AI presentation in the current BLA. AUClast and AUCinf represent AUC values following two doses administrations, while Cmax is the peak concentration after the first dose administration. Abbreviations: AI, autoinjector; CI, confidence interval; GM, geometric least-square mean; GMR, geometric least-square mean ratio; PFS, prefilled syringe. (Source of data: <ref type="table" target="#tab_0">Table 1 and Table 11</ref> <ref type="bibr">CSR P009.)</ref> Effect of tildrakizumab on PK of CYP450 substrates The effect of tildrakizumab, 200 mg administered SC at Weeks 0 and 4, on the PK of caffeine (metabolized by CYP1A2), warfarin (metabolized by CYP2C9), omeprazole (metabolized by CYP2C19), dextromethorphan (metabolized by CYP2D6), and midazolam (metabolized by CYP3A4) were evaluated in 14 to 20 evaluable subjects with moderate to severe plaque psoriasis. Changes in AUC inf of caffeine, warfarin, omeprazole, and midazolam were not considered clinically relevant. The AUC inf of dextromethorphan was increased by 20%. <ref type="table" target="#tab_67">Table  62</ref> to <ref type="table" target="#tab_71">Table 66</ref> provides the statistical comparison of the plasma PK parameters of each CYP450 substrate in the probe cocktail: midazolam, S-warfarin, 5hydroxyomeprazole/omeprazole, dextromethorphan, and caffeine, respectively.     randomized to receive 0.1 mg/kg (n=4), 0.5 mg/kg (n=4), 3 mg/kg (n=8), and 10 mg/kg (n=6) or placebo (n=7). The results of tildrakizumab PK parameters are summarized in <ref type="table" target="#tab_18">Table 67</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.5.2.3">Study P05776: A single dose study of SC tildrakizumab in healthy subjects</head><p>Study P05776 was a randomized single-dose PK study of tildrakizumab following SC administration in healthy subjects. A total of 37 subjects were randomized: 23 male and 14 female; ages of 18-45 years; 27 (73%) of the subjects were Caucasian. Subjects were randomized to receive 50 mg tildrakizumab (n=14), 200 mg tildrakizumab (n=14), and placebo (n=9). The results of tildrakizumab PK parameters are summarized in <ref type="table" target="#tab_19">Table 68</ref>. Chinese subjects were assigned to one of 3 dose groups: 50 mg (8 Japanese, 7 White, and 4 Chinese), 200 mg (6 Japanese, 6 White, and 4 Chinese) and 400 mg (8 Japanese, 6 White, and 4 Chinese). In Part 2, 6 Japanese subjects received 10 mg/kg IV of tildrakizumab. The tildrakizumab PK parameters are summarized in <ref type="table" target="#tab_21">Table 69</ref>. The PK results supported that:</p><p>PK of tildrakizumab in Japanese and Caucasian healthy subjects appeared to be similar. Tildrakizumab showed dose proportional PK over the dose range from 50 mg to 400 mg following SC administration. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.5.2.5">Study P05382: A rising multiple dose study of tildrakizumab in subjects with psoriasis</head><p>Study P05382 was a 3-part, multiple-dose, randomized, placebo-controlled, double-blind (within dose group) trial in subjects with moderate to severe plaque psoriasis.</p><p>In Part 1, subjects were randomized to active or placebo (3:1) within each dose cohort: 0.1 mg/kg (n=3), 0.5 mg/kg (n=3), 3 mg/kg (n=7), 10 mg/kg (n=6) or placebo (n=6). Subjects received treatment on Day 1, Day 56 and Day 84.</p><p>In Part 2, subjects were randomized to active or placebo (3:1) within each dose cohort: 3 mg/kg (n=15), 10 mg/kg (n=14) or placebo (n=11). Subjects received treatment on Day 1, Day 28 and Day 56.</p><p>In Part 3, subjects were randomized to receive 0.05 mg/kg (n=6), 0.1 mg/kg (n=3) or placebo (n=3) on Day 1, Day 56, and Day 84. PK Results:</p><p>Tildrakizumab in general showed dose-proportional increases in exposure. The mean clearance values ranged from 1.57 to 2.50 mL/day/kg and the mean apparent volume of distribution (during the terminal phase) ranged from 58.3 to 91.6 mL/kg. The mean apparent half-life values ranged from 20.2 to 26.9 days.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.5.2.6">Study P010 and Study P011: tildrakizumab PK in phase 3 trials</head><p>Reference ID: 4233639</p><p>Tildrakizumab PK data in Phase 3 trials in subjects with psoriasis were pooled with PK data from Phase 1/2 trials for population PK analysis. A summary of observed tildrakizumab concentrations in Phase 3 trials (P010 and P011) is presented in <ref type="table" target="#tab_18">Table 70</ref>. In both phase 3 trials, subjects received tildrakizumab (100 mg or 200 mg) at Week 0, Week 4, and every 12 weeks thereafter. PK concentrations after Week 28 are not presented because subjects were re-randomized to receive different tildrakizumab treatment by their clinical responses at Week 28. (Source of data: <ref type="table" target="#tab_0">Table 11-51 and Table 11</ref> <ref type="bibr">CSR P010;</ref><ref type="bibr">CSR P011)</ref> Immunogenicity</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.5.3.1">Immunogenicity incidences</head><p>In the combined Phase 3 trials, P010 and P011, approximately 4.3% (26/611) and 3.6% (22/614) of subjects had treatment-emergent anti-drug antibodies (TE-ADA) to tildrakizumab following the initial 12 weeks treatment with the 100 mg or 200 mg dosage regimens, respectively. The TE-ADA incidences were 6.8% (25/369) and 8.8% (29/329) following treatment up to 64 weeks for the 100 mg or 200 mg dosage regimens, respectively. The incidences for neutralizing antibodies (NAb) among TE-ADA+ subjects were 40.0% (10/25) and 37.9% (11/29) for the 100 mg or 200 mg dosage regimens through Week 64, respectively. More detailed immunogenicity incidences based on different ADA categories and the definition of the ADA categories are summarized in <ref type="table" target="#tab_0">Table 71 and Table 72</ref>. Definitions of subjects ADA status are summarized below: ADA negative (ADA-): All pre-treatment and post-dose samples were negative and the drug concentration in the last post-dose sample was below the drug tolerance level for the ADA assay.</p><p>ADA inconclusive: All pre-treatment and post-dose samples were negative and the drug concentration in the last post-dose sample was equal or above the drug tolerance level for the ADA assay.  Definitions of subjects ADA status are described in <ref type="table" target="#tab_0">Table 71</ref> Table 71 <ref type="bibr">Summary of Clinical Pharmacology)</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.4.3.2">Impact of immunogenicity on pharmacokinetics</head><p>The PK results showed that subjects who developed TE-ADA-NAb were associated with lower tildrakizumab concentrations compared with ADA negative subjects. The effect of ADA on tildrakizumab concentrations was evaluated in subjects receiving continuous 100 mg or 200 mg doses through 52-64 weeks in Phase 2 and Phase 3 trials ( <ref type="figure" target="#fig_3">Figure 18</ref>). Definitions of subjects ADA status are described in <ref type="table" target="#tab_0">Table 71</ref> (Source of data: <ref type="figure" target="#fig_3">Figure 13</ref> and <ref type="figure" target="#fig_3">Figure 15</ref>, Immunogenicity Summary Report 04fcnm.pdf)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.4.3.3">Impact of immunogenicity on efficacy</head><p>The pooled efficacy results from Phase 2 and Phase 3 trials showed that subjects who developed TE-ADA-NAb had reduced response rate compared with ADA negative subjects. For example, the proportions of subjects who achieved PASI 75 response were 50% and 25% for the 100 mg and 200 mg dosage regimens in TE-ADA-NAb subjects, respectively, in comparison to 63.9% and 63.5% in ADA negative subjects <ref type="table" target="#tab_4">(Table 73</ref>). Similar negative impact of TE-ADA-NAb on efficacy was also observed when using PASI 90, PASI 100 and PGA as efficacy endpoints (data not shown). The PK characteristics of tildrakizumab The relationship between covariates and exposure; e.g. psoriatic subject characteristics such as body weight, gender, age, race and ethnicity (Hispanic, Japanese).</p><p>To explore the potential impact of the lyophilized formulation (Phase 1 and 2) versus the solution formulation in prefilled syringe (Phase 3) on exposure</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data:</head><p>The population PK model was developed based on data from three Phase 1 trials (P05776, P06306, and P009), one Phase 2 trial (P05495), and two Phase 3 trials (P010 and P011). Only active arms and SC treatment arms were included. The full PK analysis dataset consisted of 2106 subjects and 18491 observations in total, among which, 87 subjects were healthy and 2019 were subjects with psoriasis. The final PK datasets included 2098 subjects with 17321 observation records. Descriptive statistics of continuous covariates and categorical covariates are shown in <ref type="table" target="#tab_18">Table 75</ref> and <ref type="table" target="#tab_18">Table 76</ref>, respectively. <ref type="figure" target="#fig_8">Figure 22</ref>. All covariate effects except for BW were found to be small to modest. Heavy subjects had lower exposure. Extremes of weight (range: 40.6-222.2 kg) positively correlated to a -53% to +163% change in clearance and to a -43% to +107% change in volume compared to a subject with median weight. Extremes of serum albumin (range: 31-55 g/L) negatively correlated to a +36% to a -15% change in clearance compared to a subject with median albumin levels. Asians had 19% higher clearance than Whites. Alternatively, Japanese had a 17% greater clearance than Whites. Female subjects had a 10% higher clearance and a 7% higher volume than male subjects. Healthy subjects had 31% higher bioavailability than subjects with psoriasis. The lyophilized formulation had 5% lower bioavailability than the pre-filled syringe.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 22: Impact of Covariate on Tildrakizumab AUC ss (100 mg Dose Administrated Every 12 Weeks)</head><p>The applicant's final population PK model for tildrakizumab is reasonable. The model adequately characterized the PK profile of tildrakizumab as indicated in the goodness-of-fit plots and the Visual Predictive Check plots. The inter-individual variability expressed as CV% was modest for clearance (38.2%) and the volume compartment (23.8%) suggesting that key PK parameters were reasonably estimated from available data. The population PK analysis was verified by the viewer and is deemed acceptable. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods:</head><p>Exposure-Response for Week 12 PASI Response:</p><p>A maximum drug effect (E max ) logistic-regression E-R model was used to describe Week 12 PASI response. logit(Pri) = Placebo response + E max Ã Cavg12,i / (EC50 + Cavg12,i) Where Pri is the probability of the PASI response of subject i, Cavg12,i is the average concentration of the first 12 weeks of treatment of subject i and EC50 is the concentration achieving 50% of the E max Longitudinal PK-PD An indirect-effect model with drug-suppression of plaque formation and placebo-induced healing rate (the rate at which the psoriatic skin lesions heal over time either due to placebo or active treatment) was utilized in the PK-PD model. The model is illustrated in <ref type="figure" target="#fig_8">Figure 23</ref>. subjects per arm. The PK-PD simulations utilized 400 subjects per arm and 100 trial replications.</p><p>The E-R models were developed in R version 3.2.3 and the longitudinal PK-PD model was developed in non-linear mixed effects software (NONMEM) version 7.2. Simulations were performed in R.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results:</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exposure Efficacy Models</head><p>The E max model parameters for Week-12 PASI response are summarized in <ref type="table" target="#tab_0">Table 81</ref>. Maximum drug effects were estimated as 62.2% for PASI 75, 37.9% for PASI 90 and 14.6% for PASI 100. The EC50 estimates were 0.36 g/mL for PASI 75, 0.46 g/mL for PASI 90 and 0.55 g/mL for PASI 100. Subjects with greater weight had less placebo response for PASI 75, PASI 90 and PASI 100. Also, subjects with greater baseline PASI score and older subjects had less PASI 100 placebo response. The E-R relationship is illustrated in <ref type="figure" target="#fig_8">Figure 2</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Longitudinal PK-PD Model</head><p>The PK-PD approach provides an evaluation of the overall profile of tildrakizumab that can be used to make inferences for dose recommendations. <ref type="table" target="#tab_19">Table 82</ref> summarizes the parameters of the PK-PD model. Maximum placebo response was estimated as 19%, and maximum drug effect was set to 100% PASI reduction from baseline. The EC50 was 0.25 g/mL, which is similar to the EC50s from the exposure-efficacy modeling.</p><p>BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 201  <ref type="table" target="#tab_14">Table 83</ref>. Subjects in the lowest quartile of the 100-mg cohort had a similar PASI response rate as the subjects in the lowest quartile of the 200-mg cohort. Similar results were also observed in subjects in the highest exposure quartile. The results are consistent with the ER models, where the ER relationship plateaued at doses of 100 mg or higher.  <ref type="table" target="#tab_14">Table S3</ref> on page 17 of  Simulated PASI response for different sub-populations are summarized in <ref type="table" target="#tab_15">Table 84</ref>. Compared to 100 mg, the 200-mg regimen increased PASI 75 by 4%, PASI 90 by 3% and PASI 100 by 2% in the heaviest subjects. Compared to 200 mg, the 400-mg regimen did not increase PASI 75 by more than 2%.  <ref type="table" target="#tab_19">Table 85</ref> summarizes longitudinal PK-PD model simulations for the 100-mg and 200-mg doses and the effects of dose-titration in 100-mg partial responders. Compared to 100 mg, the 200-mg regimen increased PASI 75 by 7% and PASI 90 by 10% at Week 52 for the overall population. Titrating partial responders from 100 to 200 mg at 28 weeks had limited impact; although 15% more partial responders became PASI 75 responders, this increased the overall response rate by 2% because partial responders constituted a small portion of the overall population. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PK-PD Model Simulations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exposure-Response Analysis for safety</head><p>The relationship of safety endpoints and the average exposure was explored in Part 1 (Weeks 1 to 12) of the two Phase 3 trials (P010 and P011). The AE event rates were tabulated by quartiles of the Cavg12 for each dose group <ref type="table" target="#tab_19">(Table 86)</ref>.</p><p>There was no trend in 0-12 AEs across exposure quartiles going from the lowest exposure quartile of the 100-mg group to the highest exposure quartile of the 200-mg group. Subjects at the highest exposure quartile of 200 mg had AE rates similar to those subjects in the lowest exposure quartile of the 100-mg regimen.  <ref type="table" target="#tab_14">Table S3</ref>, Applicant's PK-PD report 04kx06.pdf) BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 204 Integrated Risk-Benefit Analysis <ref type="figure" target="#fig_8">Figure 24</ref> shows the risk of Part 1&amp;2 infections/infestations relative to the PASI75 responder rate at Week28 for 100-mg or 200-mg doses in different weight subgroups. Collectively, the two regimens had similar risk-benefit profiles. The E max model for Week 12 PASI response appears reasonable. The treatment response has reached plateau at dose of 100 mg. Additional dose such as 200 mg only increase efficacy marginally. Subjects with greater weight had lower response for PASI 75, PASI 90 and PASI 100. Also, subjects with greater baseline PASI score and older subjects had less PASI 100 response at Week 12.</p><p>E-R analysis did not reveal significant relationship for Week 12 PASI 75 response and AEs. Treatment with 200 mg for heavy subjects did not show significant benefits. Therefore, the 200mg dose is not recommended in the label.</p><p>BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 205 14 Office Director (ODE III) I concur with the recommendation of the Division of Dermatology and Dental Products to approve ILUMYA (tildrakizumab) injection for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The recommended dose is 100 mg, administered subcutaneously. Data submitted in the BLA support the conclusion that the benefits of treatment with tildrakizumab in the intended population outweigh the identified risks. Product labeling and a Medication Guide will adequately communicate these benefits and risks to healthcare providers and patients, respectively. A REMS will not be required. Post-marketing required studies will assess: 1) maternal, fetal and infant risks of women exposed to tildrakizumab during pregnancy, 2) the long-term safety of tildrakizumab, and 3) the pharmacokinetics, safety and efficacy of tildrakizumab in pediatric subjects with moderate-to-severe plaque psoriasis ages 6 to less than 18 years.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Julie Beitz, MD</head><p>Reference ID: 4233639</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.6">Patient Experience Data</head><p>Patient experience data pertaining and submitted with this application are outlined in <ref type="table" target="#tab_0">Table 1</ref>.  <ref type="figure">-------------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. <ref type="figure">-----------------------------------------------------------------------------------------------------</ref> The applicant submitted data from two adequate and well-controlled trials [Trial P010 and Trial P011], which provided evidence of the effectiveness of tildrakizumab for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In addition, the applicant conducted a comprehensive assessment of the safety of tildrakizumab in the target population. The size of the safety database and the safety evaluations were sufficient to characterize the local and systemic treatment-emergent adverse reactions. The applicant established the benefit of tildrakizumab for the proposed indication. Approval is supported by the data included in this submission.</p><formula xml:id="formula_23">---- /s/ ---------------------------------------------------</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendation:</head><p>The clinical team recommends approval of ILUMYA (tildrakizumab-asmn) injection, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.</p><p>- <ref type="figure">------------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.</p><p>- <ref type="figure">----------------------------------------------------------------------------------------------------</ref>   </p><formula xml:id="formula_24">---- /s/ ---------------------------------------------------</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Assessment of Protocols and Study Reports</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes</head><p>Endpoints and methods of analysis are specified in the protocols/statistical analysis plans.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes</head><p>Interim analyses (if present) were pre-specified in the protocol with appropriate adjustments in significance level. DSMB meeting minutes and data are available.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NA</head><p>Appropriate details and/or references for novel statistical methodology (if present) are included (e.g., codes for simulations).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>NA</head><p>Investigation of effect of missing data and discontinued follow-up on statistical analyses appears to be adequate.   <ref type="figure">None  -------------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Electronic Data Assessment</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Filing Issues</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.2.">Information Requests/Review Issues</head><p>- <ref type="figure">----------------------------------------------------------------------------------------------------</ref> You may submit information, including publicly available information, regarding US-licensed Enbrel and EU-approved etanercept to justify the extent of the data (comparative analytical data and potentially comparative PK/PD data) needed to establish a bridge between the EU-approved etanercept comparator and US-licensed Enbrel. For example, in support of an adequate scientific bridge between EU-approved etanercept and USlicensed Enbrel, you may submit detailed data and information to allow FDA to assess whether US-licensed Enbrel and EU-approved etanercept are manufactured at the same drug substance and drug product sites using the same processes (e.g. the drug substance and drug product manufacturing processes used for the manufacture of EU-approved etanercept are performed according to the manufacturing process and controls described in the BLA approved for US-licensed Enbrel), the same release criteria (e.g. specifications and Quality Unit batch release requirement), and the same cell bank. Such data and information could help support and justify the extent of data needed to establish a scientific bridge between US-licensed Enbrel and EU-approved etanercept, but may not be sufficient to establish a scientific bridge in the absence of data from o Provide, or identify the location in the submission of, the coding dictionary.</p><formula xml:id="formula_25">---- /s/ ---------------------------------------------------</formula><p>ï· Is an Advisory committee meeting needed to discuss this application?</p><p>o No. The safety profile is expected to be similar to that of other biologic products approved for this indication. Preliminary review of the guselkumab application did not raise significant safety or efficacy issues that were unexpected for a biologic of this class.</p><p>ï· Were there agreements made at the application's pre-submission meeting (and documented in the minutes) regarding certain late submission components that could be submitted 30 days after receipt of the original application?</p><p>At the Pre-BLA meeting held on August 31, 2016, the applicant agreed to conduct a retrospective evaluation of suicidal ideation and behavior using the Columbia Classification Algorithm of Suicide Assessment (C-CASA) for all subjects enrolled in Tildrakizumab clinical trials for all indications. The report is to be submitted at the time of the 120 day safety update.</p><p>ï· If so, were the late submission components all submitted within 30 days? N/A ï· Was the application otherwise complete upon submission, including those applications where there were no agreements regarding late submission components?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Yes.</head><p>On initial overview of the NDA/BLA application for filing: You may submit information, including publicly available information, regarding US-licensed Enbrel and EU-approved etanercept to justify the extent of the data (comparative analytical data and potentially comparative PK/PD data) needed to establish a bridge between the EU-approved etanercept comparator and US-licensed Enbrel. For example, in support of an adequate scientific bridge between EU-approved etanercept and USlicensed Enbrel, you may submit detailed data and information to allow FDA to assess whether US-licensed Enbrel and EU-approved etanercept are manufactured at the same drug substance and drug product sites using the same processes (e.g. the drug substance and drug product manufacturing processes used for the manufacture of EU-approved etanercept are performed according to the manufacturing process and controls described in the BLA approved for US-licensed Enbrel), the same release criteria (e.g. specifications and Quality Unit batch release requirement), and the same cell bank. Such data and information could help support and justify the extent of data needed to establish a scientific bridge between US-licensed Enbrel and EU-approved etanercept, but may not be sufficient to establish a scientific bridge in the absence of data from a comparative study or studies of US-licensed Enbrel and EU-approved etanercept.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Content</head><p>o Provide, or identify the location in the submission of, the coding dictionary.</p><p>- <ref type="figure">------------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.</p><p>- <ref type="figure">----------------------------------------------------------------------------------------------------</ref> </p><formula xml:id="formula_26">---- /s/ ---------------------------------------------------</formula></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Overview of clinical trials and clinical pharmacology program</head><p>The tildrakizumab psoriasis development program included 8 clinical studies in support of the proposed indication:</p><p>ï· Five Phase 1 studies in healthy subjects and subjects with psoriasis:</p><p>â See Appendix 1 for the detailed summary of study design, tildrakizumab doses, and clinical pharmacology evaluations in these clinical trials.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Biopharmaceutics</head><p>Tildrakizumab drug substance (DS) is expressed by Chinse Hamster Ovary (CHO) cell line. There had been two tildrakizumab DS manufacturing processes (Process 1 and Process 2) throughout different clinical development stages. Process 1 was the initial tildrakizumab DS manufacturing process which was used to supply Phase 1/2 clinical trials. Process 2 was used to supply Phase 3 clinical trials and is the commercial DS manufacturing process. Manufacturing changes from Process 1 to Process 2 included a manufacturing scale change in order to meet increased supply demands during clinical development. The Applicant conducted analytical comparability evaluations to support manufacturing changes of the DS used in clinical trials.</p><p>Three different tildrakizumab drug products including lyophilized powder (LYO), 1.0 mL PFS, and 1.0 mL autoinjector (AI) have been used across the clinical trials <ref type="table" target="#tab_14">(Table 3</ref>.2). The two pivotal Phase 3 studies</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analytical methods for PK measurements</head><p>Tildrakizumab concentrations in human serum were quantified using a validated electrochemiluminescent (ECL) bridging assay. The PK assay validation reports (00M8G7.pdf and 03T5F4.pdf) are found in Module 5.3.1.4.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">Dose selection and exposure-response (E-R) relationship</head><p>In addition to the Phase 2 dose ranging study results, the Applicant conducted integrated E-R (population PK/PD) analyses for efficacy and safety using combined data from the Phase 2 study (P05495) and Phase 3 studies (P010 and P011) to justify the proposed dosing regimen. The summary of the dose section rationale, E-R for efficacy, E-R for safety are found in Clinical Overview (Section 3) and Summary of Clinical Pharmacology <ref type="figure" target="#fig_3">(Sections 1.5 and 2.6)</ref>. The exposure-response analysis report (04KX06.pdf), the associated datasets, and analysis programs are found in Module 5.3.5.3.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.">Immunogenicity</head><p>The summaries of the immunogenicity results were provided in Clinical Overview (Section 3.6.1) and</p><p>Summary of Clinical Pharmacology <ref type="figure" target="#fig_3">(Section 4.1)</ref>. The Applicant also submitted an Immunogenicity Summary Report (04FCNM.pdf) in Module 5.3.5.3 that provided the detailed information of immunogenicity assessment methods and results. Immunogenicity incidences and their clinical impacts on PK, efficacy and safety were assessed and reported in the BLA.</p><p>The serum anti-drug antibodies (ADA) were detected using an ECL assay on the Meso Scale Discovery (MSD) platform. Confirmed ADA positive samples were tested for neutralizing ADA (NAb). NAb was detected using a competitive ligand binding assay. The immunogenicity assay validation reports are located in Module 5.3.1.4. The sensitivity and drug tolerance level of the ADA and NAb immunogenicity assays used in Phase 3 trials are summarized in <ref type="table" target="#tab_14">Table 3</ref>.5.  Reviewer's comments on drug tolerance of the ADA assays: For the detection of 500 ng/mL ADA positive control, the ECL binding ADA assay had a drug tolerance level of of tildrakizumab in serum and the NAb assay had a drug tolerance level of of tildrakizumab in serum. In psoriasis Phase 3 trials, the meanÂ±SD serum tildrakizumab concentrations following the 200 mg and 100 mg dosing regimens are presented in <ref type="figure">Figure 3</ref>.5. As a reference point, the meanÂ±SD steady state trough concentrations at Week 16 were 2.25Â±1.88 mcg/mL and 1.22Â±0.939 for the 200 mg and 100 mg doses, respectively, in Study P010; and 2.99Â±2.16 mcg/mL and 1.47Â±1.12 for the 200 mg and 100 mg doses, respectively, in Study P011. The initial assessment of the PK data does not indicate that drug interference would be a major issue for the ADA assay to detect ADA &gt;500 ng/mL because the meanÂ±SD steady state serum tildrakizumab levels appear to be generally below the drug tolerance level of of the ADA assay. In contrast, the detection of NAb could be interfered with the presence of tildrakizumab in serum because the meanÂ±SD steady state serum tildrakizumab concentrations were above the drug tolerance level of of the NAb assay. The initial assessment indicates that drug interference to the NAb assay presents a review issue for the Clinical Pharmacology and OBP review teams.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.6.">Drug-drug interactions (DDI)</head><p>The Applicant conducted a clinical DDI study (Study P009) that evaluated the effect of tildrakizumab on the PK of five CYP450 probe substrates (midazolam, omeprazole, caffeine, dextromethorphan, and warfarin+vitamin K) in subjects with psoriasis. Clinical Study Report for Study P009 was located in </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.7.">Proposal for a pediatric program</head><p>No clinical studies have been conducted to evaluate tildrakizumab in pediatric patients with psoriasis. According to the Agreed Initial Pediatric Stud Plan (Agreed iPSP), the Applicant has requested (1) a waiver of studies for evaluation of tildrakizumab in pediatric patients with psoriasis from 0 to &lt;6 years of age, and (2) a deferral of studies for evaluation of tildrakizumab in pediatric patients with psoriasis from 6 to &lt;18 years of age. Module 1.9.4 of the BLA contains the Agreed iPSP.   <ref type="figure">-----------------------------------------------------------------------------------------------------</ref> On initial overview of the NDA/BLA application for filing:</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Content Parameter Yes No Comment</head><p>1 Is the pharmacology/toxicology section organized in accord with current regulations and guidelines for format and content in a manner to allow substantive review to begin? X 2 Is the pharmacology/toxicology section indexed and paginated in a manner allowing substantive review to begin? X 3 Is the pharmacology/toxicology section legible so that substantive review can begin?</p><p>X 4 Are all required and requested IND studies in accord with 505 (b)(1) and (b)(2) including referenced literature) completed and submitted (carcinogenicity, mutagenicity, teratogenicity, effects on fertility, juvenile studies, acute and repeat dose adult animal studies, animal ADME studies, safety pharmacology, etc)?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>X</head><p>The sponsor provided published literature to help assess the carcinogenic potential of the biologic product.</p><p>5 If the formulation to be marketed is different from the formulation used in the toxicology studies, have studies by the appropriate route been conducted with appropriate formulations? (For other than the oral route, some studies may be by routes different from the clinical route intentionally and by desire of the FDA).</p><p>Not applicable.</p><p>6 Does the route of administration used in the animal studies appear to be the same as the intended human exposure route? If not, has the applicant submitted a rationale to justify the alternative route?  <ref type="figure">-----------------------------------------------------------------------------------------------------</ref>  <ref type="figure">-----------------------------------------------------------------------------------------------------</ref> Overall, the rates of psychiatric AEs found in the studies during the placebo-controlled phase was around 2% on study drug (versus 1% placebo), and did not demonstrate nominally statistically significant differences between the study drug population and placebo. The retrospective C-CASA analysis did not uncover any additional pertinent SI/B events during the placebo-controlled period. During the Safety Update reporting period, two suicides did occur during the Phase 3 extension studies, but these did not appear directly related to the study drug. I conclude that based on the data provided, there is no clear association between tildrakizumab and SI/B or other psychiatric conditions.</p><p>However, there remain some documented possible effects with other interleukin (IL) inhibitors and psychiatric AEs, as well as increased baseline psychiatric risk in subjects with psoriasis, that warrant ongoing monitoring and caution. The two extension phase suicides (and those in other psoriasis drug trials) point to this issue of baseline psychiatric risk, even apart from drug-related concerns. Although psychiatric safety monitoring has limitations and will not detect or prevent many psychiatric AEs or even most suicides, it is still a reasonable, cost-efficient, and relatively simple way to potentially address some events as they develop and trigger additional psychiatric attention as warranted. I strongly recommend that in future protocols for patients with psoriasis, or those who at least have a psychiatric history (including psychotropic medication use), prospective psychiatric safety monitoring be performed during clinical trials, including the extension phase, at each visit.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>II. Background</head><p>Tildrakizumab is a novel high affinity humanized immunoglobulin G1/kappa antibody that specifically binds to the IL-23p19 subunit and blocks the interaction of human IL-23 with the IL-23 receptor. Tildrakizumab, in a 100 mg/mL solution, is administered as a subcutaneous injection via 1 mL single-dose prefilled glass syringe for the treatment of adults with moderateto-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.</p><p>Other psoriasis systemic therapies have targeted receptors such as IL-12, IL-23, IL-17, and Tumor Necrosis Factor (TNF)-Î±. Some of these receptors have been associated with downstream psychiatric effects and are theorized to modulate neurotransmission.</p><p>IL-23 is a cytokine, produced mainly by activated myeloid cells, signaled by a heterodimeric IL-23 receptor complex combining an IL-23 receptor and IL-12RÎ²1. IL-23 is known to drive autoimmune reactions in mouse models and human diseases via activation of a subset of T cells (Th17). Tildrakizumab is postulated to improve psoriasis via selective IL-23 blockade, and may leave IL-12 activity largely unaffected.</p><p>Increasing evidence suggests that cytokines are key mediators in the pathophysiology of major depressive disorder (possibly via hypothalamic-pituitary-adrenal (HPA) axis effects) and other psychiatric disorders like schizophrenia as well. Research studies have also noted altered cytokine levels (particularly IL-6 elevations in one review 1 and IL-2 and IL-4 and Transforming Growth Factor (TGF)-Î² in another meta-analysis 2 ) in the cerebrospinal fluid of suicide attempters and completers compared to non-suicidal subjects. Psoriasis patients are also wellknown to have higher rates of depression, although it is unclear if the rates are mainly due to a primary immune-mediated cause, the high psychosocial burden of the illness, or a combination of both factors contributing to that increased risk. Adverse psychiatric effects with other IL inhibitors and anti-TNF-Î± agents used to treat psoriasis remain an area of concern. These agents include brodalumab (IL-17A inhibitor), infliximab (TNF-Î± inhibitor) and apremilast (PDE-4 inhibitor, which has downstream effects on cytokine blockade including IL-23 and IL-12), which have raised questions of potential disinhibition, anxiety, mood changes and/or lability, or suicidality. (Complicating matters is that some anti-psoriatic drugs like etanercept and adalimumab that are TNF-Î± blockers may also have antidepressant activity.) A literature review shows no known clear associations between IL-23 and psychiatric symptoms, although some researchers postulate that IL-23 has such effects and shows altered levels in schizophrenia 3 . One recent study showed no changes in IL-23 plasma levels after antidepressant treatment in patients with MDD 4 , but another showed possible increased serum IL-23 levels in patients with schizophrenia who were on depot antipsychotic medication versus healthy controls 5 . The clinical implications of these studies remain unclear. As noted above, one Phase 2 (P003, also referred to as P05495) and two Phase 3 clinical trials (P010 and P011) were performed with tildrakizumab. A total of 1994 subjects with moderate to severe plaque psoriasis were exposed to tildrakizumab during these Phase 2/3 trials in all phases (1413 during the placebo-controlled phase). The two Phase 3 trials used tildrakizumab doses of 100 mg and 200 mg and had a placebo-controlled phase only up until Week 12, after which subjects were re-randomized and continued dosing until Week 28. (Study P011 also had an active comparator arm using etanercept.) The Phase 2 trial had four different dose arms (5 mg, 25 mg, 100 mg, and 200 mg) and a placebo arm until Week 16 (before dose adjustment and continued dosing until Week 52). For adverse event analysis, these trials were pooled during The Sponsor used MedDRA version 19.1 to code AE terms to preferred terms in the Phase 2 and 3 studies. I reviewed all the ADAE.xpt datasets for coding accuracy between AETERM and AEDECOD and found them satisfactory from a psychiatric AE perspective. I also reviewed subjects under the Injury, Poisoning, and Procedural Complications SOC under AEBODSYS, and no obvious miscodings of hidden psychiatric events were evident; they were all likely accidental/non-psychiatric in nature based on the limited information provided, except for the events that were coded already as psychiatric.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>III. Review of Clinical Data</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A. Selection of Relevant Clinical Trials</head><p>Psychiatric AE terms were found under AEBODSYS category for Psychiatric Disorder SOC. Under AEDECOD (preferred terms) they were as follows:</p><p>P003-insomnia, adjustment disorder with depressed mood, stress, nervousness, mood swings, depression P010-insomnia, anxiety, depression, irritability, agitation, mood swings, libido decreased, panic attack, suicide attempt, adjustment disorder P011-depression, major depression, insomnia, emotional disorder, anxiety, irritability, sleep disorder There were also numerous AEs coded under fatigue or tiredness, but I decided not to include them as psychiatric events since it would be difficult to distinguish their etiology from both the underlying medical condition of psoriasis and possible systemic drug effects versus any depressive etiology. Fatigue/tiredness AEs did not occur on drug at rates higher than placebo. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>i. Psychiatric AE Analysis</head><p>From my own JMP-based dataset review of ADAE.xpt from the Sponsor-provided pooled dataset, I found the following numbers of psychiatric SOC AEs: For placebo comparison, I determined the following: Dropout rates were fairly low and the treatment periods were similar (12 weeks for Phase 3, 16 weeks for the smaller Phase 2); therefore, the crude rates are expected to be reasonably reliable for comparing the treatment groups, and exposure-adjusted reporting rates are not presented, although the placebo-controlled period for P003 was 4 weeks longer than the others.  3 (0.4%) 1 (0.1%) 2 (2%) 6 (0.4%) 1 (0.3%) ALL Sleep (Insomnia) 3 (1%) 4 (0.6%) 7 (1%) 0 11 (0.7%) 2 (0.6%) ALL Psychiatric AEs** 5 (1.6%) 13 (1.8%) 15 (2.1%) 4 (4%) 32 (2.1%) 3 (0.8%) *Zero psychiatric AEs in Tildrakizumab 5 mg arm (N=42) of Study P003. **Three subjects had two psychiatric AEs during the placebo-controlled phase, one from each study. One was on placebo (P010), one was on 100 mg (P011), and one was on 200 mg (P003). Those duplicate subjects were removed from the totals in this row but not in the individual subcategory AE counts above. There were no nominally significant differences between tildrakizumab versus placebo for the above psychiatric AEs or subcategories per Fisher's exact test, even if via crude rates psychiatric AEs occurred at a higher rate on drug (2%) versus placebo (1%). However, power is limited by sample size, and exposure durations varied slightly with the Phase 2 versus Phase 3 trials.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ii. Suicidal Ideation and Behavior (SI/B)</head><p>No SI/B-related deaths were reported in any of these three studies during the base study period. There were two suicides as per the October 3, 2017 Safety Update Report that occurred during the extension phase (one subject originally from P010 and one from P011).</p><p>There was also one subject in P010 who died reportedly from a toxic reaction between fluoxetine and cyclobenzaprine (although it is unclear how long the subject had been on those medications, or if elevated doses were taken-the autopsy report did note "prescription drug abuse") during the extension phase. The subject had a past history of depression and suicidal ideation. (There were also two deaths secondary to alcohol abuserelated medical sequelae during the Phase 2 and 3 trials, one of whom was adjudicated as "unknown cause" during C-CASA analysis.)</p><p>There was one suicide attempt during the placebo-controlled phase in Study P010, and two suicidal ideation events during the extension phase in Study P011. (There was also one suicidal ideation event in Phase 1 Study 007.) All of these events occurred on tildrakizumab.</p><p>Reference ID: 4169815</p><formula xml:id="formula_27">(b) (6) 8</formula><p>The differences between drug and placebo for the 12 to 16 week phase for SI/B events are not nominally statistically significant. Extension phase SI/B events are unlikely to be drug-related, given the length of time subjects have been exposed to drug before events occur without prior incident.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>iii. Case Summaries</head><p>Brief case summaries and WHO based causality assessments of the five SI/B events and two suspicious deaths from the tildrakizumab Phase 2 and 3 studies (and one SI/B event from Phase 1) were as follows: Unlikely, due to temporality, also had previous psychiatric history and medications (and facial nerve pain which has known suicide risk)</p><p>*Recoded after C-CASA analysis as SI event based on SAE report, originally coded as "depression" and "bipolar disorder" AEs only. **Recoded after C-CASA analysis as death of unknown cause ***Occurred since initial submission, during extension phase</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>iv. Anxiety and Insomnia</head><p>Reference ID: 4169815 (b) <ref type="bibr">(6)</ref> No clear associations are evident between tildrakizumab and anxiety and insomnia AEs when looking at the placebo-controlled AE data. There is no clear evidence of activation-related phenomena with this drug based on reported AEs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>v. Concomitant Medications</head><p>Subjects in each treatment arm were taking similar percentages of at least one concomitant psychotropic medication (slightly less in the etanercept group). This seems to indicate similar rates of baseline psychiatric morbidity between treatment groups. 23 subjects with psychiatric AEs (out of 38 total, 61%) were taking concomitant psychotropic medications at some point during the study (17 during screening, or 45%): 6 (2 of them during screening) from Study P003, 11 (7 during screening) from P010, and 6 (4 during screening) from P011. All but one (on etanercept who was on it during screening) were on study drug as well. This data indicates that the population on study drug developing psychiatric AEs might have had more pre-existing psychiatric morbidity than those developing psychiatric AEs who were not on study drug.</p><p>Treatment groups also were taking similar amounts of concomitant steroid medications (which have the potential to adversely affect mood, sleep, and anxiety). Thus, it does not seem likely that steroid medications confounded the comparison of psychiatric event rates. Of note, my AE results were slightly different than the Sponsor who noted the following Psychiatric AEs in the pooled placebo-controlled dataset in their Integrated Summary of Safety: Placebo: 3 (0.8%) Mine was 3. Tildrakizumab 100 mg: 13 (1.8%) Mine was 13. Tildrakizumab 200 mg: 14 (2.0%) Mine was 15. (I had one additional agitation AE that the Sponsor omitted.) Tildrakizumab 100+200: 27 (1.9%) Mine was 28. Etanercept: 5 (1.6%) Mine was 5.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>G. Scale Data</head><p>The quality-of-life scales used are not designed for the assessment of primary psychiatric symptomatology. No other psychiatric scales were used in these studies.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IV. Other Consults/History</head><p>Tildrakizumab (an IL-23 p19 subunit inhibitor) is one of a few approved and/or studied medications that also act on IL-23, such as guselkumab (a monoclonal antibody to the p19 subunit to IL-23, FDA-approved in July 2017), ustekinumab (a monoclonal antibody to the p40 subunit of IL-12 and IL-23, FDA-approved in September 2009) and No clear SI/B or depression or anxiety signals were noted during the trials for these medications thus far.</p><p>Guselkumab had one completed suicide occur during the extension phase which was not felt to be related to the study medication, as per our division's prior consult review by John Umhau MD on 4/10/2017. No suicide attempts and one suicidal ideation AE on guselkumab during the placebo-controlled phase were noted in the trials. Both subjects with SI/B events had prior histories of depression. Retrospective C-CASA adjudication only noted an incidence rate of 0.10 per 100 subject-years for SI/B events for subjects on guselkumab. (Similar rates were found with secukinumab 0.06/100 and ixekizumab 0.14/100.) Overall psychiatric AEs on guselkumab also did not occur at a higher rate than placebo.</p><p>Other cytokine receptor inhibitors have been approved for the treatment of psoriasis, with concerns about effects on psychiatric symptoms and SI/B; in particular, brodalumab, which is an IL-17a receptor antagonist, received a boxed warning due to six suicides that occurred during its clinical trial program. Apremilast is a PDE-4 inhibitor that has some downstream effects on IL-23 and had some possible associations with depression and anxiety (leading to inclusion in the label). However, overall, the current literature on IL-23 and association with any psychiatric effects remains extremely limited and unremarkable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>V. Conclusions and Recommendations</head><p>Overall, the rates of psychiatric AEs were low in the tildrakizumab treatment group in the Phase 2 and 3 studies reviewed above. The low rates might, in part, be due to lack of formal psychiatric symptom monitoring in these trials; however, this interpretation can be counterbalanced by the lack of any psychiatric exclusion criteria for these studies (aside from substance abuse exclusion in one trial) and baseline elevated rates of depression and suicide risk in subjects with psoriasis. There was a slightly higher crude rate incidence of psychiatric AEs in the drug treatment group versus placebo (2% versus 1%) in the placebo-controlled phases of the Phase 2 and 3 trials, but these differences were not nominally statistically significant. SI/B events were extremely rare before C-CASA adjudication; only one confirmed suicide attempt occurred during the Phase 2 and 3 trials, in a subject with high psychiatric comorbidity (diagnosis of schizophrenia and on antipsychotic medication), although the timing of the incident (11 days after first dose) does not completely rule out a possible drug association.</p><p>Retrospective C-CASA adjudication only uncovered one additional suicidal ideation event (associated with a depression and bipolar AE previously reported) during the extension period and added one death of unknown cause (unlikely to be due to study medication, with concomitant alcohol abuse) which occurred in the placebo-controlled period.</p><p>During the update period up until 10/3/17, one additional suicidal ideation event and two suicides occurred during the extension studies. None of these new events appear to be associated with the study drug, and they all occurred in the context of pre-existing psychiatric morbidity.</p><p>For depression, anxiety, and insomnia events in these studies, drug causality seemed unlikely.</p><p>Other IL inhibitors have had potential psychiatric and CNS effects, and a class association cannot be completely ruled out at this time, although no clear signals are noted thus far and postmarketing data evaluation is ongoing.</p><p>My recommendations are as follows:</p><p>1. Given the two suicides recently reported in the extension safety update, and other ones that have occurred in clinical trial programs in patients with psoriasis, if not already implemented, I strongly recommend that DDDP ask Sponsors that in future protocols for all patients with psoriasis, or at the very least those who have a reported psychiatric history (including medications) before or during the trial, prospective psychiatric safety monitoring during clinical trials, including the extension phase, occur at each visit. This monitoring should include suicidal ideation and behavior monitoring that maps to C-CASA categories (such as the Columbia Suicide Severity Rating Scale (C-SSRS) or Sheehan Suicidality Tracking Scale (S-STS)), and at least one psychiatric symptom monitoring scale such as the Brief Psychiatric Rating Scale (BPRS) (which screens for a wide range of psychiatric conditions) and/or a depression scale such as the Patient Health Questionnaire (PHQ) or Physician Depression Questionnaire (PDQ). Anxiety or insomnia scales can also be considered as well. (The HADS (Hospital Anxiety and Depression Scale) has been used in some psoriasis trials.)</p><p>This psychiatric safety monitoring remains prudent given the baseline increased SI/B and psychiatric risk with subjects with psoriasis, plus the added risk of unknown potential immune modulator drug effects on psychiatric symptoms. All screening tools for suicidality and depression remain limited in terms of ability to predict or prevent SI/B events. Evidence on screening-related outcomes also remains inconclusive and contradictory, although of interest, the Canadian Dermatology-Rheumatology Comorbidity Initiative came to a consensus recommendation of depression screening for patients with psoriasis in the clinical setting. 6</p><p>Overall, this safety monitoring is a relatively simple and efficient method to potentially proactively intervene with at least some psychiatric concerns as they arise, and to provide better care and protection for clinical subjects in a population known to be at increased risk of psychiatric events. The data collected is also potentially helpful in terms of determining any existing direct drug-related effects or other causes or trends associated with SI/B or depression in this population.</p><p>2. Informed Consent documents should also advise subjects to contact the investigator if they experience new or worsening depression or suicidal ideation, because the intervals between visits can be very wide in some extension studies.</p><p>3. I do not recommend exclusion of subjects with psoriasis with a psychiatric history and/or medications from future trials, as it is important for them to be studied, in part because they represent a significant portion of real-world patients with psoriasis. For those subjects with a history of suicidality, the reviewer(s) and Sponsor(s) should usually consider that exclusion determination on a case-by-case risk-benefit basis for each protocol. As a general rule, those with recent suicidal behavior (i.e., attempts) within the past month and/or active SI/B on screening should be excluded and referred as needed to appropriate psychiatric intervention.</p><p>4. I do not recommend specific psychiatric warning language in the tildrakizumab label at this time, as there is insufficient evidence of increased risk of SI/B or other psychiatric issues thus far with tildrakizumab, in terms of direct drug-related effect, based on the current clinical trial data available. There is also no preliminary research thus far showing any clear association with IL-23 and psychiatric sequelae.</p><p>- <ref type="figure">----------------------------------------------------------------------------------------------------</ref> </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>-response for safety by concentration quartiles by Week 12 of Phase 3 trails (P010 and P011) ........................................................................................................... 71 Table 15: Effect of body weight on meanÂ±SD serum tildrakizumab concentrations in Phase 3 trials .............................................................................................................................. 72 Table 16: Effect of body weight on clinical responses at Week 12 in Phase 3 trials ...... 73 Table 17: Model simulated Week 12 PASI response by body weight categories: 100 mg versus 200 mg ............................................................................................................................ 73</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>(</head><label></label><figDesc>Based on 12-Week Follow up).............................................................................................. 141Table 46: Subject Enrollment in Phase 1 Trials .................................................................. 149 Table 47: Location of the labeling discussion...................................................................... 159 Table 48: Investigators with Financial Disclosure Forms 3455 for Trials P010 and P011 ............................................................................................................................... ...................... 165 Table 49: Investigators Not Certified; Due Diligence Completed ..................................... 165 Table 50: Upper Respiratory Infections ................................................................................ 168 Table 51: Injection-site Reactions ......................................................................................... 168 Table 52: Fatigue ..................................................................................................................... 169 Table 53: Diarrhea ................................................................................................................... 169 Table 54: Back Pain................................................................................................................. 170 Table 55: Abdominal Pain....................................................................................................... 170 Table 56: Nausea ..................................................................................................................... 171 Table 57: Tildrakizumab products with different drug substances, formulations, and/or presentations used in clinical trials........................................................................................ 174 Table 58: Summary of assay validation parameters of the ECL assay for measurement of tildrakizumab concentrations in human serum................................................................ 175 Table 59: Sensitivity and drug tolerance of immunoassays for detection of anti-drug antibodies (ADA) in tildrakizumab clinical trials................................................................... 177 Table 60: Sensitivity and drug tolerance of immunoassays for detection of neutralizing anti-drug antibodies (NAb) in tildrakizumab clinical trials .................................................. 177 BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 8</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc>Study P009) .................................................................................. 179Table 63: Summary of S-warfarin PK parameters following a single oral dose of 10 mg warfarin as part of a CYP probe cocktail at Day 1 (baseline) and Day 57 (following two SC doses of 200 mg tildrakizumab at Weeks 0 and 4) in subjects with moderate to severe plaque psoriasis (Study P009) .................................................................................. 179Table 64: Summary of ratio of plasma 5-hydroxyomeprazole/ omeprazole PK parameters following a single oral dose of 40 mg omeprazole as part of a CYP probe cocktail at Day 1 (baseline) and Day 57(following two SC doses of 200 mg tildrakizumab at Weeks 0 and 4) in subjects with moderate to severe plaque psoriasis (Study P009) ............................................................................................................................. 179 Table 65: Summary of dextromethorphan PK parameters following a single oral dose of 30 mg dextromethorphan as part of a CYP probe cocktail at Day 1 (baseline) and Day 57 (following two SC doses of 200 mg tildrakizumab at Weeks 0 and 4) in subjects with moderate to severe plaque psoriasis (Study P009)............................................................ 180 Table 66: Summary of caffeine PK parameters following a single oral dose of 200 mg caffeine as part of a CYP probe cocktail at Day 1 (baseline) and Day 57 (following two SC doses of 200 mg tildrakizumab at Weeks 0 and 4) in subjects with moderate to severe psoriasis (Study P009) ............................................................................................... 180 Table 67: Mean (CV%) tildrakizumab PK parameters following single IV administration in healthy subjects (Study P05661)....................................................................................... 181 Table 68: Mean (CV%) tildrakizumab PK parameters following single SC administration in healthy subjects (Study P05776)....................................................................................... 181 Table 69: Geometric mean (CV%) tildrakizumab PK parameters following single SC or IV administration in healthy subjects (Study P06306)........................................................ 181 Table 70: MeanÂ±SD serum tildrakizumab concentrations in Phase 3 trials (P010 and P011)................................................................................................................................ .......... 183 Table 71: Summary of immunogenicity incidences through Week 12 in Phase 3 trials (P010 and P011). ..................................................................................................................... 183 Table 72: Summary of immunogenicity incidences through Week 64 in Phase 3 trials (P010 and P011). ..................................................................................................................... 184</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 1 :</head><label>1</label><figDesc>Dose-response for PASI 75 and PGA of "cleared" or "minimal" at Week 12 in Phase 2 study P05495 .............................................................................................................. 69 Figure 2: Exposure-response for PASI 75, PASI 90, and PASI 100 in Phase 2 and Phase 3 trials (P05495, P010, and P011).............................................................................. 69 Figure 3: PASI 75 response overtime through Week 28 in Trials P010 and P011.......... 71 Figure 4: Proportion of subjects with PASI 75 response in PASI partial responders at Week 28: subjects initially randomized to tildrakizumab 100 mg at Week 0 and rerandomized to 100 and 200 mg at Week 28.......................................................................... 71 Figure 5: Schematic Overview of Trial P010 ......................................................................... 87 Figure 6: Schematic Overview of Trial P011 ......................................................................... 88 Figure 7: Multiplicity Testing Strategy for Trial P010............................................................ 89 Figure 8: Multiplicity Testing Strategy for Trial P011............................................................ 90 Figure 9: Results for PGA Response (1) and PASI 75 Through Week 28 for Trial P010 . 99 Figure 10: Results for PGA Response (1) and PASI 75 Through Week 28 for Trial P011 ............................................................................................................................... ...................... 100 Figure 11: Maintenance of Response (PASI 75 and PGA Response (1) ) in Trial P010 . 101 Figure 12: PGA Response (1) and PASI 75 at Week 12 by Sex, Age, Race, Weight, Baseline PGA Score and Prior Use of Biologic Therapy for Trial P010 .......................... 103 Figure 13: PGA Response (1) and PASI 75 at Week 12 by Sex, Age, Race, Weight, Baseline PGA Score and Prior Use of Biologic Therapy for Trial P011 .......................... 104 Figure 14: PGA Response (1) and PASI 75 at Week 12 by Country for Trial P010 ........ 105 Figure 15: PGA Response (1) and PASI 75 at Week 12 by Country for Trial P011 ........ 106 Figure 16: Physician Global Assessment (PGA) ................................................................ 166 Figure 17: Psoriasis Area and Severity Index (PASI) ........................................................ 167 Figure 18: Mean tildrakizumab concentration-time profiles by subject ADA status in Phase 2 and Phase 3 trials..................................................................................................... 185 Figure 19: Goodness of Fit Plots for the Base Population PK Model .............................. 190 Figure 20: Goodness of Fit Plots for the Final Population PK Model for Tildrakizumab192 Figure 21: Prediction-Corrected VPC Stratified by Trial .................................................... 193 Figure 22: Impact of Covariate on Tildrakizumab AUCss (100 mg Dose Administrated Every 12 Weeks) ...................................................................................................................... 196 Figure 23: Longitudinal PK-PD Model Schematic Diagram .............................................. 199 Figure 24: Risk-Benefit Analysis for the Part 1&amp;2 Adverse Events (Week 0-28) and PASI 75 Response (Week 28) ............................................................................................... 204</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Proposed indication :</head><label>indication</label><figDesc>For the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Proposed dosing regimens: 100 mg tildrakizumab administered by subcutaneous (SC) injection at Weeks 0, 4, and every 12 weeks thereafter Proposed dosage form: Single use prefilled syringe (PFS): 100 mg of tildrakizumab in 1.0 mL solution (100 mg/mL)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head></head><label></label><figDesc>Phase 2/3 trials: The applicant used an E max logisticregression model with average serum tildrakizumab concentrations from Week 0 to Week 12 to describe exposure-response relationships for PASI 75, PASI 90 and PASI 100 in pooled Phase 2 and Phase 3 trials with 1883 subjects. The results demonstrated exposureresponse relationships for the three PASI efficacy variables(Figure 2).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 1 :</head><label>1</label><figDesc>Dose-response for PASI 75 and PGA of "cleared" or "minimal" at Week 12 in Phase 2 study P05495 Tildrakizumab 5 mg, 25 mg, 100 mg, or 200 mg was administered by subcutaneous injection at Weeks 0, 4, and every 12 weeks thereafter till Week 52. (Source of data: Reviewer's plot using Applicant's data presented in</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>Figure 2 :</head><label>2</label><figDesc>Exposure-response for PASI 75, PASI 90, and PASI 100 in Phase 2 and Phase 3 trials (P05495, P010, and P011) An E max logistic-regression model with average serum tildrakizumab concentrations from Week 0 to Week 12 were used to describe the exposure-response relationship for PASI 75, PASI 90 and PASI 100. Points were PASI response probability with 95% confidence interval. The red line and shaded region represent model fit values with 95% uncertainty bands. (Source of data:Figure 3, Figure 4andFigure 5, population PK/PD report 04kx06.pdf)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head></head><label></label><figDesc>Phase 2: P05495 (P003): randomized, placebo-controlled, parallel-group, dose-ranging, 5-arm, (5, 25 100, 200 mg SC vs placebo) trial in 355 subjects with moderate to severe plaque psoriasis (52-week dosing period and 20 week follow-up period) Phase 3: P010: randomized, double-blind, placebo-controlled, multi-center, trial to evaluate the safety and efficacy of 2 doses (100 mg or 200 mg SC) of tildrakizumab vs placebo in adult subjects with moderate to severe plaque psoriasis which includes an optional long-term safety extension period (up to 4 years) (64 week dosing period and 20 week follow-up period) P011: randomized, double-blind, placebo-controlled, multi-center, trial to evaluate thsafety and efficacy of 2 doses (100 mg or 200 mg SC) of tildrakizumab vs placebo and etanercept in adult subjects with moderate to severe plaque psoriasis which includes an optional longterm safety extension period (up to 4 years) (52 week dosing period and 20 week follow-): ascending single IV dose trial (0.1, 0.5, 3, 10 mg/kg IV vs placebo) in 29 healthy volunteers (HV) P05776 (P005): randomized, double-blind, placebo-controlled, ascending, single SC dose trial (50 or 200 mg SC vs placebo) in 37 healthy volunteers (HV) P06306 (P007): Phase 1 open-label, single dose PK (50, 200, 400 mg SC or 10 mg/kg IV)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head></head><label></label><figDesc>: o Arm A (N=300): tildrakizumab 200 mg at Weeks 0 and 4 o Arm B (N=300): tildrakizumab 100 mg at Weeks 0 and 4 o Arm C (N=150): placebo at Weeks 0 and 4 Part 2 (Weeks 12 to 28): all subjects assigned to placebo in Part 1 were re-randomized at Week 12 in a 1:1 ratio to either tildrakizumab 200 mg or 100 mg. These subjects received their new treatment at Weeks 12 and 16. Subjects in Arm A and Arm B received placebo at Week 12 to maintain the blind and their assigned treatment (200 or 100 mg of tildrakizumab) at Week 16. Part 3 (Weeks 28 to 64): beginning at Week 28, treatment for all subjects was based on their level of response (i.e., improvement in PASI from baseline). o Subjects originally randomized to tildrakizumab 200 mg (Arm A):Non-responders (PASI &lt; 50%) at Week 28 were discontinued.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_11"><head>o</head><label></label><figDesc>Arm A (N=300): tildrakizumab 200 mg at Weeks 0 and 4, and placebo for etanercept twice weekly o Arm B (N=300): tildrakizumab 100 mg at Weeks 0 and 4, and placebo for etanercept twice weekly o Arm C (N=150): placebo at Weeks 0 and 4, and placebo for etanercept twice weekly o Arm D (N=300): etanercept 50 mg twice weekly and placebo for tildrakizumab at Weeks 0 and 4 Reference ID: 4233639</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_12"><head></head><label></label><figDesc>(3) U.S. sample sizes = (N T200 , N T100 , N E ) = (86, 85, 87); Non-U.S. sample sizes = (N T200 , N T100 , N E ) =(228, 222, 226). (4) Comparison against placebo. P-value based on a CMH test stratified by baseline weight ( 90 kg / &gt;90 kg) and prior exposure to biologic therapy for psoriasis (Yes/No).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_13"><head>Figure 9 and</head><label>9</label><figDesc>Figure 10present the results for PGA response and PASI 75 through Week 28 for Trials P010 and P011, respectively.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_14"><head></head><label></label><figDesc>A 57-year-old male , had an adverse event of mycoplasma pneumonia on Day 407 after 5 doses of tildrakizumab 100mg. Approximately 42 days after the last dose of study medication he developed a cough. On Day 414, a chest x-ray was performed showing mycoplasma pneumonia. He received azithromycin hydrate (IV) and hydrocortisone sodium succinate (IV), codeine phosphate, fluticasone propionate, and salmeterol xinafoate. Gradually, his symptoms improved on Day 505 and he was released from followup. The event was assessed as possibly related. Etanercept A 67-year-old White female with a medical history of hyperglycemia who received etanercept experienced a severe drug-related infection of herpes zoster on Day 165. She was treated with antiviral and pain medication. The study medication was resumed on Day 189. A 64-year-old White female , with a history of Type 2 diabetes mellitus who received etanercept experienced a severe, drug-related infection event of urosepsis. On day 107, when she presented to the hospital her laboratory parameters were significant for hyperglycemia and blood and urine cultures positive for Escherichia coli. The event resolved on Day 132 with insulin and antibiotic therapy. Treatment with etanercept resumed on Day 168.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_15"><head>A</head><label></label><figDesc>22-year-old White male with a history of depression experienced suicidal ideation on Day 918, depression on Day 922 and was admitted to the hospital on Day 928 after 27 Picardi A, Lega I, Tarolla E. Suicide risk in skin disorders. Clin Dermatol. 2013; 31(1):47-56.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_16"><head>PROTOCOL</head><label></label><figDesc>Multiple-Dose Tolerability, Safety, and Pharmacokinetic Study of Intravenous tildrakizumab (SCH 900222; MK-3222) in Patients with Psoriasis."</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_18"><head></head><label></label><figDesc>Was a list of clinical investigators provided: Yes No (Request list from applicant) Total number of investigators identified: 70 Number of investigators who are sponsor employees (including both full-time and part-time employees): 0 Number of investigators with disclosable financial interests/arrangements (Form FDA 3455): 0 If there are investigators with disclosable financial interests/arrangements, identify the number of investigators with interests/arrangements in each category (as defined in 21 CFR 54.2(a), (b), (c) and (f)):</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_19"><head></head><label></label><figDesc>investigators identified: 127 Number of investigators who are sponsor employees (including both full-time and part-time employees): 0 Number of investigators with disclosable financial interests/arrangements (Form FDA 3455): 2 If there are investigators with disclosable financial interests/arrangements, identify the number of investigators with interests/arrangements in each category (as defined in 21 CFR 54.2(a), (b), (c) and (f)):</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_20"><head></head><label></label><figDesc>investigators identified: 146 Number of investigators who are sponsor employees (including both full-time and part-time employees): 0 Number of investigators with disclosable financial interests/arrangements (Form FDA 3455): 1 If there are investigators with disclosable financial interests/arrangements, identify the Reference ID: 4233639 number of investigators with interests/arrangements in each category (as defined in 21 CFR 54.2(a), (b), (c) and (f)):</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_21"><head></head><label></label><figDesc>n = number of participants with adverse reaction (m) in the subgroup (n) Source: Statistical Review's Tables</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_22"><head></head><label></label><figDesc>n = number of participants with adverse reaction (m) in the subgroup (n) Source: Statistical Review's</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_23"><head></head><label></label><figDesc>n = number of participants with adverse reaction (m) in the subgroup (n) Source: Statistical Review's Tables BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 171</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_24"><head></head><label></label><figDesc>n = number of participants with adverse reaction (m) in the subgroup (n) Source: Statistical Review's Tables BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 173</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_25"><head></head><label></label><figDesc>median): 39 years (range: 22-63 years) Race: 20 Caucasian (100%) Body weight (meanÂ±SD): 84Â±12 kg Baseline psoriasis area and severity (PASI): median 17; range: 12-42 PK of tildrakizumab: Tildrakizumab PK results following SC administrations of tildrakizumab 200 mg on Day 1 and on Day 29 via PFS or AI are summarized in</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_26"><head></head><label></label><figDesc>Treatment-emergent ADA (TE-ADA): TE-ADA include (1) subjects who had negative pretreatment sample and at least one positive post-dose sample and (2) subjects who had both positive pre-treatment sample and positive post-dose sample and the titer increased by 2-fold. o TE-ADA positive NAb negative: TE-ADA positive but negative for NAb o TE-ADA positive NAb positive: TE-ADA positive and positive for NAb Non-treatment-emergent ADA (non-TE-ADA): non-TE-ADA include (1) subjects who had positive pre-treatment sample and post-dose samples were negative; and (2) subjects who had positive pre-treatment and post-dose samples with a &lt; 2-fold increase in titer post-dose. o Non-TE-ADA positive NAb negative: Non-TE-ADA positive and negative for NAb o Non-TE-ADA positive NAb positive: Non-TE-ADA positive and positive for NAb (Source of data: Tables 2.7.2:14-16, Summary of Clinical Pharmacology)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_27"><head>Figure 18 :</head><label>18</label><figDesc>Mean tildrakizumab concentration-time profiles by subject ADA status in Phase 2 and Phase 3 trials.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_28"><head>Figure 24 :</head><label>24</label><figDesc>Risk-Benefit Analysis for the Part 1&amp;2 Adverse Events (Week 0-28) and PASI 75 Response (Week 28) (Source of data: Figure 2.7.2, Summary of Clinical Pharmacology; Figure S3 on page 22 of Applicant's PK-PD report 04kx06.pdf)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_29"><head>Figure 3 . 5 .</head><label>35</label><figDesc>Serum tildrakizumab concentrations observed in Phase 3 studies. (Source of Data: CSR for Studies P010 and P011; Figure 2.7.25:7, Summary of Clinical Pharmacology)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_31"><head>1</head><label></label><figDesc>subject was randomized but not dosed) â 10 mg/kg IV (N=6) â Placebo IV (N=6) Part 2 (Day 1, 28, and 56): â 3 mg/kg IV (N=15) â 10 mg/kg IV (N=14) â Placebo IV (N=11) Part 3 (Day 1, 56, and 84): â 0.05 mg/kg IV (N=6) â 0.1 mg/kg IV (N=3) â Placebo IV (N=3)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_34"><head></head><label></label><figDesc>Sun Pharma) submitted a BLA currently under review by the Division of Dermatology and Dental Products (DDDP) for tildrakizumab for the indication of psoriasis on 3/24/2017. Efficacy was evaluated in two Phase 3, randomized, placebo-controlled, doubleblind trials (P010 and P011). Placebo-controlled data from the first 12 weeks of the two Phase 3 trials was pooled with placebo-controlled data from the first 16 weeks of the Phase 2 study, P003. (The Phase 3 trials also each had a 192-week long-term safety extension phase.) Psychiatric adverse events (AEs), including three suicidal ideation and behavior (SI/B) events, were identified by DDDP from the Sponsor's initial submission; DDDP is requesting that the Division of Psychiatry Products (DPP) review the psychiatric AE study data in the tildrakizumab trials and the requested results of a retrospective Columbia Classification and Assessment of Suicidal Adverse Events (C-CASA) tabulation analysis to provide input on whether there are any concerns about a psychiatric or SI/B AE signal, and if so, what follow-up and labeling guidance should be provided.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_35"><head>1</head><label></label><figDesc>Gananca L et al. The role of cytokines in the pathophysiology of suicidal behavior. Psychoneuroendocrinology 63(2016): 296-310. 2 Ducasse D et al. A meta-analysis of cytokines in suicidal behavior.Brain, Behavior, and Immunity. 46(2015): 203-211.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_36"><head>3</head><label></label><figDesc>Debnath M and Berk M. Functional implications of the IL-23/IL-17 immune axis in schizophrenia. Molecular Neurobiology. Nov 2016: Epub ahead of print. 4 Kim J, et al. Plasma levels of IL-23 and Il-17 before and after antidepressant treatment in patients with major depressive disorder. Psychiatry Investigation 10(2013): 294-299. 5 O'Connell KE, et al. Increased IL-23 levels in schizophrenia patients treated with depot antipsychotic medication. Cytokine. 73(2015): 196-8.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 :</head><label>1</label><figDesc>Summary of Treatment Armamentarium for Moderate to Severe Plaque Psoriasis ............................................................................................................................... ....... 30 Table 2: Site Inspection Results .............................................................................................. 39 Table 3: Active Pharmaceutical Ingredient CQA Identification, Risk and Lifecycle Knowledge Management .......................................................................................................... 40 Table 4: Drug Substance CQA Process Risk Identification and Lifecycle Knowledge Management. .............................................................................................................................. 41 Table 5: Drug Product CQA Identification, Risk, and Lifecycle Management .................. 44 Table 6: Establishment Information......................................................................................... 47 Table 7: Summary of PK/TK data for tildrakizumab.............................................................. 52 Table 8: Number of sexually mature females and sexually mature/peri-pubertal males in the 3-month and 9-month monkey studies............................................................................. 56 Table 9: Tildrakizumab milk/maternal monkey serum concentrations and ratios ............ 58 Table 10: Tildrakizumab infant/maternal monkey serum concentrations and ratios ....... 59 Table 11: Multiples of human exposure for NOAELs identified in pivotal toxicology studies............................................................................................................................... ........... 63 Table 12: Summary of clinical pharmacology review ........................................................... 64 Table 13: Summary of clinical pharmacology and immunogenicity of tildrakizumab ...... 67 Table 14: Exposure</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 18 :</head><label>18</label><figDesc>Summary of geometric mean ratio (GMR) and 90% confidence interval (CI) of the GMR for Cmax and AUCinf of the probe substrates in Study P010 ............................... 74 Table 19: Listing of Clinical Trials Relevant to BLA 761067 ............................................... 77 Table 20: Office of Computational Science (OCS) findings ................................................ 82 Table 21: Secondary Efficacy Endpoints................................................................................ 88 Table 22: Disposition of Subjects Through Week 12 for Trials P010 and P011 .............. 91 Table 23: Demographics for Trials P010 and P011.............................................................. 92 Table 24: Baseline Disease Characteristics for Trials P010 and P011............................. 93 Table 25: Results for the Co-Primary Efficacy Endpoints at Week 12 .............................. 93 Table 26: Missing Data for the Co-Primary Efficacy Endpoints by Week ......................... 94 Table 27: Results for Co-Primary Efficacy Endpoints at Week 12 with Different Approaches for Handling Missing Data .................................................................................. 95 Table 28: Results for the Secondary Efficacy Endpoints Against Placebo at Week 12 . 95 Table 29: Results for the Secondary Efficacy Endpoints Against Etanercept at Week 12 ............................................................................................................................... ........................ 96 Table 30: Co-Primary and Secondary Efficacy Endpoints included in the Multiplicity Testing Strategy ......................................................................................................................... 97 Table 31: Maintenance of Response (Trial P010) ................................................................ 98 Reference ID: 4233639 BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 7</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 32 :</head><label>32</label><figDesc>Subject Population, Placebo Controlled Safety Period (Trials P003, P010, and P011)............................................................................................................................... ........... 108 Table 33: Deaths during the Phase 3 base period ............................................................. 116 Table 34: Deaths during the Phase 3 extension period ..................................................... 117 Table 35: Serious Adverse Events (SAEs) by System Organ Class (SOC)................... 118 Table 36: SAEs reported during the Placebo-controlled period by SOC and PT (Selected SOCs with more than 1 subject) .......................................................................... 118 Table 37: Subjects with Serious Adverse Events (Selected SOCs exposure adjusted rates, all subjects as treated) ................................................................................................. 120 Table 38: Pooled TEAE of Gastroenteritis and Related Events, Placebo-Controlled Period ............................................................................................................................... .......... 128 Table 39: Treatment-Emergent Adverse Events Reported by 1% in One or More Tildrakizumab Groups and More Frequently than in the Placebo Group in the Plaque Psoriasis Trials 1, 2, and 3*.................................................................................................... 129 Table 40: Adverse Reactions Reported by 1% in Subjects treated with Tildrakizumab 100 mg and More Frequently than in the Placebo Group in the Plaque Psoriasis Trials 1, 2, and 3* ................................................................................................................................ 130 Table 41: Number of Subjects with Malignancies During the Base Period (Excluding Non-Melanoma Skin Cancer) ................................................................................................. 137 Table 42: Exposure Adjusted Rates for Malignancy from the Pooled Phase 2/Phase 3 Trials Compared with the SEER Data .................................................................................. 138 Table 43: Subjects with adjudicated MACE during the Base period................................ 139 Table 44: Subjects with adjudicated MACE in pooled Phase 3 extension trials ............ 140 Table 45: Number of Treatment Emergent Adverse Reactions -Exposure Adjusted</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 61 :</head><label>61</label><figDesc>Summary of tildrakizumab PK parameters following a single SC dose administration of 200 mg tildrakizumab via PFS or AI (Study P009)............................... 178</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 73 :</head><label>73</label><figDesc>Effect of ADA on PASI 75 response rate at Week 12 in pooled Phase 2 and Phase 3 trials (P010 and P011)............................................................................................. 185 Table 74: Summary of incidences for hypersensitivity and injection-site reaction in placebo-controlled safety pool in Phase 2 and Phase 3 trials (P010 and P011)........... 186 Table 75: Summary of Continuous Covariates.................................................................... 188 Table 76: Summary of Categorical Covariates.................................................................... 189 Table 77: Parameter Estimates of the Base Model for Tildrakizumab ............................ 190 Table 78: Parameter Estimates of the Final Model ............................................................ 191 Table 79: Geometric Means of Post hoc and Derived PK Parameters ........................... 194 Table 80: Overview of Subjects in the PK-PD and E-R analyses .................................... 198 BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 9</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 81 :</head><label>81</label><figDesc>Week 12 PASI Response Model Parameters.................................................... 200 Table 82: Longitudinal PK-PD Model Parameters .............................................................. 201 Table 83: PASI Response by Exposure Quartile in Part 1 of Trial P010 and P011 ...... 201 Table 84: Comparison of Week 12 PASI Response by Dose/Sub-Population .............. 202 Table 85: Impact of Titration to 200 mg in Partial Responders at Week 28 ................... 203 Table 86: Adverse Events and PASI Response by Exposure Quartile in Part 1 of TrialP010 and P011 ......................................................................................................................... 203</figDesc><table><row><cell>Table of Figures</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head></head><label></label><figDesc>injection, for subcutaneous use 15 Glossary</figDesc><table><row><cell cols="2">BLA Multi-disciplinary Review and Evaluation -BLA 761067 BLA Multi-disciplinary Review and Evaluation -BLA 761067</cell></row><row><cell cols="2">ILUMYA (tildrakizumab) injection, for subcutaneous use ILUMYA (tildrakizumab) injection, for subcutaneous use</cell></row><row><cell cols="2">DDDP LDL PPP 1 Executive Summary Division of Dermatology and Dental Products low density lipoprotein palmoplantar pustulosis</cell></row><row><cell>DLQI LMW PREA</cell><cell>Dermatology Life Quality Index low molecular weight Pediatric Research Equity Act</cell></row><row><cell>DMC LOCF PRM</cell><cell>data monitoring committee last observation carried forward primary reference material</cell></row><row><cell>DMSO DP LOQ mAb PRO PS-80</cell><cell>dimethyl sulfoxide drug product limit of quantitation monoclonal antibody patient reported outcome polysorbate 80 Product Introduction</cell></row><row><cell>DS MACE PsA</cell><cell>drug substance major adverse cardiovascular events psoriatic arthritis</cell></row><row><cell>AC ECG MCB PSD</cell><cell>advisory committee electrocardiogram Master Cell Bank Psoriasis Symptom Diary</cell></row><row><cell>ADA eCRF MCP-1 PSSD</cell><cell>anti-drug antibodies electronic case report form Monocyte chemotactic protein-1 Psoriasis Symptom and Sign Diary</cell></row><row><cell>ADaM eCTD MedDRA PSUR</cell><cell>Analysis Data Model electronic common technical document Medical Dictionary for Regulatory Activities Periodic Safety Update report</cell></row><row><cell>ADME ELISA MG PT</cell><cell>absorption, distribution, metabolism, excretion enzyme linked immunosorbent assay medication guide Preferred term</cell></row><row><cell>AE EOP2 MI PUVA</cell><cell>adverse event End of Phase 2 multiple imputation, myocardial infarction Psoralen and ultraviolet-A</cell></row><row><cell>AESI EP mITT QTc</cell><cell>adverse event of special interest erythrodermic psoriasis modified intent to treat Corrected QT interval</cell></row><row><cell>ALP ePPND MMAEX RA</cell><cell>alkaline phosphatase enhanced pre-and post-natal development mixed-mode anion exchange rheumatoid arthritis</cell></row><row><cell>ALT/SGPT ETASU MRHD RBC</cell><cell>alanine aminotransferase/serum glutamic pyruvic transaminase elements to assure safe use maximum recommended human dose red blood cell</cell></row><row><cell>ANOVA FDA MSX REMS</cell><cell>analysis of variance Food and Drug Administration methionine sulfoximine risk evaluation and mitigation strategy</cell></row><row><cell cols="2">ARIA FDAAA NCI-CTCAE National Cancer Institute-Common Terminology Criteria for Adverse Event Active Risk and Identification Analysis Food and Drug Administration Amendments Act of 2007 RNS rigid needle shield</cell></row><row><cell cols="2">AST/SGOT aspartate aminotransferase/serum glutamic oxaloacetic transaminase FDASIA Food and Drug Administration Safety and Innovation Act NDA new drug application SAE serious adverse event</cell></row><row><cell>AUC FOCBP NME SAP</cell><cell>Area under the curve females of child-bearing potential new molecular entity statistical analysis plan</cell></row><row><cell>BCC GC-MS NMSC SC</cell><cell>basal cell carcinoma gas chromatography-mass spectrometry non-melanoma skin cancer subcutaneous</cell></row><row><cell>BLA GCP NOAEL SCC</cell><cell>biologics license application good clinical practice no observed adverse event level squamous cell carcinoma</cell></row><row><cell>BMI G-CSF NRI SE-HPLC</cell><cell>Body mass index granulocyte-colony stimulating factor non-responder imputation size exclusion high performance liquid chromatography</cell></row><row><cell>BPCA GLP NRS SGE</cell><cell>Best Pharmaceuticals for Children Act good laboratory practice numerical rating scale special government employee</cell></row><row><cell>BRF GM-CSF NSAID SIB</cell><cell>Benefit Risk Framework Granulocyte-Macrophage Colony Stimulating Factor non-steroidal anti-inflammatory drug suicidal ideation and behavior</cell></row><row><cell>BSA GPP NSTEMI SOC</cell><cell>body surface area generalized pustular psoriasis non-ST-elevation myocardial infarction System organ class</cell></row><row><cell>BW GRMP OB STAT</cell><cell>boxed warning good review management practice Office of Biostatistics signal transducer and activator of transcription</cell></row><row><cell>CABG HDL OCP STDM</cell><cell>coronary artery bypass graft high density lipoprotein Office of Clinical Pharmacology Study Data Tabulation Model</cell></row><row><cell>CBER HF OCS TB</cell><cell>Center for Biologics Evaluation and Research heart failure Office of Computational Science tuberculosis</cell></row><row><cell>C-CASA HIV ODE III TDAR</cell><cell>Columbia Classification Algorithm for Suicide Assessment human immunodeficiency virus Office of Drug Evaluation III T-cell dependent antibody response</cell></row><row><cell>CDC HMW OPDP Th-17</cell><cell>complement dependent cytotoxicity high molecular weight Office of Prescription Drug Promotion T-Helper 17 cell</cell></row><row><cell cols="2">CDER HPLC-UV-MS high performance liquid chromatography-ultraviolet-mass spectrometry Center for Drug Evaluation and Research OPQ Office of Pharmaceutical Quality TEAE treatment emergent adverse event</cell></row><row><cell>CD4+ HSV OSE TIA</cell><cell>cluster of differentiation 4 positive Herpes simplex virus Office of Surveillance and Epidemiology transient ischemic attack</cell></row><row><cell>CDRH HUA OSI TK</cell><cell>Center for Devices and Radiological Health hospitalization for unstable angina Office of Scientific Investigation toxicokinetic</cell></row><row><cell>CDTL HV PASI TNF</cell><cell>Cross-Discipline Team Leader healthy volunteers Psoriasis Area and Severity Index tumor necrosis factor</cell></row><row><cell>CEX ICF PASI 75 ULN</cell><cell>cation exchange informed consent form At least a 75% improvement from Baseline in the PASI Upper limit of normal</cell></row><row><cell>CFR ICH PBMC URI</cell><cell>Code of Federal Regulations International Conference on Harmonization peripheral blood mononuclear cells upper respiratory infection</cell></row><row><cell>CHF ICP-MS PBRER USP</cell><cell>congestive heart failure inductively coupled plasma-mass spectrometry Periodic Benefit-Risk Evaluation Report United States Pharmacopeia</cell></row><row><cell>CHO-K1 IFU PD UVB</cell><cell>Chinese hamster ovary cells, subclone K1 instructions for use pharmacodynamics ultraviolet B</cell></row><row><cell>CI IGA PeRC VIN</cell><cell>Confidence interval Investigator's Global Assessment Pediatric Review Committee viral inactivated and neutralized intermediate</cell></row><row><cell>cIEF IgG1 PFB VTE</cell><cell>capillary isoelectric focusing Immunoglobulin G1 lambda pre-formulated bulk venous thromboembolic event</cell></row><row><cell>CMC IgG1 PFS W&amp;P</cell><cell>chemistry, manufacturing, and controls Immunoglobulin G1 kappa pre-filled syringe Warnings and Precautions</cell></row><row><cell>CMH IL1 PFSFID WBC</cell><cell>Cochran-Mantel-Haenszel interleukin 1 alpha SelfDose facilitated injection device white blood cell</cell></row><row><cell>CO 2 IL-17A PFS-U WCB</cell><cell>carbon dioxide interleukin 17A UltraSafe PLUS Passive Delivery System Working Cell Bank</cell></row><row><cell>COSTART IL-23 PGA WRM</cell><cell>Coding Symbols for Thesaurus of Adverse Reaction Terms interleukin 23 Physician's Global Assessment working reference material</cell></row><row><cell>CQA IND PI</cell><cell>critical quality attribute Investigational New Drug prescribing information</cell></row><row><cell>CRF IP-10 PK</cell><cell>case report form interferon-inducible protein 10 pharmacokinetics</cell></row><row><cell>CRO iPSP PMC</cell><cell>contract research organization initial pediatric study plan postmarketing commitment</cell></row><row><cell>CRT ISE PML</cell><cell>clinical review template integrated summary of effectiveness periventricular multifocal leukoencephalopathy</cell></row><row><cell>cSDS ISR PMR</cell><cell>capillary sodium dodecyl sulfate Injection site reaction postmarketing requirement</cell></row><row><cell>CSR ISS PP</cell><cell>clinical study report integrated summary of safety per protocol</cell></row><row><cell>CSS ITT PPD</cell><cell>Controlled Substance Staff intent to treat postpartum day</cell></row><row><cell>CV IV PPI</cell><cell>Cardiovascular intravenous patient package insert</cell></row><row><cell></cell><cell>16 18</cell></row><row><cell>Reference ID: 4233639 Reference ID: 4233639</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head></head><label></label><figDesc>Feldman, Steven R., MD. PhD; Epidemiology, Clinical Manifestations, and Diagnosis of Psoriasis; UpToDate.com; updated December 9, 2015 Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 May;58(5):826-50.BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 29</figDesc><table /><note>23 Blauvelt, Andrew and Ehst, Benjamin D, Pathophysiology of Psoriasis; UpToDate.com; updated July 8, 20154 Menter A, Gottlieb A, Feldman SR, Van Voorhees AS et al.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_9"><head>Table 1 : Summary of Treatment Armamentarium for Moderate to Severe Plaque Psoriasis Product</head><label>1</label><figDesc></figDesc><table><row><cell>(s)</cell><cell>Relevant</cell><cell>Dosage</cell><cell>Efficacy</cell><cell>Important Safety</cell><cell>Other</cell></row><row><cell>Name/year</cell><cell>Indication</cell><cell>&amp; Admin</cell><cell>Information</cell><cell>and Tolerability</cell><cell>Comments</cell></row><row><cell>approved</cell><cell></cell><cell></cell><cell></cell><cell>Issues</cell><cell></cell></row><row><cell cols="2">FDA Approved Treatments</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Antimetabolite/ Immunosuppressant</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Methotrexate</cell><cell>Severe,</cell><cell>Starting Dose</cell><cell>No efficacy</cell><cell>Boxed Warning (BW)-</cell><cell>Major AE derm</cell></row><row><cell>1972</cell><cell>recalcitrant,</cell><cell>Schedules</cell><cell>information for</cell><cell>potentially fatal toxic</cell><cell>dosing: Liver</cell></row><row><cell></cell><cell>disabling,</cell><cell>1. Weekly single</cell><cell>psoriasis in the</cell><cell>reactions including bone</cell><cell>enzymes</cell></row><row><cell></cell><cell>psoriasis not</cell><cell>oral, intramuscular</cell><cell>label.</cell><cell>marrow suppression,</cell><cell>stomatitis,</cell></row><row><cell></cell><cell>adequately</cell><cell>(IM) or intravenous</cell><cell></cell><cell>aplastic anemia, and</cell><cell>diarrhea,</cell></row><row><cell></cell><cell>responsive to</cell><cell>(IV) dose schedule:</cell><cell></cell><cell>gastrointestinal toxicity</cell><cell>nausea and</cell></row><row><cell></cell><cell>other forms of</cell><cell>10 to 25 mg per</cell><cell></cell><cell>with concomitant</cell><cell>vomiting,</cell></row><row><cell></cell><cell>therapy; but</cell><cell>week until adequate</cell><cell></cell><cell>NSAID 6 Tx;</cell><cell>lymphopro-</cell></row><row><cell></cell><cell>only when</cell><cell>response is</cell><cell></cell><cell>hepatotoxicity,</cell><cell>liferative</cell></row><row><cell></cell><cell>diagnosis</cell><cell>achieved.</cell><cell></cell><cell>pulmonary toxicity,</cell><cell>disorders;</cell></row><row><cell></cell><cell>established, by</cell><cell>2. Divided oral dose</cell><cell></cell><cell>kidney toxicity,</cell><cell></cell></row><row><cell></cell><cell>biopsy and/or</cell><cell>schedule: 2.5 mg at</cell><cell></cell><cell>opportunistic infections,</cell><cell>Recommend</cell></row><row><cell></cell><cell>dermatologic</cell><cell>12-hour intervals for</cell><cell></cell><cell>malignant lymphoma,</cell><cell>Periodic liver</cell></row><row><cell></cell><cell>consultation.</cell><cell>three doses.</cell><cell></cell><cell>tumor lysis syndrome,</cell><cell>biopsy if tx</cell></row><row><cell></cell><cell>Must rule out</cell><cell>30 mg/wk should</cell><cell></cell><cell>severe skin toxicity,</cell><cell>long-term</cell></row><row><cell></cell><cell>undiagnosed</cell><cell>not ordinarily be</cell><cell></cell><cell>fetal death and</cell><cell></cell></row><row><cell></cell><cell>concomitant</cell><cell>exceeded.</cell><cell></cell><cell>anomalies "should not</cell><cell>Pregnancy: X</cell></row><row><cell></cell><cell>disease affecting</cell><cell></cell><cell></cell><cell>be used in pregnant</cell><cell></cell></row><row><cell></cell><cell>immune</cell><cell></cell><cell></cell><cell>women with psoriasis"</cell><cell></cell></row><row><cell></cell><cell>responses.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Tumor Necrosis Factor Inhibitors</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Infliximab</cell><cell>Chronic severe</cell><cell>5 mg/kg IV at 0, 2</cell><cell>From the label: 3</cell><cell>BW: risk of serious</cell><cell>Pregnancy: B</cell></row><row><cell>(Remicade)</cell><cell>(extensive or</cell><cell>and 6 weeks, then</cell><cell>R,DB,PC 7 trials</cell><cell>infections (bacterial</cell><cell></cell></row><row><cell>2006</cell><cell>disabling)</cell><cell>every 8 weeks</cell><cell>PASI75 at week 10</cell><cell>sepsis, TB, invasive</cell><cell></cell></row><row><cell></cell><cell>plaque psoriasis,</cell><cell></cell><cell>1-Inflix 8 (5mg/kg)-</cell><cell>fungal and</cell><cell></cell></row><row><cell></cell><cell>candidates for</cell><cell></cell><cell>80% vs 3% placebo</cell><cell>opportunistic),</cell><cell></cell></row><row><cell></cell><cell>phototherapy or</cell><cell></cell><cell>2-Inflix (5mg/kg)-</cell><cell>malignancies including</cell><cell></cell></row><row><cell></cell><cell>systemic therapy</cell><cell></cell><cell>75% vs 2% placebo</cell><cell>Hepatosplenic T-cell</cell><cell></cell></row><row><cell></cell><cell>and when other</cell><cell></cell><cell>3-Inflix (5mg/kg)-</cell><cell>lymphomas</cell><cell></cell></row><row><cell></cell><cell>systemic</cell><cell></cell><cell>88% vs Inflix</cell><cell>(adolescents and young</cell><cell></cell></row><row><cell></cell><cell>therapies are</cell><cell></cell><cell>(3mg/kg) 72% vs 6%</cell><cell>adults)</cell><cell></cell></row><row><cell></cell><cell>medically less</cell><cell></cell><cell>placebo</cell><cell>Warnings: Hep B</cell><cell></cell></row><row><cell></cell><cell>appropriate.</cell><cell></cell><cell></cell><cell>reactivation, heart</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>failure, hepatotoxicity,</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>cytopenias,</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>hypersensitivity events,</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>malignancy</cell><cell></cell></row><row><cell cols="3">6 Non-steroidal anti-inflammatory drug</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">7 R=randomized, DB=double blind, PC= placebo controlled</cell><cell></cell><cell></cell></row><row><cell cols="2">8 Inflix=infliximab</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_10"><head>Name/year approved Relevant Indication Dosage &amp; Admin Efficacy Information Important Safety and Tolerability Issues Other Comments</head><label></label><figDesc></figDesc><table><row><cell cols="4">BLA Multi-disciplinary Review and Evaluation -BLA 761067</cell><cell></cell><cell></cell></row><row><cell cols="4">ILUMYA (tildrakizumab) injection, for subcutaneous use</cell><cell></cell><cell></cell></row><row><cell cols="3">Product (s) 3 Regulatory Background</cell><cell></cell><cell></cell><cell></cell></row><row><cell>1996</cell><cell>other therapies</cell><cell>per day,</cell><cell>Mean change in</cell><cell>and for 3 years</cell><cell>skeletal</cell></row><row><cell></cell><cell>or whose clinical</cell><cell>Maintenance doses</cell><cell>PGA at 8 weeks</cell><cell>following due to</cell><cell>abnormalities,</cell></row><row><cell></cell><cell>condition</cell><cell>of 25 to 50 mg per</cell><cell>A-Acitretin(50mg)-2</cell><cell>teratogenicity, no</cell><cell>lipids ,</cell></row><row><cell></cell><cell>contraindicates</cell><cell>day may be given</cell><cell>vs -0.29 on placebo</cell><cell>ethanol ingestion by</cell><cell>Cardiovascular</cell></row><row><cell></cell><cell>the use of other</cell><cell>dependent upon an</cell><cell>B-Acitretin (50mg)-</cell><cell>females of childbearing</cell><cell>risk ,</cell></row><row><cell></cell><cell>treatments</cell><cell>individual patient's</cell><cell>1.57 vs Acitretin (25</cell><cell>potential (FOCBP) due</cell><cell>Ophthalmologi</cell></row><row><cell></cell><cell></cell><cell>response to initial</cell><cell>mg)-1.06 vs -0.06 on</cell><cell>to metabolism to</cell><cell>c effects,</cell></row><row><cell></cell><cell></cell><cell>Rx</cell><cell>placebo</cell><cell>etretinate and 1/2life,</cell><cell>Pancreatitis,</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(no multiplicity</cell><cell>REMS (Do Your</cell><cell>capillary leak</cell></row><row><cell></cell><cell></cell><cell></cell><cell>adjustment for trial</cell><cell>P.A.R.T.) participation</cell><cell>syndrome,</cell></row><row><cell></cell><cell></cell><cell></cell><cell>B)</cell><cell>required for FOCBP-see</cell><cell>pseudotumor</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Drugs @ FDA for</cell><cell>cerebri,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>details.</cell><cell>exfoliative</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Patients cannot donate</cell><cell>dermatitis,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>blood for 3 years post</cell><cell>depression</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Rx, See label for data</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>on pregnancies in</cell><cell>Pregnancy</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>partners of male</cell><cell>category X</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>patients on acitretin</cell><cell></cell></row><row><cell cols="3">Phosphodiesterase 4 (PDE4) inhibitor</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Apremilast</cell><cell>Moderate to</cell><cell>To reduce risk of</cell><cell>From the label: 2 R,</cell><cell>W&amp;P: depression,</cell><cell>Diarrhea,</cell></row><row><cell>(Otezla)</cell><cell>severe psoriasis,</cell><cell>gastrointestinal</cell><cell>DB, PC trials</cell><cell>weight decrease, drug</cell><cell>nausea, URI,</cell></row><row><cell>2014</cell><cell>candidates for</cell><cell>symptoms, titrate to</cell><cell>PASI75 at 16 weeks</cell><cell>interactions with strong</cell><cell>headache</cell></row><row><cell>Cyclosporine</cell><cell>Adult, phototherapy or</cell><cell>Starting dose: 2.5 recommended dose</cell><cell>From the label: 1-aprem 17 33% vs</cell><cell>BW-Should only be P450 enzyme inducers</cell><cell>Pregnancy</cell></row><row><cell>1997</cell><cell>nonimmuno-systemic therapy</cell><cell>mg/kg/day, taken of 30 mg PO twice</cell><cell>PASI75 -51% at 8 5% in placebo</cell><cell>used by MDs (rifampin, phenobarbital,</cell><cell>Category C Pregnancy</cell></row><row><cell></cell><cell>compromised</cell><cell>twice daily, dosage daily</cell><cell>weeks, 79% at 16 2-aprem 28.8% vs</cell><cell>experienced in carbamazepine</cell><cell>Category C</cell></row><row><cell></cell><cell>patients with</cell><cell>by 0.5 mg/kg/day</cell><cell>weeks 5.8% in placebo</cell><cell>management of phenytoin)</cell><cell></cell></row><row><cell cols="2">severe recalcitrant disabling psoriasis who have failed at least one systemic therapy Phototherapy PUVA-8-MOP Severe, (methoxsalen) recalcitrant, + UVA therapy disabling psoriasis not responsive to other forms of therapy</cell><cell>at 2-week intervals, to a maximum of 4.0 mg/kg/day. 20 -70 mg PO (based on weight) taken 2-4 hours before exposure to UVA light</cell><cell>No efficacy information for psoriasis in the label.</cell><cell>systemic immunosuppressive Rx, BW: Should only be susceptibility to used by MDs who have infections and special competence in development of psoriasis management neoplasia including Warnings: serious skin lymphoma, also burning, hypertension, ocular damage, aging of nephrotoxicity which the skin, skin cancer with doses. In (including melanoma) psoriasis patients with history of PUVA, UVB, coal tar or radiation Rx-risk of skin malignancies</cell><cell>Nausea, erythema, pruritus, must avoid all exposure to sunlight (even through windows) to eyes and skin for 24 hours after ingestion; Pregnancy category C</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Warnings:</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Hepatotoxicity, hyper-</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>kalemia, thrombotic</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>microangiopathy,</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>progressive multifocal</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>leukoencephalopathy</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(PML), malignancies,</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>serious infection,</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>neurotoxicity</cell><cell></cell></row><row><cell>Retinoid</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Acitretin</cell><cell>Severe psoriasis</cell><cell>Starting dose: 25 to</cell><cell>From the label: 2</cell><cell>BW-pregnancy must be</cell><cell>W&amp;P:</cell></row><row><cell>(Soriatane)</cell><cell>unresponsive to</cell><cell>50 mg orally (PO)</cell><cell>DB, PC trials-</cell><cell>prevented during Rx</cell><cell>hepatotoxicity,</cell></row><row><cell></cell><cell></cell><cell></cell><cell>35</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_13"><head></head><label></label><figDesc>BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 40 be approved for human use under conditions specified in the package insert.</figDesc><table><row><cell>B. Approval Action Letter Language:</cell></row><row><cell>Manufacturing location:</cell></row><row><cell>o Drug Substance:</cell></row><row><cell>o Drug Product: MSD Ireland, Dublin Road, Carlow, Ireland</cell></row><row><cell>Fill size and dosage form: 100 mg/ 1 mL single-dose prefilled syringe with staked needle</cell></row><row><cell>and rigid needle shield</cell></row><row><cell>Dating period:</cell></row><row><cell>o Drug Product: 36 months: 2-8Â°C</cell></row><row><cell>o Drug Substance:</cell></row><row><cell>o Stability:</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_14"><head>Table 3 : Active Pharmaceutical Ingredient CQA Identification, Risk and Lifecycle Knowledge Management. Drug Substance Tildrakizumab Quality Summary CQA Identification, Risk, and Lifecycle Knowledge Management</head><label>3</label><figDesc></figDesc><table><row><cell>CQA (type)</cell><cell>Risk</cell><cell>Origin</cell><cell>Control Strategy</cell><cell>Other</cell></row><row><cell>Biological Potency by</cell><cell>Efficacy</cell><cell>Intrinsic to the</cell><cell>Potency is tested at DS</cell><cell>N/A</cell></row><row><cell>Cell Based Assay</cell><cell></cell><cell>molecule,</cell><cell>and DP lot release and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>impacted by</cell><cell>stability</cell><cell></cell></row><row><cell></cell><cell></cell><cell>oxidation,</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>glycation,</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>deamidation,</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>aggregation, and</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>fragmentation</cell><cell></cell><cell></cell></row><row><cell>Reference ID: 4233639</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_15"><head>Table 4 : Drug Substance CQA Process Risk Identification and Lifecycle Knowledge Management</head><label>4</label><figDesc></figDesc><table><row><cell>.</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CQA (type)</cell><cell>Risk</cell><cell>Origin</cell><cell>Control Strategy</cell><cell>Other</cell></row><row><cell>Appearance</cell><cell>Safety</cell><cell>Controlled by the</cell><cell></cell><cell>N/A</cell></row><row><cell></cell><cell></cell><cell>manufacturing</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>process</cell><cell></cell><cell></cell></row><row><cell>Reference ID: 4233639</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_17"><head></head><label></label><figDesc>The applicant has provided sufficient characterization of the device, functional performance testing, biocompatibility, sterility, shelf life, and shipping studies to support the safe and effective use of the device. As a result, CDRH/ODE recommends approval for the BLA for this combination product."</figDesc><table><row><cell>BLA Multi-disciplinary Review and Evaluation -BLA 761067</cell></row><row><cell>ILUMYA (tildrakizumab) injection, for subcutaneous use</cell></row><row><cell>5 Nonclinical Pharmacology/Toxicology</cell></row><row><cell>50</cell></row></table><note>The device was reviewed by Lieutenant Commander Keith Marin, MS, MBA; Center for Devices and Radiological Health, Office of Device Evaluation (CDRH/ODE). LCDR Marin concluded: "</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_18"><head>Table 7 : Summary of PK/TK data for tildrakizumab Type of Study Major Findings Absorption</head><label>7</label><figDesc></figDesc><table><row><cell>Rising single dose SC or IV PK and</cell><cell>Monkey (single dose)</cell></row><row><cell>tolerability of SCH 900222 in male</cell><cell>T1/2:</cell></row><row><cell>cynomolgus monkeys (Study# D-</cell><cell>40 mg/kg IV: 22.8 day</cell></row><row><cell>54072)</cell><cell>0.4 mg/kg SC: 21.3 day</cell></row><row><cell></cell><cell>4 mg/kg SC: 18.9 day</cell></row><row><cell></cell><cell>40 mg/kg SC: 10.0 day</cell></row><row><cell></cell><cell>Cmax:</cell></row><row><cell></cell><cell>40 mg/kg IV: 1470 g/ml</cell></row><row><cell></cell><cell>0.4 mg/kg SC: 5.13 g/ml</cell></row><row><cell></cell><cell>4 mg/kg SC: 45.5 g/ml</cell></row><row><cell></cell><cell>40 mg/kg SC: 439 g/ml</cell></row><row><cell></cell><cell>Tmax:</cell></row><row><cell></cell><cell>0.4 mg/kg SC: 4.67 day</cell></row><row><cell></cell><cell>4 mg/kg SC: 3.33 day</cell></row><row><cell></cell><cell>40 mg/kg SC: 3.0 day</cell></row><row><cell></cell><cell>AUC:</cell></row><row><cell></cell><cell>40 mg/kg IV: 16200 g day/ml</cell></row><row><cell></cell><cell>0.4 mg/kg SC: 148 g day/ml</cell></row><row><cell></cell><cell>4 mg/kg SC: 1200 g day/ml</cell></row><row><cell></cell><cell>40 mg/kg SC: 6520 g day/ml</cell></row><row><cell></cell><cell>Bioavailability:</cell></row><row><cell></cell><cell>0.4 mg/kg SC: 91.5%</cell></row><row><cell></cell><cell>4 mg/kg SC: 74.3%</cell></row><row><cell></cell><cell>40 mg/kg SC: 40.4%</cell></row><row><cell>Distribution</cell><cell></cell></row><row><cell>Stability and tissue distribution of</cell><cell></cell></row><row><cell>SCH 900222 in CD-1 female mice</cell><cell></cell></row><row><cell>(Study# D-54349)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_19"><head>Table 8 : Number of sexually mature females and sexually mature/peri-pubertal males in the 3-month and 9-month monkey studies</head><label>8</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_20"><head>Table 7 fetal developmental toxicity and toxicokinetic study of SCH 900222 administered subcutaneously in pregnant cynomolgus monkeys (Study# SNBL.120.06)</head><label>7</label><figDesc></figDesc><table><row><cell>for TK</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_21"><head>Table 9 : Tildrakizumab milk/maternal monkey serum concentrations and ratios</head><label>9</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_22"><head>Table 10 : Tildrakizumab infant/maternal monkey serum concentrations and ratios</head><label>10</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_23"><head>Table 12 : Summary of clinical pharmacology review</head><label>12</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_25"><head>Table 13 : Summary of clinical pharmacology and immunogenicity of tildrakizumab Pharmacology</head><label>13</label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_26"><head>Table 18 :</head><label>18</label><figDesc></figDesc><table><row><cell>CYP Probe</cell><cell cols="2">Cmax (Day 57/Day 1)</cell><cell cols="2">AUCinf (Day 57/Day 1)</cell></row><row><cell>Substrates</cell><cell>GMR</cell><cell>90CI%</cell><cell>GMR</cell><cell>90CI%</cell></row><row><cell>Midazolam</cell><cell>1.06</cell><cell>[0.86, 1.29]</cell><cell>1.11</cell><cell>[0.94, 1.32]</cell></row><row><cell>Warfarin</cell><cell>0.99</cell><cell>[0.95, 1.03]</cell><cell>1.07</cell><cell>[0.98, 1.17]</cell></row><row><cell>Omeprazole</cell><cell>0.99</cell><cell>[0.85, 1.15]</cell><cell>0.96</cell><cell>[0.77, 1.19]</cell></row><row><cell>Dextromethorphan</cell><cell>1.17</cell><cell>[0.96, 1.43]</cell><cell>1.20</cell><cell>[1.00, 1.45]</cell></row><row><cell>Caffeine</cell><cell>0.96</cell><cell>[0.88, 1.05]</cell><cell>1.14</cell><cell>[1.01, 1.28]</cell></row></table><note>Summary of geometric mean ratio (GMR) and 90% confidence interval (CI) of the GMR for C max and AUC inf of the probe substrates in Study P010(Source of data: CSR P010. See appendix for more information.) BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 75 7 Statistical and Clinical and Evaluation</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_27"><head>Table 19 : Listing of Clinical Trials Relevant to BLA 761067</head><label>19</label><figDesc></figDesc><table><row><cell>Trial</cell><cell>Trial Design</cell><cell>Regimen/ schedule/ route</cell><cell>Study Endpoints</cell><cell>Treatment</cell><cell>No. of</cell><cell>Study Population</cell><cell>No. of</cell></row><row><cell>Identity</cell><cell></cell><cell></cell><cell></cell><cell>Duration/</cell><cell>subjects</cell><cell></cell><cell>Centers and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Follow Up</cell><cell>enrolled</cell><cell></cell><cell>Countries</cell></row><row><cell cols="3">Controlled Studies to Support Efficacy and Safety</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>P010</cell><cell>Phase 3,</cell><cell>BASE</cell><cell>Co-primary</cell><cell>Duration of</cell><cell>-772</cell><cell>Males &amp; females</cell><cell>112 sites</cell></row><row><cell></cell><cell>64-Week,</cell><cell>Placebo SC (n=155)</cell><cell>efficacy</cell><cell>the base</cell><cell></cell><cell>age 18-82 years</cell><cell>Australia</cell></row><row><cell></cell><cell>multicenter,</cell><cell>Weeks 0 and 4 and re-</cell><cell>-proportion of</cell><cell>study :</cell><cell></cell><cell>with moderate to</cell><cell>Canada</cell></row><row><cell></cell><cell>randomized,</cell><cell>random at Week 12 to</cell><cell>subjects who</cell><cell>4-week</cell><cell></cell><cell>severe plaque-</cell><cell>Japan</cell></row><row><cell></cell><cell>double-blind</cell><cell>tildrakizumab 100 or 200 mg</cell><cell>achieved PASI 75</cell><cell>screening</cell><cell></cell><cell>type psoriasis with</cell><cell>UK</cell></row><row><cell></cell><cell>placebo -</cell><cell>SC at Weeks 16 and 20</cell><cell>response at Week</cell><cell>period + 64-</cell><cell></cell><cell>or without PsA</cell><cell>US</cell></row><row><cell></cell><cell>controlled trial to</cell><cell>followed by q8w through</cell><cell>12 and the</cell><cell>week</cell><cell></cell><cell>(max 30%</cell><cell>.</cell></row><row><cell></cell><cell>assess safety</cell><cell>Week 64</cell><cell>proportion of</cell><cell>treatment</cell><cell></cell><cell>affected) for at</cell><cell></cell></row><row><cell></cell><cell>and efficacy</cell><cell>Tildrakizumab 200 mg SC</cell><cell>subjects with a</cell><cell>period</cell><cell></cell><cell>least 6 months</cell><cell></cell></row><row><cell></cell><cell>followed by an</cell><cell>(n=308)</cell><cell>PGA score of 0</cell><cell>+ 20-week</cell><cell></cell><cell>who were</cell><cell></cell></row><row><cell></cell><cell>optional long</cell><cell>Tildrakizumab 100 mg SC</cell><cell>("cleared") or 1</cell><cell>follow-up</cell><cell></cell><cell>candidates for</cell><cell></cell></row><row><cell></cell><cell>term safety</cell><cell>(n=309)</cell><cell>("minimal"), with at</cell><cell></cell><cell></cell><cell>phototherapy or</cell><cell></cell></row><row><cell></cell><cell>extension</cell><cell>Weeks 0, 4, and 16, followed</cell><cell>least a 2-grade</cell><cell></cell><cell></cell><cell>systemic therapy.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>by q12w through Week 28</cell><cell>reduction from</cell><cell></cell><cell></cell><cell>Subjects may</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>baseline, at Week</cell><cell></cell><cell></cell><cell>have prior</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Open-label extension:</cell><cell>12</cell><cell></cell><cell></cell><cell>exposure to</cell><cell></cell></row><row><cell></cell><cell></cell><cell>All subjects receive</cell><cell></cell><cell></cell><cell></cell><cell>biological</cell><cell></cell></row><row><cell></cell><cell></cell><cell>tildrakizumab 100 mg or 200</cell><cell></cell><cell></cell><cell></cell><cell>therapies (max</cell><cell></cell></row><row><cell></cell><cell></cell><cell>mg SC q12w to Week 192</cell><cell></cell><cell></cell><cell></cell><cell>40%). Moderate to</cell><cell></cell></row><row><cell></cell><cell></cell><cell>followed by a 20-week</cell><cell></cell><cell></cell><cell></cell><cell>severe psoriasis</cell><cell></cell></row><row><cell></cell><cell></cell><cell>washout period</cell><cell></cell><cell></cell><cell></cell><cell>defined as PASI</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>score 12, PGA</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>score 3 and BSA</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>10%.</cell><cell></cell></row><row><cell>P011</cell><cell>Phase 3,</cell><cell>BASE</cell><cell>Co-primary</cell><cell>Duration of</cell><cell>-1090</cell><cell>Males &amp; females</cell><cell>123 sites</cell></row><row><cell></cell><cell>52-Week,</cell><cell>Placebo SC (n=156)</cell><cell>efficacy</cell><cell>the base</cell><cell></cell><cell>age 19-81 years</cell><cell>Canada</cell></row><row><cell></cell><cell>multicenter,</cell><cell>Weeks 0 and 4 and re-</cell><cell>-proportion of</cell><cell>study:</cell><cell></cell><cell>with moderate to</cell><cell>Austria</cell></row><row><cell></cell><cell>randomized,</cell><cell>random at Week 12 to</cell><cell>subjects who</cell><cell>4-week</cell><cell></cell><cell>severe plaque-</cell><cell>Belgium</cell></row><row><cell></cell><cell>double-blind</cell><cell>tildrakizumab 100 or 200 mg</cell><cell>achieved PASI 75</cell><cell>screening</cell><cell></cell><cell>type psoriasis with</cell><cell>Czech</cell></row><row><cell></cell><cell>placebo-and</cell><cell>SC at Weeks 16 and 20</cell><cell>response at Week</cell><cell>period + 52-</cell><cell></cell><cell>or without PsA for</cell><cell>US</cell></row><row><cell></cell><cell>active-</cell><cell>followed by q8w through</cell><cell>12 and the</cell><cell>week</cell><cell></cell><cell>at least 6 months</cell><cell>Denmark</cell></row><row><cell></cell><cell>comparator-</cell><cell>Week 64</cell><cell>proportion of</cell><cell>treatment</cell><cell></cell><cell>who were</cell><cell>France</cell></row><row><cell></cell><cell>controlled to</cell><cell>Tildrakizumab 200 mg SC</cell><cell>subjects with a</cell><cell>period</cell><cell></cell><cell>candidates for</cell><cell>Germany</cell></row><row><cell></cell><cell>assess safety</cell><cell>(n=314)</cell><cell>PGA score of 0</cell><cell>+ 20-week</cell><cell></cell><cell>phototherapy or</cell><cell>Hungry</cell></row><row><cell></cell><cell>and efficacy</cell><cell>Tildrakizumab 100 mg SC</cell><cell>("cleared") or 1</cell><cell>follow-up</cell><cell></cell><cell>systemic therapy.</cell><cell>Italy</cell></row><row><cell>Reference ID: 4233639</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_28"><head>Table 20 :</head><label>20</label><figDesc>final statistical analysis plan (SAP) was submitted and most relevant analysis decisions (e.g., pooling of sites, analysis population membership, etc.) were made prior to unblinding.</figDesc><table /><note>Office of Computational Science (OCS) findingsSource: JumpStart Data Fitness Session 5/1/2017 BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 83A</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_29"><head>Table 22 : Disposition of Subjects Through Week 12 for Trials P010 and P011</head><label>22</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>Trial P010</cell><cell></cell><cell></cell><cell cols="2">Trial P011</cell><cell></cell></row><row><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell><cell></cell></row><row><cell></cell><cell>200 mg</cell><cell>100 mg</cell><cell>Placebo</cell><cell>200 mg</cell><cell>100 mg</cell><cell>Etanercept</cell><cell>Placebo</cell></row><row><cell></cell><cell>(N=308)</cell><cell>(N=309)</cell><cell>(N=155)</cell><cell>(N=314)</cell><cell>(N=307)</cell><cell>(N=313)</cell><cell>(N=156)</cell></row><row><cell>Discontinued</cell><cell>10 (3%)</cell><cell>9 (3%)</cell><cell>9 (6%)</cell><cell>14 (4%)</cell><cell>12 (4%)</cell><cell>24 (8%)</cell><cell>14 (9%)</cell></row><row><cell>Adverse Event</cell><cell>5</cell><cell>0</cell><cell>0</cell><cell>2</cell><cell>1</cell><cell>5</cell><cell>2</cell></row><row><cell>Death</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Lack of Efficacy</cell><cell>0</cell><cell>1</cell><cell>2</cell><cell>1</cell><cell>0</cell><cell>0</cell><cell>2</cell></row><row><cell>Lost to Follow-Up</cell><cell>1</cell><cell>2</cell><cell>1</cell><cell>1</cell><cell>2</cell><cell>3</cell><cell>3</cell></row><row><cell>Non-Compliance</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>1</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Physician Decision</cell><cell>0</cell><cell>3</cell><cell>1</cell><cell>0</cell><cell>0</cell><cell>4</cell><cell>0</cell></row><row><cell>Pregnancy</cell><cell>1</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>1</cell><cell>1</cell><cell>0</cell></row><row><cell>Progressive Disease</cell><cell>0</cell><cell>0</cell><cell>1</cell><cell>0</cell><cell>0</cell><cell>1</cell><cell>0</cell></row><row><cell>Protocol Violation</cell><cell>1</cell><cell>0</cell><cell>1</cell><cell>2</cell><cell>1</cell><cell>0</cell><cell>1</cell></row><row><cell>Withdrawal by Subject</cell><cell>2</cell><cell>3</cell><cell>3</cell><cell>5</cell><cell>7</cell><cell>6</cell><cell>5</cell></row><row><cell>Other</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>2</cell><cell>0</cell><cell>4</cell><cell>1</cell></row></table><note>Source: Statistical Reviewer's Analysis (same as Applicant's Analysis)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_30"><head>Table 23 : Demographics for Trials P010 and P011</head><label>23</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>Trial P010</cell><cell></cell><cell></cell><cell cols="2">Trial P011</cell><cell></cell></row><row><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell><cell></cell></row><row><cell></cell><cell>200 mg</cell><cell>100 mg</cell><cell>Placebo</cell><cell>200 mg</cell><cell>100 mg</cell><cell>Etanercept</cell><cell>Placebo</cell></row><row><cell></cell><cell>(N=308)</cell><cell>(N=309)</cell><cell>(N=155)</cell><cell>(N=314)</cell><cell>(N=307)</cell><cell>(N=313)</cell><cell>(N=156)</cell></row><row><cell>Age (years) (1)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (SD)</cell><cell>47 (13)</cell><cell>46 (13)</cell><cell>48 (14)</cell><cell>45 (14)</cell><cell>45 (14)</cell><cell>46 (14)</cell><cell>46 (12)</cell></row><row><cell>Median</cell><cell>48</cell><cell>46</cell><cell>48</cell><cell>45</cell><cell>44</cell><cell>48</cell><cell>46</cell></row><row><cell>Range</cell><cell>18 -76</cell><cell>18 -82</cell><cell>19 -76</cell><cell>19 -80</cell><cell>19 -80</cell><cell>19 -81</cell><cell>20 -76</cell></row><row><cell>&lt; 65</cell><cell>279 (91%)</cell><cell>281 (91%)</cell><cell>136 (88%)</cell><cell>289 (92%)</cell><cell>280 (91%)</cell><cell>282 (90%)</cell><cell>142 (91%)</cell></row><row><cell>65</cell><cell>29 (9%)</cell><cell>28 (9%)</cell><cell>18 (12%)</cell><cell>25 (8%)</cell><cell>27 (9%)</cell><cell>31 (10%)</cell><cell>14 (9%)</cell></row><row><cell>Sex</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>226 (73%)</cell><cell>207 (67%)</cell><cell>100 (65%)</cell><cell>225 (72%)</cell><cell>220 (72%)</cell><cell>222 (71%)</cell><cell>112 (72%)</cell></row><row><cell>Female</cell><cell>82 (27%)</cell><cell>102 (33%)</cell><cell>55 (35%)</cell><cell>89 (28%)</cell><cell>87 (28%)</cell><cell>91 (29%)</cell><cell>44 (28%)</cell></row><row><cell>Race</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>White</cell><cell>209 (68%)</cell><cell>217 (70%)</cell><cell>101 (65%)</cell><cell>284 (90%)</cell><cell>279 (91%)</cell><cell>289 (92%)</cell><cell>144 (92%)</cell></row><row><cell>Black</cell><cell>8 (3%)</cell><cell>12 (4%)</cell><cell>6 (4%)</cell><cell>8 (3%)</cell><cell>7 (2%)</cell><cell>8 (3%)</cell><cell>1 (1%)</cell></row><row><cell>Asian</cell><cell>83 (27%)</cell><cell>70 (23%)</cell><cell>42 (27%)</cell><cell>14 (4%)</cell><cell>9 (3%)</cell><cell>10 (3%)</cell><cell>3 (2%)</cell></row><row><cell>Other</cell><cell>8 (3%)</cell><cell>10 (3%)</cell><cell>6 (4%)</cell><cell>8 (3%)</cell><cell>12 (4%)</cell><cell>6 (2%)</cell><cell>8 (5%)</cell></row><row><cell>Weight (kg)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mean (SD)</cell><cell>89 (24)</cell><cell>89 (24)</cell><cell>88 (26)</cell><cell>88 (21)</cell><cell>89 (22)</cell><cell>88 (21)</cell><cell>89 (23)</cell></row><row><cell>Median</cell><cell>86</cell><cell>86</cell><cell>85</cell><cell>86</cell><cell>88</cell><cell>86</cell><cell>86</cell></row><row><cell>Range</cell><cell>41 -222</cell><cell>41 -192</cell><cell>46 -180</cell><cell>51 -165</cell><cell>50 -195</cell><cell>46 -160</cell><cell>44 -166</cell></row><row><cell>90 kg</cell><cell>182 (59%)</cell><cell>183 (59%)</cell><cell>93 (60%)</cell><cell>180 (57%)</cell><cell>176 (57%)</cell><cell>180 (58%)</cell><cell>90 (58%)</cell></row><row><cell>&gt; 90 kg</cell><cell>126 (41%)</cell><cell>126 (41%)</cell><cell>62 (40%)</cell><cell>134 (43%)</cell><cell>131 (43%)</cell><cell>133 (42%)</cell><cell>66 (42%)</cell></row><row><cell>Prior Biologic</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Therapy</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>71 (23%)</cell><cell>71 (23%)</cell><cell>35 (23%)</cell><cell>38 (12%)</cell><cell>39 (13%)</cell><cell>37 (12%)</cell><cell>20 (13%)</cell></row><row><cell>No</cell><cell>237 (77%)</cell><cell>238 (77%)</cell><cell>120 (77%)</cell><cell>276 (88%)</cell><cell>268 (87%)</cell><cell>276 (88%)</cell><cell>136 (87%)</cell></row><row><cell>Country</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>U.S.</cell><cell>126 (41%)</cell><cell>131 (42%)</cell><cell>69 (45%)</cell><cell>86 (27%)</cell><cell>85 (28%)</cell><cell>87 (28%)</cell><cell>44 (28%)</cell></row><row><cell>Non-U.S.</cell><cell>182 (59%)</cell><cell>178 (58%)</cell><cell>86 (55%)</cell><cell>228 (73%)</cell><cell>222 (72%)</cell><cell>226 (72%)</cell><cell>112 (72%)</cell></row></table><note>Source: Statistical Reviewer's Analysis (same as Applicant's Analysis) (1) Age for one subject randomized to placebo in Trial P010 was missing.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_31"><head>Table 24 : Baseline Disease Characteristics for Trials P010 and P011</head><label>24</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>Trial P010</cell><cell></cell><cell></cell><cell cols="2">Trial P011</cell><cell></cell></row><row><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell><cell></cell></row><row><cell></cell><cell>200 mg</cell><cell>100 mg</cell><cell>Placebo</cell><cell>200 mg</cell><cell>100 mg</cell><cell>Etanercept</cell><cell>Placebo</cell></row><row><cell></cell><cell>(N=308)</cell><cell>(N=309)</cell><cell>(N=155)</cell><cell>(N=314)</cell><cell>(N=307)</cell><cell>(N=313)</cell><cell>(N=156)</cell></row><row><cell>PGA</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>n</cell><cell>308</cell><cell>309</cell><cell>154</cell><cell>311</cell><cell>307</cell><cell>310</cell><cell>155</cell></row><row><cell>1 -Minimal</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>2 (1%)</cell><cell>0</cell><cell>0</cell></row><row><cell>2 -Mild</cell><cell>0</cell><cell>1 (&lt;1%)</cell><cell>0</cell><cell>14 (5%)</cell><cell>9 (3%)</cell><cell>7 (2%)</cell><cell>7 (5%)</cell></row><row><cell>3 -Moderate</cell><cell cols="4">202 (66%) 206 (67%) 111 (72%) 193 (62%)</cell><cell>196 (64%)</cell><cell>193 (62%)</cell><cell>91 (59%)</cell></row><row><cell>4 -Marked</cell><cell>95 (31%)</cell><cell>95 (31%)</cell><cell>41 (27%)</cell><cell>97 (31%)</cell><cell>95 (31%)</cell><cell>103 (33%)</cell><cell>52 (34%)</cell></row><row><cell>5 -Severe</cell><cell>11 (4%)</cell><cell>7 (2%)</cell><cell>2 (1%)</cell><cell>7 (2%)</cell><cell>5 (2%)</cell><cell>7 (2%)</cell><cell>5 (3%)</cell></row><row><cell>PASI</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>n</cell><cell>308</cell><cell>309</cell><cell>154</cell><cell>314</cell><cell>307</cell><cell>312</cell><cell>155</cell></row><row><cell>Mean (SD)</cell><cell>20.7 (8.5)</cell><cell>20.0 (7.9)</cell><cell>19.3 (7.1)</cell><cell>19.8 (7.5)</cell><cell>20.5 (7.6)</cell><cell>20.2 (7.4)</cell><cell>20.0 (7.6)</cell></row><row><cell>Median</cell><cell>18.2</cell><cell>17.2</cell><cell>17.2</cell><cell>17.2</cell><cell>18.4</cell><cell>18.4</cell><cell>18.3</cell></row><row><cell>Range</cell><cell>12 -66</cell><cell>9 -59.4</cell><cell>12 -51.8</cell><cell>5.3 -54.6</cell><cell>8.4 -54.8</cell><cell>8.4 -52.5</cell><cell>12 -55.8</cell></row><row><cell>Percent BSA</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>n</cell><cell>308</cell><cell>309</cell><cell>154</cell><cell>309</cell><cell>307</cell><cell>310</cell><cell>155</cell></row><row><cell>Mean (SD)</cell><cell>31</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_33"><head>Table 25 : Results for the Co-Primary Efficacy Endpoints at Week 12 Trial P010 Trial P011 Tildrakizumab Placebo</head><label>25</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell></row><row><cell></cell><cell>200 mg</cell><cell>100 mg</cell><cell></cell><cell>200 mg</cell><cell>100 mg</cell><cell>Placebo</cell></row><row><cell>FAS Population (1)</cell><cell>N=308</cell><cell>N=309</cell><cell>N=154</cell><cell>N=314</cell><cell>N=307</cell><cell>N=156</cell></row><row><cell>PGA Response (3)</cell><cell>182 (59%)</cell><cell>179 (58%)</cell><cell>11 (7%)</cell><cell>186 (59%)</cell><cell>168 (55%)</cell><cell>7 (4%)</cell></row><row><cell>P-value (4)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>--</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>--</cell></row><row><cell>PASI 75</cell><cell>192 (62%)</cell><cell>197 (64%)</cell><cell>9 (6%)</cell><cell>206 (66%)</cell><cell>188 (61%)</cell><cell>9 (6%)</cell></row><row><cell>P-value (4)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>--</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>--</cell></row><row><cell>PP Population (2)</cell><cell>N=295</cell><cell>N=302</cell><cell>N=148</cell><cell>N=271</cell><cell>N=275</cell><cell>N=134</cell></row><row><cell>PGA Response (3)</cell><cell>174 (59%)</cell><cell>177 (59%)</cell><cell>11 (7%)</cell><cell>169 (62%)</cell><cell>154 (56%)</cell><cell>7 (5%)</cell></row><row><cell>P-value (4)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>--</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>--</cell></row><row><cell>PASI 75</cell><cell>187 (63%)</cell><cell>194 (64%)</cell><cell>9 (6%)</cell><cell>183 (68%)</cell><cell>168 (61%)</cell><cell>7 (5%)</cell></row><row><cell>P-value (4)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>--</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>--</cell></row><row><cell cols="4">Source: Statistical Reviewer's Analysis (same as Applicant's Analysis)</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_34"><head>Table 26 : Missing Data for the Co-Primary Efficacy Endpoints by Week</head><label>26</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>Trial P010</cell><cell></cell><cell></cell><cell>Trial P011</cell><cell></cell></row><row><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell></row><row><cell></cell><cell>200 mg</cell><cell>100 mg</cell><cell>Placebo</cell><cell>200 mg</cell><cell>100 mg</cell><cell>Placebo</cell></row><row><cell></cell><cell>(N=308)</cell><cell>(N=309)</cell><cell>(N=154)</cell><cell>(N=314)</cell><cell>(N=307)</cell><cell>(N=156)</cell></row><row><cell>PGA</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Baseline</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>3 (1.0%)</cell><cell>0</cell><cell>1 (0.6%)</cell></row><row><cell>Week 4</cell><cell>6 (2.0%)</cell><cell>4 (1.3%)</cell><cell>3 (2.0%)</cell><cell>9 (3.0%)</cell><cell>6 (2.0%)</cell><cell>6 (4.0%)</cell></row><row><cell>Week 8</cell><cell>14 (4.8%)</cell><cell>6 (2.0%)</cell><cell cols="2">8 (5.5%) 15 (5.0%)</cell><cell>9 (3.0%)</cell><cell>10 (6.8%)</cell></row><row><cell>Week 12</cell><cell>8 (2.7%)</cell><cell>8 (2.7%)</cell><cell cols="2">9 (6.2%) 17 (5.7%)</cell><cell>10 (3.4%)</cell><cell>14 (9.9%)</cell></row><row><cell>PASI</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Baseline</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>1 (0.6%)</cell></row><row><cell>Week 4</cell><cell>5 (1.7%)</cell><cell>2 (0.7%)</cell><cell>2 (1.3%)</cell><cell>6 (1.9%)</cell><cell>4 (1.3%)</cell><cell>6 (4.0%)</cell></row><row><cell>Week 8</cell><cell>11 (3.7%)</cell><cell>5 (1.6%)</cell><cell cols="2">7 (4.8%) 12 (4.0%)</cell><cell>8 (2.7%)</cell><cell>10 (6.8%)</cell></row><row><cell>Week 12</cell><cell>8 (2.7%)</cell><cell>8 (2.7%)</cell><cell cols="2">9 (6.2%) 12 (4.0%)</cell><cell>10 (3.4%)</cell><cell>14 (9.9%)</cell></row></table><note>Source: Statistical Reviewer's Analysis Full Analysis Set (FAS): all randomized subjects who received at least one dose of study product.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_35"><head>Table 27 : Results for Co-Primary Efficacy Endpoints at Week 12 with Different Approaches for Handling Missing Data</head><label>27</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>Trial P010</cell><cell></cell><cell></cell><cell>Trial P011</cell><cell></cell></row><row><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell></row><row><cell></cell><cell>200 mg</cell><cell>100 mg</cell><cell>Placebo</cell><cell>200 mg</cell><cell>100 mg</cell><cell>Placebo</cell></row><row><cell></cell><cell>(N=308)</cell><cell>(N=309)</cell><cell>(N=154)</cell><cell>(N=314)</cell><cell>(N=307)</cell><cell>(N=156)</cell></row><row><cell>PGA Response (1)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>NRI (Primary)</cell><cell>59%</cell><cell>58%</cell><cell>7%</cell><cell>59%</cell><cell>55%</cell><cell>4%</cell></row><row><cell>LOCF (2)</cell><cell>60%</cell><cell>59%</cell><cell>8%</cell><cell>61%</cell><cell>56%</cell><cell>5%</cell></row><row><cell>MI (3)</cell><cell>60%</cell><cell>59%</cell><cell>10%</cell><cell>61%</cell><cell>56%</cell><cell>10%</cell></row><row><cell>Worst Case (4)</cell><cell>59%</cell><cell>58%</cell><cell>13%</cell><cell>59%</cell><cell>55%</cell><cell>13%</cell></row><row><cell>PASI 75</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>NRI (Primary)</cell><cell>62%</cell><cell>64%</cell><cell>6%</cell><cell>66%</cell><cell>61%</cell><cell>6%</cell></row><row><cell>LOCF (2)</cell><cell>63%</cell><cell>64%</cell><cell>6%</cell><cell>67%</cell><cell>63%</cell><cell>6%</cell></row><row><cell>MI (3)</cell><cell>63%</cell><cell>65%</cell><cell>8%</cell><cell>67%</cell><cell>63%</cell><cell>9%</cell></row><row><cell>Worst Case (4)</cell><cell>62%</cell><cell>64%</cell><cell>12%</cell><cell>66%</cell><cell>61%</cell><cell>15%</cell></row></table><note>Source: Statistical Reviewer's Analysis (NRI, LOCF and MI same as Applicant's Analysis)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_36"><head>Table 28 : Results for the Secondary Efficacy Endpoints Against Placebo at Week 12 Trial P010 Trial P011 Tildrakizumab</head><label>28</label><figDesc>Full Analysis Set (FAS): all randomized subjects who received at least one dose of study product. Missing data was imputed using non-responder imputation (NRI). Subjects with missing baseline value were also imputed using NRI.(2) Comparison against placebo. P-value based on a CMH test stratified by baseline weight ( 90 kg / &gt;90 kg) and prior exposure to biologic therapy for psoriasis (Yes/No).Trial P011 included etanercept as an active comparator. In Trial P011, all subjects randomized to etanercept in the U.S. sites received U.S. licensed Enbrel (etanercept). Subjects randomized to etanercept at all other sites received EU approved etanercept. Because the applicant did not establish an adequate scientific bridge between U.S. licensed Enbrel and EU approved etanercept, these products are considered distinct products for the purpose of this review.</figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell></row><row><cell></cell><cell>200 mg</cell><cell>100 mg</cell><cell>Placebo</cell><cell>200 mg</cell><cell>100 mg</cell><cell>Placebo</cell></row><row><cell>Endpoint</cell><cell>(N=308)</cell><cell>(N=309)</cell><cell>(N=154)</cell><cell>(N=314)</cell><cell>(N=307)</cell><cell>(N=156)</cell></row><row><cell>PASI 90 (1)</cell><cell>109 (35%)</cell><cell>107 (35%)</cell><cell>4 (3%)</cell><cell>115 (37%)</cell><cell>119 (39%)</cell><cell>2 (1%)</cell></row><row><cell>P-value (2)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>--</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>--</cell></row><row><cell>PASI 100 (1)</cell><cell>43 (14%)</cell><cell>43 (14%)</cell><cell>2 (1%)</cell><cell>37 (12%)</cell><cell>38 (12%)</cell><cell>0</cell></row><row><cell>P-value (2)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>--</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>--</cell></row><row><cell cols="4">Source: Statistical Reviewer's Analysis (same as Applicant's Analysis)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>(1)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_37"><head>Table 29</head><label>29</label><figDesc>presents the results for the secondary efficacy endpoints against etanercept in the overall population (all sites) and by country (U.S. vs. Non-U.S.) for Trial P011. In the overall population, all of the secondary endpoints between tildrakizumab 200 mg and etanercept had pvalues less than 0.05 (i.e., all p-values 0.003); however, for tildrakizumab 100 mg, the secondary endpoint of PGA response at Week 12 had a p-value of 0.066. In the U.S. only subgroup, none of the secondary endpoints between tildrakizumab 100 mg and etanercept had p-values less than 0.05 and only the secondary endpoints at Week 28 for tildrakizumab 200 mg had p-values less than 0.05 (i.e., p-values 0.032). It should be noted that while the response rates for both doses of tildrakizumab were consistently lower in the U.S. subgroup compared to the non-U.S. subgroup for all of the secondary endpoints presented in</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_38"><head>Table 29 : Results for the Secondary Efficacy Endpoints Against Etanercept at Week 12</head><label>29</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">Tildrakizumab</cell><cell></cell><cell cols="2">P-Value (4)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>200 mg</cell><cell>100 mg</cell></row><row><cell></cell><cell>200 mg</cell><cell>100 mg</cell><cell>Etanercept</cell><cell>vs.</cell><cell>vs.</cell></row><row><cell>Endpoint</cell><cell>(N=314)</cell><cell>(N=307)</cell><cell>(N=313)</cell><cell>Etanercept</cell><cell>Etanercept</cell></row><row><cell>PGA Response (1) at Week 12 (2)</cell><cell>186 (59%)</cell><cell>168 (55%)</cell><cell>149 (48%)</cell><cell>0.003</cell><cell>0.066</cell></row><row><cell>U.S. (3)</cell><cell>45 (52%)</cell><cell>41 (48%)</cell><cell>41 (47%)</cell><cell>0.494</cell><cell>0.826</cell></row><row><cell>Non-U.S. (3)</cell><cell>141 (62%)</cell><cell>127 (57%)</cell><cell>108 (48%)</cell><cell>0.002</cell><cell>0.038</cell></row><row><cell>PASI 75 at Week 12 (2)</cell><cell>206 (66%)</cell><cell>188 (61%)</cell><cell>151 (48%)</cell><cell>&lt;0.001</cell><cell>0.001</cell></row><row><cell>U.S. (3)</cell><cell>48 (56%)</cell><cell>45 (53%)</cell><cell>44 (51%)</cell><cell>0.487</cell><cell>0.677</cell></row><row><cell>Non-U.S. (3)</cell><cell>158 (69%)</cell><cell>143 (64%)</cell><cell>107 (47%)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell></row><row><cell>PGA Response (1) at Week 28 (2)</cell><cell>207 (66%)</cell><cell>190 (62%)</cell><cell>131 (42%)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell></row><row><cell>U.S. (3)</cell><cell>53 (62%)</cell><cell>38 (45%)</cell><cell>38 (44%)</cell><cell>0.019</cell><cell>0.888</cell></row><row><cell>Non-U.S. (3)</cell><cell>154 (68%)</cell><cell>152 (68%)</cell><cell>93 (41%)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell></row><row><cell>PASI 75 at Week 28 (2)</cell><cell>217 (69%)</cell><cell>216 (70%)</cell><cell>155 (50%)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell></row><row><cell>U.S. (3)</cell><cell>58 (67%)</cell><cell>51 (60%)</cell><cell>45 (52%)</cell><cell>0.032</cell><cell>0.256</cell></row><row><cell>Non-U.S. (3)</cell><cell>159 (70%)</cell><cell>165 (74%)</cell><cell>110 (49%)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell></row><row><cell>PASI 90 at Week 12 (2)</cell><cell>115 (37%)</cell><cell>119 (39%)</cell><cell>67 (21%)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell></row><row><cell>U.S. (3)</cell><cell>23 (27%)</cell><cell>26 (31%)</cell><cell>24 (28%)</cell><cell>0.908</cell><cell>0.677</cell></row><row><cell>Non-U.S. (3)</cell><cell>92 (40%)</cell><cell>93 (42%)</cell><cell>43 (19%)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell></row><row><cell>PASI 100 at Week 12 (2)</cell><cell>37 (12%)</cell><cell>38 (12%)</cell><cell>15 (5%)</cell><cell>0.001</cell><cell>&lt;0.001</cell></row><row><cell>U.S. (3)</cell><cell>4 (5%)</cell><cell>9 (11%)</cell><cell>6 (7%)</cell><cell>0.521</cell><cell>0.410</cell></row><row><cell>Non-U.S. (3)</cell><cell>33 (14%)</cell><cell>29 (13%)</cell><cell>9 (4%)</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell></row></table><note>Source: Statistical Reviewer's Analysis</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_39"><head>Table 30 : Co-Primary and Secondary Efficacy Endpoints included in the Multiplicity Testing Strategy</head><label>30</label><figDesc>The protocols for Trials P010 and P011 included the assessment of patient reported outcomes (PROs). Both trials included the Dermatology Life Quality Index (DLQI). Trial P010 also included the Short Form(36)Health Survey (SF-36), the European Quality of Life-5 Dimensions (EQ-5D), Health Assessment Questionnaire (HAQ) [Japan sites only], Patient Global Assessment of Disease (PGAD) [Japan sites only], and Patient Global Assessment of Pain (PGAP) [Japan sites only]</figDesc><table><row><cell>Family/Order</cell></row><row><cell>Endpoint</cell></row><row><cell>Designation</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_40"><head>Table 31 : Maintenance of Response (Trial P010)</head><label>31</label><figDesc></figDesc><table><row><cell>Treatment Arm (Induction</cell><cell>Maintenance)</cell><cell>PASI 75 (1)</cell><cell>PGA Response (1,2)</cell></row><row><cell cols="2">Maintenance of Response at Week 64:</cell><cell></cell><cell></cell></row><row><cell cols="2">Tildrakizumab 200 mg to Tildrakizumab 200 mg</cell><cell>107/119 (90%)</cell><cell>74/93 (80%)</cell></row><row><cell cols="2">Tildrakizumab 200 mg to Placebo (3)</cell><cell>34/119 (29%)</cell><cell>23/96 (24%)</cell></row><row><cell cols="2">Tildrakizumab 100 mg to Tildrakizumab 100 mg</cell><cell>98/116 (84%)</cell><cell>64/93 (69%)</cell></row><row><cell cols="2">Tildrakizumab 100 mg to Placebo (3)</cell><cell>25/114 (22%)</cell><cell>12/88 (14%)</cell></row><row><cell cols="2">Time (weeks) to Loss of Response:</cell><cell></cell><cell></cell></row><row><cell cols="2">Tildrakizumab 200 mg to Placebo (3)</cell><cell>24.0</cell><cell>20.0</cell></row><row><cell cols="2">Tildrakizumab 100 mg to Placebo (3)</cell><cell>20.0</cell><cell>16.0</cell></row></table><note>Source: Statistical Reviewer's Analysis (1) Missing data was imputed using non-responder imputation (NRI).</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_41"><head>in Special/Subgroup Populations 7.2.8.1. Sex, Age, Race, Weight, Baseline Disease Severity, and Prior Use of Biologic Therapy</head><label></label><figDesc>BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use102The applicant evaluated rebound of psoriasis during Part 3 of Trial P010 following withdrawal of tildrakizumab treatment among re-randomized tildrakizumab responders. Rebound of disease was defined as worsening of psoriasis over baseline PASI score (PASI &gt;125%), or new pustular, erythrodermic, or more inflammatory psoriasis occurring within 2 months of stopping therapy. No subjects in either treatment group (100 mg placebo or 200 mg placebo), experienced rebound of disease during Part 3 (Weeks 32 to 64).</figDesc><table><row><cell>Findings</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_42"><head></head><label></label><figDesc>Yes, there is reasonable possibility of drug relationship. There is evidence of exposure to test drug. The temporal sequence of the AE onset relative to the administration of the test drug is reasonable. The AE is more likely explained by the test drug than by another cause. No, there is not a reasonable possibility of drug relationship. Subject did not receive the test drug OR temporal sequence of the AE onset relative to administration of the test drug is not reasonable OR there is another obvious cause of the AE. (Also entered for a subject with overdose without an associated AE.) An AE was classified as being treatment-emergent if it was a new AE that occurred after the treatment start date, or any existing AE that occurred during Screening that increased in severity or worsened after the treatment start date.A serious adverse event was defined as any untoward medical occurrence or effect that at any dose:Percentage of subjects with serious infections, defined as any infection meeting the regulatory definition of a serious adverse event (SAE), or any infection requiring IV antibiotics whether or not reported as an SAE, as per the regulatory definition. Percentage of subjects with malignancies excluding non-melanoma skin cancer (NMSC) and carcinoma in situ of the cervix. Percentage of subjects with major cardiovascular adverse events (MACE), including nonfatal stroke, nonfatal myocardial infarction, or cardiovascular (CV) death. Percentage of subjects with injection site reactions (ISRs). Percentage of subjects with drug-related hypersensitivity reactions (eg, anaphylaxis, urticaria, angioedema).</figDesc><table><row><cell>Results in death;</cell></row><row><cell>Is life threatening;</cell></row><row><cell>Requires hospitalization or prolongation of existing inpatients' hospitalization;</cell></row><row><cell>Results in persistent or significant disability or incapacity; and/or</cell></row><row><cell>Is a congenital anomaly or birth defect;</cell></row><row><cell>Is a cancer;</cell></row><row><cell>Is associated with an overdose;</cell></row><row><cell>Is an Other Important Medical Event.</cell></row><row><cell>The applicant also classified AEs as Tier 1, Tier 2, or Tier 3 according to the criteria below. Tier</cell></row><row><cell>1 AE included:</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_44"><head></head><label></label><figDesc>Subjects were evaluated at screening for tuberculosis with an intradermal tuberculin skin test(Mantoux)  or QuantiFERON gold TB test. A chest x-ray (posterior-anterior and lateral views) or a chest CT scan was required for any subject who had a positive intradermal skin test or positive QuantiFERON gold TB test, or who had recent close contact with a person with active TB, or had signs or symptoms suggestive of active TB upon medical history and/or physical examination, or if required by local guidelines or regulations as part of routine TB screening.If either the tuberculin skin or QuantiFERON-TB Gold test was positive and the chest x-ray was negative, the subject was considered to have latent TB infection (LTBI). Subjects with LTBI could be included if they received prophylactic treatment for LTBI or have previously completed an adequate course of prophylactic treatment according to local guidelines or regulations BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use 114 without subsequent new exposure to active TB. Subjects were asked at each visit about potential tuberculosis exposure, and assessed for symptoms of active TB including cough, weight loss, fever, and night sweats.</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_45"><head></head><label></label><figDesc>Trial P003: at every visit throughout the trial from Baseline through Week 52, and End of Treatment Trial P010: at every visit throughout the trial from Baseline through Week 64 as well as the Extension through Extension Week 192 (except Extension Week 13 and 109 visits), 6 and 20 weeks after the last dose received, and End of Treatment Trial P011: at every visit throughout the trial from Baseline through Week 244 and End of Treatment During the Phase 2/3 trials (Trial P003, P010, and P011), clinical laboratory evaluation included serology for Hepatitis B and C, as well as a HIV antibody test were performed at Screening. Routine clinical laboratory evaluation during these trials also included: Hematology: red blood cell (RBC), hematocrit, hemoglobin, platelets, white blood cell (WBC), eosinophils, neutrophils, lymphocytes, monocytes, and basophils Serum chemistry: Potassium, sodium, chloride, bicarbonate, creatinine, blood urea nitrogen (BUN), total bilirubin, alkaline phosphatase, aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), total protein, albumin, calcium, inorganic phosphorus, glucose, hsCRP, and fasting lipid panel (lipids at Baseline, Week 12 (P010, P011) or Week 16 (P003), and Week 52 only). Urinalysis: pH, specific gravity, protein, glucose, ketones, blood, and microscopic exam (only if dipstick is positive). Week 4, 12, 22, 28, 36, 46, and 52 during the Base study; Week 60, 76, then every 24 weeks until End of Treatment in Extension Study, then 20 weeks after last dose Because the 3 trials had different visit schedules, for the purpose of comparison of results across time, only the trial visits common across the Phase 2/3 trials were summarized. Baseline; Week 12, 28; 20 weeks after last dose during follow-up period, and End of Treatment Because the 3 trials had different visit schedules, for the purpose of comparison of vital signs across time, only the trial visits common across the Phase 2 and 3 trials are summarized. Complete PE at Screening, Week 12, 52; 20 weeks after last dose, and End of Treatment During the Phase 2/3 trials, investigators performed 12 lead ECGs at the following timepoints: Screening, Week 4, 12, 28, 64, Extension Weeks 12, 24, then every 24 weeks, 20 weeks after last dose and End of Treatment Trial P011: Screening, Week 4, 12, 28, 52; Week 60, 76, then Q24 Weeks during Extension study; 20 weeks after last dose, and End of Treatment</figDesc><table><row><cell>Common time points for measurement of vital signs across the Phase 2/3 trials during the base</cell></row><row><cell>period were Weeks 0, 4, 8, 12, 16, 28, 40, and 52.</cell></row><row><cell>Investigators performed directed or complete physical examinations periodically during the</cell></row><row><cell>conduct of the Phase 2/3 trials. Physical examinations were performed at the following</cell></row><row><cell>timepoints:</cell></row><row><cell>Trial P003</cell></row><row><cell>Trial P003: Screening, Week 4, 8, 52, and End of Treatment</cell></row><row><cell>Trial P010:</cell></row><row><cell>Clinical laboratory parameters were assessed at the following timepoints:</cell></row><row><cell>Trial P003: Screening, Baseline, Week 2, 4, 8, 16, 20, 28, 40, 52, 56, 64, 72, and End of</cell></row><row><cell>Common time points for measurement of laboratory values across the Phase 2/3 trials during</cell></row><row><cell>the base period were Weeks 0, 4, and 12/16 (Week 12 [P010 and P011] and Week 16 [P003]),</cell></row><row><cell>28, and 52.</cell></row></table><note>Treatment Trial P010: Screening, Baseline, Week 4, 12, 22, 28, 36, 44, 52, and 64 during the Base study; Extension Week 12, 24, then every 24 weeks until End of Treatment in Extension Study, then 20 weeks after last dose Trial P011: Screening, Baseline,Vital signs were assessed at every clinic visit during the Phase 2/3 trials. Measurement of vital signs included temperature, respiratory rate, resting pulse rate and blood pressure. Height (cm) was measured at screening in all three trials. Weight (kg) was measured at the following timepoints: Trial P003: Every visit from Screening to Week 52, Week 72, and End of Treatment Trial P010: Baseline; Week 12 and 28 Trial P011:o Complete PE: Screening, Week 16, 52, 72, and End of Treatment o Directed PE: Baseline, every visit Week 2-12, 20-46, and 56-68 Trial P010: Complete PE at Screening, Week 12, 64, and End of Treatment. Trial P011:</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_46"><head>Table 37 : Subjects with Serious Adverse Events (Selected SOCs exposure adjusted rates, all subjects as treated) Body System or Organ Class</head><label>37</label><figDesc></figDesc><table><row><cell></cell><cell>Tildra 100mg</cell><cell>Tildra 200mg</cell><cell>Placebo</cell><cell>Etanercept</cell></row><row><cell></cell><cell>N (%)</cell><cell>N (%)</cell><cell>N (%)</cell><cell>50mg, N (%)</cell></row><row><cell>Subjects (N)</cell><cell>1083</cell><cell>1041</cell><cell>588</cell><cell>313</cell></row><row><cell>With SAE N</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(100 subj yr)</cell><cell>58 (5.81)</cell><cell>67 (7.21)</cell><cell>14 (6.4)</cell><cell>20 (13.4)</cell></row><row><cell>Without SAE N</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>(100 subj yr)</cell><cell cols="2">1025 (102.67) 974 (104.86)</cell><cell>574 (262,27)</cell><cell>293 (190.98)</cell></row><row><cell>Cardiac disorders</cell><cell>6 (0.6)</cell><cell>8 (0.86)</cell><cell>1 (0.46)</cell><cell>2 (1.30)</cell></row><row><cell>Gastrointestinal</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>disorders</cell><cell>8 (0.8)</cell><cell>4 (0.43)</cell><cell>1 (0.46)</cell><cell>0 (0.0)</cell></row><row><cell>Hepatobiliary disorders</cell><cell>3 (0.3)</cell><cell>1 (0.11)</cell><cell>0 (0.0)</cell><cell>1 (0.65)</cell></row><row><cell>Infections and</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>infestations</cell><cell>10 (1.00)</cell><cell>15 (1.61)</cell><cell>2 (0.91)</cell><cell>2 (1.30)</cell></row><row><cell>Neoplasms *</cell><cell>15 (1.50)</cell><cell>10 (1.08)</cell><cell>3 (1.37)</cell><cell>5 (3.26)</cell></row><row><cell>Nervous system</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>disorders</cell><cell>2 (0.20)</cell><cell>5 (0.54)</cell><cell>2 (0.91)</cell><cell>2 (1.30)</cell></row><row><cell>Musculoskeletal</cell><cell>3 (0.3)</cell><cell>8 (0.86)</cell><cell>1 (0.46)</cell><cell>1 (0.65)</cell></row></table><note>Source: Adapted from Table 5.3.5.3.3-psoriasis: 58*Only selected skin cancers are included as SAEs</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_47"><head>Table 38 : Pooled TEAE of Gastroenteritis and Related Events, Placebo-Controlled Period Tildrakizumab 100 mg (N=705) n (%) Tildrakizumab 200 mg (N=708) n (%) Total Tildrakizumab (N=1413) n % Etanercept</head><label>38</label><figDesc></figDesc><table><row><cell>1</cell><cell>Placebo</cell></row><row><cell>50 mg</cell><cell>(N=357)</cell></row><row><cell>(N=313)</cell><cell>n (%)</cell></row><row><cell>n (%)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_48"><head>Table 39 : Treatment-Emergent Adverse Events Reported by 1% in One or More Tildrakizumab Groups and More Frequently than in the Placebo Group in the Plaque Psoriasis Trials 1, 2, and 3*</head><label>39</label><figDesc>Injection site reactions include injection site urticaria, pruritus, pain, reaction, erythema, inflammation, edema, swelling, bruising, hematoma, and hemorrhage c Abdominal pain includes abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort d Fatigue was added to AR table after applicant response to request ot separate US-licensed and EU-approved etanercept data Source: Compiled by reviewer in JReview using ISS dataset</figDesc><table><row><cell>Adverse Reaction</cell><cell cols="2">Tildrakizumab</cell><cell>Placebo</cell><cell>US Licensed</cell><cell>EU Approved</cell></row><row><cell></cell><cell>100 mg</cell><cell>200 mg</cell><cell></cell><cell>Enbrel</cell><cell>Etanercept</cell></row><row><cell></cell><cell>(N=705)</cell><cell>(N=708)</cell><cell>(N=355)</cell><cell>(N=87)</cell><cell>(N=226)</cell></row><row><cell></cell><cell>N (%)</cell><cell>N (%)</cell><cell>N (%)</cell><cell>N (%)</cell><cell>N (%)</cell></row><row><cell>Upper respiratory infections a</cell><cell>98 (13.9)</cell><cell>90 (12.7)</cell><cell>41 (11.5)</cell><cell>7 (8.0)</cell><cell>37 (16.4)</cell></row><row><cell>Injection-site Reactions b</cell><cell>24 (3.4)</cell><cell>29 (4.1)</cell><cell>7 (2.0)</cell><cell>11 (12.6)</cell><cell>45 (19.9)</cell></row><row><cell>Fatigue</cell><cell>17 (2.4)</cell><cell>7 (1)</cell><cell>6 (1.7)</cell><cell>1 (1.1)</cell><cell>3 (1.3)</cell></row><row><cell>Diarrhea</cell><cell>13 (1.8)</cell><cell>10 (1.4)</cell><cell>5 (1.4)</cell><cell>0 (0)</cell><cell>4 (1.8)</cell></row><row><cell>Back pain</cell><cell>9 (1.3)</cell><cell>12 (1.7)</cell><cell>4 (1.1)</cell><cell>1 (1.1)</cell><cell>3 (1.3)</cell></row><row><cell>Abdominal pain c</cell><cell>9 (1.3)</cell><cell>7 (1.0)</cell><cell>2 (0.6)</cell><cell>2 (2.3)</cell><cell>4 (1.8)</cell></row><row><cell>Gastroenteritis</cell><cell>8 (1.1)</cell><cell>13 (1.8)</cell><cell>4 (1.1)</cell><cell>0 (0)</cell><cell>6 (2.7)</cell></row><row><cell>Nausea</cell><cell>7 (1.0)</cell><cell>11 (1.6)</cell><cell>3 (0.8)</cell><cell>0 (0)</cell><cell>1 (0.4)</cell></row><row><cell>Dizziness</cell><cell>5 (0.7)</cell><cell>10 (1.4)</cell><cell>0</cell><cell>1 (1.1)</cell><cell>5 (2.2)</cell></row></table><note>b</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_49"><head>Table 40 : Adverse Reactions Reported by 1% in Subjects treated with Tildrakizumab 100 mg and More Frequently than in the Placebo Group in the Plaque Psoriasis Trials 1</head><label>40</label><figDesc></figDesc><table><row><cell>, 2,</cell></row></table><note>a Upper respiratory infections include nasopharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, and pharyngitisb Injection site reactions include injection site urticaria, pruritus, pain, reaction, erythema, inflammation, edema, swelling, bruising, hematoma, and hemorrhagec Abdominal pain includes abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort Source: Compiled by reviewer in JReview using ISS dataset</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_51"><head></head><label></label><figDesc>Dose Clinical Study to Evaluate the Effect of Tildrakizumab (MK-3222 [SCH 900222]) on Cytochrome P450 Isoenzymes and the Relative Bioavailability of Two MK-3222 Drug Product Images in Subjects with Moderate to Severe Psoriasis."</figDesc><table><row><cell>There were no clinically meaningful changes in laboratory parameters, vital signs or ECG</cell></row><row><cell>parameters.</cell></row><row><cell>PROTOCOL P009 (2 doses)</cell></row><row><cell>"A Randomized, Fixed-Sequence, Parallel Group, Open-Label, Multiple-</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_52"><head></head><label></label><figDesc>both Trial P010 and Trial P011, subjects were initially randomized to receive tildrakizumab 100 mg, tildrakizumab 200 mg or placebo at Week 0 and 4. Trial P011 also included etanercept 50 mg twice weekly as an active comparator. Subjects randomized to etanercept in U.S. sites received U.S.-licensed Enbrel; subjects randomized to etanercept in all other sites received EUapproved etanercept. The applicant did not establish an adequate scientific bridge between U.S.-licensed Enbrel and EU-approved etanercept. In the subgroup who received U.S.-licensed Enbrel, none of the secondary endpoints comparing tildrakizumab 100 mg and etanercept had p-values less than 0.05. Refer to Sections 7.2.5.4.In addition, the response rates for the 100 mg and 200 mg tildrakizumab doses were similar. There was no additional benefit to the use of the 200-mg dose over the 100-mg dose in any subgroup including subjects weighing 90 kg.</figDesc><table><row><cell>Refer to Sections 7.4.2, 7.3.1 and 13.5. Therefore, labeling will not include data comparing</cell></row><row><cell>tildrakizumab with etanercept or comparing tildrakizumab 100 mg dose with tildrakizumab 200</cell></row><row><cell>mg dose. Only tildrakizumab 100 mg will be recommended in labeling.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_53"><head>Table 48 : Investigators with Financial Disclosure Forms 3455 for Trials P010 and P011 Investigator Trial/Site Country # Subjects Randomized Description of Disclosure</head><label>48</label><figDesc></figDesc><table><row><cell>USA</cell><cell>7</cell><cell>On 08-08-2012,</cell><cell>initially responded that</cell></row><row><cell></cell><cell></cell><cell cols="2">he had no financial interest or arrangements to</cell></row><row><cell></cell><cell></cell><cell cols="2">report. He subsequently updated his financial</cell></row><row><cell></cell><cell></cell><cell cols="2">disclosure information as noted below:</cell></row><row><cell></cell><cell></cell><cell>Updated Equity Interest:</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Amount: $55,000.00</cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">Comment: Stock valued at $55,000.00 as</cell></row><row><cell></cell><cell></cell><cell cols="2">reported by the investigator on 10-31-2012</cell></row><row><cell>USA</cell><cell>2</cell><cell cols="2">Significant Payments of Other Sorts:</cell></row><row><cell></cell><cell></cell><cell>Amount: $26,000.00</cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">Comment: $26,000.00 for consultation fee in 2012</cell></row><row><cell></cell><cell></cell><cell cols="2">as reported by the investigator on 12-12-2012.</cell></row><row><cell>USA</cell><cell>8</cell><cell>Equity Interest:</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Amount: $141,946.00</cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">Comment: Held stock in Schering-Plough.</cell></row><row><cell></cell><cell></cell><cell cols="2">Schering-Plough sold to Merck in January 2013.</cell></row><row><cell></cell><cell></cell><cell cols="2">Investigator learned of sale in November 2013.</cell></row><row><cell></cell><cell></cell><cell>The amount was donated</cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">in November 2013 as reported</cell></row><row><cell></cell><cell></cell><cell cols="2">by investigator on 12-09-2013.</cell></row><row><cell cols="3">Source: Compiled by Reviewer from Applicant's submission</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_54"><head>Table 49 : Investigators Not Certified; Due Diligence Completed Investigator Trial/Site Country # Subjects Randomized Reason</head><label>49</label><figDesc></figDesc><table><row><cell>Germany 4901-11;</cell><cell>Did not return form with requested information.</cell></row><row><cell>4931-3</cell><cell>Investigator Left Site.</cell></row><row><cell></cell><cell>Due Diligence attempts to obtain forms were made</cell></row><row><cell></cell><cell>on 10-24-2014, 05-10-2015, 07-15-2015, 07-16-</cell></row><row><cell></cell><cell>2015, 07-20-2015, and 07-25-2016.</cell></row><row><cell cols="2">Source: Compiled by Reviewer from Applicant's submission</cell></row><row><cell>Reference ID: 4233639</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_55"><head>Table 50 : Upper Respiratory Infections Subgroups Tildrakizumab</head><label>50</label><figDesc></figDesc><table><row><cell></cell><cell>100 mg</cell><cell>Placebo</cell></row><row><cell></cell><cell>(N=705)</cell><cell>(N=355)</cell></row><row><cell></cell><cell>m/n* (%)</cell><cell>m/n* (%)</cell></row><row><cell>Sex</cell><cell></cell><cell></cell></row><row><cell>Males</cell><cell>70/503 (13.9)</cell><cell>29/249 (11.6)</cell></row><row><cell>Females</cell><cell>28/202 (13.9)</cell><cell>12/106 (11.3)</cell></row><row><cell>Age (years)</cell><cell></cell><cell></cell></row><row><cell>18-64</cell><cell>94/644 (14.6)</cell><cell>39/319 (12.2)</cell></row><row><cell>65+</cell><cell>4/61 (6.6)</cell><cell>2/36 (5.6)</cell></row><row><cell>Race</cell><cell></cell><cell></cell></row><row><cell>White</cell><cell>77/569 (13.5)</cell><cell>35/278 (12.6)</cell></row><row><cell>Black</cell><cell>1/21 (4.8)</cell><cell>1/7 (14.3)</cell></row><row><cell>Asian</cell><cell>16/93 (17.2)</cell><cell>5/56 (8.9)</cell></row><row><cell>Other</cell><cell>1/22 (4.5)</cell><cell>0/14 (0.0)</cell></row><row><cell>Baseline Weight (kg)</cell><cell></cell><cell></cell></row><row><cell>90 kg</cell><cell>58/416 (13.9)</cell><cell>23/211 (10.9)</cell></row><row><cell>&gt; 90 kg</cell><cell>40/289 (13.8)</cell><cell>18/144 (12.5)</cell></row><row><cell>Baseline PGA Score</cell><cell></cell><cell></cell></row><row><cell>1 -Minimal</cell><cell>0/2 (0.0)</cell><cell>--</cell></row><row><cell>2 -Mild</cell><cell>0/10 (0.0)</cell><cell>0/7 (0.0)</cell></row><row><cell>3 -Moderate</cell><cell>65/464 (14.0)</cell><cell>28/229 (12.2)</cell></row><row><cell>4 -Marked</cell><cell>32/211 (15.2)</cell><cell>10/105 (9.5)</cell></row><row><cell>5 -Severe</cell><cell>1/18 (5.6)</cell><cell>3/13 (23.1)</cell></row><row><cell cols="3">*m/n = number of participants with adverse reaction (m) in the subgroup (n)</cell></row><row><cell>Source: Statistical Review's Tables</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_56"><head>Table 51</head><label>51</label><figDesc></figDesc><table><row><cell cols="2">: Injection-site Reactions</cell><cell></cell></row><row><cell></cell><cell>Tildrakizumab 100 mg</cell><cell>Placebo</cell></row><row><cell></cell><cell>(N=705)</cell><cell>(N=355)</cell></row><row><cell>Subgroups</cell><cell>m/n* (%)</cell><cell>m/n* (%)</cell></row><row><cell>Sex</cell><cell></cell><cell></cell></row><row><cell>Males</cell><cell>15/503 (3.0)</cell><cell>4/249 (1.6)</cell></row><row><cell>Females</cell><cell>9/202 (4.5)</cell><cell>3/106 (2.8)</cell></row><row><cell>Age (years)</cell><cell></cell><cell></cell></row><row><cell>18-64</cell><cell>23/644 (3.6)</cell><cell>6/319 (1.9)</cell></row><row><cell>65+</cell><cell>1/61 (1.6)</cell><cell>1/36 (2.8)</cell></row><row><cell>Race</cell><cell></cell><cell></cell></row><row><cell>White</cell><cell>23/569 (4.0)</cell><cell>7/278 (2.5)</cell></row><row><cell>Black</cell><cell>0/21 (0.0)</cell><cell>0/7 (0.0)</cell></row><row><cell>Asian</cell><cell>0/93 (0.0)</cell><cell>0/56 (0.0)</cell></row><row><cell>Other</cell><cell>1/22 (4.5)</cell><cell>0/14 (0.0)</cell></row><row><cell>Baseline Weight (kg)</cell><cell></cell><cell></cell></row><row><cell>90 kg</cell><cell>12/416 (2.9)</cell><cell>5/211 (2.4)</cell></row><row><cell>&gt; 90 kg</cell><cell>12/289 (4.2)</cell><cell>2/144 (1.4)</cell></row><row><cell>Baseline PGA Score</cell><cell></cell><cell></cell></row><row><cell>1 -Minimal</cell><cell>0/2 (0.0)</cell><cell>--</cell></row><row><cell>2 -Mild</cell><cell>0/10 (0.0)</cell><cell>1/7 (14.3)</cell></row><row><cell>3 -Moderate</cell><cell>16/464 (3.4)</cell><cell>3/229 (1.3)</cell></row><row><cell>4 -Marked</cell><cell>7/211 (3.3)</cell><cell>3/105 (2.9)</cell></row><row><cell>5 -Severe</cell><cell>1/18 (5.6)</cell><cell>0/13 (0.0)</cell></row><row><cell cols="3">*m/n = number of participants with adverse reaction (m) in the subgroup (n)</cell></row><row><cell>Source: Statistical Review's Tables</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_57"><head>Table 52</head><label>52</label><figDesc></figDesc><table><row><cell>: Fatigue</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Tildrakizumab 100 mg</cell><cell>Placebo</cell></row><row><cell></cell><cell>(N=705)</cell><cell>(N=355)</cell></row><row><cell>Subgroups</cell><cell>m/n* (%)</cell><cell>m/n* (%)</cell></row><row><cell>Sex</cell><cell></cell><cell></cell></row><row><cell>Males</cell><cell>11/503 (2.2)</cell><cell>5/249 (2.0)</cell></row><row><cell>Females</cell><cell>6/202 (3.0)</cell><cell>1/106 (0.9)</cell></row><row><cell>Age (years)</cell><cell></cell><cell></cell></row><row><cell>18-64</cell><cell>17/644 (2.6)</cell><cell>6/319 (1.9)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_58"><head>Table 53</head><label>53</label><figDesc></figDesc><table><row><cell>: Diarrhea</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Tildrakizumab 100 mg</cell><cell>Placebo</cell></row><row><cell></cell><cell>(N=705)</cell><cell>(N=355)</cell></row><row><cell>Subgroups</cell><cell>m/n* (%)</cell><cell>m/n* (%)</cell></row><row><cell>Sex</cell><cell></cell><cell></cell></row><row><cell>Males</cell><cell>9/503 (1.8)</cell><cell>4/249 (1.6)</cell></row><row><cell>Females</cell><cell>4/202 (2.0)</cell><cell>2/106 (1.9)</cell></row><row><cell>Age (years)</cell><cell></cell><cell></cell></row><row><cell>18-64</cell><cell>10/644 (1.6)</cell><cell>5/319 (1.6)</cell></row><row><cell>65+</cell><cell>3/61 (4.9)</cell><cell>1/36 (2.8)</cell></row><row><cell>Race</cell><cell></cell><cell></cell></row><row><cell>White</cell><cell>13/569 (2.3)</cell><cell>6/278 (2.2)</cell></row><row><cell>Black</cell><cell>0/21 (0.0)</cell><cell>0/7 (0.0)</cell></row><row><cell>Asian</cell><cell>0/93 (0.0)</cell><cell>0/56 (0.0)</cell></row><row><cell>Other</cell><cell>0/22 (0.0)</cell><cell>0/14 (0.0)</cell></row><row><cell>Baseline Weight (kg)</cell><cell></cell><cell></cell></row><row><cell>90 kg</cell><cell>8/416 (1.9)</cell><cell>3/211 (1.4)</cell></row><row><cell>&gt; 90 kg</cell><cell>5/289 (1.7)</cell><cell>3/144 (2.1)</cell></row><row><cell>Baseline PGA Score</cell><cell></cell><cell></cell></row><row><cell>1 -Minimal</cell><cell>0/2 (0.0)</cell><cell>--</cell></row><row><cell>2 -Mild</cell><cell>1/10 (10.0)</cell><cell>0/7 (0.0)</cell></row><row><cell>3 -Moderate</cell><cell>8/464 (1.7)</cell><cell>5/229 (2.2)</cell></row><row><cell>4 -Marked</cell><cell>3/211 (1.4)</cell><cell>1/105 (1.0)</cell></row><row><cell>5 -Severe</cell><cell>1/18 (5.6)</cell><cell>0/13 (0.0)</cell></row><row><cell cols="3">*m/n = number of participants with adverse reaction (m) in the subgroup (n)</cell></row><row><cell>Source: Statistical Review's Tables</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_59"><head>Table 54</head><label>54</label><figDesc></figDesc><table><row><cell>: Back Pain</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Tildrakizumab 100 mg</cell><cell>Placebo</cell></row><row><cell></cell><cell>(N=705)</cell><cell>(N=355)</cell></row><row><cell>Subgroups</cell><cell>m/n* (%)</cell><cell>m/n* (%)</cell></row><row><cell>Sex</cell><cell></cell><cell></cell></row><row><cell>Males</cell><cell>8/503 (1.6)</cell><cell>2/249 (0.8)</cell></row><row><cell>Females</cell><cell>1/202 (0.5)</cell><cell>2/106 (1.9)</cell></row><row><cell>Age (years)</cell><cell></cell><cell></cell></row><row><cell>18-64</cell><cell>9/644 (1.4)</cell><cell>3/319 (0.9)</cell></row><row><cell>65+</cell><cell>0/61 (0.0)</cell><cell>1/36 (2.8)</cell></row><row><cell>Race</cell><cell></cell><cell></cell></row><row><cell>White</cell><cell>9/569 (1.6)</cell><cell>4/278 (1.4)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_60"><head>Table 56</head><label>56</label><figDesc></figDesc><table><row><cell>: Nausea</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Tildrakizumab 100 mg</cell><cell>Placebo</cell></row><row><cell></cell><cell>(N=705)</cell><cell>(N=355)</cell></row><row><cell>Subgroups</cell><cell>m/n* (%)</cell><cell>m/n* (%)</cell></row><row><cell>Sex</cell><cell></cell><cell></cell></row><row><cell>Males</cell><cell>4/503 (0.8)</cell><cell>2/249 (0.8)</cell></row><row><cell>Females</cell><cell>3/202 (1.5)</cell><cell>1/106 (0.9)</cell></row><row><cell>Age (years)</cell><cell></cell><cell></cell></row><row><cell>18-64</cell><cell>6/644 (0.9)</cell><cell>1/319 (0.3)</cell></row><row><cell>65+</cell><cell>1/61 (1.6)</cell><cell>2/36 (5.6)</cell></row><row><cell>Race</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_61"><head>Table 57</head><label>57</label><figDesc></figDesc><table><row><cell cols="3">: Tildrakizumab products with different drug substances, formulations, and/or</cell></row><row><cell cols="2">presentations used in clinical trials.</cell><cell></cell></row><row><cell>DS</cell><cell>Process 1</cell><cell>Process 2</cell></row><row><cell>Products</cell><cell>Lyophilized powder (LYO)</cell><cell>Solution (100 mg/mL) 1.0 mL PFS 1.0 mL AI</cell></row><row><cell></cell><cell>P05661</cell><cell></cell></row><row><cell>Phase 1</cell><cell>P05776</cell><cell></cell></row><row><cell></cell><cell>P06306</cell><cell></cell></row><row><cell>Reference ID: 4233639</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_62"><head>Table 58 : Summary of assay validation parameters of the ECL assay for measurement of tildrakizumab concentrations in human serum.</head><label>58</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">Assay performance</cell></row><row><cell>Validation parameters</cell><cell>Validation report at Site 1: 00M8G7 Associated clinical trials: P05661, P05776, P06306, and P05382</cell><cell>Validation report at Site 2: 03T5F4 Associated clinical trials: P05495, P009,</cell></row><row><cell></cell><cell></cell><cell>P010, and P011</cell></row><row><cell>Assay Range</cell><cell>3.13 to 400 ng/mL (100% serum)</cell><cell>3.12 to 400 ng/mL (100% serum)</cell></row><row><cell></cell><cell>0.78 to 100 ng/mL (25% serum)</cell><cell>0.78 to 100 ng/mL (25% serum)</cell></row><row><cell>QC accuracy</cell><cell>Intra-assay: -13.7% to 12.2%</cell><cell>Intra-assay: -15.8% to 13.8%</cell></row><row><cell></cell><cell>Inter-assay: -3.6% to 4.6%</cell><cell>Inter-assay: -4.7% to -1.7%</cell></row><row><cell>QC precision</cell><cell>Intra-assay: CV 12.7%</cell><cell>Intra-assay: CV 7.5%</cell></row><row><cell></cell><cell>Inter-assay: CV 8.4%</cell><cell>Inter-assay: CV 10.6%</cell></row><row><cell>Sensitivity</cell><cell>3.13 ng/mL</cell><cell>3.12 ng/mL</cell></row><row><cell>Selectivity</cell><cell>10 of 10 individual serum samples from</cell><cell>4 of 5 serum samples from donors with</cell></row><row><cell></cell><cell>donors with psoriasis were within Â±20%</cell><cell>psoriasis were within 25% of nominal</cell></row><row><cell></cell><cell>of the nominal concentrations at low</cell><cell>concentrations at LLOQ concentrations.</cell></row><row><cell></cell><cell>quality control and high quality control</cell><cell>All 5 un-spiked samples were &lt;LLOQ.</cell></row><row><cell></cell><cell>concentrations. All 10 un-spiked</cell><cell></cell></row><row><cell></cell><cell>samples were &lt;LLOQ.</cell><cell></cell></row><row><cell>Incurred sample</cell><cell>Study P06306: 84.7% of samples</cell><cell>Study P05495: 89.1% of samples passed</cell></row><row><cell>reanalysis</cell><cell>passed</cell><cell>Study P009: 100% of samples passed</cell></row><row><cell>Minimum</cell><cell>1:4</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_63"><head>Table 59</head><label>59</label><figDesc></figDesc><table><row><cell cols="4">: Sensitivity and drug tolerance of immunoassays for detection of anti-drug</cell></row><row><cell cols="3">antibodies (ADA) in tildrakizumab clinical trials</cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">ADA immunoassays</cell></row><row><cell>Validation</cell><cell>Frist generation</cell><cell>Second generation</cell><cell>Third Generation</cell></row><row><cell>Reports</cell><cell>03N59V.pdf</cell><cell>04HH7P.pdf</cell><cell>04GNBP.pdf</cell></row><row><cell></cell><cell></cell><cell>00TMQS.pdf</cell><cell></cell></row><row><cell>Sensitivity</cell><cell>15.0 ng/mL</cell><cell>5.0 ng/mL</cell><cell>11.1 ng/mL</cell></row><row><cell></cell><cell>(Rabbit polyclonal</cell><cell>(</cell><cell>(Rabbit polyclonal anti-CDR</cell></row><row><cell></cell><cell>anti-MK-3222</cell><cell>rabbit polyclonal anti-</cell><cell>enriched anti-MK-3222 antibody)</cell></row><row><cell></cell><cell>antibody)</cell><cell>MK-3222 antibody)</cell><cell></cell></row><row><cell>Drug tolerance</cell><cell>Not quantified</cell><cell>1.11 mcg/mL</cell><cell>6 mcg/mL (500 ng/mL ADA)</cell></row><row><cell></cell><cell></cell><cell>(700 ng/mL ADA)</cell><cell>&lt; 1 mcg/mL (30 ng/mL ADA)</cell></row><row><cell>Related clinical</cell><cell>P05661</cell><cell>P05495</cell><cell>P010</cell></row><row><cell>trials</cell><cell>P05776</cell><cell></cell><cell>P011</cell></row><row><cell></cell><cell>P06306</cell><cell></cell><cell></cell></row><row><cell></cell><cell>P05382</cell><cell></cell><cell></cell></row><row><cell cols="4">ADA, anti-drug antibodies; CDR, complementarity determining region; MK-3222=tildrakizumab; (Source of data: Applicant's</cell></row><row><cell cols="4">"Summary of Biopharmaceutic Studies/Associated Bioanalytical Methods" and related validation report.)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_64"><head>Table 60 : Sensitivity and drug tolerance of immunoassays for detection of neutralizing anti-drug antibodies (NAb) in tildrakizumab clinical trials Validation Reports</head><label>60</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>(b) (4)</cell><cell></cell></row><row><cell></cell><cell></cell><cell cols="2">NAb immunoassays</cell></row><row><cell></cell><cell>Frist generation</cell><cell>Second generation</cell><cell>Third Generation</cell></row><row><cell></cell><cell>03T5FB.pdf</cell><cell>00TMQV.pdf</cell><cell>04HGDW.pdf</cell></row><row><cell>Sensitivity</cell><cell>2000 ng/mL</cell><cell>Not further</cell><cell>62.5 ng/mL</cell></row><row><cell></cell><cell>(Rabbit polyclonal</cell><cell>characterized</cell><cell>(Rabbit polyclonal anti-MK-3222</cell></row><row><cell></cell><cell>anti-SCH 900222</cell><cell></cell><cell>antibody)</cell></row><row><cell></cell><cell>antibodies)</cell><cell></cell><cell></cell></row><row><cell>Drug tolerance</cell><cell>Not quantified</cell><cell>Not quantified</cell><cell>99 ng/mL (500 ng/mL ADA)</cell></row><row><cell>Related clinical</cell><cell>P05661</cell><cell>P05495</cell><cell>P010</cell></row><row><cell>studies</cell><cell>P05776</cell><cell></cell><cell>P011</cell></row><row><cell></cell><cell>P06306</cell><cell></cell><cell></cell></row><row><cell></cell><cell>P05382</cell><cell></cell><cell></cell></row><row><cell cols="4">ADA, anti-drug antibodies; CDR, complementarity determining region; SCH 900222=tildrakizumab; MK-3222=tildrakizumab; NAb,</cell></row><row><cell cols="4">neutralizing antibodies. (Source of data: Applicant's "Summary of Biopharmaceutic Studies/Associated Bioanalytical Methods" and</cell></row><row><cell>related validation report.)</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">Clinical Pharmacology Studies</cell><cell></cell></row><row><cell cols="4">13.5.2.1 Study P009: A clinical drug interaction study that evaluated the</cell></row><row><cell cols="4">effect of tildrakizumab on PK of CYP450 substrates in subjects with</cell></row><row><cell cols="2">psoriasis</cell><cell></cell><cell></cell></row><row><cell>Reference ID: 4233639</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_66"><head>Table 61</head><label>61</label><figDesc></figDesc><table><row><cell cols="9">: Summary of tildrakizumab PK parameters following a single SC dose</cell></row><row><cell cols="7">administration of 200 mg tildrakizumab via PFS or AI (Study P009)</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>AI</cell><cell></cell><cell></cell><cell>PFS</cell><cell></cell><cell></cell><cell>AI/PFS</cell></row><row><cell>PK parameters</cell><cell>N</cell><cell>(CV%) GM</cell><cell>95% CI</cell><cell>N</cell><cell>(CV%) GM</cell><cell>95% CI</cell><cell>GMR</cell><cell>90%CI</cell></row><row><cell>AUCinf (day*mcg/mL)</cell><cell>9</cell><cell>1310 (45.6%)</cell><cell>(953, 1800)</cell><cell>9</cell><cell>1120 (49.2%)</cell><cell>(814, 1540)</cell><cell>1.17</cell><cell>(0.81, 1.70)</cell></row><row><cell>AUClast (day*mcg/mL)</cell><cell>10</cell><cell>1070 (78.2%)</cell><cell>(722, 1590)</cell><cell>9</cell><cell>1100 (47.9%)</cell><cell>(725, 1660)</cell><cell>0.98</cell><cell>(0.61, 1.57)</cell></row><row><cell>Cmax (mcg/mL)</cell><cell>10</cell><cell>16.0 (43.3%)</cell><cell>(12.3, 20.7)</cell><cell>9</cell><cell>14.8 (36.5%)</cell><cell>(11.3, 19.5)</cell><cell>1.08</cell><cell>(0.79, 1.47)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_67"><head>Table 62</head><label>62</label><figDesc></figDesc><table><row><cell cols="9">: Summary of midazolam PK parameters following a single oral dose of 2 mg</cell></row><row><cell cols="9">midazolam as part of a CYP probe cocktail at Day 1 (baseline) and Day 57 (following two</cell></row><row><cell cols="9">SC doses of 200 mg tildrakizumab at Weeks 0 and 4) in subjects with moderate to severe</cell></row><row><cell cols="4">plaque psoriasis (Study P009)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>PK</cell><cell></cell><cell cols="2">Day 1</cell><cell></cell><cell cols="2">Day 57</cell><cell cols="2">Day 57/Day 1</cell></row><row><cell>parameters</cell><cell>N</cell><cell>GM</cell><cell>95% CI</cell><cell>N</cell><cell>GM</cell><cell>95% CI</cell><cell>GMR</cell><cell>90%CI</cell></row><row><cell>AUCinf (hr*ng/mL)</cell><cell>16</cell><cell>24.6</cell><cell>(19.8, 30.7)</cell><cell>15</cell><cell>27.3</cell><cell>(23.4, 32.0)</cell><cell>1.11</cell><cell>(0.94, 1.32)</cell></row><row><cell>AUClast (hr*ng/mL)</cell><cell>16</cell><cell>21.6</cell><cell>(17.6, 26.5)</cell><cell>15</cell><cell>23.9</cell><cell>(20.8, 27.5)</cell><cell>1.11</cell><cell>(0.96, 1.28)</cell></row><row><cell>Cmax (hr*ng/mL)</cell><cell>16</cell><cell>9.15</cell><cell>(7.51, 11.2)</cell><cell>15</cell><cell>9.66</cell><cell>(8.04, 11.6)</cell><cell>1.06</cell><cell>(0.86, 1.29)</cell></row><row><cell cols="9">Abbreviations: GM, geometric least-square mean; GMR, geometric least-square mean ratio. (Source of data: Table 11-2, CSR</cell></row><row><cell>P009.)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_68"><head>Table 63 : Summary of S-warfarin PK parameters following a single oral dose of 10 mg warfarin as part of a CYP probe cocktail at Day 1 (baseline) and Day 57 (following two SC doses of 200 mg tildrakizumab at Weeks 0 and 4) in subjects with moderate to severe plaque psoriasis (Study P009) PK parameters Day</head><label>63</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>1</cell><cell></cell><cell></cell><cell></cell><cell>Day 57</cell><cell cols="2">Day 57/Day 1</cell></row><row><cell></cell><cell>N</cell><cell>GM</cell><cell>95% CI</cell><cell>N</cell><cell>GM</cell><cell>95% CI</cell><cell>GMR</cell><cell>90%CI</cell></row><row><cell>AUCinf (hr*ng/mL)</cell><cell>19</cell><cell cols="5">15600 (13200, 18400) 17 16700 (13900, 20100)</cell><cell>1.07</cell><cell>(0.98, 1.17)</cell></row><row><cell>AUClast (hr*ng/mL)</cell><cell>19</cell><cell cols="5">13400 (11600, 15300) 17 14100 (12000, 16400)</cell><cell>1.05</cell><cell>(0.97, 1.14)</cell></row><row><cell>Cmax (hr*ng/mL)</cell><cell>19</cell><cell>381</cell><cell>(348, 418)</cell><cell>17</cell><cell>377</cell><cell>(344, 414)</cell><cell>0.99</cell><cell>(0.95, 1.03)</cell></row><row><cell cols="9">Abbreviations: GM, geometric least-square mean; GMR, geometric least-square mean ratio. (Source of data: Table 11-3, CSR</cell></row><row><cell>P009.)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_69"><head>Table 64 :</head><label>64</label><figDesc></figDesc><table><row><cell>0 and 4)</cell></row></table><note>Summary of ratio of plasma 5-hydroxyomeprazole/ omeprazole PK parameters following a single oral dose of 40 mg omeprazole as part of a CYP probe cocktail at Day 1 (baseline) and Day 57 (following two SC doses of 200 mg tildrakizumab at Weeks</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_70"><head>Table 65</head><label>65</label><figDesc></figDesc><table><row><cell cols="9">: Summary of dextromethorphan PK parameters following a single oral dose of</cell></row><row><cell cols="9">30 mg dextromethorphan as part of a CYP probe cocktail at Day 1 (baseline) and Day 57</cell></row><row><cell cols="9">(following two SC doses of 200 mg tildrakizumab at Weeks 0 and 4) in subjects with</cell></row><row><cell cols="6">moderate to severe plaque psoriasis (Study P009)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>PK</cell><cell></cell><cell cols="2">Day 1</cell><cell></cell><cell cols="2">Day 57</cell><cell cols="2">Day 57/Day 1</cell></row><row><cell>parameters</cell><cell>N</cell><cell>GM</cell><cell>95% CI</cell><cell>N</cell><cell>GM</cell><cell>95% CI</cell><cell>GMR</cell><cell>90%CI</cell></row><row><cell>AUCinf (hr*ng/mL)</cell><cell>15</cell><cell>6.85</cell><cell>(3.81, 12.3)</cell><cell>14</cell><cell>8.24</cell><cell>(4.51, 15.1)</cell><cell>1.20</cell><cell>(1.00, 1.45)</cell></row><row><cell>AUClast (hr*ng/mL)</cell><cell>15</cell><cell>5.48</cell><cell>(2.94, 10.2)</cell><cell>14</cell><cell>6.74</cell><cell>(3.49, 13.0)</cell><cell>1.23</cell><cell>(1.01, 1.50)</cell></row><row><cell>Cmax (hr*ng/mL)</cell><cell>15</cell><cell>0.872</cell><cell>(0.494, 1.54)</cell><cell>14</cell><cell>1.02</cell><cell>(0.573, 1.82)</cell><cell>1.17</cell><cell>(0.96, 1.43)</cell></row><row><cell cols="9">Abbreviations: GM, geometric least-square mean; GMR, geometric least-square mean ratio. (Source of data: Table 11-5, CSR</cell></row><row><cell>P009.)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_71"><head>Table 66 : Summary of caffeine PK parameters following a single oral dose of 200 mg caffeine as part of a CYP probe cocktail at Day 1 (baseline) and Day 57 (following two SC doses of 200 mg tildrakizumab at Weeks 0 and 4) in subjects with moderate to severe psoriasis (Study P009) PK parameters Day</head><label>66</label><figDesc></figDesc><table><row><cell></cell><cell>1</cell><cell></cell><cell></cell><cell>Day 57</cell><cell></cell><cell cols="2">Day 57/Day 1</cell></row><row><cell>N</cell><cell>GM</cell><cell>95% CI</cell><cell>N</cell><cell>GM</cell><cell>95% CI</cell><cell>GMR</cell><cell>90%CI</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_72"><head>Table 67</head><label>67</label><figDesc></figDesc><table><row><cell cols="7">: Mean (CV%) tildrakizumab PK parameters following single IV administration in</cell></row><row><cell cols="3">healthy subjects (Study P05661)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Dose</cell><cell>N</cell><cell>Cmax</cell><cell>AUClast</cell><cell>AUCinf</cell><cell>t1/2</cell><cell>CL</cell></row><row><cell>(mg/kg)</cell><cell></cell><cell>(mcg/mL)</cell><cell>(mcg*day/mL)</cell><cell>(mcg*day/mL)</cell><cell>(Day)</cell><cell>(mL/day/kg)</cell></row><row><cell>0.1</cell><cell>3-4</cell><cell>2.51 (7%)</cell><cell>40.1 (15%)</cell><cell>40.4 (16%)</cell><cell>29.4 (12%)</cell><cell>2.52 (15%)</cell></row><row><cell>0.5</cell><cell>3-4</cell><cell>14.1 (4%)</cell><cell>252 (23%)</cell><cell>254 (24%)</cell><cell>29.7 (20%)</cell><cell>2.04 (23%)</cell></row><row><cell>3</cell><cell>4-6</cell><cell>68.7 (9%)</cell><cell>1470 (24%)</cell><cell>1490 (25%)</cell><cell>26.9 (44%)</cell><cell>2.11 (23%)</cell></row><row><cell>10</cell><cell>6</cell><cell>261 (8%)</cell><cell>4540 (5%)</cell><cell>4560 (5%)</cell><cell>24.6 (25%)</cell><cell>2.20 (5%)</cell></row><row><cell cols="3">(Source of data: Table 11, CSR 05661.)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_73"><head>Table 68 : Mean (CV%) tildrakizumab PK parameters following single SC administration in healthy subjects (Study P05776) DoseStudy P06306: influence of race on single dose PK of tildrakizumab in healthy subjects</head><label>68</label><figDesc></figDesc><table><row><cell></cell><cell>N</cell><cell>Cmax</cell><cell>Tmax</cell><cell>AUClast</cell><cell>AUCinf</cell><cell>t1/2</cell><cell>CL/F</cell></row><row><cell>(mg)</cell><cell></cell><cell>(mcg/mL)</cell><cell>(day)</cell><cell>(mcg*day/mL)</cell><cell>(mcg*day/mL)</cell><cell>(Day)</cell><cell>(mL/day/kg)</cell></row><row><cell>50</cell><cell cols="2">9-11 6.73 (26%)</cell><cell>6</cell><cell>261 (20%)</cell><cell>267 (21%)</cell><cell>25.1 (12%)</cell><cell>197 (27%)</cell></row><row><cell>200</cell><cell cols="2">1011 26.6 (38%)</cell><cell>6</cell><cell>1100 (46%)</cell><cell>1130 (47%)</cell><cell>24.5 (22%)</cell><cell>282 (119%)</cell></row><row><cell cols="5">Tmax is median value. (Source of data: Table 11, CSR 05776)</cell><cell></cell><cell></cell></row><row><cell cols="8">13.5.2.4 Study P06306 was an open-label, non-randomized, single-dose PK study in Japanese, Chinese</cell></row><row><cell cols="8">and White healthy subjects. Study P06306 had 2 parts. In Part 1, 22 Japanese, 19 White and 12</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_74"><head>Table 69 :</head><label>69</label><figDesc></figDesc><table><row><cell>Dose</cell><cell>Race</cell><cell>Cmax</cell><cell>Tmax</cell><cell>AUClast</cell><cell>AUCinf</cell><cell>t 1/2</cell><cell>CL/F</cell></row></table><note>Geometric mean (CV%) tildrakizumab PK parameters following single SC or IV administration in healthy subjects (Study P06306)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_75"><head>Table 70 : MeanÂ±SD serum tildrakizumab concentrations in Phase 3 trials (P010 and P011).</head><label>70</label><figDesc></figDesc><table><row><cell></cell><cell cols="2">Study P010</cell><cell cols="2">Study P010</cell></row><row><cell>Time</cell><cell>Tildrakizumab</cell><cell>Tildrakizumab</cell><cell>Tildrakizumab</cell><cell>Tildrakizumab</cell></row><row><cell></cell><cell>200 mg</cell><cell>100 mg</cell><cell>200 mg</cell><cell>100 mg</cell></row><row><cell>Week 4</cell><cell>9.09Â±3.87 (n=294)</cell><cell>4.58Â±1.77 (n=301)</cell><cell>9.61Â±3.77 (n=290)</cell><cell>4.82Â±1.61 (n=283)</cell></row><row><cell>Week 12</cell><cell>5.37Â±3.53 (n=284)</cell><cell>2.80Â±1.73 (n=295)</cell><cell>6.23Â±3.26 (n=286)</cell><cell>3.01Â±1.46 (n=282)</cell></row><row><cell>Week 16</cell><cell>2.25Â±1.88 (n=273)</cell><cell>1.22Â±0.94 (n=275)</cell><cell>2.99Â±2.16 (n=269)</cell><cell>1.47Â±1.12 (n=270)</cell></row><row><cell>Week 28</cell><cell>2.12Â±1.71 (n=263)</cell><cell>1.10Â±0.82 (n=258)</cell><cell>2.50Â±1.75 (n=260)</cell><cell>1.22Â±0.78 (n=231)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_76"><head>Table 71 : Summary of immunogenicity incidences through Week 12 in Phase</head><label>71</label><figDesc></figDesc><table><row><cell>3 trials</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_77"><head>Table 72 : Summary of immunogenicity incidences through Week 64 in Phase</head><label>72</label><figDesc></figDesc><table><row><cell>3 trials</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_78"><head>Table 73 : Effect of ADA on PASI 75 response rate at Week 12 in pooled Phase 2 and Phase 3 trials (P010 and P011).</head><label>73</label><figDesc></figDesc><table><row><cell>Subjects ADA status</cell><cell cols="2">PASI 75 response (%) Tildrakizumab 100 mg Tildrakizumab 200 mg</cell></row><row><cell>ADA-</cell><cell>379/593 (63.9%)</cell><cell>237/373 (63.5%)</cell></row><row><cell>ADA inconclusive</cell><cell>17/25 (68.0%)</cell><cell>172/242 (71.1%)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_79"><head>Table 80 : Overview of Subjects in the PK-PD and E-R analyses</head><label>80</label><figDesc></figDesc><table><row><cell>Source of data: Table 3 on page 35 of Applicant's PK-PD report (04kx06.pdf)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_80"><head>Table 81 : Week 12 PASI Response Model Parameters</head><label>81</label><figDesc></figDesc><table><row><cell>Source: Table S1 on page 14 of Applicant's PK-PD report (04kx06.pdf)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_81"><head>Table 82 : Longitudinal PK-PD Model Parameters</head><label>82</label><figDesc></figDesc><table><row><cell>Source of data: Table 9 on page 47 of Applicant's PK-PD report (04kx06.pdf)</cell></row><row><cell>Summary of Week 12 PASI Response and Exposure is shown in</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_82"><head>Table 83 : PASI Response by Exposure Quartile in Part 1 of Trial P010 and P011</head><label>83</label><figDesc></figDesc><table /><note>Source:</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_83"><head>Table 84 : Comparison of Week 12 PASI Response by Dose/Sub-Population</head><label>84</label><figDesc></figDesc><table><row><cell>Source of data: Table 13 on page 57 of Applicant's PK-PD report (04kx06.pdf)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_84"><head>Table 85 : Impact of Titration to 200 mg in Partial Responders at Week 28</head><label>85</label><figDesc></figDesc><table><row><cell>(Source of data: Table 17, Applicant's exposure-response report 04kx06.pdf)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_85"><head>Table 86 : Adverse Events and PASI Response by Exposure Quartile in Part 1 of Trial P010 and P011</head><label>86</label><figDesc></figDesc><table /><note>(Source of data:</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_86"><head>Table 1 : Patient Experience Data Relevant to this Application</head><label>1</label><figDesc></figDesc><table><row><cell>x The patient experience data that was submitted as part of the</cell><cell>Section where discussed,</cell></row><row><cell>application include:</cell><cell>if applicable</cell></row><row><cell>x Clinical outcome assessment (COA) data, such as</cell><cell></cell></row><row><cell>x Patient reported outcome (PRO)</cell><cell>7.2.6</cell></row><row><cell>Observer reported outcome (ObsRO)</cell><cell></cell></row><row><cell>x Clinician reported outcome (ClinRO)</cell><cell>7</cell></row><row><cell>Performance outcome (PerfO)</cell><cell></cell></row><row><cell>Qualitative studies (e.g., individual patient/caregiver interviews,</cell><cell></cell></row><row><cell>focus group interviews, expert interviews, Delphi Panel, etc.)</cell><cell></cell></row><row><cell>Patient-focused drug development or other stakeholder meeting</cell><cell></cell></row><row><cell>summary reports</cell><cell></cell></row><row><cell>Observational survey studies designed to capture patient</cell><cell></cell></row><row><cell>experience data</cell><cell></cell></row><row><cell>Natural history studies</cell><cell></cell></row><row><cell>Patient preference studies (e.g., submitted studies or scientific</cell><cell></cell></row><row><cell>publications)</cell><cell></cell></row><row><cell>Other: (Please specify)</cell><cell></cell></row><row><cell cols="2">x Patient experience data that were not submitted in the application, but were</cell></row><row><cell>considered in this review:</cell><cell></cell></row><row><cell>Input informed from participation in meetings with patient</cell><cell></cell></row><row><cell>stakeholders</cell><cell></cell></row><row><cell>x Patient-focused drug development or other stakeholder</cell><cell>2</cell></row><row><cell>meeting summary reports</cell><cell></cell></row><row><cell>Observational survey studies designed to capture patient</cell><cell></cell></row><row><cell>experience data</cell><cell></cell></row><row><cell>Other: (Please specify)</cell><cell></cell></row><row><cell>Patient experience data was not submitted as part of this application.</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_89"><head>Table 1 : Summary of Trials to be Assessed in the Statistical Review</head><label>1</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Number of</cell><cell></cell><cell></cell></row><row><cell>Trial</cell><cell>Study Sites</cell><cell>Treatment Arms</cell><cell>Subjects</cell><cell>Dates</cell><cell>Study Population</cell></row><row><cell></cell><cell></cell><cell>Tildrakizumab 200 mg</cell><cell>86</cell><cell></cell><cell>Age â¥ 18 years,</cell></row><row><cell>P003 (Phase 2b) Supportive</cell><cell>65 (12 countries)</cell><cell>Tildrakizumab 100 mg Tildrakizumab 25 mg Tildrakizumab 5 mg</cell><cell>89 92 42</cell><cell>10/29/2010 -10/24/2012</cell><cell>diagnosis of chronic plaque psoriasis of at least 6 months,</cell></row><row><cell></cell><cell></cell><cell>Placebo</cell><cell>46</cell><cell></cell><cell>candidates for</cell></row><row><cell>P010 (Phase 3) Pivotal</cell><cell>118 (5 countries)</cell><cell>Tildrakizumab 200 mg Tildrakizumab 100 mg Placebo</cell><cell>308 309 155</cell><cell>12/10/2012 -10/28/2015</cell><cell>systemic therapy and/or phototherapy, PASI â¥ 12, PGA â¥ 3</cell></row><row><cell>P011 Pivotal (Phase 3)</cell><cell>(13 countries) 132</cell><cell>Tildrakizumab 200 mg Tildrakizumab 100 mg Etanercept Placebo</cell><cell>314 307 313 156</cell><cell>9/28/2015 2/12/2013 -</cell><cell>(moderate), BSA â¥ 10%</cell></row><row><cell>Reference ID: 4099373</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_90"><head>Table 2 : Summary of Information Based Upon Review of the Protocol(s) and the Study Report(s)</head><label>2</label><figDesc></figDesc><table><row><cell>Content Parameter</cell><cell>Response/Comments</cell></row><row><cell>Designs utilized are appropriate for the indications</cell><cell></cell></row><row><cell>requested.</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_91"><head>Table 3 : Information Regarding the Data</head><label>3</label><figDesc></figDesc><table><row><cell>Content Parameter</cell><cell>Response/Comments</cell></row><row><cell>Dataset location</cell><cell>\\CDSESUB1\evsprod\BLA761067\0000\m5\datasets</cell></row><row><cell>Were analysis datasets provided?</cell><cell>Yes</cell></row><row><cell>Dataset structure (e.g., SDTM or ADaM)</cell><cell>SDTM and ADaM</cell></row><row><cell>Are the define files sufficiently detailed?</cell><cell>Yes</cell></row><row><cell>List the dataset(s) that contains the</cell><cell>adpasipg.xpt</cell></row><row><cell>primary endpoint(s)</cell><cell></cell></row><row><cell>Are the analysis datasets sufficiently</cell><cell>Yes</cell></row><row><cell>structured and defined to permit analysis of</cell><cell></cell></row><row><cell>the primary endpoint(s) without excess</cell><cell></cell></row><row><cell>data manipulation?</cell><cell></cell></row><row><cell>Safety data are organized to permit</cell><cell>Yes. The applicant submitted ISS datasets.</cell></row><row><cell>analyses across clinical trials in the</cell><cell></cell></row><row><cell>NDA/BLA.</cell><cell></cell></row><row><cell>Reference ID: 4099373</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_92"><head>Table 4 : Initial Overview of the NDA/BLA for Refuse-to-file (RTF): Content Parameter Yes No NA Commentsto be Conveyed to the Applicant 5.1. Refuse-to-File Issues None</head><label>4</label><figDesc></figDesc><table><row><cell>Index is sufficient to locate necessary</cell><cell>X</cell></row><row><cell>reports, tables, data, etc.</cell><cell></cell></row><row><cell>ISS, ISE, and complete study reports are</cell><cell>X</cell></row><row><cell>available (including original protocols,</cell><cell></cell></row><row><cell>subsequent amendments, etc.)</cell><cell></cell></row><row><cell>Safety and efficacy were investigated for</cell><cell>X</cell></row><row><cell>gender, racial, and geriatric subgroups.</cell><cell></cell></row><row><cell>Data sets are accessible, sufficiently</cell><cell>X</cell></row><row><cell>documented, and of sufficient quality (e.g.,</cell><cell></cell></row><row><cell>no meaningful data errors).</cell><cell></cell></row><row><cell>Application appears to be free from any</cell><cell>X</cell></row><row><cell>other deficiency that render the application</cell><cell></cell></row><row><cell>unreviewable, administratively incomplete,</cell><cell></cell></row><row><cell>or inconsistent with regulatory requirements</cell><cell></cell></row><row><cell cols="2">IS THE APPLICATION FILEABLE FROM A STATISTICAL PERSPECTIVE?</cell></row><row><cell>Yes</cell><cell></cell></row><row><cell>5. Comments</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_95"><head>PREGNANCY, LACTATION, AND FEMALES AND MALES OF REPRODUCTIVE POTENTIAL USE 31</head><label></label><figDesc>For chronically administered drugs, the ICH guidelines recommend 1500 patients overall, 300-600 patients for six months, and 100 patients for one year. These exposures MUST occur at the dose or dose range believed to be efficacious.2  The "coding dictionary" consists of a list of all investigator verbatim terms and the preferred terms to which they were mapped. It is most helpful if this comes in as a SAS transport file so that it can be sorted as needed; however, if it is submitted as a PDF document, it should be submitted in both directions (verbatim -&gt; preferred and preferred -&gt; verbatim).If the Application is not fileable from the clinical perspective, state the reasons and provide comments to be sent to the Applicant.o Provide your rationale/discussion regarding the acceptability of your foreign data. The acceptance of the foreign clinical data depends on its ability to be extrapolated to the US population. Refer to the ICH guidance for industry, E5 Ethnic factors in the Acceptability of Foreign Clinical Data, September 2006.</figDesc><table><row><cell cols="3">CLINICAL FILING CHECKLIST FOR NDA/BLA or Supplement CLINICAL FILING CHECKLIST FOR NDA/BLA or Supplement CLINICAL FILING CHECKLIST FOR NDA/BLA or Supplement CLINICAL FILING CHECKLIST FOR NDA/BLA or Supplement</cell></row><row><cell>Content Parameter Content Parameter Content Parameter Content Parameter</cell><cell>Yes No NA Yes No NA Yes No NA Yes No NA</cell><cell>Comment Comment Comment Comment</cell></row><row><cell>Administered at Weeks 0 and 4 in Part 1 (Week 0-16), then the arythmogenic potential of the product (e.g., QT interval 32. If relevant, has the applicant submitted information to</cell><cell>X</cell><cell>available TQT study was Not relevant</cell></row><row><cell>5. Are all documents submitted in English or are English every 12 weeks until Week 52*. studies, if needed)? assess the abuse liability of the product?</cell><cell>X</cell><cell>needed for this large</cell></row><row><cell>translations provided when necessary? FOREIGN STUDIES</cell><cell></cell><cell>molecule. ECGs were</cell></row><row><cell>LABELING *All subjects who did not achieve PASI 75 response at 33. Has the applicant submitted a rationale for assuming the</cell><cell>X</cell><cell>obtained during Phase Not located</cell></row><row><cell>6. Has the applicant submitted a draft prescribing information Week 16 (except those subjects assigned to a 200 mg dose) applicability of foreign data in the submission to the U.S.</cell><cell>X</cell><cell>2 and Phase 3 trials.</cell></row><row><cell>that appears to be consistent with the Physician Labeling had the dose level escalated for continued treatment in Part 22. Has the applicant presented a safety assessment based on all population?</cell><cell>X</cell><cell>NME. Not approved in</cell></row><row><cell>Rule (PLR) regulations and guidances (see 2. current worldwide knowledge regarding this product? DATASETS</cell><cell></cell><cell>any jurisdiction.</cell></row><row><cell cols="3">http://www.fda.gov/Drugs/GuidanceComplianceRegulatory Information/LawsActsandRules/ucm084159 htm SUMMARIES 7. Has the applicant submitted all the required discipline summaries (i.e., Module 2 summaries)? 8. Has the applicant submitted the integrated summary of safety (ISS)? 9. Has the applicant submitted the integrated summary of efficacy (ISE)? 10. Has the applicant submitted a benefit-risk analysis for the product? 11. Indicate if the Application is a 505(b)(1) or a 505(b)(2). 505(b)(2) Applications 23. For chronically administered drugs, have an adequate 34. Has the applicant submitted datasets in a format to allow Location in submission: Module 5.3.5.1 reasonable review of the patient data? number of patients (based on ICH guidelines for exposure 1 ) EFFICACY 16. Do there appear to be the requisite number of adequate and 35. Has the applicant submitted datasets in the format agreed to been exposed at the dosage (or dosage range) believed to be previously by the Division? efficacious? well-controlled studies in the application? Pivotal Study #1: MK-3222 P010: "A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab new drug belongs? in a legible format (deaths, serious adverse events, and Moderate-to-Severe Chronic Plaque Psoriasis" are known to occur with the drugs in the class to which the 39. Has the applicant submitted all required Case Report Forms Long-Term Safety Extension Study, in Subjects With 26. Has the applicant adequately evaluated the safety issues that CASE REPORT FORMS (SCH 900222/MK-3222), Followed by an Optional 24. For drugs not chronically administered (intermittent or 36. Are all datasets for pivotal efficacy studies available and complete for all indications requested? short course), have the requisite number of patients been exposed as requested by the Division? 25. Has the applicant submitted the coding dictionary 2 used for mapping investigator verbatim terms to preferred terms? 37. Are all datasets to support the critical safety analyses o Submit information to BLA 761067 to establish an adequate scientific X X X X Clinical Overview Section 6 X 505(b)(1) X X X X X X X X X Unable to locate X available and complete? 38. For the major derived or composite endpoints, are all of the raw data needed to derive these endpoints included? bridge between the EU-approved etanercept used in Trial P011 and US-X licensed Enbrel.</cell></row><row><cell cols="3">Parameter FORMAT/ORGANIZATION/LEGIBILITY 1. Identify the general format that has been used for this application, e.g. electronic common technical document (eCTD). 2. Is the clinical section legible and organized in a manner to allow substantive review to begin? 3. Is the clinical section indexed (using a table of contents) and paginated in a manner to allow substantive review to begin? 4. For an electronic submission, is it possible to navigate the application in order to allow a substantive review to begin (e.g., are the bookmarks adequate)? 12. If appropriate, what is the relied upon listed drug(s)? 13. Did the applicant provide a scientific bridge demonstrating the relationship between the proposed product and the listed drug(s)/published literature? 27. Have narrative summaries been submitted for all deaths and adverse dropouts)? Indication: moderate-to-severe chronic plaque psoriasis. adverse dropouts (and serious adverse events if requested 40. Has the applicant submitted all additional Case Report 14. Describe the scientific bridge (e.g., BA/BE studies) DOSAGE 15. If needed, has the applicant made an appropriate attempt to determine the correct dosage regimen for this product (e.g., appropriately designed dose-ranging studies)? Study Number: P003 Study Title: "Randomized, Double-Blinded, Placebo-by the Division)? Forms (beyond deaths, serious adverse events, and adverse Pivotal Study #2: MK-3222 P011: "A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-drop-outs) as previously requested by the Division? OTHER STUDIES 28. Has the applicant submitted all special studies/data requested by the Division during pre-submission discussions? 29. For Rx-to-OTC switch and direct-to-OTC applications, are the necessary consumer behavioral studies included (e.g., label comprehension, self selection and/or actual use)? Severe Chronic Plaque Psoriasis PEDIATRIC USE Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in 30. Has the applicant submitted the pediatric assessment, or Indication: moderate-to-severe chronic plaque psoriasis provided documentation for a waiver and/or deferral? Subjects with Moderate-to-Severe Chronic Plaque Psoriasis" Sample Size: 355 Treatment Arms: Placebo SC (n=46) Administered at Weeks 0 and 4 in Part 1 (Week 0-16), then every 12 weeks until Week 52*. Tildrakizumab 5 mg SC (n=42) Administered at Weeks 0 and 4 in Part 1 (Week 0-16), then 17. Do all pivotal efficacy studies appear to be adequate and well-controlled within current divisional policies (or to the . For applications with labeling required to be in Pregnancy extent agreed to previously with the applicant by the and Lactation Labeling Rule (PLLR) format, has the Division) for approvability of this product based on applicant submitted a review of the available information proposed draft labeling? 18. Do the endpoints in the pivotal studies conform to previous Agency commitments/agreements? Indicate if there were not previous Agency agreements regarding primary/secondary endpoints. regarding use in pregnant, lactating women, and females and males of reproductive potential (e.g., published FINANCIAL DISCLOSURE literature, pharmacovigilance database, pregnancy registry) 41. Has the applicant submitted the required Financial in Module 1 (see Disclosure information? http://www.fda.gov/Drugs/DevelopmentApprovalProcess/D GOOD CLINICAL PRACTICE every 12 weeks until Week 52*. Tildrakizumab 25 mg SC (n=92) Administered at Weeks 0 and 4 in Part 1 (Week 0-16), then 19. Has the application submitted a rationale for assuming the evelopmentResources/Labeling/ucm093307 htm)? 42. Is there a statement of Good Clinical Practice; that all ABUSE LIABILITY clinical studies were conducted under the supervision of an applicability of foreign data to U.S. population/practice of IRB and with adequate informed consent procedures? medicine in the submission? every 12 weeks until Week 52*. every 12 weeks until Week 52*. previously requested by the Division? Administered at Weeks 0 and 4 in Part 1 (Week 0-16), then consistent with Center guidelines and/or in a manner Tildrakizumab 100 mg SC (n=89) SAFETY 20. Has the applicant presented the safety data in a manner IS THE CLINICAL SECTION OF THE APPLICATION FILEABLE? ___Yes_____ Yes No NA Comment X eCTD X X X Bookmarks missing in annotated CRFs; however, an alternative method for X X X Narratives for X X X malignancy, serious or opportunistic X infection, serious Human factors cardiovascular event, severe AE, anaphylaxis/hypersens X itivity reactions, serum-sickness or serum-sickness like reactions, elevated X Agreed iPSP Module liver function (AST or 1.9.4 ALT â¥3 times upper limit of normal and X total bilirubin â¥2 times X Information in draft upper limit of normal), labeling text pregnancies, and discontinuations (D/C) X for any reason. Phase 3 Protocols were reviewed under X Module 1.3.4 SPA (Agreement letter 7/18/2012) X X 2.5 Clinical Overview Unable to locate Reviewer's Guide) (Study Data MedDRA v 19.1 X Pivotal trials:</cell></row><row><cell>Tildrakizumab 200 mg SC (n=86) 21. Has the applicant submitted adequate information to assess</cell><cell>X</cell><cell>navigating CRFs is Agency agreed that no</cell></row><row><cell cols="3">File name: 5_Clinical Filing Checklist for NDA_BLA or Supplement 010908 File name: 5_Clinical Filing Checklist for NDA_BLA or Supplement 010908 File name: 5_Clinical Filing Checklist for NDA_BLA or Supplement 010908 File name: 5_Clinical Filing Checklist for NDA_BLA or Supplement 010908</cell></row><row><cell>3 4 5 6</cell><cell></cell><cell></cell></row><row><cell>Reference ID: 4099245 Reference ID: 4099245 Reference ID: 4099245</cell><cell></cell><cell></cell></row></table><note>1</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_97"><head></head><label></label><figDesc>Study P05661: single IV dose PK trial in healthy subjects â Study P05776: single SC dose PK trial in healthy subjects</figDesc><table><row><cell>â Study P06306: intrinsic factor PK trial in healthy Japanese, Chinese, and Caucasian subjects</cell></row><row><cell>â Study P05382: multiple IV doses PK trial in subjects with psoriasis</cell></row><row><cell>â Study P009: relative BA between PFS and AI and effect of tildrakizumab on PK of CYP450</cell></row><row><cell>isoenzymes in subjects with psoriasis</cell></row><row><cell>ï· One Phase 2 dose ranging study in subjects with psoriasis:</cell></row><row><cell>â Study P05495</cell></row><row><cell>ï· Two Phase 3 efficacy/safety pivotal trials in subjects with psoriasis:</cell></row><row><cell>â Study P010</cell></row><row><cell>â Study P011</cell></row><row><cell>The Applicant also submitted study results from a Phase 1 clinical trial conducted in subjects Crohn's</cell></row><row><cell>disease (Study P05839) to support the BLA.</cell></row><row><cell>See Synopsis of Individual Studies in Module 2.7.6 and Tabular Listing of all Clinical Studies in Module</cell></row><row><cell>5.2 for additional information.</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_98"><head>Table 3 .5. Sensitivity and drug tolerance level of the ADA and NAb immunogenicity assays used in Phase 3 trials.Table 2</head><label>32</label><figDesc>The ADA and NAb assay validation parameters were determined using rabbit polyclonal anti-CDR enriched anti-MK-3222 antibodies as positive control. ADA, anti-drug antibodies; CDR, complementarity determining region; MK-3222=tildrakizumab; NAb, neutralizing antibodies. (Source of Data:</figDesc><table><row><cell>.7.7:8 and Table 2.7.7:11,</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_101"><head>Table 1 Subject Population, Placebo-Controlled Safety Period (Trials P003, P010, P011)</head><label>1</label><figDesc></figDesc><table /><note>(From Mid-Cycle Meeting Agenda Summary, Kevin Clark MD and Melinda McCord MD)</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_102"><head>Table 2 Rates of Fatigue/Tiredness AEs in Phase 2 and 3 Tildrakizumab Studies (Placebo-Controlled Phase)</head><label>2</label><figDesc></figDesc><table><row><cell>Arm</cell><cell>AEs</cell><cell>Crude Incidence Rate</cell></row><row><cell>Etanercept 50 mg</cell><cell>4</cell><cell>4/313=1.2%</cell></row><row><cell>Tildrakizumab 100 mg</cell><cell>18</cell><cell>4/705=0.6%</cell></row><row><cell>Tildrakizumab 200 mg</cell><cell>7</cell><cell>7/708=1.0%</cell></row><row><cell>Placebo</cell><cell>5</cell><cell>5/357=1.4%</cell></row><row><cell cols="2">E. Review of Psychiatric Adverse Event Data</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_103"><head>Table 3 Psychiatric AE Subjects/Events in Phase 2 and 3 Tildrakizumab AE Trials-Placebo-Controlled Period (Until End of Week 16/Day 112 for P003, End of Week 12/Day 84 for P010 and P011)</head><label>3</label><figDesc></figDesc><table><row><cell>Study</cell><cell cols="2">Subjects with Psychiatric AEs Events</cell></row><row><cell>P003 (also includes 5 and 25</cell><cell>4</cell><cell>5</cell></row><row><cell>mg)</cell><cell></cell><cell></cell></row><row><cell>P010</cell><cell>19</cell><cell>20</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_104"><head>Table 4 Psychiatric AE Subjects Tildrakizumab versus Placebo in Phase 3 AD RCTs Study Tildraki zumab 100 mg Crude Rate</head><label>4</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell>Tildraki</cell><cell>Crude Rate</cell><cell>Placeb</cell><cell>Crude Rate</cell></row><row><cell></cell><cell></cell><cell>zumab</cell><cell></cell><cell>o</cell></row><row><cell></cell><cell></cell><cell>200 mg</cell><cell></cell><cell></cell></row><row><cell>P003</cell><cell>1</cell><cell>1/705=0.14% 4</cell><cell cols="2">4/708=0.56% 0</cell><cell>0%</cell></row><row><cell>P010</cell><cell>6</cell><cell>6/705=0.85% 10</cell><cell cols="2">10/708=1.4% 3</cell><cell>3/357=0.84%</cell></row><row><cell>P011</cell><cell>4</cell><cell>4/705=0.57% 2</cell><cell cols="2">2/708=0.28% 0</cell><cell>0%</cell></row><row><cell>Pooled</cell><cell>11</cell><cell>11/705=1.6% 16</cell><cell cols="2">16/708=2.3% 3</cell><cell>3/357=0.84%</cell></row><row><cell>Total</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_105"><head>Table</head><label></label><figDesc></figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_106"><head>Table 6 P-Values via Two-Tailed Fisher's Exact Test</head><label>6</label><figDesc></figDesc><table><row><cell>Tildrakizumab 100+200 mg Psychiatric AEs</cell><cell>0.18</cell></row><row><cell>versus Placebo</cell><cell></cell></row><row><cell>Tildrakizumab All Doses Psychiatric AEs versus</cell><cell>0.13</cell></row><row><cell>Placebo</cell><cell></cell></row><row><cell>Tildrakizumab 100+200 mg Depression AEs</cell><cell>0.61</cell></row><row><cell>versus Placebo</cell><cell></cell></row><row><cell>Tildrakizumab All Doses Depression AEs versus</cell><cell>0.36</cell></row><row><cell>Placebo</cell><cell></cell></row><row><cell>Tildrakizumab 100+200 mg Anxiety AEs versus</cell><cell>0.32</cell></row><row><cell>Placebo</cell><cell></cell></row><row><cell>Tildrakizumab All Doses Anxiety AEs versus</cell><cell>1</cell></row><row><cell>Placebo</cell><cell></cell></row><row><cell>Etanercept Psychiatric AEs versus Placebo</cell><cell>0.48</cell></row><row><cell>Etanercept Depression AEs versus Placebo</cell><cell>0.47</cell></row><row><cell>* Sleep, SI/B all p=1</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_107"><head>Table 7 Tildrakizumab Program SI/B Case Summaries</head><label>7</label><figDesc></figDesc><table><row><cell>Subject ID</cell><cell cols="2">Study Event</cell><cell>Original</cell><cell>Summary</cell><cell>Causality</cell></row><row><cell></cell><cell></cell><cell>Type</cell><cell>Treatment</cell><cell></cell><cell>Assessment</cell></row><row><cell>(b) (6)</cell><cell></cell><cell></cell><cell>Arm</cell><cell></cell></row><row><cell></cell><cell>P007</cell><cell>SI/B (SI)</cell><cell>N/A</cell><cell>24 year old Japanese M</cell><cell>Unlikely, due</cell></row><row><cell></cell><cell>(Phase</cell><cell></cell><cell></cell><cell>with severe suicidal</cell><cell>to temporality</cell></row><row><cell></cell><cell>1)</cell><cell></cell><cell></cell><cell>ideation (suicide note</cell><cell>and outside</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>and plan) on Day 63</cell><cell>stressors</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>after previous single</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>400 mg tildrakizumab</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>dose on Day 1,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>substantial gambling</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>debt and other</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>psychosocial stressors</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>noted</cell></row><row><cell></cell><cell>P010</cell><cell cols="2">SI/B (SA) Tildrakizumab</cell><cell>43 year old Asian M</cell><cell>Possible, due</cell></row><row><cell></cell><cell></cell><cell></cell><cell>200 mg</cell><cell>with history of</cell><cell>to temporality,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>schizophrenia and on</cell><cell>but subject</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>multiple psychotropic</cell><cell>had marked</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>medications</cell><cell>pre-existing</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(risperidone,</cell><cell>risk factors</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>benzodiazepines, etc.)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>who attempted suicide</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(abdominal wound with</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>knife) on Day 12 after</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>one dose of</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>tildrakizumab 200 mg</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>on Day 1. Reportedly</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>cited cause of attempt</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>as distress over dystonic</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>symptoms.</cell></row><row><cell>*</cell><cell>P011</cell><cell>SI/B (SI)</cell><cell cols="3">Tildrakizumab 35 year old multiracial F Unlikely, due</cell></row><row><cell>Reference ID: 4169815</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_108"><head>Table 8 Phase 2 and 3 Subjects Taking Concomitant Psychotropic Medications at Screening</head><label>8</label><figDesc></figDesc><table><row><cell cols="2">Psychotropic Medications Number of Subjects-</cell><cell>Number of Subjects-</cell><cell>Number of</cell></row><row><cell></cell><cell>Tildrakizumab Arms</cell><cell>Placebo Arms</cell><cell>Subjects-</cell></row><row><cell></cell><cell>(100 and 200 mg)</cell><cell>(N=357)</cell><cell>Etanercept</cell></row><row><cell></cell><cell>N=1413</cell><cell></cell><cell>(N=313)</cell></row><row><cell>"Psychoanaleptics," i.e.</cell><cell>135 (9.6%)</cell><cell>35 (9.8%)</cell><cell>27 (8.6%)</cell></row><row><cell>stimulants and</cell><cell></cell><cell></cell><cell></cell></row><row><cell>antidepressants</cell><cell></cell><cell></cell><cell></cell></row><row><cell>"Psycholeptics," i.e.</cell><cell>108 (7.6%)</cell><cell>28 (7.8%)</cell><cell>17 (5.4%)</cell></row><row><cell>benzodiazepines, sleep</cell><cell></cell><cell></cell><cell></cell></row><row><cell>medications,</cell><cell></cell><cell></cell><cell></cell></row><row><cell>antipsychotics</cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_109"><head>Table 9 Phase 2 and 3 Subjects Taking Concomitant Steroid Medications During Base Period of Studies</head><label>9</label><figDesc></figDesc><table><row><cell>Treatment Arm</cell><cell>Subjects on Steroid</cell></row><row><cell></cell><cell>Medications</cell></row><row><cell>Tildrakizumab (100 and 200</cell><cell>874 (62%)</cell></row><row><cell>mg) N=1413</cell><cell></cell></row><row><cell>Placebo N=357</cell><cell>226 (63%)</cell></row><row><cell>Etanercept N=313</cell><cell>167 (53%)</cell></row></table><note></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4233639</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="16">Gus= GuselkumabReference ID: 4233639</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4233639(b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4) (b) (4)BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use63Reference ID: 4233639(b) (4)BLA Multi-disciplinary Review and Evaluation -BLA 761067 ILUMYA (tildrakizumab) injection, for subcutaneous use</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Yes, the overall data from Phase 2 and Phase 3 trials provide evidence that tildrakizumab is effective for the treatment of adult patients with moderate to severe psoriasis. The dose-and exposure-response relationships for efficacy provide supportive evidence of effectiveness. See Reference ID: 4233639</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="18">The applicant decided not to conduct the second trial (P012) Reference ID: 4233639(b) (4)</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">a Upper respiratory infections include nasopharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, and pharyngitis Reference ID: 4233639</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="19">Tier 2 AEs:1. AEs (excluding worsening of underlying psoriasis unless it meets criteria for an SAE), 2. Serious adverse events (SAEs), 3. Drug-related AEs 4. Discontinuations due to AEs. 5. Subjects reporting specific AEs. 6. Discontinuations due to drugrelated AEs 7. Deaths. 8. Subjects with anti-drug ant bodies (ADAs) associated with AEs. Tier 3 AEs:1. Laboratory assessments 2. Any other AEs not analyzed in Tier 1 and Tier 2 Reference ID: 4233639 (b) (4)</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="20">External committees adjudicated all MACE and deaths.Reference ID: 4233639(b) (6) (b) (6)</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="28">FDA Briefing Document Dermatologic and Ophthalmic Drugs Advisory Committee Meeting July 19, 2016Reference ID: 4233639(b) (6) (b) (6)</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4232918</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4099245</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4097055</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4097046</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4197671</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4194832</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Reference ID: 4169815</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="6">Roubille C, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. Journal of Rheumatology. 42(10):1767-1780.</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="13.5.2.2">Study P05661: A rising single-dose study of IV tildrakizumab in healthy subjects</head><p>Study P05661 was a randomized rising single-dose PK study of tildrakizumab following IV infusion in healthy subjects. A total of 29 adult subjects were randomized: 11 male and 18 female; ages of 18 to 44 years; 25 (86%) of the subjects were Caucasian. Subjects were</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exposure-response analysis</head><p>The applicant submitted a separate exposure-response analysis report for tildrakizumab entitled Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Analysis of MK-3222 in Psoriasis Patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Objectives:</head><p>The primary objectives of the E-R and longitudinal PK-PD model analyses were to: Quantify E-R for Week 12 PASI endpoints Understand the impact of key subject characteristics, especially weight, on the E-R relationship Compare projected PASI endpoints for 100 and 200 mg fixed-dose regimens relative to alternate weight-based regimens Characterize the longitudinal population PK-PD of PASI reduction for SC tildrakizumab in subjects with psoriasis Project the PASI response (PASI 75, PASI 90 and PASI 100 responders) over time for proposed tildrakizumab regimens in the induction and maintenance phases</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data:</head><p>Subjects from one Phase 2 trial (P05495) and two Phase 3 trials (P010 and P011) were included in the E-R and PK-PD modeling analyses. All subjects treated with tildrakizumab or placebo with valid post-treatment PASI results were included in the E-R analysis. Subjects treated with etanercept in Trial P011 were excluded in the modeling analysis. The average concentration from Week 1 to Week 12 was calculated using the individual PK parameters obtained from the final population pharmacokinetic (POP PK) model. Week 12 PASI 75, PASI 90 and PASI 100 response were imputed, if necessary, using last-observation-carried forward (LOCF).</p><p>The longitudinal PK-PD model analysis included the same subjects used in the E-R analyses. Time-course PASI results were collected up to Week 72. Time-matched tildrakizumab concentration were calculated using the individual PK parameters and the actual administered dose.</p><p>The baseline of the dataset for the PK-PD and E-R analysis is summarized in <ref type="table">Table 80</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 23: Longitudinal PK-PD Model Schematic Diagram</head><p>The mathematical description of the model is given as:</p><p>Where i denotes subject and P max is the maximum placebo response. The plaque formation rate is represented by the zero-order constant for production of the response (kin). PASI is the fraction of baseline, which ranges from 0 to 1. The plaque degradation rate is represented by the first-order rate constant for loss of the response (kout). The variables PTR1, PTR2, and PTR3 reference three sequential PASI transit compartments, each with transit rate constant (ktr). The drug effect is a standard Emax model, where Cpij is the predicted time course from the POP PK model using posthoc parameters. The placebo effect is a sudden increase in healing, which persists throughout the trial. The residual error model was additive in the logittransformed PASI reduction.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Covariates</head><p>The impact of covariates, including weight, age, sex, race, region (Japan/non-Japan), psoriatic arthritis, prior biologic use, baseline PASI and trial, on the E-R model was tested using a forward addition (P &lt; 0.01) and backward elimination (P &lt; 0.001) approach. Covariates found to be significant in the E-R analysis were also tested in the PK-PD analysis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Simulations</head><p>Simulations were used to characterize PASI response based on population parameters from the PK-PD/E-R models, including sampled covariates from the Phase 2 and 3 subject populations. This approach incorporated PK-PD/E-R model variability and parameter uncertainty. Simulations of Week 12 PASI response were performed by simulating 10000 trials with 10000 This BLA is not to support a Rx to OTC switch.</p><p>12 If the applicant is entirely or in part supporting the safety of their product by relying on nonclinical information for which they do not have the right to the underlying data (i.e., a 505(b)(2) application referring to a previous finding of the agency and/or literature), have they provided a scientific bridge or rationale to support that reliance? If so, what type of bridge or rationale was provided (e.g., nonclinical, clinical PK, other)?</p><p>Not applicable.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IS THE PHARMACOLOGY/TOXICOLOGY SECTION OF THE APPLICATION FILEABLE? __YES__</head><p>If the NDA/BLA is not fileable from the pharmacology/toxicology perspective, state the reasons and provide comments to be sent to the Applicant.</p><p>Not applicable.</p><p>Please identify and list any potential review issues to be forwarded to the Applicant for the 74day letter.</p><p>None.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Office of Clinical Pharmacology Review</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BLA Number 761,067</head><p>Link to EDR \\CDSESUB1\evsprod\BLA761067\761067.enx</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Submission Date</head><p>March 23, 2017</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Submission Type</head><p>Original BLA, New Molecular Entity (Standard Review)</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Brand Name ILUMYAÂ®</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Generic Name Tildrakizumab</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dosage Form and Strength</head><p>Single-use prefilled syringe: 100 mg of tildrakizumab in 1.0 mL solution</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Route of Administration Subcutaneous injection</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Proposed Indication</head><p>For the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy The Office of Clinical Pharmacology (OCP) review for this BLA is complete and has been added to the Multi-disciplinary Review and Evaluation, which will be uploaded to DARRTS when it is finalized.</p><p>From a Clinical Pharmacology standpoint, the BLA is acceptable to support approval provided that the Applicant and the FDA reach an agreement regarding the labeling language. There is no recommended clinical pharmacology PMC or PMR for this BLA.</p><p>Refer to the Multi-disciplinary Review and Evaluation for detailed information.</p><p>Reference <ref type="figure">ID: 4197671   -------------------------------------------------------------------------------------------------------</ref>--This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.</p><p>- <ref type="figure">----------------------------------------------------------------------------------------------------</ref> ILUMYA (tildrakizumab) injection Drug class:</p><p>Interleukin-23 antagonist Indication:</p><p>Psoriasis Route:</p><p>Subcutaneous injection Applicant:</p><p>Merck Sharp &amp; Dohme Corp.</p><p>The applicant submitted an original 351(a) BLA application for ILUMYA (tildrakizumab) injection indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis. ILUMYA is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23. The nonclinical review for this BLA application is complete and has been added to the Multi-disciplinary Review and Evaluation, which will be uploaded to DARRTS when it is finalized. Refer to the Multi-disciplinary Review and Evaluation for detailed information.</p><p>ILUMYA is approvable from a Pharmacology/Toxicology perspective. There are no recommended nonclinical PMCs/PMRs for this BLA.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">The clinical review is complete and has been added to the Multi-disciplinary Review and Evaluation, which will be uploaded to DARRTS when it is finalized. Refer to the Multi-disciplinary Review and Evaluation for the details</title>
		<idno>ID: 4233639</idno>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Both Phase 3 trials also had an optional long-term safety extension phase up to 192 weeks, with 621 subjects on 100 mg and 616 subjects on 200 mg</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main">No completed suicides occurred during these trials during the Phase 2 and 3 study base period (prior to the extension phase). The Sponsor identified three possible SI/B events (all on tildrakizumab) in the entire program, including one from Phase 1 and two from Phase 3 (one of which was during the extension phase), according to the original submission</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The analysis noted one additional SI/B case during Phase 3 not previously counted: one subject with two suicidal ideation events during a single hospitalization (counted as one SI/B event; this event was not noted in the original submission, although AEs of worsening of depression and bipolar disorder for the same hospitalization were initially reported). They also noted three additional SI/B cases in the updated extension period</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C-Casa</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">The Sponsor then conducted an additional Retrospective Columbia Classification Algorithm of Suicide Assessment</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
		</imprint>
	</monogr>
	<note>including two suicides and one suicidal ideation event</note>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main">No psychiatric exclusion criteria specified. P011: Excluded subjects with a history of alcohol or drug abuse in the past year. C. Psychiatric Safety Monitoring None of the Phase 2 and 3 studies used specific psychiatric or suicidality scales for safety monitoring or indicated special follow-up procedures in adverse event monitoring protocols. A couple of Quality of Life scales were used in the studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename></persName>
		</author>
		<imprint>
			<biblScope unit="volume">010</biblScope>
		</imprint>
	</monogr>
	<note>Psychiatric Inclusion/Exclusion Criteria P003: No psychiatric exclusion criteria specified. but none had specific psychiatric symptom questions</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Day 14, 28, 42, 56, 84, 112 and Follow-Up. AE monitoring at all visits. No specific psychiatric scales. (Only Quality of Life scales: Health Assessment Questionnaire, which is a PRO noting degrees of pain and disability, and Dermatology Life Quality Index (DLQI), both assessed at Baseline and at Day 84</title>
	</analytic>
	<monogr>
		<title level="m">P003: Assessments at Screening, Baseline (up to 28 days post-screening)</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Baseline (up to Day 28), monthly intervals. DLQI and HAQ at Baseline</title>
	</analytic>
	<monogr>
		<title level="m">P010: Assessments at Screening</title>
		<imprint/>
	</monogr>
	<note>Week 12, 28, 40, 52, 64. P011: Same as P010 except only DLQI not HAQ</note>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">This lack of any psychiatric safety monitoring in these clinical trials is concerning, given the increasing evidence of psychiatric morbidity in patients with psoriasis, and given that suicides have</title>
		<imprint/>
	</monogr>
	<note>occurred in other psoriasis trials</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">D. Coding of Psychiatric Adverse Events Reference ID</title>
		<imprint>
			<biblScope unit="page">4169815</biblScope>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
